fluorodeoxyglucose f18 has been researched along with Neoplasms in 1417 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (0.71) | 18.7374 |
| 1990's | 108 (7.62) | 18.2507 |
| 2000's | 513 (36.20) | 29.6817 |
| 2010's | 601 (42.41) | 24.3611 |
| 2020's | 185 (13.06) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Dang, Y; Ding, R; Feng, M; He, Y; Li, G; Li, S; Liu, H; Qi, C; Wang, X; Xu, J; Zhang, S; Zhao, M | 1 |
| Advani, P; Chumsri, S; Li, Z; Pai, T; Parent, E; Sharma, A | 1 |
| Chen, L; Du, F; Gao, MJ; Hu, JB; Huang, ZK; Liu, Y; Lou, C; Zhou, J | 1 |
| Okazawa, H | 1 |
| Emmett, L; Hamad, N; R Di Ciaccio, P | 1 |
| Dalal, I; Griffith, B; Patel, PY | 1 |
| Ou, X; Yao, X | 1 |
| Chen, H; Meng, T; Pang, Y; Shang, Q | 1 |
| Afshar-Oromieh, A; Alberts, I; Buesser, D; Caluori, P; Conti, M; Cumming, P; Eriksson, L; Hu, J; Mingels, C; Panin, V; Rominger, A; Sari, H; Schepers, R; Shah, V; Shi, K | 1 |
| Dong, A; Ji, X | 1 |
| Chen, X; Huang, Z; Sun, R; Wei, J; Zeng, C | 1 |
| Ankrah, J; Chen, MK; Hirata, K; Lu, Y; Menard, D; Onofrey, JA; Revilla, EM; Shao, D; Shi, L; Toyonaga, T; Zhang, J | 1 |
| Alberts, I; Conti, M; Daube-Witherspoon, ME; Eriksson, L; Karp, JS; Mingels, C; Pantel, AR; Rominger, A; Sari, H; Shi, K; Viswanath, V | 1 |
| Beecher, G; Dubey, D; Ernste, F; Klein, CJ; Liewluck, T; Mandrekar, J; McKeon, A; Mills, JR; Milone, M; Naddaf, E; Pittock, SJ; Shelly, S; Triplett, J; Zekeridou, A | 1 |
| Chen, H; Chen, X; Feng, L; Guo, Z; Huang, J; Li, Y; Lin, Q; Liu, Z; Shi, C; Wen, X; Yao, L; Zeng, X; Zhang, D; Zhang, X; Zhao, L; Zhuang, R | 1 |
| Bergamini, A; Bettinardi, V; Bezzi, C; Cioffi, R; Fallanca, F; Ghezzo, S; Gianolli, L; Mangili, G; Mapelli, P; Mathoux, G; Monaco, L; Picchio, M; Presotto, L; Sabetta, G; Samanes Gajate, AM; Zambella, E | 1 |
| Aide, N; Dercle, L; Dimitrakopoulou-Strauss, A; Gheysens, O; Glaudemans, AWJM; Hicks, RJ; Humbert, O; Iravani, A; Lopci, E; Pandit-Taskar, N; Sachpekidis, C; Scott, AM; Seban, RD; Wahl, RL; Weber, W | 1 |
| Dong, Y; Han, Y; Wu, H; Zhou, W | 1 |
| Li, L; Li, Y; Xiao, L | 1 |
| Akhurst, TJ; Augensen, F; Beattie, BJ; Humm, JL | 1 |
| Beutler, BD; Tchelepi, H; Whang, G | 1 |
| Cortés-Penfield, NW; Thottacherry, E | 1 |
| Gu, J; He, Y; Hu, P; Liu, G; Shi, H; Tan, H; Yu, H; Zhang, Y | 1 |
| Cheng, C; Liu, Y; Zhang, L; Zhang, Z; Zuo, C | 1 |
| Alavi, A; Hunt, SJ; Saucedo, J; Vossough, A; Zandifar, A | 1 |
| Abazari, MA; Ghazani, MA; Kashkooli, FM; Rahmim, A; Soltani, M | 1 |
| Suga, K | 1 |
| de Jong, TL; Jager, PL; Koopman, D; Stevens, H; Tegelaar, A; van Dalen, JA; van Dijk, JD | 1 |
| Bille, A; Cook, GJR; Goh, V; Hughes, DJ; Papa, S; Spicer, J; Subesinghe, M; Taylor, B | 1 |
| Fukushi, M; Inoue, K; Mitsumoto, T; Takabatake, M | 1 |
| Cheng, KL; Chiou, JY; Huang, JY; Lan, CT; Tung, KC; Weng, JH | 1 |
| Chen, X; Liu, L; Sun, R; Zeng, G | 1 |
| Boellaard, R; Borra, RJH; Brouwers, AH; Dierckx, RAJO; Glaudemans, AWJM; Lammertsma, AA; Noordzij, W; Slart, RHJA; Tsoumpas, C; van Sluis, J; van Snick, JH | 1 |
| Bai, Z; Chen, C; Nedzvedz, O; Wang, J; Yao, X; Ye, S | 1 |
| Fowler, JS; Kaunitz, JD; Mandelkern, M | 1 |
| Chen, Z; Cheng, Z; Duan, Y; Gu, F; Hu, Z; Liang, D; Wang, H; Wang, Y; Zhang, N; Zhang, Q; Zheng, H; Zhou, Y | 1 |
| Al-Harrasi, A; Ali, A; Aziz, S; Cao, S; Chen, KH; Corcoran, E; Elliot, G; Elsharabasy, RM; Emara, AA; Fan, DD; Fayez, M; Funk, T; Ghareeb, AH; Gu, X; Guo, M; Halim, SA; He, Q; He, Z; Hu, K; Iqbal, A; Iqbal, M; Khan, A; Kurtulus, S; Lam, J; Lee, J; Li, Y; Liu, J; Liu, Z; Long, L; Lu, H; Mao, Z; Meyer, MJ; Molony, RD; Piquet, M; Qu, F; Ruddy, D; Shen, L; Song, J; Sun, J; Tang, J; Tang, Y; Trabucco, G; Varadarajan, M; Wang, HQ; Wang, Q; Waqas, M; Xia, C; Yang, FM; Yang, L; Yang, Y; Zeng, X; Zhang, G; Zhang, T; Zhang, X; Zhou, M; Zhou, Y; Zhou, Z; Zhu, Z | 1 |
| Cheon, GJ; Choi, H; Chung, JK; Kang, KW; Kim, YH; Lee, CH; Oh, S; Paeng, JC; Youn, H | 1 |
| Endoh, H; Kaira, K; Oriuchi, N | 1 |
| Kiani Shahvandi, M; Moradi Kashkooli, F; Rahmim, A; Saboury, B; Soltani, M | 1 |
| Graham, RN; Panagiotidis, E | 1 |
| Afshar-Oromieh, A; Alberts, I; Casey, ME; Conti, M; Cumming, P; Eriksson, L; Mingels, C; Rominger, A; Sari, H; Shi, K | 1 |
| Deng, Y; Ding, Z; He, L; Xie, H; Zhang, W | 1 |
| Alvarado, LA; Chatterjee, P; Dwivedi, AK; Sharma, P | 1 |
| Boellaard, R; Bogaerts, J; Collette, S; deVries, EGE; Hoekstra, OS; Huang, E; Litiere, S; Schwartz, L; Seymour, L; Shankar, LK | 1 |
| Cui, Y; Dai, J; Huang, S; Jiang, Y; Ju, S; Li, C; Mao, H; Peng, XG; Wu, H; Zhao, Y | 1 |
| Cai, W; Ha, LN; Hsu, JC; Li, X; Son, MH | 1 |
| Costa, P; Figueiredo, L; Oliveira, R | 1 |
| Bogaerts, J; Litière, S | 1 |
| Koyasu, S; Nakamoto, Y; Shirakawa, C; Takada, M; Toi, M | 1 |
| Appleyard, M; Gilhotra, RA; Grimpen, F; Malacova, E; Remedios, M; Ryan, K; Song, L | 1 |
| Becher, T; Cohen, P; Eljalby, M; Huang, X; Jiang, CS; Schöder, H; Vaughan, R; Wibmer, AG | 1 |
| Horikawa, S; Maeda, C; Nakayama, R; Tokunaga, K; Umeoka, S | 1 |
| Avci, E; Barut, IT; Dagtekin, A; Karabag, H; Karatas, D; Sayar, H; Uygur, S | 1 |
| Cui, R; Guo, R; Jia, C; Liang, M; Wu, M | 1 |
| Chen, J; Li, X; Xiong, W; Xue, L | 1 |
| Abdel-Kawi, M; Abdelazeem, A; El-Kassas, M; Ghandour, A; Hussien, N; Romeih, M; Taalab, K | 1 |
| Dong, Z; Guo, Z; Liu, W; Xie, P; Yang, L | 1 |
| Mizuta, J; Ohnishi, H; Yamane, M; Yokoyama, A | 1 |
| Cordier, F; Creytens, D; D'Asseler, Y; De Man, K; Debacker, JM; Deron, P; Descamps, B; Huvenne, W; Keereman, V; Libbrecht, S; Maris, L; Schelfhout, V; Van de Vijver, K; Vanhove, C | 1 |
| Correia, MITD; Costa-Silva, L; da Silva, TA; Faria Levindo Coelho, B; Lamego Resende, L; Rosária Silva Ferreira, Á | 1 |
| Akdemir, ÜÖ; Atay, LÖ; Ateş, SG; Aydos, U; Balcı, E; Karadeniz, C | 1 |
| Hirata, K; Kotani, T; Matsushima, S; Nakai, Y; Tamaki, N; Yamada, K | 1 |
| Bouillot, C; Carlier, T; Chérel, M; Costes, N; Gouard, S; Le Crom, B; Marionneau-Lambot, S; Merlin, T; Stute, S; Taheri, N; Visvikis, D | 1 |
| Dehdashti, F; Parihar, AS; Wahl, RL | 1 |
| Bělohlávek, O; Jarůšková, M; Šmakal, M | 1 |
| Higashikawa, K; Hirata, K; Kuge, Y; Magata, Y; Nakajima, K; Natsume, T; Ogawa, M; Sugikawa, A; Suzuki, C; Suzuki, M; Takahashi, S; Takakura, H; Tomita, M; Yasui, H | 1 |
| Klement, RJ; Sweeney, RA | 1 |
| Chen, Z; Duan, W; Huang, J; Liu, P; Lu, J | 1 |
| Jiao, B; Liu, S; Ma, X; Wong, C; Zhao, H | 1 |
| Arregle, F; Bohbot, Y; Bourg, C; Casalta, JP; Cosyns, B; Deharo, F; Di Lena, C; Donal, E; Gouriet, F; Habib, G; Hubert, S; Martel, H; Philip, M; Selton Suty, C; Tribouilloy, C | 1 |
| Aarntzen, EHJG; Braam, P; Bussink, J; Kaanders, JHAM; Rütten, H; van den Bosch, S; van der Maazen, RWM; Verheij, M | 1 |
| Gallagher, EJ; Seth, S | 1 |
| Amadori, E; Andalò, A; Barone, D; Cavallucci, M; Diano, D; Ferroni, F; Maurizio, L; Oboldi, D; Petralia, G; Prochowski Iamurri, A; Rossi, A; Sintuzzi, E | 1 |
| Abdel-Wahab, O; Diamond, EL; Durham, BH; Francis, JH; Lacouture, ME; Panageas, KS; Petrova-Drus, K; Rampal, RK; Reiner, AS; Rotemberg, V; Yabe, M | 1 |
| Kwon, DH; Litt, HK; Velazquez, AI | 1 |
| Duarte, PS | 1 |
| Kohan, A; Mesci, A; Metser, U; Mirshahvalad, SA; Murad, V; Ortega, C; Veit-Haibach, P | 1 |
| Li, X; Zhang, W | 1 |
| Agrawal, A; Bakshi, G; Choudhury, S; Ghosh, S; Joshi, A; Maitre, P; Menon, S; Murthy, V; Norohna, V; Pal, M; Prabhash, K; Prakash, G; Purandare, N; Puranik, A; Rangarajan, V; Shah, S | 1 |
| Chen, S; Du, Y; Li, C; Wang, G; Yu, S; Zhong, Y | 1 |
| Masse, M; Razzouk-Cadet, M | 1 |
| Battistella, P; Kucharczak, F; Mariano-Goulart, D; Paunet, T; Sagnes, J | 1 |
| Artemov, D; Flavahan, K; Ittig, SJ; Jain, SK; Kasper, CA; Ordonez, AA; Parveen, S; Saupe, F; Shin, H; Turner, ML | 1 |
| Hirata, K; Kudo, K; Takahata, M; Takenaka, J; Watanabe, S | 1 |
| Estler, A; Küstner, T; la Fougère, C; Nikolaou, K; Schmidt, H; Seith, F; Vogel, J | 1 |
| Arai, W; Iwasaki, S; Kaneda, T; Morimoto, R; Otsuka, T; Sakuraba, M; Takasugi, T; Tanaka, A; Tsuji, T | 1 |
| Barrington, SF; Eaton, D; Greener, T; Guerrero-Urbano, T; Michaelidou, A; Miles, E; Pike, LC; Thomas, CM | 1 |
| Drabkin, MJ; Kishore, SA; Sofocleous, CT | 1 |
| Abed, Z; Ahmadi, A; Ghaznavi, H; Irajirad, R; Khoei, S; Najafabad, BK; Shakeri-Zadeh, A; Sheervalilou, R; Shiran, MB | 1 |
| Beels, L; de Jonghe, PJ; de Spiegeleer, B; Maes, A; Sathekge, M; Van de Wiele, C | 1 |
| Anzai, Y | 1 |
| Bos, SA; Bredella, MA; Chu, K; Gill, CM; Torriani, M | 1 |
| Alavi, A; Barrio, JR; Huang, SC; Krohn, KA; Satyamurthy, N; Scafoglio, CS; Yu, AS | 1 |
| Aide, N; Prigent, K | 1 |
| Basu, S; Parghane, RV | 1 |
| Banks, KP; Christensen, CT; Peacock, JG | 1 |
| Sarikaya, A; Sarikaya, I | 1 |
| Diab, RH; Erasmus, JJ; Gladish, GW; Mawlawi, OR; Meier, JG; Peterson, CB | 1 |
| Güveniş, A; Koç, A | 2 |
| Bates, H; Endres, P; Heidari, P; Lawrence, D; Qualls, D; Reynolds, K; Seethapathy, H; Sise, M; Tajmir, S | 1 |
| Ulaner, GA | 1 |
| Alauddin, MM; Khawli, LA | 1 |
| Chacko, AM; Cheng, P; Goggi, JL; Hartimath, SV; Husaini, MA; Hwang, Y; Jiang, L; Jieu, B; Johannes, C; Khanapur, S; Larbi, A; Ramasamy, B; Renia, L; Robins, EG; Tan, PW; Tan, YX; Yong, FF; Yuen, TY | 1 |
| Grewal, RK; Le Gal, G; Le Roux, PY; Robin, P; Salaun, PY | 1 |
| Jeavons, S; Law, P; McGill, G; Miles, KA; Ngai, S; O'Mahoney, E; Oh, G; Yu, C | 1 |
| Andersen, MH; Bruun, NE; Bundgaard, H; Haarmark, C; Holle, SLK; Høilund-Carlsen, PF; Iversen, KK; Klein, CF; Loft, A; Tønder, N | 1 |
| Hatazawa, J; Kato, H; Kawano, M; Kimura, T; Komura, N; Kozasa, K; Kuroda, H; Mabuchi, S; Matsumoto, Y; Sasano, T; Shimura, K; Takahashi, R; Yokoi, E | 1 |
| Bisdas, S; Brunetti, A; Cuocolo, A; Cuocolo, R; Gaudieri, V; Maurea, S; Nappi, C; Romeo, V; Stanzione, A | 1 |
| Andreucci, E; Bianchini, F; Calorini, L; Peppicelli, S; Ruzzolini, J | 1 |
| Fukushima, M; Kojima, S; Nishizawa, S; Okada, H; Shinke, T; Teramukai, S; Torizuka, T | 1 |
| Takahashi, M; Yamaya, T | 1 |
| Hu, F; Lan, X; Liu, F; Shao, F; Zhang, X | 1 |
| Fukunaga, H; Matsuya, Y; Omura, M; Tokuuye, K | 1 |
| Pomerantz, BJ | 1 |
| Aboagye, EO; Allott, L | 1 |
| Bohn, P; Damilleville-Martin, M; Decazes, P; Modzelewski, R; Thureau, S; Vera, P | 1 |
| Huo, L; Wang, X | 1 |
| Gardin, I | 1 |
| Alexiou, G; Asimakopoulos, A; Fotopoulos, A; Jabbour, P; Kyritsis, AP; Markoula, S; Sioka, C | 1 |
| Baranyai, T; Borbély, K; Garai, I; Patkó, PZ | 1 |
| Schlehr, E; Schlehr, JM; Sinha, P; Sinha, S | 1 |
| Jiang, T; Ren, S; Zhou, C | 1 |
| Beer, AJ; Prasad, V; Schmidt, SA; Surov, A; Wienke, A | 1 |
| Baldari, G; Bola, S; Cidda, C; Graziani, T; Migliari, S; Ruffini, L; Sammartano, A; Scarlattei, M; Silva, M; Sverzellati, N | 1 |
| Colandrea, M; Fracassi, SLV; Funicelli, L; Gilardi, L; Grana, CM; Travaini, LL | 1 |
| Fujita, S; Hotokezaka, Y; Ideguchi, R; Sasaki, M; Uetani, M | 1 |
| Aide, N; Coudrais, N; Enilorac, B; Houdu, B; Lasnon, C; Nganoa, C; Salomon, T | 1 |
| Fanti, S; Lopci, E | 1 |
| Becker, J; Krause, BJ; Schwarzenböck, SM | 1 |
| Weber, W | 1 |
| Dawson, SJ; Wong, SQ | 1 |
| Abgral, R; Bourhis, D; Calais, J; Leclère, JC; Lucia, F; Salaün, PY; Schick, U; Vera, P | 1 |
| Dedeoglu, SE; Kubat, B; Sayman, H; Tetikkurt, C; Tetikkurt, S | 1 |
| Maliha, PG; Probst, S; Singerman, J | 1 |
| Iagaru, A; Moradi, F | 1 |
| Calais, J; Mona, CE | 1 |
| Bozzetti, F; Stanga, Z | 1 |
| Bonardel, G; Grellier, JF; Guernou, M; Lussato, D; Queneau, M | 1 |
| Balzer, B; Ho, AS; Manzoor, D; Shafqat, I; Wu, AW | 1 |
| Bodet-Milin, C; Fleury, V; Kraeber-Bodere, F; Labbe, C; Liberge, R; Pallardy, A; Rousseau, C | 1 |
| Aasen, T; Abdul Moin, NI; Abdul Wafi, S; Aboukameel, A; Abu-Bakar, N; Acharya, A; Ackermans, L; Adaramoye, O; Adarsh, KV; Adeosun, WA; Ahmad, NH; Ahmadi, F; Akanni, O; Akbar, M; Akbulak, RO; Akev, N; Akkaya, Ö; Al-Rashed, S; AlAbbad, S; Alabi, O; Alappat, BJ; Alcalá, S; Alcoutlabi, M; Aleppo, G; Alexander Ross, JB; Alexander, JH; Alexander, R; Alias, A; Alimba, C; Alken, FA; Allan, R; Alpers, M; Alsbou, EM; Amarasiri, SS; An, T; Anastasiadis, F; Anastassiadou, M; Anderson, KC; Andronikos, P; Anheyer, D; Annapurna, K; Anorlu, RI; Anten, MM; Anthopoulos, TD; Araujo-Castillo, RV; Aravamudhan, S; Arawwawala, LDAM; Arulsamy, N; Arunamata, A; Asghar, A; Asiri, AM; Aslanidou, T; Astrakhantseva, IV; Astutik, E; Attanayake, AP; Atwater, BD; Audureau, E; Augusto, S; Bakare, A; Banach, M; Bandelier, P; Banerjee, S; Barral, M; Bascuñán, J; Bates, FS; Bauer, NJC; Bayrak, BB; Beck, RW; Beckervordersantforth, J; Beeri, R; Begum, R; Beldi-Ferchiou, A; Bellingham, G; Ben-Tal, N; Bendib, I; Bergenstal, RM; Berger, MF; Bernasconi, G; Berry, S; Beuvon, F; Bi, WJ; Bi, Z; Bianconi, V; Bibi, I; Blank, BR; Bliemeister, E; Bobkowski, W; Bode, AM; Booth, CM; Bose, U; Boyd, K; Brancato, A; Brenmoehl, J; Brogi, E; Bronzo, P; Brooks, T; Brown, D; Brown, DN; Bruce, D; Buan, MEM; Bueno-Hernández, F; Bugielski, B; Bulavaitė, A; Buscagan, TM; Buxton, R; Caffaro, MM; Cai, Q; Cai, X; Cai, Y; Calhoun, P; Callander, N; Cambier, S; Camparo, P; Canales-Vargas, EJ; Canham, K; Cantu, J; Cao, J; Cao, JW; Cao, P; Cao, T; Cao, X; Caravella, BA; Carcadea, E; Carè, J; Carmichael, P; Carrasco Cabrera, L; Carteaux, G; Carvalho, PDS; Casarez, E; Cazorla, M; Celestrin, CP; Chakraborty, NK; Chan, B; Chandarlapaty, S; Chandgude, AL; Chang, CC; Chang, JH; Chang, X; Chang, Y; Chankhanittha, T; Chantanis, S; Chapovetsky, A; Chavan, S; Chen, B; Chen, D; Chen, F; Chen, G; Chen, H; Chen, J; Chen, K; Chen, KJ; Chen, KP; Chen, L; Chen, MA; Chen, Q; Chen, S; Chen, W; Chen, WF; Chen, X; Chen, Y; Cheng, D; Cheng, J; Cheng, Q; Cheon, GJ; Chiu, SC; Cho, CH; Cho, J; Choi, H; Choi, JS; Choi, YH; Christie, P; Chu, CH; Chu, Y; Chung, DH; Chung, F; Cline, JP; Cohen, A; Cohen, AD; Cohen, NJ; Comen, E; Compter, I; Cong, J; Cong, Z; Cooper, A; Cornud, F; Costa, C; Costa, S; Covey, A; Cowan, AM; Cramer, H; Cruz-Rivera, C; Cui, J; Cui, M; Cui, Y; Cui, YH; Culquichicón, C; Cushman, T; D'Auria, SJ; da Silva, J; Dalgediene, I; Danenberg, HD; Das, S; Dasgupta, K; Daubit, IM; de Oliveira, PD; de Prost, N; De Ruysscher, D; Dearman, K; Decato, D; Delfau-Larue, MH; Deng, L; Dhakate, SR; Dharuman, V; Di Costanzo, N; Dickler, MN; Dinehart, EE; Ding, D; Dinh, TK; Divya, KP; Djifack Tadongfack, T; Do, T; Domínguez-Roldan, R; Domínguez-Zambrano, E; Dömling, A; Donato, MD; Dong, JH; Dong, W; Dong, X; Dong, XR; Dong, Y; Dong, Z; Downs, M; Drutskaya, MS; Du, B; Du, F; Du, H; Du, L; Du, X; Duan, Z; Duangthip, D; Dunstand-Guzmán, E; Duong, F; Eckert, DJ; Edelhäuser, BAH; Eekers, DBP; Efendi, F; Efraimidis, P; Ehrenberg, H; Ehsanbakhsh, Z; Eickholt, C; Eksterowicz, J; El Mobadder, M; El-Araby, IE; El-Magd, MA; El-Tarabany, MS; Elgorban, AM; Engelmann, D; English, KL; Esfandiari, H; Eslami, B; Espinosa-Cuevas, A; Eswara, S; Faber, E; Fan, XH; Fan, Y; Fang, J; Fang, Z; Fantin, VR; Fei, P; Feng, G; Feng, H; Feng, J; Feng, X; Feng, XJ; Fennell, TR; Fernández-Moreira, V; Ferraz, ABF; Ferreras, KN; Flores, K; Flores-Pérez, I; Flox, C; Fluharty, FL; Fokouong Tchoffo, E; Folefack, GO; Foroutan, T; Fort, D; Fourati, S; Fousas, S; Frapard, T; Freguia, S; Friedman, DJ; Friedman, LS; Fu, D; Fu, Q; Fu, Y; Fujinami, S; Furihata, K; Gal, RL; Gan, H; Gao, C; Gao, F; Gao, R; Gao, SS; Gao, W; Gao, XC; Gao, Y; Gao, Z; Garozi, L; Ge, J; Georgiopoulos, A; Gerakiou, K; Ghazimirsaeed, SM; Ghazimirsaeed, ST; Gimeno, MC; Gjestad, R; Glurich, I; Goetchius, E; Goland, S; Goldstein, S; Gonçalves, CM; Gonçalves, H; Gong, Q; Gonzalez, D; Goplen, FK; Gorshkova, EN; Gotsman, I; Govindasamy, V; Granger, CB; Greco, L; Grigoriadou-Skouta, E; Grigoropoulos, P; Grivicich, I; Gromov, NV; Gruber, S; Grytczuk, M; Grzech-Leśniak, K; Gu, L; Gu, S; Gu, Z; Guadagnini, D; Guan, H; Guilliams, M; Guo, J; Guo, L; Gupta, A; Gupta, SK; Gurzu, S; Gutleb, AC; Haban, A; Hablitz, JJ; Hadisuyatmana, S; Hahn, S; Haiges, R; Hallal-Calleros, C; Hamed, M; Hammad, N; Hammer, N; Han, C; Hao, Y; Harnett, J; Has, EMM; Hassanpour, K; Hatzopoulos, D; Hawaldar, R; He, X; He, Y; He, YY; He, Z; Heberman, D; Heckl, D; Hegde, H; Henson, MA; Hernández-Velázquez, VM; Herrera, E; Hijazi, Z; Hirayama, K; Hirth, JM; Hoeben, A; Hohnloser, SH; Hong, M; Hood, K; Hoplock, LB; Hopman, WM; Horlbogen, LM; Hossein Rashidi, B; Hou, G; Hou, H; Hou, J; Hou, Y; Hu, J; Hu, W; Hu, X; Hua, W; Huang, G; Huang, H; Huang, J; Huang, T; Huang, W; Huang, Y; Huang, YD; Huang, Z; Hudis, CA; Hue, S; Huo, J; Hussain, M; Hvas, AM; Ichii, T; Ide Zeuna, J; Ilyas, S; Inoue, T; Iranzo, A; Irfan, M; Iwasa, Y; Iwashita, Y; Izgorodina, EI; J R, A; Jaber, WA; Jaborek, JR; Jacobus, SJ; Jadeja, SD; Jafarabadi, M; Jalan, D; Jamil, MI; Jarrah, S; Jarvis, D; Jayatilaka, KAPW; Jemal-Turki, A; Jeon, YK; Jeong, N; Jeong, SH; Jeong, SY; Jermy, M; Jhaveri, K; Ji, H; Ji, K; Ji, RY; Jiang, F; Jiang, J; Jiang, X; Jiang, Y; Jiao, Q; Jilani, K; Jiménez-Guerrero, P; Jin, L; Jo, YH; Johnson, JG; Johnson, ML; Jones, WS; Jose, S; Jularic, M; Jung, I; Jung, YJ; Jungen, C; Junttila, MR; Kache, S; Kahanovitch, U; Kalantzi, KI; Kallio, T; Kamnoedboon, P; Kang, CH; Kang, H; Kang, J; Kang, KW; Kapoor, P; Karmakar, D; Kartalis, A; Kauranen, P; Kazocina, A; Keikha, F; Keltai, M; Kershaw, SV; Kettani, M; Khalvati, S; Khandhar, S; Khosla, N; Kiely, CJ; Kim, CC; Kim, H; Kim, MJ; Kim, Y; Kim, YH; Kim, YT; Kimoto, E; Kiyu, A; Klatt, N; Kobayashi, M; Koh, J; Köhler, R; Kondadasula, SV; Kong, H; Kong, W; Kong, X; Kotidis, A; Kotwal, A; Kouvari, M; Kozhinov, AN; Kruger, D; Kuang, S; Kuang, Y; Kubota, M; Kuklik, P; Kumar, P; Kumar, SK; Kuo, YF; Kurup, SP; Kusuhara, H; Kuswanto, H; Lacouture, ME; Lambin, P; Lang, CC; Langroudi, FH; Lanman, RB; Larsen, OH; Laskin, J; Le, VH; Leach, M; Lee, BG; Lee, DF; Lee, DS; Lee, HJ; Lee, SB; Lee, YA; Lei, Y; Lekashvili, O; Lelj, F; Lemin, AS; Lemoine, J; Leuschner, R; Li, B; Li, BT; Li, C; Li, D; Li, F; Li, G; Li, H; Li, HW; Li, J; Li, M; Li, P; Li, Q; Li, S; Li, W; Li, X; Li, XY; Li, Y; Li, Z; Lian, Y; Liang, C; Liao, J; Liao, W; Liao, Y; Lin, D; Lin, W; Lin, YL; Lindbäck, J; Lindsay, AP; Ling, J; Linser, PJ; Liu, C; Liu, H; Liu, JJ; Liu, L; Liu, Q; Liu, SF; Liu, X; Liu, Y; Liu, Z; Liu, ZM; Lo Sterzo, C; Lo, ECM; Lobchuk, MM; Lodge, TP; Logotheti, S; Lonial, S; Lopes, G; Lopes, RD; Lopez, J; Lopez, SA; López-Santos, AL; López-Sendón, JL; Loring, Z; Louis, C; Lovita, AND; Lu, DZ; Lu, H; Lu, J; Lu, K; Lu, TT; Lu, Y; Luengo, A; Lum, LG; Luna, JM; Luo, L; Luo, R; Luo, T; Luo, X; Luo, Z; Lv, B; Lymperopoulos, N; Lyras, A; Lyu, Y; M Kannan, A; Ma, H; Ma, M; Ma, Q; Ma, S; Ma, WY; Ma, Y; Maalouf, E; Machado, FA; Maeda, K; Magrans, JO; Maharani, A; Maia, G; Mainwaring, RD; Maji, TK; Majumdar, K; Mannarino, MR; Mansuri, MS; Marinescu, SC; Markatos, G; Marquardt, S; Marraiki, N; Martens, C; Martínez, TJ; Marumo, K; Maruyama, H; Marwani, HM; Marzo, I; Masrati, G; Matamba, P; Mathialagan, S; Matys, J; Mayatra, JM; Mboua, PC; McArthur, T; McCrimmon, RJ; McIntosh, S; McSpadden, S; Medina-Campos, ON; Medvedovsky, AT; Mei, Z; Mekontso-Dessap, A; Menezes, AMB; Meng, J; Meng, P; Meng, Y; Menter, A; Mets, MB; Mets-Halgrimson, R; Metzger, T; Metzler-Nolte, N; Meyer, C; Mi, Y; Michailoviene, V; Mikrogeorgiou, A; Militz, H; Miller Iii, TF; Minarowska, A; Mir, S; Miron, I; Miyake, T; Moayer, F; Modi, S; Moeller, SJ; Mohamad, MN; Mohammed, EHM; Mokhonov, VV; Mondal, A; Moore, J; Moravcova, M; Mordi, IR; Mordi, NA; Mortensen, NP; Moscariello, C; Moser, J; Moynahan, ME; Mu, J; Mu, W; Mudduwa, LKB; Mukherjee, S; Mukhtar, A; Mulkey, DK; Murr, N; Mushtaq, Z; Muthuswamy, N; Mutlu, O; Muto, C; Myroforou, I; Na, KJ; Nabi, M; Nagornov, KO; Nagy, RJ; Naik, A; Nakajima, K; Nam, KT; Nam, YW; Namburath, M; Nammour, S; Namour, A; Namour, M; Nanan, S; Natsume, H; Nave, S; Naveed, A; Nazir, H; Ndubaku, C; Nedospasov, SA; Neradilek, MB; Newcomb, C; Nguépy Keubo, FR; Nguyen, M; Ning, J; Ning, Q; Noguchi, S; Nordahl, SHG; Nordfalk, KF; Norton, L; Noupoue, EM; Nouri, SS; Nowak, JK; Núñez, K; Oakes, K; Odegaard, JI; Ogorodnikova, OL; Ogunsuyi, O; Oh, HK; Oh, HR; Oh, KH; Ohgi, K; Okunade, KS; Oliveira, AG; Olorunfemi, G; Olsen, ML; Olson, BA; Omari, KW; Ondruschka, B; Orfali, R; Orkopoulos, A; Orlowski, RZ; Oser, SM; Oser, TK; Özcan, M; Padilla, V; Paeng, JC; Pajuelo-Lozano, N; Pal, SK; Palmieri, S; Palomeque, E; Pan, W; Panagiotakos, DB; Pandey, M; Pang, D; Pang, Q; Pangarah, CA; Panny, A; Paparella, A; Papirio, S; Papouskova, K; Parang, K; Park, HJ; Park, IK; Park, S; Parker, TL; Parkhomenko, A; Parmon, VN; Parsons, B; Parsons, J; Patel, PR; Patil, S; Patsourakos, NG; Patterson, KC; Pavlidis, P; Pedernera, M; Pedersen, R; Pedraza-Chaverri, J; Pellegrini, M; Peña-Chora, G; Pereira, EDM; Pereira, MADS; Peretz, A; Perez-Padilla, R; Perlman, GY; Perona, R; Petras, C; Phuntsho, S; Picada, JN; Pinder, TA; Piper, LFJ; Pirozzi, F; Pirro, M; Pleckaityte, M; Ploutz-Snyder, LL; Ploutz-Snyder, R; Pogorzelski, A; Poles, L; Postma, AA; Prager, A; Prakash, J; Punn, R; Pützer, BM; Qi, J; Qi, MC; Qi, Y; Qian, J; Qian, Y; Qiang, L; Qiu, J; Qu, Y; Rabiu, KA; Rahighi, S; Rahman, MM; Rahmani, B; Rajkumar, SV; Ramanathan, R; Raras, TYM; Rashi, Y; Rasool, G; Rathore, MG; Ratnawati, R; Ratola, N; Raucci, U; Ray, SK; Razavi, P; Razazi, K; Razek, S; Razi, SS; Reback, M; Reddy, K; Rees, DC; Reginatto, FH; Reich, H; Reis-Filho, JS; Ren, X; Ren, Y; Renner, G; Rey, G; Reymen, B; Riaz, M; Ricci, A; Richardson, PG; Richter, C; Riga, M; Ritchie, C; Rivoal, S; Roberts, W; Robson, ME; Rocha, GZ; Rodrigues, AD; Rogach, AL; Rojas, A; Rosenberg, A; Rosenberg, E; Rosenheck, RA; Roslan, K; Rothenberger, C; Rouschop, KMA; Rubagumya, F; Ryan, CM; Ryder, JW; Saad, MJA; Sacan, O; Sacchi, A; Sahebkar, A; Saini, A; Sainz, B; Sajo, EA; Sakizadeh, J; Saleh, AA; Salgado Júnior, IB; Salvi, R; Samoylova, YV; Samuni, A; Sanchez, DM; Sanchez-Perez, I; Santos, M; Sarapulova, A; Sardot, T; Saud, N; Sauerbier, P; Scaltriti, M; Schaeffer, B; Schalk, DL; Scherschel, K; Schijven, MP; Schreuder, HWR; Schuhmacher, M; Schultz-Lebahn, A; Schwarzl, J; Scott, JM; Sebayang, SK; Seeger, ZL; Segabinazi Peserico, C; Selenica, P; Serio, A; Seruga, B; Shah, A; Shah, C; Shah, PD; Shahrokh Tehraninezhad, E; Shan, A; Shao, Z; Sharma, AMR; Sharma, RK; Shen, J; Shen, R; Shi, X; Shi, Y; Shi, ZE; Shih, YC; Shimohata, H; Shimpi, N; Shin, SH; Shon, HK; Shuvy, M; Siddique, AB; Siegbahn, A; Sikandar, M; Silvani, Y; Singh, A; Singh, AK; Singh, D; Singh, JS; Singh, KP; Singh, M; Situ, B; Skipper, MT; Skouloudi, M; Sloane, BF; Smyrnioudis, N; Snyder, MA; Söhnchen, C; Solis Condor, R; Solit, DB; Someya, S; Song, H; Song, J; Song, W; Song, Y; Sorokina, KN; Soshi, S; Soyer, P; Spitschak, A; Sreekrishnan, TR; Srinivasan, M; Staruschenko, A; Steel, A; Stefan-van Staden, RI; Stein, AM; Strayer, H; Struthers, AD; Su, H; Su, Q; Su, X; Sudore, RL; Sugimura, H; Sugiyama, Y; Sujuti, H; Sumner, SJ; Sun, B; Sun, D; Sun, H; Sun, J; Sun, JY; Sun, X; Sun, Y; Sun, Z; Sung, YC; Surenaud, M; Sutimantanapi, D; Suwandaratne, NS; Swaroop, S; Sychrova, H; Syed, A; Szczepanik, M; Szederjesi, J; Szodorai, R; Tacy, TA; Tadelle, RM; Takayasu, M; Tammeveski, K; Tan, H; Tan, M; Tang, HX; Tang, S; Tang, X; Tanokura, M; Tao, F; Tao, H; Tarafdari, A; Tarín-Carrasco, P; Tasson Tatang, C; Teixeira, JP; Thakur, A; Theobald, A; Thevenot, P; Thomaidis, K; Tian, J; Tillib, SV; Toma, C; Tomita, M; Tonchev, I; Tong, F; Toy, W; Trypuć, M; Tselepis, AD; Tsetseris, L; Tsikouri, GE; Tsikouris, EI; Tsoplifack, CB; Tsoumani, ME; Tsujimoto, R; Tsybin, YO; Tu, J; Tu, TM; Turco, M; Turkyilmaz, IB; Uddin, MJ; Ung, J; Unsihuay, D; Utsunomiya, T; Vagenende, B; Vaishnav, J; Valdes, C; Validad, MH; Valle, J; van Ginkel, MPH; van Grevenstein, WMU; Vanderpuye, V; Vasan, N; Vasilenko, EA; Vasques, GJ; Vavoulis, P; Verani, A; Veziroglu, E; Viegas, A; Vitali, MG; Vitsas, G; Voccio, JP; Vogiatzidis, C; Volow, A; Volpin, F; Vourvahis, M; Wagner, LI; Walkowiak, J; Wallace, R; Wallentin, L; Wan, D; Wan, L; Wan, T; Wang, C; Wang, F; Wang, FN; Wang, H; Wang, J; Wang, L; Wang, Q; Wang, S; Wang, T; Wang, W; Wang, X; Wang, XW; Wang, Y; Wang, YS; Wang, Z; Ward, J; Ward, L; Waseem, R; Watson, DF; Weber, P; Wehrmeister, FC; Wei, CH; Wei, H; Wei, L; Wei, Q; Wei, Y; Weinstock, RS; Weiss, M; Welborn, M; Wen, L; Wen, LM; Wen, Q; Wen, Z; Wesseling, P; Westerbergh, J; White, K; Wick, MP; Willems, S; Wiyasa, IWA; Wójciak, R; Wolkenhauer, O; Won, HH; Wong, J; Woo, YC; Wood, LS; Wu, CT; Wu, CY; Wu, D; Wu, G; Wu, J; Wu, K; Wu, M; Wu, Q; Wu, T; Wu, W; Wu, X; Wu, XT; Wu, Y; Xi, D; Xi, J; Xiang, W; Xiang, Y; Xiao, M; Xiao, Z; Xie, H; Xie, Q; Xie, S; Xie, X; Xing, M; Xing, YL; Xu, C; Xu, X; Xu, Y; Xu, Z; Xue, F; Xue, XD; Yaglioglu, HG; Yamada, H; Yamashita, M; Yan, W; Yan, Z; Yanardag, R; Yang, D; Yang, H; Yang, K; Yang, QQ; Yang, R; Yang, S; Yang, T; Yang, X; Yang, Y; Yao, H; Yao, Y; Yari, D; Yassin, MT; Ye, C; Ye, J; Ye, Q; Yildiz, EA; Ying, S; Yoon, H; Yu, D; Yu, K; Yu, N; Yu, PL; Yuan, C; Yuan, D; Yuan, LJ; Yuan, Z; Yuen, N; Zagatto, AM; Zakaria, Y; Zalewski, AM; Zamora, S; Zavorotinskaya, T; Zeid, JL; Zeinoun, T; Zeng, C; Zerby, HN; Zhan, X; Zhang, A; Zhang, D; Zhang, E; Zhang, F; Zhang, H; Zhang, J; Zhang, L; Zhang, M; Zhang, P; Zhang, Q; Zhang, QY; Zhang, RG; Zhang, S; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, CK; Zhao, H; Zhao, J; Zhao, K; Zhao, Q; Zhao, S; Zhao, T; Zhao, XQ; Zhao, Y; Zhao, Z; Zheng, J; Zheng, L; Zheng, Y; Zhou, B; Zhou, G; Zhou, L; Zhou, T; Zhou, X; Zhu, C; Zhu, J; Zhu, Y; Zhu, ZQ; Zhuang, T; Zimmermannova, O; Zin, NNINM; Zisimos, K; Zoghebi, KA; Zonder, JA; Zou, C; Zwirner, J | 1 |
| Dong, J; Ji, Z; Xu, W | 1 |
| Blanes García, AM; Cabrera Martín, MN; Carreras Delgado, JL; Couto Caro, RM; Ferrando-Castagnetto, F; García-Esquinas, MG; Ortega Candil, A; Pedrera Canal, M; Rodríguez Rey, C; Valhondo-Rama, R; Wakfie-Corieh, CG | 1 |
| Albornoz Almada, MC; Boulvard Chollet, XLE; Cabrera Villegas, A; Cañete Sánchez, FM; Delgado Bolton, RC; Garrastachu, P; Mangas Losada, M; Ramírez Lasanta, R; Romero Robles, LG | 1 |
| Gu, B; He, X; Luo, Z; Song, S; Wang, J | 1 |
| Jain, D | 1 |
| Bacanovic, S; Becker, AS; Blüthgen, C; Burger, IA; Eberhard, M; Franckenberg, S; Frick, L; Moos, R; Nagel, HW; Schawkat, K; Volbracht, J; Wolfrum, C; Zellweger, C | 1 |
| Albertini, MR; Cho, SY; Huff, DT; Jeraj, R | 1 |
| Brady, SL; Chism, CB; Doubrovin, M; Han, Y; Hossain, AKMM; Li, Y; Naik, MH; Rossi, M; Shulkin, BL; Wong, KK; Wu, S | 1 |
| Anderson, MA; Bradley, W; Kilcoyne, A; Kurra, V; Lee, SI; Mojtahed, A | 1 |
| González, E; Martí, A; Morón, S; Rojas, J | 1 |
| Brown, K; Chhabra, A; Dosunmu, EB; Duan, X; Ho, V; Kay, FU; Öz, OK | 1 |
| Choi, JY; Hahn, SY; Kim, JH; Lim, Y; Park, KW; Shin, JH | 1 |
| Almubarak, H; Beanlands, RS; Chow, ALS; Chow, BJW; Crean, AM; Kay, R; Leung, ECY; Mais, HE; Rowe, JM; Ruddy, T; Small, GR | 1 |
| Hicks, RJ; Kallur, KG; Mileshkin, L; Roselt, PJ; Tothill, RW | 1 |
| Atkins, A; Betzer, O; Motiei, M; Popovtzer, A; Popovtzer, R; Rahimipour, S; Sadan, T; Tzror-Azankot, C | 1 |
| Asami, T; Dam, TT; Kim, M; Kurihara, J; Ogawa, M; Shimizu, T; Suzuki, K; Yamaguchi, T; Yokoo, S | 1 |
| Champion, L; Dercle, L; Schwartz, LH; Seban, RD | 1 |
| Kagamu, H; Kaira, K; Kuji, I | 1 |
| Akin, EA; Green, C; Zeman, MN | 1 |
| Alberts, I; Ashar-Oromieh, A; Bohn, KP; Mingels, C; Prenosil, G; Rominger, A; Sachpekidis, C; Shi, K; Viscione, M | 1 |
| Antoch, G; Bruckmann, NM; Herrmann, K; Ingenwerth, M; Kirchner, J; Lahner, H; Rischpler, C; Sawicki, LM; Theurer, S; Umutlu, L | 1 |
| Kumar, R; Yadav, D | 1 |
| Anati, T; Bernstine, H; Gorenberg, M; Groshar, D; Priss, M; Steinmetz, AP; Turko, O | 1 |
| Ma, C; Xu, BX; Yu, BX; Zhang, WH | 1 |
| Taveira, M | 1 |
| Chandel, NS; Han, S | 1 |
| Beyer, T; Cal-Gonzalez, J; Chung, D; Kench, PL; Kertész, H; Kitsos, T; London, K; Rausch, I; Saleh, H | 1 |
| Chen, S; Deng, Z; Dong, Y; Hu, P; Qi, C; Shi, H; Tan, H; Wang, Y; Yu, H; Zhang, Y | 1 |
| Baldari, S; Burger, IA; Capozza, M; Deandreis, D; Huellner, MW; Laudicella, R; Liberini, V; Terreno, E | 1 |
| Okamoto, S; Shiga, T; Tamaki, N | 1 |
| Fan, W; Li, Y; Xiong, L; Zhang, H; Zhang, W; Zhang, X; Zhou, C | 1 |
| Ali, T; Bathini, VG; Edmiston, KL; Gerber, JM; McIntosh, LJ; Mittal, K; Rosen, MP; Walsh, WV; Whalen, GF | 1 |
| Aigner, RM; Nazerani-Hooshmand, T; Pernthaler, B; Weitzer, F | 1 |
| Iwata, M; Terasawa, T; Toyama, H; Tsuzuki, S; Watanabe, A | 1 |
| De Bruycker, S; Dockx, Y; Huizing, M; Pauwels, P; Staelens, S; Stroobants, S; Van den Wyngaert, T; Vangestel, C | 1 |
| Eida, S; Fujita, S; Hotokezaka, H; Hotokezaka, Y; Katayama, I; Sasaki, M; Sumi, M; Takagi, Y | 1 |
| Champion, L; Dercle, L; Schwartz, LH; Seban, RD; Yeh, R | 1 |
| Bai, M; Jin, P; Li, J; Meng, X; Meng, Y; Wu, L; Yu, J | 1 |
| Agrawal, A; Gnanasegaran, G; Purandare, N; Puranik, A; Rajkotia, S; Rangarajan, V; Shah, S | 1 |
| Cao, C; Hu, Z; Shi, X; Tian, J; Zhang, Z | 1 |
| Bedoui, M; Huchet, V; Jacquet, T; Jehanno, N | 1 |
| Civelek, AC; He, ZX; Li, XF; Li, YM; Yao, Y | 1 |
| Abouzied, M; Almuhaideb, A; Alsugair, A; Fathala, A | 1 |
| Farwell, MD; Iyalomhe, O | 1 |
| Bauckneht, M; Bruno, S; Cossu, V; Lanfranchi, F; Marini, C; Orengo, AM; Raffa, S; Ravera, S; Sambuceti, G | 1 |
| Castro, AC; Mamede, M; Paulino, E; Ribeiro, TH; S, R | 1 |
| Pinker, K; Riedl, C; Weber, WA | 1 |
| Bogoni, M; Cerci, JJ; Cerci, RJ; Delbeke, D; Fanti, S; Krauzer, C; Pereira, CC; Sakamoto, DG; Tabacchi, E; Vitola, JV | 1 |
| Fukuda, K; Iwabuchi, Y; Jinzaki, M; Katagiri, M; Matsusaka, Y; Murata, M; Nakahara, T; Ogata, Y; Yamada, Y | 1 |
| Jiang, S; Liu, S; Ma, H; Nie, D; Sun, A; Tang, G; Tang, X; Zhang, Z | 1 |
| Abadi-Korek, I; Bernstine, H; Domachevsky, L; Goldberg, N; Groshar, D; Nidam, M; Stein, D | 1 |
| Chism, CB; Macapinlac, HA; Pan, T; Ravizzini, GC | 1 |
| Huang, T; Jin, Z; Li, XF; Shen, B; Sun, Y | 1 |
| Coy, JF | 1 |
| Bingham, PM; Mintz, A; Sai, KKS; Zachar, Z | 1 |
| Fei, B; Schuster, DM | 1 |
| Andresen, TL; Bendix, PM; Jørgensen, JT; Kjaer, A; Kristensen, LK; Melander, F; Norregaard, K; Oddershede, LB; Simón, M | 1 |
| Buerke, B; Heindel, W; Schäfers, M; Schröder, JB; Sundermann, B; Warnecke, T; Weckesser, M | 1 |
| Lacut, K; Lavigne, C; Le Gal, G; Le Roux, PY; Merah, A; Pastre, J; Planquette, B; Prévot-Bitot, N; Robin, P; Salaun, PY | 1 |
| Adams, HJA; de Klerk, JMH; Dubois, SV; Heggelman, BGF; Kwee, TC; Nix, M | 1 |
| Metser, U; Tau, N | 1 |
| Bai, X; Tie, N; Wang, X; Zhao, J | 1 |
| Andersen, HR; Andreasen, RA; Bang, JC; Chrysidis, S; Emamifar, A; Farahani, ZA; Gerke, O; Gildberg-Mortensen, R; Hansen, IMJ; Hansen, PS; Hermann, AP; Hess, S; Laustrup, H; le Greves, S; Marcussen, N; Olsen, RN; Svendstrup, F; Thye-Rønn, P; Toftegaard, P | 1 |
| Aydin, S | 1 |
| Nakadate, M; Oyama, J; Tateishi, U; Toriihara, A; Yamaga, E | 1 |
| Raunik, W; Tubin, S | 1 |
| Conrad, G; Dressler, EV; George, A; Memon, AA; Sinha, P; Wagner, LM | 1 |
| Frary, EC; Gerke, O; Hess, S; Laustrup, H | 1 |
| Choudhury, P; Gupta, M | 1 |
| Kao, PF; Tsao, TC; Tyan, YS; Weng, JH; Yang, SF | 1 |
| Flavell, R; Neumann, K; Wilson, DM | 1 |
| Boellaard, R; de Jong, EEC; Dingemans, AC; Groen, HJM; Hoekstra, OS; Lambin, P; Smit, EF; van Elmpt, W | 1 |
| Dimitrakopoulou-Strauss, A; Hoffend, J; Sachpekidis, C | 1 |
| Kuang, A; Liu, B; Ma, H; Ren, P; Shen, G | 1 |
| Douglas, A; Lau, E; Slavin, M; Thursky, K | 1 |
| Abraham, T; Benchekroun, MT; Garg, G | 1 |
| Ahuja, S; Colletti, PM; Delgado-Bolton, R; Esposito, G; Griffeth, L; Iagaru, AH; Jadvar, H; Kauffman, J; Krause, BJ; Nadel, H; Quinn, DI; Rohren, E; Subramaniam, RM; Zukotynski, K | 1 |
| Choi, IH; Kim, HJ; Kim, SY; Lee, R; Lee, SM; Lkhamsuren, K; Park, IH; Park, YN; Shin, JS; Son, M; Song, JH; Yoo, KH | 1 |
| Bauriaud, M; Caselles, O; Chaltiel, L; Courbon, F; Dierickx, L; Fernandez, A; Gabiache, E; Vallot, D; Zerdoud, S | 1 |
| Downey, RJ; Michor, F; Moreira, A; Riester, M; Xu, Q; Zheng, J | 1 |
| Decazes, P; Dubray, B; Thureau, S; Vera, P | 1 |
| Chirindel, A; Lodge, MA; Mhlanga, JC; Subramaniam, RM; Wahl, RL | 1 |
| Cain, T; Haeusler, GM; Lau, E; Mechinaud, F; Thursky, K; Wang, SS | 1 |
| Achmad, A; Bhattarai, A; Heryanto, YD; Higuchi, T; Tsushima, Y; Yudistiro, R | 1 |
| Daldrup-Link, HE; Gulaka, PK; Muehe, AM; Pareek, A; Spunt, SL; Theruvath, AJ | 1 |
| Kim, BJ; Kim, HD; Kim, HS; Kim, JH | 1 |
| Lococo, F; Manenti, A; Pedrazzoli, C; Zizzo, M | 1 |
| Andree, C; Buck, AK; Gorin, MA; Higuchi, T; Javadi, MS; Lapa, C; Pienta, KJ; Pomper, MG; Rowe, SP; Werner, RA | 1 |
| Cheng, SC; Hudson, M; Jacene, HA; Kim, CK; Rosica, D; Sakellis, C; Van den Abbeele, AD | 1 |
| Cho, YS; Kim, BT; Lee, KH; Moon, SH; Park, JM; Park, SB; Sun, JM | 1 |
| Honda, H; Isoda, T; Kamei, R; Sagiyama, K; Togao, O; Watanabe, Y | 1 |
| Ardenkjaer-Larsen, J; Clemmensen, AE; Gutte, H; Hansen, AE; Holst, P; Johannesen, HH; Kjaer, A; Klausen, TL; Kristensen, AT; Larsen, MME; Rahbek, S; Schøier, C | 1 |
| Chen, Q; Miao, Y; Wang, P; Wei, J | 1 |
| Katz, SI; Mankoff, DA | 1 |
| Thieke, C | 1 |
| Boughdad, S; Buvat, I; Frouin, F; Goya-Outi, J; Nioche, C; Orlhac, F; Pellot-Barakat, C; Reuzé, S; Robert, C; Soussan, M | 1 |
| Calistri, L; Grazzini, G; Nardi, C | 1 |
| Ackerman, D; Gade, TP; Lee, SC; Mankoff, DA; Pantel, AR | 1 |
| Avivar-Valderas, A; Barry, ST; Critchlow, SE; Cruzalegui, F; Cumberbatch, M; Delpuech, O; Eberlein, C; Hancox, U; Klinowska, T; Lenaghan, C; Lynch, JT; Maynard, J; Polanska, UM; Polanski, R; Trigwell, C | 1 |
| Bos, SA; Bredella, MA; Gill, CM; Martinez-Salazar, EL; Torriani, M | 1 |
| Guermazi, A; Jamar, F; Lecouvet, FE; Lhommel, R; Pasoglou, VP; Van Nieuwenhove, S | 1 |
| Bignardi, S; Comelli, A; Ippolito, M; Petrucci, G; Russo, G; Sabini, MG; Stefano, A; Yezzi, A | 1 |
| Aliyu, SA; Archibald, SJ; Avery, G; Cawthorne, C; Crooks, MG; Hart, SP; Kadir, T; Morice, AH; Willaime, JMY | 1 |
| Ay, MR; Ghafarian, P; Ketabi, A; Mahdavi, SR; Mosleh-Shirazi, MA; Rahmim, A | 1 |
| Aide, N; Fanti, S; Hicks, RJ; Le Tourneau, C; Lheureux, S; Lopci, E | 1 |
| Sasamori, H; Uno, K; Wu, J | 1 |
| Chambers, G; Frood, R; Patel, C; Scarsbrook, A | 1 |
| Ahn, BC; Jeong, SY; Kim, SJ; Lee, J; Lee, SW; Pak, K | 1 |
| Hara, T; Inoki, Y; Inoue, Y; Miyatake, H; Nagahara, K | 1 |
| Kjær, A; Loft, A | 1 |
| Abe, T; Fujimoto, K; Fukumoto, Y; Kurata, S; Saku, K; Shintani, Y; Shojima, T; Tahara, N; Takagi, K; Takaseya, T; Tanaka, H | 1 |
| Ahmed, F; Chang, P; Makkar, J; Mutasa, S; Schwartz, L; Shaish, H | 1 |
| Gou, B; Liu, G; Liu, J; Liu, X; Wang, Y; You, L; Zhu, X | 1 |
| Abed, Z; Beik, J; Ghaznavi, H; Kamran Kamrava, S; Mahabadi, VP; Mirrahimi, M; Shakeri-Zadeh, A; Shiralizadeh Dezfuli, A; Shiri, I | 1 |
| Fang, L; Hu, B; Hu, T; Li, Y; Li, Z; Yao, Z; Yu, Y; Zhang, Z; Zhao, Y; Zheng, W | 1 |
| Camacho, V; Carrió, I; Domènech, A; Duch, J; Estorch, M; Fernández, A; Flotats, A; Fuentes-Ocampo, F; López-Mora, DA; Ruiz, A; Sizova, M | 1 |
| Alavi, A; Alvarez, J; Chiesa Fuxench, ZC; Gelfand, JM; Mehta, NN; Noe, MH; Papadopoulos, M; Shin, DB; Takeshita, J; Torigian, DA; Wan, MT; Werner, TJ | 1 |
| Abikhzer, G; Hudson, M; Maliha, PG; Probst, S; Singerman, J | 1 |
| Baratto, L; Hatami, N; Mittra, E; Nobashi, T; Reddy, SA; Srinivas, S; Toriihara, A; Yohannan, TK | 1 |
| Alavi, A; Carlin, S; Cheon, GJ; Chung, JK; Kang, KW; Kim, MJ; Kwon, J; Lee, CH; Lee, Y; Youn, H | 1 |
| Hoffman, RM | 1 |
| Lewis, DY; Witney, TH | 1 |
| Crespi, A; Crivellaro, C; De Ponti, E; Dolci, C; Guerra, L; Landoni, C; Morzenti, S; Spadavecchia, C; Todde, S; Turolla, EA | 1 |
| Busch, M; Drescher, R; Freesmeyer, M; Gühne, F; Seifert, P | 1 |
| Adler, SS; Basuli, F; Choyke, PL; Green, MV; Jagoda, EM; Kuo, F; Roy, J; Seidel, J; Williams, MR; Wong, K; Xu, B | 1 |
| Harinstein, ME; Jahangir, E; Moslehi, J; Murthy, VL | 1 |
| Brøndserud, MB; Hess, S; Høilund-Carlsen, PF; Pedersen, C; Rosenvinge, FS | 1 |
| Boni, R; Bulten, BF; de Geus-Oei, LF; Erba, PA; Massri, K; Slart, RHJA; Sollini, M; van Laarhoven, HWM | 1 |
| Fuentes, DT; Hormuth, DA; Jarrett, AM; Lima, EABF; McKenna, MT; Yankeelov, TE | 1 |
| Antoch, G; Beyer, T; Eiber, M; Gatidis, S; Grueneisen, JS; Herrmann, K; Nikolaou, K; Purz, S; Quick, HH; Rausch, I; Rischpler, C; Schaefer, JF; Umutlu, L; Veit-Haibach, P | 2 |
| Antunovic, L; Gennaro, N; Pepe, G | 1 |
| Koh, YW; Lee, D; Lee, SJ | 1 |
| Aboagye, EO; Alam, IS; Barnes, C; Braga, M; Brickute, D; Carroll, L; Kaliszczak, MA; Lau, D; Nguyen, QD; Stevens, E; Trousil, S | 1 |
| Akdemir, ÜÖ; Atay Kapucu, LÖ; Aydos, U; Karabacak, NI; Karadeniz, C; Kaya, Z; Okur, A; Pinarli, FG; Samanci, C; Uslu-Beşli, L | 1 |
| Ehlers, K; Gerke, O; Høilund-Carlsen, PF; Motschall, E; Vach, W | 1 |
| Adamhasan, F; Koçyiğit-Deveci, E; Küpeli, S; Yağci-Küpeli, B | 1 |
| Alongi, P; Altini, C; Asabella, AN; Baldari, S; Caobelli, F; Cardile, D; Chiaravalloti, A; Ciaccio, A; Cistaro, A; Cuppari, L; Di Pierro, G; Evangelista, L; Fanti, S; Kokomani, A; Lambertini, A; Laudicella, R; Lima, GM; Linguanti, F; Margotti, S; Pacella, S; Panareo, S; Popescu, CE; Quartuccio, N; Rubini, G; Scalisi, S; Scalorbi, F; Schillaci, O; Schiorlin, I; Sturiale, L; Vento, A | 1 |
| Anbai, A; Hashimoto, M; Hatakeyama, K; Kumagai, S; Okuyama, E; Takagi, N; Wada, Y | 1 |
| Meyer, HJ; Surov, A; Wienke, A | 1 |
| Higashi, T; Ishizu, K; Kagawa, S; Kusano, K; Nakamoto, R; Okuyama, C; Takahashi, M; Yamauchi, H | 1 |
| Bisi, G; Deandreis, D; Finessi, M | 1 |
| Gross, MD; Manganaro, MS; Rahman, WT; Rubello, D; Townsend, DM; Viglianti, BL; Wale, DJ; Wong, KK | 1 |
| Gámez-Cenzano, C; Llinares-Tello, E; Martí-Climent, JM; Reynés-Llompart, G; Sabaté-Llobera, A | 1 |
| Conson, M; Del Vecchio, S; Fonti, R | 1 |
| Aparici, CM; Pampaloni, MH; Sebro, R | 1 |
| Bagci, U; Chen, X; Miller-Jaster, K; Mollura, DJ; Yao, J | 1 |
| Ambrosini, V; Chondrogiannis, S; Fanti, S; Ferretti, A; Mezzetti, S; Montesi, V; Nanni, C; Rubello, D; Zompatori, M | 1 |
| Braun, H; Dörfler, A; Kalender, WA; Kuwert, T; Lell, M; Quick, HH; Uder, M; von Gall, C; Wiesmüller, M; Zeilinger, M; Ziegler, S | 1 |
| Hernandez-Pampaloni, M; Mari-Aparici, C; Sebro, R | 1 |
| Betti, M; Castagnoli, A; Dona, M; Fisicaro, D; Fulcheri, C; Orlandini, LC | 1 |
| Browning, ZS; Lenox, MW; Mackenzie, DS; Patterson, RM; Wilkes, AA | 1 |
| Chapman, GJ; Hall, NC; Lee, R; Martin, EW; Murrey, DA; Povoski, SP | 2 |
| Bhattacharya, A; Manohar, K; Mittal, BR | 1 |
| Lunn, MP; Nitkunan, A; Plant, GT; Schon, F | 1 |
| Aramaki, T; Asakura, K; Bekku, E; Endo, M; Moriguchi, M; Sawada, A | 1 |
| Dai, XZ; Han, JK; Li, FQ; Li, XJ; Song, ZG; Zhao, ZH | 1 |
| Brooks, FJ | 1 |
| Choyke, PL; Kobayashi, H; Mitsunaga, M; Nakajima, T; Sano, K | 1 |
| Bowsher, J; Das, SK; Lee, JA; McGurk, RJ | 1 |
| Carrasquillo, JA; Erinjeri, JP; Larson, SM; Nehmeh, S; Ryan, ER; Schöder, H; Siegelbaum, RH; Sofocleous, CT; Solomon, SB; Thornton, R | 1 |
| Greenspan, BS; Niederkohr, RD; Prior, JO; Rohren, EM; Schöder, H; Seltzer, MA; Zukotynski, KA | 1 |
| Drescher, R; Freesmeyer, M | 1 |
| Hosono, M; Ishikawa, K; Kanamori, S; Koike, R; Nakamatsu, K; Nishikawa, T; Nishimura, Y; Shibata, T; Tachibana, I; Tamura, M | 1 |
| Bilic, S; Burris, HA; de Vries, EG; Gietema, JA; Goldbrunner, M; Infante, JR; Oldenhuis, CN; Parker, K; Scott, JW; Sharma, S; Yang, L | 1 |
| Kaidar-Person, O; Keidar, Z; Navve, D | 1 |
| Ali, Z; Aurangabadkar, HU; Palle, L | 1 |
| Agarwal, R; Akin, EA; Ionita, JA; Sadeghi, N; Taheri, MR | 1 |
| Ametamey, SM; Fischer, CR; Groehn, V; Müller, C; Reber, J; Schibli, R | 1 |
| Alavi, A; Basu, S; Cheng, G; Kwee, TC; Lam, MG | 1 |
| Arstad, E; Golay, X; Gonçalves, M; Johnson, SP; Lythgoe, MF; Parkes, HG; Pedley, RB; Rajkumar, V; Ramasawmy, R; Rega, M; Richardson, S; Thomas, DL; Torrealdea, F; Walker-Samuel, S | 1 |
| Belka, C; Elsner, A; Ganswindt, U; Hacker, M; Landrock, S; Manapov, F; Niyazi, M | 1 |
| Bai, J; Cao, X; Dai, Z; He, W; Li, Y; Liu, F; Liu, S; Luo, J; Shan, B; Song, J; Zhang, B | 1 |
| Blake, MA; Gervais, DA; Hahn, PF; Mueller, PR; Nguyen, ML; Sahani, DV; Uppot, RN | 1 |
| Fukuda, H; Kubota, K; Matsuzawa, T | 1 |
| Hu, M; Huo, ZW; Li, MH; Liu, NB; Sun, XR; Xu, WG; Yu, JM; Zhu, L | 1 |
| Gao, G; Gong, B; Shen, W | 1 |
| Del Sole, A; Tagliabue, L | 1 |
| Cheng, NM; Fang, YH; Yen, TC | 1 |
| Besirli, K; Ergul, N; Kaya, A; Kaya, SY; Kilic, F; Ozaras, R; Yilmaz, MH | 1 |
| Crocker, I; Curran, WJ; Fox, T; Schreibmann, E; Schuster, DM | 1 |
| Catalano, OA; Guimaraes, AR; Hahn, PF; Nicolai, E; Rosen, BR; Sahani, DV; Salvatore, M; Soricelli, A; Vangel, MG | 1 |
| Kyle, SD; Law, WP; Miles, KA | 1 |
| Banerji, U; Castro, J; Lamanna, N; Mita, M; O'Brien, S; Saif, MW; Stogard, C; Takimoto, C; Von Hoff, D | 1 |
| Ahtinen, H; Hemminki, A; Joensuu, T; Kairemo, K; Koskela, A; Koski, A; Laasonen, L; Liljenback, H; Oksanen, M; Partanen, K; Roivainen, A | 1 |
| Grewal, RK; Mojtahedi, A; Ulaner, GA | 1 |
| Lyall, A; Ulaner, GA | 1 |
| Avadhani, AN; Ciunci, CA; Divgi, CR; Englander, S; Flaherty, KT; Giantonio, BJ; Harlacker, K; Kang, HC; O'Dwyer, PJ; Perini, RF; Redlinger, M; Rosen, MA; Schnall, M; Song, HK; Sun, W; Troxel, A | 1 |
| Choi, GR; Jin, GH; Lee, SB; Lee, TS; Park, HH | 1 |
| Chandarana, H; DeMello, L; Faul, D; Friedman, KP; Geppert, C; Glielmi, C; Jackson, K; Rakheja, R | 1 |
| Horev, J; Navon, G; Rivlin, M; Tsarfaty, I | 1 |
| Kung, HF; Ploessl, K; Zhu, L | 1 |
| Canevari, C; Castiglioni, I; Della Rosa, PA; Gallivanone, F; Gianolli, L; Gilardi, MC; Salvatore, C | 1 |
| Agarwal, N; Attie, KM; Bendell, JC; Blobe, GC; Condon, CH; Gordon, MS; Hurwitz, HI; Jones, SF; McClure, T; Mendelson, DS; Pearsall, AE; Sharma, S; Sherman, ML; Wilson, D; Yang, Y | 1 |
| Dosaka-Akita, H; Hirata, K; Kuge, Y; Shiga, T; Takei, T; Takeuchi, S; Tamaki, N; Zhao, S; Zhao, Y | 1 |
| Af Rosenschold, PM; Clausen, MM; Engelholm, SA; Hansen, AE; Kjaer, A; Kristensen, AT; McEvoy, FJ | 1 |
| Aldrich, J; Baker, A; Benson, H; Carpten, JD; Christoforides, A; Craig, DW; Demeure, MJ; Hostetter, G; Izatt, T; Kiefer, JA; Kurdoglu, A; Liang, WS; Marsh, V; Phillips, L; Reiman, R; Sinari, S; Von Hoff, DD; Weiss, GJ | 1 |
| Lichert, F | 2 |
| Kadrmas, DJ; Morey, AM | 1 |
| Chen, X; Eden, HS; Guo, J; Guo, N; Kiesewetter, DO; Lang, L; Li, Q; Niu, G; Xie, Q | 1 |
| Graham, MM | 3 |
| Bogaerts, J; de Vries, EG; Litière, S; Liu, Y; Sargent, D; Seymour, L; Shankar, L | 1 |
| Beattie, BJ; Burger, IA; Goldman, DA; Humm, JL; Larson, SM; Schmidtlein, CR; Vargas, HA; Zheng, J | 1 |
| Tahari, AK; Wahl, RL | 1 |
| Chondrogiannis, S; Colletti, PM; Grassetto, G; Maffione, AM; Rubello, D | 1 |
| Howman-Giles, R; London, K | 1 |
| Bornstein, S; Holland, J; Tanyi, J; Young, K | 1 |
| Li, F; Shi, X; Sun, Y; Wu, P; Zhang, Y; Zhu, Z | 1 |
| Iball, GR; Tout, D | 1 |
| Mercier, G; Paidpally, V; Senthamizhchelvan, S; Shah, BA; Subramaniam, RM | 1 |
| Matsumura, K; Nakayama, T; Sengoku, T; Takahashi, Y; Usami, M | 1 |
| Axente, M; Bass, CP; He, J; Pugachev, A; Sundaresan, G; Williamson, JF; Zweit, J | 1 |
| Imaizumi, M; Kako, Y; Kawata, S; Oku, N | 1 |
| Schlemmer, HP; Stieltjes, B; Wilhelm, T | 1 |
| Cunningham, TD; Johnson, LS; Patel, Z; Retrouvey, M; Schaaf, WE | 1 |
| Buvat, I; Garcia, CA; Maisonobe, JA; Orlhac, F; Soussan, M; Vanderlinden, B | 1 |
| Kwee, TC | 1 |
| Daldrup-Link, HE; Donig, J; Gawande, R; Khurana, A; Klenk, C; Luna-Fineman, S; Moseley, M; Qiu, D; Quon, A; Rosenberg, J; Uslu, L | 1 |
| Huang, XE; Shan, C; Wu, P; Zhang, Q | 1 |
| Hutchinson, L | 1 |
| Aboagye, EO; Agarwal, R; Alam, IS; Carroll, L; Chandrashekran, A; DeBerardinis, RJ; Harris, R; Nguyen, QD; Sala, R; Witney, TH | 1 |
| An, N; Chen, Y; Fu, L; Tian, J; Xu, B; Yin, D; Zhang, J | 1 |
| Del Sole, A; Giovanella, L; Sadeghi, R; Treglia, G | 1 |
| Fotopoulos, A; Kyritsis, AP; Sioka, C | 1 |
| Baudino, B; Bisi, G; Caroppo, P; Castelli, L; Cauda, S; D'Agata, F; Grassi, L; Mortara, P; Pinessi, L; Tonello, D; Torta, R; Zotta, M | 1 |
| Borbély, K; Kásler, M; Németh, Z | 1 |
| Daly, B; Mercier, G; Sridhar, P; Subramaniam, RM; Tan, J; Truong, MT | 1 |
| Dubner, Y; Goldin, E; Koslowsky, B; Lalazar, G; Mahamid, M; Shteingart, S; Wengrower, D | 1 |
| Kotzerke, J | 1 |
| Li, S; Li, W; Sun, L; Sun, X; Xing, L; Zhang, X; Zhao, F | 1 |
| Boreham, DR; Lemon, JA; Phan, N; Taylor, K | 1 |
| Chiti, A; Eberlein, U; Lassmann, M; Tosi, G | 1 |
| Daldrup-Link, H; Goske, M; Quon, A | 1 |
| Fernández, A; Gispert, JD; Pifarré, P; Plaza, P; Pujol, J; Simó, M | 1 |
| Cichowski, K; DeRaedt, T; Fromm, JA; Ingraham, R; Maertens, O; Malone, CF | 1 |
| Cheng, C; Hu, S; Liu, Q; Sun, G; Zhang, J; Zuo, C | 1 |
| Hall, NC; Martin, EW; Murrey, DA; Povoski, SP; Smith, SM | 1 |
| Farwell, MD; Mankoff, DA; Pryma, DA | 1 |
| Blagosklonov, O; Boulahdour, H; Prati, C; Wendling, D | 1 |
| Broussolle, C; Hot, A; Iwaz, J; Maucort-Boulch, D; Robine, A; Sève, P | 1 |
| Alavi, A; Algazy, KM; Amaravadi, RK; Chang, YC; Davis, LE; DeMichele, AM; Evans, TL; Fecher, LA; Heitjan, DF; Hu, J; Kaiser, J; O'Dwyer, PJ; Panosian, JT; Pontiggia, L; Rangwala, R; Redlinger, M; Schuchter, LM; Tan, KS; Torigian, DA; Troxel, AB; Vaughn, DJ | 1 |
| Differding, S; Geets, X; Grégoire, V; Janssens, G; Lee, JA; Sterpin, E | 1 |
| Alavi, A; Chauhan, MS; Hess, S; Jacob, MJ; Ravina, M | 1 |
| Dostbil, Z; Inal, A; Simsek, FS; Tasdemir, B; Unal, K; Yildirim, S | 1 |
| Gámez-Cenzano, C; Pino-Sorroche, F | 1 |
| Domachevsky, L; Jacene, HA; Kim, CK; Sakellis, CG | 1 |
| Beltran, LS; Chandarana, H; Friedman, KP; Geppert, C; Ponzo, F; Rakheja, R; Seltzer, AL | 1 |
| Acuff, SN; Barlow, P; Bradley, YC; Osborne, DR | 1 |
| Ichikawa, M; Koyama, K; Kurokawa, M; Momose, T; Ohtomo, K; Takahashi, M | 1 |
| McDonnell, ME; Meibom, S; Steenkamp, DW | 1 |
| Cornelis, F; Durack, JC; Erinjeri, JP; Maybody, M; Schoder, H; Siegelbaum, RH; Silk, M; Sofocleous, CT; Solomon, SB; Takaki, H | 1 |
| Beiderwellen, K; Buchbender, C; Gomez, B; Heusch, P; Köhler, J; Nensa, F; Reis, H; Ruhlmann, V; Schaarschmidt, B; Sivanesapillai, R | 1 |
| Balkay, L; Goda, K; Krasznai, Z; Krasznai, ZT; Márián, T; Mikecz, P; Nizsalóczki, E; Szabó, JP; Szalóki, G; Trencsényi, G | 1 |
| d'Amico, A | 1 |
| Inubushi, M | 1 |
| Avni, T; Bernstine, H; Gafter-Gvili, A; Groshar, D; Grossman, A; Leibovici, L; Paul, M; Raibman, S; Tadmor, B | 1 |
| Deasy, JO; Jeong, J | 1 |
| Das, S; Grimm, J; Thorek, DL | 1 |
| Aboagye, EO; Tsoumpas, C; Turkheimer, FE; Willaime, JM | 1 |
| Cheong, SJ; Jeong, HJ; Kim, EM; Lee, CM; Lim, ST; Sohn, MH | 1 |
| Gardin, I; Modzelewski, R; Monnehan, GA; Nkhali, L; Onoma, DP; Ruan, S; Thureau, S; Vera, P | 1 |
| Arends, B; Barrington, SF; Beyer, T; Bockisch, A; Boellaard, R; Chiti, A; Delbeke, D; Delgado-Bolton, R; Donohoe, KJ; Eschner, W; Giammarile, F; Graham, MM; Hoekstra, CJ; Hoekstra, OS; Holbrook, S; Kotzerke, J; Krause, BJ; Oyen, WJ; Pike, LC; Pruim, J; Stroobants, S; Tatsch, K; Testanera, G; Verzijlbergen, FJ; Visser, E; Weber, WA; Willemsen, A; Zijlstra, J | 1 |
| Allen-Auerbach, MS; Bogsrud, TV; Czernin, J; Herrmann, K; Kalkanis, D; Karantanis, D; Lowe, VJ; Pomykala, KL; Subramaniam, RM | 1 |
| Cheng, DW; d'Errico, F; Della Latta, D; Ersahin, D; Giorgetti, A; Staib, LH | 1 |
| Siegel, BA | 1 |
| Basu, S; Kumar, R; Ranade, R | 1 |
| Bradley, JD; Grigsby, PW; Huang, J; Parikh, PJ; Robinson, CG; Speirs, CK; Thorstad, WL | 1 |
| Alavi, A; Hess, S; Houshmand, S; Salavati, A; Werner, TJ; Zaidi, H | 1 |
| Gerke, O; Hermansson, R; Hess, S; Høilund-Carlsen, PF; Schifter, S; Vach, W | 1 |
| Brendle, C; Gatidis, S; Kupferschläger, J; la Fougère, C; Nikolaou, K; Pfannenberg, C | 1 |
| Flamen, P | 1 |
| DiFilippo, FP; Herrmann, KA; Hu, L; Martinez-Rios, C; Muzic, RF; Rubbert, C | 1 |
| DiFilippo, FP; Muzic, RF | 1 |
| Bangert, BA; Hu, L; Martinez-Rios, C; Teixeira, SR | 1 |
| Acevedo-Báñez, I; Borrego-Dorado, I; García-Gómez, FJ; García-Gutiérrez, M; Martínez-Castillo, R; Tirado-Hospital, JL | 1 |
| El Naqa, I; Groheux, D; Guillevin, R; Hatt, M; Hindié, E; Hustinx, R; Le Rest, CC; Majdoub, M; Martineau, A; Perdrisot, R; Pradier, O; Tixier, F; Vallières, M; Visvikis, D | 1 |
| Borbély, K | 2 |
| Balkay, L; Emri, M; Galuska, L; Garai, I; Kis, AS; Szûcs, B; Varga, J | 1 |
| Demeure, F; Hanin, FX; Moniotte, S; Vancraeynest, D | 1 |
| Daldrup-Link, HE; Donig, J; Link, M; Quon, A; Rosenberg, J; Uslu, L | 1 |
| Cao, X; Chen, X; Hu, H; Kang, F; Li, S; Liang, J; Lin, Y; Liu, M; Nie, Y; Wang, J; Wang, M; Wu, K; Yao, L | 1 |
| Duan, F; Hanna, L; Hillner, BE; Quinn, B; Shields, AF; Siegel, BA | 1 |
| Akhtar, N; Loya, A; Malik, AI; Yusuf, MA | 1 |
| Bossert, I; Calamia, I; Campus, C; Cittadini, G; Conzi, R; Derchi, LE; Fiz, F; Fornarini, G; Ghersi, C; Marini, C; Massollo, M; Morbelli, S; Sambuceti, G | 1 |
| Abu-Khalaf, MM; Azodi, M; Baumgart, MA; Chen, N; Deshpande, H; Digiovanna, MP; Doddamane, I; Gettinger, SN; Harris, LN; Hatzis, C; Hou, S; Lezon-Geyda, K; Schwartz, PE; Sullivan, C; Tuck, DP; Zelterman, D | 1 |
| Howard, SA; Krajewski, KM; Ramaiya, NH; Rohatgi, S; Tirumani, SH | 1 |
| Gatidis, S; la Fougère, C; Nikolaou, K; Schmid, M; Schmidt, H; Schraml, C; Schwenzer, NF | 1 |
| Ball, D; Caine, H; Eade, T; Foroudi, F; Kirby, K; Kron, T; MacManus, M; Pham, D; Siva, S; Stevens, MJ; Te Marvelde, L; Whalley, D | 1 |
| Brooks, FJ; Grigsby, PW | 1 |
| Haberkorn, U; Mier, W; Weber, J | 1 |
| Balkay, L; Emri, M; Krizsán, KÁ; Opposits, G; Varga, J | 1 |
| Alba Castro, JL; Aramburu Núñez, D; Coolens, C; Del Olmo Claudio, JL; Driscoll, B; Landesa-Vázquez, I; López Medina, A; Mera Iglesias, M; Muñoz, V; Salvador Gómez, F | 1 |
| Bezak, E; Jennings, M; Marcu, LG | 1 |
| Lee, ST; Scott, AM | 2 |
| Assimakopoulos, A; Fotopoulos, A; Sioka, C | 1 |
| Avramova-Cholakova, S; Garcheva, M; Ivanova, S; Petrova, E; Vassileva, J | 1 |
| Ishii, T; Kato, S; Nishikawa, Y; Saito, Y; Tsubokura, M | 1 |
| Boellaard, R; Christian, PE; Dorfman, GS; Graham, MM; Hoekstra, OS; Hoffman, JM; Kinahan, PE; Perlman, ES; Sunderland, JJ; Wahl, RL; Yap, JT | 1 |
| Chan, AM; Cline, KJ; Dayes, IS; Dhesy-Thind, SK; Freeman, MA; Gu, CS; Gulenchyn, KY; Inculet, RI; Julian, JA; Levine, MN; Pritchard, KI; You, JJ | 1 |
| Bezrukov, I; Gatidis, S; Mantlik, F; Pichler, BJ; Schäfer, JF; Schmidt, H; Schwenzer, N | 1 |
| Kebebew, E; Summers, RM; Wong, KC; Yao, J | 1 |
| Ahn, BC; Ahn, D; Choi, JH; Kim, H; Na, KJ; Sohn, JH | 1 |
| Antoch, G; Beiderwellen, K; Buchbender, C; Gomez, B; Grueneisen, J; Heusch, P; Quick, HH; Ruhlmann, V; Schaarschmidt, BM; Umutlu, L | 1 |
| Huang, SS; Shah, SN | 1 |
| Del Sole, A; Lecchi, M; Lucignani, G | 1 |
| Chen, YY; Deng, SM; Li, JH; Wu, YW; Zhang, B; Zhang, W | 1 |
| Baumgartner, C; Beer, AJ; Brandl, J; Brühschwein, A; Farrell, E; Hirschberger, J; Kreutzmann, N; Laberke, S; Meyer-Lindenberg, A; Schwaiger, M; Seiler, SM; von Thaden, AK; Wergin, MC | 1 |
| Laforest, R; Wallis, JW; Zanotti-Fregonara, P | 1 |
| Watts, RA | 1 |
| Aung, W; Endo, H; Fujibayashi, Y; Furukawa, T; Hasegawa, S; Inoue, M; Jin, ZH; Saga, T; Yoshii, Y; Yuan, Q; Zhang, MR | 1 |
| Chaal, J; Conti, M; Soderlund, AT; Tjio, G; Totman, JJ; Townsend, DW | 1 |
| Chen, X; Mi, B; Niu, G; Pan, D; Wan, W; Yang, M; Yu, C | 1 |
| Fan, C; Liang, M; Mei, X; Wu, X; Zhang, T | 1 |
| Barbosa de Lima, VA; Højgaard, L; Löfgren, J; Loft, A; von Benzon, E; Østerlind, K | 1 |
| Ai, H; Pan, T | 1 |
| Chu-Shern, JL; Khor, LK; Loi, HY; Quek, ST; Sinha, AK; Tham, IW; Townsend, D; Yan, J | 1 |
| Bengtsson, T; Binns, DS; de Crespigny, AJ; Hicks, RJ; McCarthy, TJ; Sanabria-Bohorquez, SM | 1 |
| Bissonnette, JP; Chan, TC; Li, H; Purdie, T | 1 |
| Akamatsu, G; Ikari, Y; Maebatake, A; Nishida, H; Nishio, T; Ohnishi, A; Sasaki, M; Senda, M | 1 |
| Ishihara, Y; Matsuki, T; Miura, K; Miura, N; Miyoshi, F; Ogawa, T; Ping, B; Shinohara, Y; Shiota, G; Tanabe, Y; Tanaka, N; Tsuno, S; Wang, X; Yamashita, T | 1 |
| Biemans, R; Dubois, L; Granzier, M; Lambin, P; Lieuwes, N; Nalbantov, G; Peeters, SG; Reniers, B; Trani, D; Troost, EE; Verhaegen, F; Yaromina, A | 1 |
| Beadsmoore, C; MacIver, D; Newman, D; Pawaroo, D | 1 |
| Hannukainen, JC; Santhanam, P; Solnes, L; Taïeb, D | 1 |
| Bezrukov, I; Ebinger, M; Gatidis, S; Gücke, B; Nikolaou, K; Pfannenberg, CA; Reimold, M; Schäfer, JF; Schmidt, H; Schwenzer, NF; Seitz, G | 1 |
| Boisserie, F; Brown, MP; Cebon, J; Desai, J; Dienstmann, R; Evers, S; Lassen, U; Lestini, B; Meresse, V; Schostack, K; Su, F; Tabernero, J; Zhang, W | 1 |
| Ardenkjaer-Larsen, J; Gutte, H; Hansen, AE; Henriksen, ST; Højgaard, L; Johannesen, HH; Kjær, A; Kristensen, AT; Larsen, MM; Rahbek, S | 1 |
| Chicco, A; Lin, P; Sam, S; Scott, A; Stoakes, E | 1 |
| Buresta, T; D'Andrea, A; Gravante, S; Palumbo, B; Palumbo, I; Pierotti, L; Scialpi, M | 1 |
| Gao, D; Gao, L; Jia, B; Liu, H; Liu, Z; Sun, X; Wang, F; Zhang, C; Zhu, Z | 1 |
| MacManus, M | 1 |
| Baba, S; Honda, H; Kamei, R; Sagiyama, K; Watanabe, Y | 1 |
| Chi, K; Daldrup-Link, HE; Gawande, R; Klenk, C; Leung, JT; Luna-Fineman, S; McMillan, A; Owen, D; Quon, A; Sakamoto, KM; Tran, VT | 1 |
| Aklan, B; Beiderwellen, K; Jakoby, BW; Oehmigen, M; Paulus, DH; Quick, HH; Ritt, P; Ruhlmann, M | 1 |
| Hatt, M; Visvikis, D | 1 |
| Chen, T; Cheng, D; Li, W; Ou, R; Xie, D; Xiong, L; Xu, Y; Yin, W; Zhao, L; Zheng, X | 1 |
| Iagaru, A; Kubota, K; Minamimoto, R; Mitsumoto, T; Miyata, Y; Morooka, M; Okasaki, M; Sunaoka, F | 1 |
| Bech, K; Christensen, JB; Engelmann, BE; Gad, D; Godballe, C; Gravergaard, AE; Holdgaard, PC; Høilund-Carlsen, PF; Johansen, A; Johansen, J; Karstoft, J; Knudsen, LM; Madsen, PH; Mogensen, O; Petersen, H; Rohde, M; Teilmann-Jørgensen, D | 1 |
| Cook, GJ; Corrigan, AJ; Schleyer, PJ | 1 |
| Law, P; McQueen, L; Miles, K; Ngai, S | 1 |
| Doruyter, A; Sathekge, M; Vorster, M; Warwick, JM | 1 |
| Lodge, MA; Marcus, C; Rahmim, A; Sheikhbahaei, S; Subramaniam, RM; Wray, R | 1 |
| Budde, RP; Lam, MG; Scholtens, AM; Verberne, HJ | 1 |
| Disselhorst, JA; Divine, MR; Katiyar, P; Kohlhofer, U; Pichler, BJ; Quintanilla-Martinez, L | 1 |
| Antoch, G; Beiderwellen, K; Bockisch, A; Buchbender, C; Forsting, M; Heusch, P; Kühl, H; Quick, HH; Ruhlmann, V | 1 |
| Caz, V; de Miguel, E; Elvira, M; Grande, AG; Largo, C; Lopez-Plaza, B; Santamaria, M; Tabernero, M | 1 |
| Hara, T; Ishii, S; Ito, H; Kikuchi, K; Kumamoto, K; Miyajima, M; Shimao, D; Shishido, F; Takawa, M | 1 |
| Shao, X; Wang, X; Wang, Y | 1 |
| Cho, YS; Choe, YS; Jung, KH; Lee, JH; Lee, KH; Moon, SH; Park, JW | 1 |
| Fujii, H | 1 |
| Miwa, K; Miyaji, N; Murata, T; Sasaki, M; Umeda, T; Wagatsuma, K | 1 |
| Hatano, K; Kodama, T; Kotaka, K; Koyama, K; Mitsumoto, T; Tohyama, N | 1 |
| Hu, K; Huang, T; Li, S; Liang, X; Tang, G; Wang, H; Wu, Z | 1 |
| Eiber, M; Ettl, J; Gerngross, C; Graner, FP; Herhaus, P; Keller, U; Philipp-Abbrederis, K; Schwaiger, M; Vag, T; Wester, HJ | 1 |
| Barron, CC; Bilan, PJ; Tsakiridis, T; Tsiani, E | 1 |
| Bol, A; Bol, V; Gallez, B; Grégoire, V; Neveu, MA | 1 |
| Alavi, A; Gholami, S; Høilund-Carlsen, PF; Kwee, TC; Rubello, D; Werner, TJ | 1 |
| de Geus-Oei, LF; Oyen, WJG; van der Graaf, WTA; van Erp, NP; van Herpen, CML; Vlenterie, M; Willemsen, AECAB | 1 |
| d'Errico, F; Larocca, TF; Machado, MA; Menezes, VO; Namías, M; Queiroz, CC; Soares, MB; Souza, SO | 1 |
| Cartin-Ceba, R; Johnson, GB; Nelson, DR; Specks, U | 1 |
| Abourbeh, G; Betzer, O; Dreifuss, T; Mishani, E; Motiei, M; Panet, H; Popovtzer, A; Popovtzer, R; Santana, J | 1 |
| Lodge, MA; O, JH; Wahl, RL | 1 |
| Akamatsu, G; Baba, S; Kidera, D; Maebatake, A; Mikasa, S; Miwa, K; Morita, K; Sasaki, M; Takeshita, T; Tsutsui, Y | 1 |
| Doyle-Lindrud, S | 1 |
| Boisgard, R; Jan, S; Kuhnast, B; Martínez-Rovira, I; Pottier, G | 1 |
| Jang, HJ; Kim, JH; Min, SJ | 1 |
| Randall, EK | 1 |
| Büther, F; Schäfers, KP; Schäfers, M; Vehren, T | 1 |
| Britton, T; Robinson, N | 1 |
| Alenezi, A; Alqahtani, S; Soliman, K | 1 |
| Hino, M; Matsumoto, K; Senda, M; Shimizu, K; Yamamoto, S | 1 |
| Denœux, T; Jardin, F; Lian, C; Ruan, S; Vera, P | 1 |
| Chung, JH; Kim, SY; Lee, JJ | 1 |
| Havariyoun, G | 1 |
| Minamimoto, R | 1 |
| Abreu, C; Carolino, E; Grilo, A; Lucena, F | 1 |
| Duan, F; Hanna, L; Hillner, BE; Sachedina, A; Shields, AF; Siegel, BA; Subramaniam, RM | 1 |
| Hirata, Y; Nakano, M; Okazaki, F; Sawaki, K; Takashiba, S; Yamashiro, K | 1 |
| Bendix, PM; Jørgensen, JT; Kjaer, A; Norregaard, K; Oddershede, LB; Tian, P | 1 |
| Fatima, N; Tahseen, R; Zaman, A; Zaman, MU; Zaman, U | 1 |
| Berwouts, D; De Neve, W; De Wolf, K; Goethals, I; Lambert, B; Madani, I; Olteanu, LA; Ost, P; Speleers, B | 1 |
| Hara, T; Ishii, S; Ito, H; Kubo, H; Kuroiwa, D; Miyajima, M; Nanbu, T; Oriuchi, N; Sekino, H; Suenaga, H; Sugawara, S | 1 |
| Aboagye, EO; Adams, JE; Aerts, HJ; Barrington, SF; Beer, AJ; Boellaard, R; Bohndiek, SE; Brady, M; Brindle, KM; Brown, G; Buckley, DL; Chenevert, TL; Clarke, LP; Collette, S; Cook, GJ; deSouza, NM; Dickson, JC; Dive, C; Evelhoch, JL; Faivre-Finn, C; Gallagher, FA; Gilbert, FJ; Gillies, RJ; Goh, V; Griffiths, JR; Groves, AM; Halligan, S; Harris, AL; Hawkes, DJ; Hoekstra, OS; Huang, EP; Hutton, BF; Jackson, A; Jackson, EF; Jayson, GC; Jones, A; Koh, DM; Lacombe, D; Lambin, P; Lassau, N; Leach, MO; Lee, TY; Leen, EL; Lewis, JS; Liu, Y; Lythgoe, MF; Manoharan, P; Maxwell, RJ; McShane, LM; Miles, KA; Morgan, B; Morris, S; Ng, T; O'Connor, JP; Padhani, AR; Parker, GJ; Partridge, M; Pathak, AP; Peet, AC; Punwani, S; Reynolds, AR; Robinson, SP; Shankar, LK; Sharma, RA; Soloviev, D; Stroobants, S; Sullivan, DC; Taylor, SA; Tofts, PS; Tozer, GM; van Herk, M; Walker-Samuel, S; Wason, J; Waterton, JC; Williams, KJ; Workman, P; Yankeelov, TE | 1 |
| Beyer, T; Gillies, RJ | 1 |
| Barbosa, FG; Delso, G; Hakami, YA; Hüllner, M; Pietsch, C; Queiroz, MA; Sah, BR; Stolzmann, P; Veit-Haibach, P; von Schulthess, GK; Wollenweber, SD | 1 |
| Da Cunha-Bang, C; Fischer, BM; Gustafsson, F; Iversen, M; Johannesen, HH; Kjær, A; Lundgren, JD; Rasmussen, A; Sengeløv, H; Sørensen, SS; Wareham, NE | 1 |
| Mena, E; Pattanayak, P; Sheikhbahaei, S; Solnes, LB; Subramaniam, RM; Taghipour, M | 1 |
| Bazmara, H; Casey, ME; Rahmim, A; Sefidgar, M; Soltani, M; Subramaniam, RM; Wahl, RL | 1 |
| Cliffe, H; Patel, C; Prestwich, R; Scarsbrook, A | 1 |
| Alexander, S; Amaral, J; Connolly, B; Nihayah, S; Parra, D; Shammas, A; Vali, R | 1 |
| Jeavons, SJ; Law, WP; Maggacis, N; Miles, KA | 1 |
| Barkhodari, A; Holley, D; Iagaru, A; Jamali, M; Minamimoto, R; Vasanawala, S; Zaharchuk, G | 1 |
| Eiber, M; Fendler, WP; Herrmann, K; Stief, CG | 1 |
| Bengel, FM; Derlin, T | 1 |
| Berthelsen, AK; Birk Christensen, C; Højgaard, L; Loft-Jakobsen, A; Munck Af Rosenschöld, P; Roed, H | 1 |
| Lodge, MA | 1 |
| Dunphy, M; Mannelli, L; Ulaner, GA | 1 |
| Dierckx, RA; Van de Wiele, C | 1 |
| Gatenby, RA; Gillies, RJ; Robey, I | 1 |
| Plathow, C; Weber, WA | 1 |
| Buerkle, A; Weber, WA | 1 |
| Alber, M; Thorwarth, D | 1 |
| Amthauer, H; Barrington, S; Begent, J; Biassoni, L; Franzius, C; Hahn, K; Hain, S; Højgaard, L; Juergens, KU; Kluge, R; Lynch, T; Pfluger, T; Stauss, J; Voelker, T | 1 |
| Basu, S | 2 |
| Aide, N; Chasle, J; Dutoit, S; Gauduchon, P; Herlin, P; Labiche, A; Montravers, F; Paciencia, M; Poulain, L | 1 |
| Gao, ZR; Jia, Q; Lan, XL; Wei, H; Wu, ZJ; Zhang, YX | 1 |
| Abad, MJ; Arsenak, M; Caridad, V; Colmenter, LF; Guillén, N; Martín, R; Taylor, P | 1 |
| Chen, Y; Xiong, QF | 1 |
| Daisaki, H; Hamashima, C; Kakinuma, R; Kakizoe, T; Kanou, D; Moriyama, N; Murano, T; Shoda, H; Terauchi, T | 1 |
| Ayala, F; García, T; Gonzalez-Billalabeitia, E; Gonzalez-Cabezas, P; Macías, JA; Vicente, E; Vicente, V; Zafra, M | 1 |
| Dahlbom, M; Dimock, C; Heckathorne, E | 1 |
| Boucek, JA; Francis, RJ; Green, AJ; Jones, CG; Khan, N; Turlach, BA | 1 |
| Katz, SC; Shaha, A | 1 |
| Dong, MJ; Lin, XT; Liu, ZF; Ruan, LX; Zhao, J; Zhao, K | 1 |
| Busk, M; Bussink, J; Horsman, MR; Jakobsen, S; Overgaard, J; van der Kogel, A | 1 |
| Allegri, V; Astorino, M; Biasco, G; Boschi, S; Brandi, G; Castellucci, P; Di Battista, M; Fanti, S; Lodi, F; Lopci, E; Maleddu, A; Nanni, C; Nannini, M; Pantaleo, MA | 1 |
| Fanti, S; Farace, P; Galiè, M; Nanni, C; Spinelli, A | 1 |
| Hicks, RJ | 1 |
| Csiki, Z; Garai, I; Sóvágó, J; Szabados, L; Tóth, C; Tóth, L | 1 |
| Alavi, A; Alkhawaldeh, K | 1 |
| Altmann, A; Eisenhut, M; Haberkorn, U; Mier, W | 1 |
| Blankenberg, FG | 1 |
| Daisaki, H; Iinuma, T; Inoue, T; Kato, K; Murano, T; Tateishi, U; Tateno, Y; Terauchi, T | 1 |
| Maurer, AH | 1 |
| Miles, KA | 2 |
| Bar-Shalom, R; Guralnik, L; Israel, O; Kagna, O | 1 |
| Nahmias, C; Wahl, LM | 1 |
| Coenen, HH; Haas, R; Hamacher, K; Kobbe, G; Langen, KJ; Pauleit, D; Salber, D; Stoffels, G | 1 |
| Cannon, H | 1 |
| D'Ambrosio, D; Degrassi, A; Fanti, S; Farace, P; Galiè, M; Marzola, P; Merigo, F; Nanni, C; Rubello, D; Sbarbati, A; Spinelli, A | 1 |
| Belohlavek, O; Carrio, I; Danna, M; Deniaud-Alexandre, E; Dondi, M; Inoue, T; Jeremic, B; MacManus, M; Messa, C; Nestle, U; Rosenzweig, KE; Schipani, S; Watanabe, N | 1 |
| Barentsz, JO; Desar, IM; Oyen, WJ; van der Graaf, WT; van Herpen, CM; van Laarhoven, HW | 1 |
| Ben-Haim, S; Ell, P | 1 |
| Cho, K; Fukushima, Y; Hakozaki, K; Kanaya, K; Kiriyama, T; Kumita, S; Sakurai, M; Sato, H; Shiiba, M | 1 |
| Arslan, N; Ataergin, S; Ozet, A; Ozguven, MA | 1 |
| Abolmaali, ND; Abramyuk, AM; Tokalov, SV; Zophel, K | 1 |
| Larson, SM; Schwartz, LH; Zhao, B | 1 |
| Beaulieu, S; Boucher, L; Bourdeau, I; Cohade, C; Roy, FN | 1 |
| Conti, PS; Leahy, RM; Li, Q; Li, Z; Yu, X | 1 |
| Agrawal, A; Baghel, NS; Nair, N | 1 |
| Lucignani, G | 2 |
| Malinen, E; Olsen, DR; Søvik, A | 1 |
| Cheng, Z; De, A; Gambhir, SS; Hoerner, JK; Levi, J; Namavari, M; Syud, FA; Yaghoubi, SS; Zhang, R | 1 |
| Guevara, C; Klaeser, B; Krause, T; Mueller, MD; Schmid, RA; Wiskirchen, J | 1 |
| Ono, M | 1 |
| Fukushima, M; Inubushi, M; Kodama, H; Kojima, S; Maeda, Y; Nagai, Y; Nishizawa, S; Okada, H; Teramukai, S; Zhou, B | 1 |
| Aupee, O; Bonardel, G; Foehrenbach, H; Gontier, E; Le Garlantezec, P; Soret, M; Vedrine, L | 1 |
| Baur-Melnyk, A; Delorme, S | 1 |
| Bergström, M; Murphy, PS | 1 |
| Chen, Y; Sun, YY | 1 |
| Benjamin, R; Fitzgerald, TJ; Scheutze, S; Shankar, LK; Van den Abbeele, A; Yap, J | 1 |
| Dick, DW; Gambhir, SS; Goris, ML; Iagaru, A; Mittra, E; Quon, A; Yaghoubi, SS | 1 |
| Nicolai, E; Salvatore, M; Storto, G | 1 |
| Carneiro, MP; da Fonseca, LM; Domingues, RC; Gasparetto, EL; Lopes, FC | 1 |
| Bernstine, H; Groshar, D; Sopov, V; Sosna, J; Stern, D; Yefremov, N | 1 |
| Bergman, J; Hirvonen, J; Komar, G; Minn, H; Seppänen, M; Teräs, M; Vahlberg, T | 1 |
| Buck, AK; Dechow, T; Herrmann, K; Schwaiger, M; Shen, C; Wester, HJ | 1 |
| Bundschuh, RA; Dechow, T; Herrmann, K; Krause, BJ; Schwaiger, M | 1 |
| Allen-Auerbach, M; Weber, WA | 1 |
| Weber, WA | 3 |
| Boellaard, R | 1 |
| Endres, C; Hidalgo, M; Jacene, H; Jimeno, A; Laheru, D; Ma, WW; Messersmith, WA; Pomper, MG; Song, D; Vilardell, F; Wahl, R | 1 |
| Aboagye, EO; Contractor, KB | 1 |
| Jacene, H; Kasamon, Y; Lodge, MA; Wahl, RL | 1 |
| Antoch, G; Bockisch, A; Boy, C; Heusner, TA; Krause, BJ; Poeppel, TD | 1 |
| Cheong, SJ; Jeong, HJ; Kim, DW; Kim, EM; Kim, SL; Lee, CM; Lim, ST; Sohn, MH; Yim, CY | 1 |
| Cejka, D; Fritzer-Szekeres, M; Fueger, BJ; Fuereder, T; Kuntner, C; Langer, O; Mueller, M; Preusser, M; Strommer, S; Wacheck, V; Wanek, T; Werzowa, J; Zsebedics, M | 1 |
| Weckesser, M | 1 |
| Bradley, KM; Chowdhury, FU; Gleeson, FV; Sheerin, F | 1 |
| Chun, C; Hong, KY; Kim, CW; Kim, SY; Lee, SM; Song, SC; Yang, HK | 1 |
| Del Biondo, E; Knockaert, DD; Ruttens, D; Van Boxelaer, I; Vanderschueren, S; Wauters, E | 1 |
| Han, DL; Jiang, WR; Yu, JM | 1 |
| Ball, DW; Ben-Josef, E; Benson, AB; Cohen, SJ; Coleman, RE; Delbeke, D; Ho, M; Ilson, DH; Kalemkerian, GP; Lee, RJ; Loeffler, JS; Macapinlac, HA; Morgan, RJ; Podoloff, DA; Siegel, BA; Singhal, S; Tyler, DS; Wong, RJ | 1 |
| Lazar, MA; Seale, P | 1 |
| Fujii, R; Furui, Y; Mitsutake, N; Oku, S; Yasunaga, H | 1 |
| Hama, Y; Kita, T; Kosuda, S; Shinmoto, H; Soga, S; Watanabe, S; Yano, F | 1 |
| McCarville, MB | 1 |
| He, Y; Li, G; Liu, H; Peng, C; Qi, C; Qiao, Y; Wang, X; Xu, J; Zhang, S | 1 |
| Bai, CM; Meng, QL; Ning, XH; Wang, YZ | 1 |
| Blodgett, TM; Paidisetty, S | 1 |
| Fukuda, H; Goto, R; Inoue, K; Kinomura, S; Okada, K | 1 |
| Ahn, SH; Cheon, GJ; Choi, CW; Chun, KS; Kang, JH; Lee, TS; Lim, SM; Moon, BS | 1 |
| Chung, JK; Jang, SJ; Kang, KW; Lee, DS; Lee, JW; Lee, MC; Lee, SM; Paeng, JC | 1 |
| Hara, T; Higashi, T; Ishimori, T; Ishizu, K; Kawase, S; Kawashima, H; Matsumoto, K; Nakamoto, Y; Saga, T; Suga, T; Togashi, K | 1 |
| Endo, K; Higuchi, T; Horikoshi, H; Nasu, K; Ochiai, R; Oriuchi, N; Watanabe, Y | 1 |
| Baselli, G; De Bernardi, E; Faggiano, E; Gerundini, P; Zito, F | 1 |
| Kotzerke, J; Nestle, U | 1 |
| Ford, EC; Herman, J; Wahl, RL; Yorke, E | 1 |
| Bartenstein, P; Cyran, CC; Foerster, S; Hacker, M; Nikolaou, K; Reiser, MF; Rominger, A; Saam, T; Schmidt, M; Wolpers, S | 1 |
| Oyen, WJ; van der Graaf, WT | 1 |
| Behr, TM; Erdtmann, B; Gratz, S; Hahn, U; Kaiser, W; Kemke, B; Schilling, M; Schneider, B | 1 |
| Benard, F; Powe, JE; Wilson, DC; Worsley, DF | 1 |
| Baba, S; Chatzifotiadis, D; Goudarzi, B; Horton, KM; Jacene, HA; Kamel, I; Kowalski, J; Leboulleux, S; Macura, KJ; Teytelbaum, O; Tsai, HL; Wahl, RL | 1 |
| Bourre, JC; Vuillez, JP | 1 |
| Akpinar, AT; Alper, E; Aydin, N; Ozkol, HF; Ozkol, V; Topal, NB | 1 |
| Doyeux, K; Edet-Sanson, A; Gardin, I; Hapdey, S; Vauclin, S; Vera, P | 1 |
| Gauthier, H | 1 |
| Blumer, SL; Johnson, R; Katz, DS; Motroni, B; Ring, BN; Scalcione, LR; Yung, EY | 1 |
| de Geus-Oei, LF; Oyen, WJ; Visser, EP; Vriens, D | 2 |
| Arends, B; Baum, RP; Beyer, T; Bockisch, A; Boellaard, R; Chiti, A; Comans, EF; Delbeke, D; Hoekstra, CJ; Hoekstra, OS; Kotzerke, J; Krause, BJ; Lammertsma, AA; Lonsdale, MN; Marsden, PK; Mottaghy, FM; O'Doherty, MJ; Oyen, WJ; Paans, AM; Pruim, J; Schaefer-Prokop, C; Stroobants, SG; Tatsch, K; Verzijlbergen, FJ; Visser, EP; Weber, WA; Willemsen, AT; Zijlstra, JM | 1 |
| Laing, RE; Nair-Gill, E; Radu, CG; Witte, ON | 1 |
| Avisar, E; Goodwin, WJ; Moffat, FL; Molina, MA; Serafini, AN; Sfakianakis, GN | 1 |
| Abdel-Misih, S; Bahnson, EE; Hall, NC; Johnson, MA; Knopp, MV; Martin, EW; Mojzisik, CM; Murrey, DA; Povoski, SP; Sharif, S; Young, DC | 1 |
| Basu, S; Rao, R | 1 |
| Bailey, DL | 1 |
| Cheng, C; Hamabe, Y; Inoue, T; Minamimoto, R; Oka, T; Shimoda, M | 1 |
| Boerman, OC; Dijkgraaf, I | 1 |
| Brown, C; Dempsey, MF; Elliott, AT; Gillen, G | 1 |
| Alberto, R; Welling, MM | 1 |
| Jackson, A; Trigonis, I | 1 |
| Beato Tortajada, I; Bouché Babiloni, A; Conde Moreno, A; Ferrer Albiach, C; Francés Muñoz, A; Morillo Macías, V; Rodríguez Cordón, M; Sánchez Iglesias, A | 1 |
| Buvat, I; Doyeux, K; Gardin, I; Grotus, N; Hapdey, S; Stute, S; Tylski, P; Vanderlinden, B | 1 |
| Boerman, OC; Oyen, WJ; Visser, EP | 1 |
| Li, B; Xu, H; Zhai, G; Zhang, M | 1 |
| Allen-Auerbach, MS; Benz, MR; Czernin, J | 1 |
| Adduci, AJ; Harvin, HJ | 1 |
| Cheze le Rest, C; De Ruysscher, D; Dekker, A; Descourt, P; Hatt, M; Lambin, P; Oellers, M; Pradier, O; Visvikis, D | 1 |
| Smith, TA | 3 |
| Baba, S; Engles, JM; Honda, H; Jacene, HA; Wahl, RL | 1 |
| Gilbert, FJ; Harry, VN; Parkin, DE; Semple, SI | 1 |
| Chiu, JS; Lin, YF; Yu, FC | 1 |
| Amadori, D; De Giorgi, U | 1 |
| Bournazos, A; Datseris, I; Exarhos, D; Housianakou, I; Panagiotidis, E | 1 |
| Arita, H; Fujita, S; Futami, S; Kawai, K; Kiyohara, S; Nagamachi, S; Tamura, S; Wakamatsu, H | 1 |
| Chen, J; Gidding, M; Glaus, C; Laforest, R; Welch, MJ; Xia, Y; Yang, M; Zhang, Q | 1 |
| Haug, A; Reiser, MF; Rist, C; Schmidt, GP | 1 |
| Daisaki, H; Iinuma, T; Inoue, T; Moriyama, N; Murano, T; Shimada, N; Tateishi, U; Terauchi, T | 1 |
| Bartenstein, P; Becker, A; Cumming, P; Foerster, S; Greif, M; Hacker, M; Nikolaou, K; Reiser, MF; Rist, C; Rominger, A; Saam, T; Wolpers, S | 1 |
| Bol, A; Christian, N; De Bast, M; Deheneffe, S; Grégoire, V; Labar, D; Lee, JA | 1 |
| Larson, SM; Lucignani, G | 1 |
| Boerman, OC; Chang, CH; Disselhorst, JA; Eek, A; Franssen, G; Goldenberg, DM; Laverman, P; McBride, WJ; Oyen, WJ; Rossi, EA; Schoffelen, R; Sharkey, RM; van der Graaf, WT | 1 |
| Chen, X; Jacobson, O | 1 |
| Daisaki, H; Fukukita, H; Hayashi, M; Ikari, Y; Matsumoto, K; Senda, M; Suzuki, K; Terauchi, T | 1 |
| Barbee, DL; Jeraj, R; Kissick, MW; McCall, KC | 1 |
| Boellaard, R; Hoekstra, CJ; Hoekstra, OS; Hoetjes, NJ; Krak, NC; Lammertsma, AA; van Velden, FH | 1 |
| Aung, W; Furukawa, T; Hasegawa, S; Koizumi, M; Koshikawa-Yano, M; Saga, T; Sogawa, C; Sudo, H; Sugyo, A; Tsuji, AB | 1 |
| Bohndiek, SE; Brindle, KM | 1 |
| Manukova, VA; Panchkovskaia, EV; Rudas, MS; Sergienko, VB | 1 |
| Alavi, A; Saboury, B; Torigian, DA | 1 |
| Li, J; Liu, Y; Wang, JW; Xu, LM; Zhao, S | 1 |
| Chowdhury, FU; Goldstone, AR; Patel, CN; Scarsbrook, AF | 1 |
| Hara, T; Higashi, T; Ishizu, K; Nakamoto, Y; Nishizawa, H; Saga, T; Suga, T; Togashi, K | 1 |
| Israel, O; Keidar, Z; Rabkin, Z | 1 |
| Aerts, HJ; Lambin, P; Ruysscher, DD | 1 |
| Boellaard, R; Comans, EF; Hoekstra, OS; Rizvi, SN; van Tinteren, H | 1 |
| Gonen, M; Meirelles, GS; Strauss, HW | 1 |
| Choe, JG; Han, YM; Kim, YC; Park, EK | 1 |
| Chen, Z; Li, F; Li, X; Ouyang, Q; Yu, T | 1 |
| Amthauer, H; Franzius, C; Hahn, K; Henze, G; Juergens, H; Juergens, KU; Kluge, R; Pfluger, T; Stauss, J; Stoever, B | 1 |
| Adams, MC; Turkington, TG; Wilson, JM; Wong, TZ | 1 |
| Lawrence, J; Provenzale, J; Rohren, E | 1 |
| Endo, K; Hanaoka, H; Iida, Y; Ishioka, NS; Liang, JX; Watanabe, S | 1 |
| Haubner, R | 1 |
| Chiti, A; Grégoire, V; Kirienko, M | 1 |
| Gerke, O; Høilund-Carlsen, M; Høilund-Carlsen, PF; Nielsen, MJ; Petersen, H; Vach, W | 1 |
| Franzius, C | 1 |
| Aleksandersen, TB; Kristian, A; Malinen, E; Nilsen, LB; Olsen, DR; Qu, H; Ree, AH; Røe, K; Seierstad, T | 1 |
| Fuss, M | 1 |
| Galavis, PE; Hollensen, C; Jallow, N; Jeraj, R; Paliwal, B | 1 |
| Kim, BS; Kim, IJ; Kim, K; Kim, SJ; Nam, HY; Pak, K | 1 |
| Drappatz, J; Gerbaudo, VH; Horky, LL; Hsiao, EM; Weiss, SE | 1 |
| Hoekstra, OS; Quarles van Ufford, HM; Riphagen, II; Stroobants, SG; van Tinteren, H | 1 |
| Comans, EF; Hartemink, KJ; Muller, S; Petrousjka van den Tol, M; Smulders, YM | 1 |
| Coenen, HH; Elsinga, PH; Iwata, R; Kilbourn, MR; Pillai, MR; Rajan, MG; Wagner, HN; Zaknun, JJ | 1 |
| Anderson, H; Miles, K; Singh, N | 1 |
| Klarhöfer, M; Lenz, C; Scheffler, K; Sommer, G; Winter, L | 1 |
| Fukuda, H; Iinuma, T; Inoue, T; Ito, K; Iwata, H; Jinnouchi, S; Minamimoto, R; Murano, T; Nakashima, R; Nishizawa, S; Oguchi, K; Oku, S; Senda, M; Terauchi, T; Tsukamoto, E; Uno, K; Yoshida, T | 1 |
| Beer, AJ; Brix, G; Ganter, C; Herrmann, K; Lordick, F; Lorenzen, S; Metz, S; Nekolla, SG; Rummeny, EJ; Schwaiger, M; van Marwick, S; Wester, HJ | 1 |
| Aikawa, N; Fujii, H; Fukushi, M; Hanai, K; Kitamura, H; Moriya, E; Moriyama, N; Suzuki, T; Tsuda, K; Umeda, IO; Yamaguchi, M | 1 |
| Barr, RD; Marriott, C; Portwine, C | 1 |
| Hicks, RJ; Hofman, MS | 1 |
| Chaar, BT; Muzaffar, R; Nguyen, NC; Oliver, D; Osman, MM; Reimers, HJ; Walz, B | 1 |
| Fleming, IN; Gilbert, FJ; Marsden, PK | 1 |
| Mazin, SR; Nanduri, AS | 1 |
| Faasse, T; Shreve, P; Swanston, NM | 1 |
| Segall, GM | 1 |
| Fletcher, JW; Kinahan, PE | 1 |
| Blodgett, T | 1 |
| Rohren, EM | 1 |
| Kgomo, M; Maes, A; Pottel, H; Sathekge, M; Stolz, A; Van De Wiele, C | 1 |
| Apostolova, I; Brenner, W; Buchert, R; Carlsen, IC; Derlin, T; Opfer, R; Renisch, S | 1 |
| Brower, V | 2 |
| Kim, J; Visioni, A | 1 |
| Guleryuz, S; Manning, HC; Smith, RA | 1 |
| Boellaard, R; Cheebsumon, P; Hayes, W; Hoekstra, CJ; Hoekstra, OS; Hoetjes, NJ; Kloet, RW; Lammertsma, AA; Smit, EF; Velasquez, LM | 1 |
| Desandes, E; Djaballah, W; Fay, R; Grandpierre, S; Karcher, G; Mandry, D; Marie, PY; Meneroux, B; Netter, F; Wahl, D | 1 |
| De Geus-Oei, LF; Krabbe, PF; Oyen, WJ; Van Der Heijden, HF; Van Laarhoven, HW; Visser, EP; Vriens, D | 1 |
| Alavi, A; Ambrosini, V; Basu, S; Kwee, TC; Saboury, B; Torigian, DA | 1 |
| Badawi, RD; Graham, MM; Wahl, RL | 1 |
| Bergmann, H; Dobrozemsky, G; Dudczak, R; Georg, D; Hirtl, A; Kletter, K; Knäusl, B | 1 |
| D'souza, MM; D'souza, PV; Jaimini, A; Mondal, A; Sharma, R; Singh, D; Tripathi, M | 1 |
| Biswal, S; Do, BH; Mari, C; Quon, A; Rosenberg, J; Tseng, JR | 1 |
| Estrada-Lobato, E; Medina, LA; Pérez-López, B; Pérez-Molina, JJ; Torres-Mendoza, BM; Vega-González, IF | 1 |
| Cheng, C; Dimitrakopoulou-Strauss, A; Haberkorn, U; Pan, L; Strauss, LG | 1 |
| El Fakhri, G; Karp, JS; Scheuermann, J; Surti, S; Trott, CM | 1 |
| de Geus-Oei, LF; Oyen, WJ; Quak, E; van de Luijtgaarden, AC; van der Graaf, WT | 1 |
| Chowdhury, FU; Culverwell, AD; Scarsbrook, AF | 1 |
| Ford, E; Herman, JM; Wahl, RL | 1 |
| Bentzen, SM; Gregoire, V | 1 |
| Lee, D; Shim, H; Zhu, A | 1 |
| Fujita, S; Futami, S; Kiyohara, S; Nagamachi, S; Nishii, R; Tamura, S; Wakamatsu, H | 1 |
| Bacharach, SL; Buvat, I; Carrasquillo, JA; Carson, JM; Hapdey, S; Whatley, M | 1 |
| Green, MM; Price, PM | 1 |
| Bhargava, P; Rahman, S; Wendt, J | 1 |
| Alberini, JL; Bellet, D; Champion, L; Edeline, V; Giraudet, AL; Madar, O; Paulmier, B; Pecking, AP; Poinsignon, A | 1 |
| Gao, Q; Han, D; Liu, K; Liu, Z; Ma, X; Qin, C; Tian, J; Wang, F; Yang, X; Zhang, B; Zhu, S | 1 |
| Bertagna, F; Giubbini, R | 1 |
| Chakraborty, RK; Hossain, GA; Islam, MM; Khan, N; Mahmood, S | 1 |
| Carpenter, CM; Cheng, Z; Gambhir, SS; Liu, H; Pratx, G; Sun, C; Xing, L | 1 |
| Efferth, T; Langguth, P | 1 |
| Fukuda, H | 1 |
| Liu, Y | 1 |
| Bleeker-Rovers, CP; Oyen, WJ; van der Graaf, WT; Vos, FJ | 1 |
| Alessio, AM; Manchanda, V; Mohr, BC; Parisi, MT; Phillips, GS; Sammer, M | 1 |
| Caponigro, F; Ciarmiello, A; Milano, A; Perri, F | 1 |
| Hawkins, RA; Kumar, R; Wang, ZJ; Yeh, BM | 1 |
| Fukuda, H; Iinuma, T; Inoue, T; Ito, K; Iwata, H; Jinnouchi, S; Kawamoto, M; Minamimoto, R; Murano, T; Nakashima, R; Nishizawa, S; Oguchi, K; Oku, S; Senda, M; Terauchi, T; Tsukamoto, E; Uno, K; Yoshida, T | 1 |
| Cafagna, D; Iuele, F; Lasciarrea, M; Maggialetti, A; Maggialetti, N; Niccoli-Asabella, A; Notaristefano, A; Palmiotti, G; Pinto, D; Rubini, G | 1 |
| Kajander, S; Kemppainen, J; Minn, H; Seppänen, M | 1 |
| de Geus-Oei, LF; Disselhorst, JA; Oyen, WJ; Visser, EP; Vriens, D | 2 |
| Cooley, T; Davison, JM; Mercier, G; Peller, PJ; Subramaniam, RM; Surasi, DS | 1 |
| Choi, JJ; Jeong, SH; Kang, BJ; Kim, SH; Lee, JH; Yim, HW; Yoo, IeR | 1 |
| Abdul Razak, HR; Ackerly, T; Geso, M; Martin, R; Nordin, AJ; Van Every, B | 1 |
| Gupta, A; Jeph, S; Karunanithi, S; Kumar, R; Malhotra, A; Naswa, N; Sharma, P | 1 |
| Heilbrun, M; Hoffman, JM; Kraiss, LW; Morton, KA; Pendleton, RC; Rondina, MT; Vinik, R; Wanner, N; Zimmerman, GA | 1 |
| Kudva, G; Muzaffar, R; Nguyen, NC; Osman, MM | 1 |
| Cameron, MJ; French, CA; Niederkohr, RD | 1 |
| Aschoff, P; Beyer, T; Bezrukov, I; Hofmann, M; Mantlik, F; Pichler, BJ; Schölkopf, B; Steinke, F | 1 |
| Chan, WL; Dura, R; Freund, J; Hickey, A; Pohlen, JM; Ramsay, SC; Szeto, ER; Tarlinton, LC; Young, A | 1 |
| Kaste, SC | 2 |
| Burris, HA; Dumez, H; English, PA; Fowst, C; Gerletti, P; Infante, JR; Jakubczak, JL; Jones, SF; Pierce, KJ; Schöffski, P; Van Mieghem, E; Xu, H | 1 |
| Boellaard, R; Cheebsumon, P; Hoekstra, OS; Lammertsma, AA; van Velden, FH; Yaqub, M | 1 |
| Baker, JA; Bashir, MR; Brown, KJ; Paulson, EK; Tyler, DS | 1 |
| Knudsen, LS; Loft, A; Nielsen, SD; Pedersen, TI; Roed, C; Skinhoj, P | 1 |
| Calabria, F; Cicciò, C; Danieli, R; Manenti, G; Schillaci, O; Simonetti, G; Squillaci, E; Strigari, L | 1 |
| Hatazawa, J | 1 |
| Larson, SM | 2 |
| Chengapa, A; Dick, DW; Gambhir, SS; Iagaru, A; Lin, FI; Mittra, ES; Nallapareddy, K; Rao, JE | 1 |
| Núñez Miller, R; Pozo, MA | 1 |
| Bahnson, EE; Chow, AZ; Gaglani, JR; Hall, NC; Hitchcock, CL; Knopp, MV; Kuhrt, MP; Martin, EW; Mojzisik, CM; Murrey, DA; Povoski, SP | 1 |
| Engelholm, SA; Hansen, AE; Kjær, A; Kristensen, AT; Law, I; McEvoy, FJ | 1 |
| Huo, J; Jin, Z; Lin, X; Pang, Y; Ren, J; Wang, X; Zhang, J; Zhang, W; Zhang, Y | 1 |
| Niederkohr, RD | 1 |
| Chen, TB; Chiu, NT; Hsu, CC; Huang, YC; Kuo, CY; Lee, BF; Li, SH; Wang, PW | 1 |
| Denisenko, AN; Kostenikov, NA; Maslennikova, AV; Orlova, AG; Prianikova, TI; Vinogradova, IuN | 1 |
| Cheng, D; Hnatowich, D; Liu, G; Liu, X; Liu, Y; Rusckowski, M; Wang, Y | 1 |
| Cho, A; Kang, WJ; Kim, J; Lee, JD; Lee, JH; Moon, HJ; Yun, M | 1 |
| Bal, C; Jeph, S; Kumar, R; Malhotra, A; Naswa, N; Patnecha, M; Reddy, RM; Sharma, P; Singh, H | 1 |
| De Zutter, A; Depicker, A; Goethals, I; Ham, H; Mertens, J; Smeets, P; Van de Wiele, C | 1 |
| Benz, MR; Buck, AK; Czernin, J; Herrmann, K; Krause, BJ; Pomykala, KL | 1 |
| Aboagye, EO; Alam, IS; Awais, RO; Brickute, D; Carroll, L; Nguyen, QD; Smith, G; Tomasi, G; Turton, DR; Twyman, FJ; Witney, TH | 1 |
| Al-Nahhas, A; de Geus-Oei, LF; Uebleis, C; Zerizer, I | 1 |
| Amin, A; Bockisch, A; Rosenbaum, SJ | 1 |
| Grigsby, PW; Yang, F | 2 |
| Bading, JR | 1 |
| Gao, M; Miller, KD; Sledge, GW; Wang, M; Zheng, QH | 1 |
| Bonabi, S; Broglie, MA; Haile, SR; Schmidt, F; Stoeckli, SJ | 1 |
| Balink, H; Hooisma, GA; Houtman, PM; Lensen, KD; Slart, RH | 1 |
| Marcus, DM; Shim, H; Shu, HK; Zhu, A | 1 |
| Bhang, HE; Pomper, MG | 1 |
| Basu, S; Mallath, MK | 1 |
| Kawanaka, K; Murakami, R; Nakaguchi, Y; Oya, N; Sakamoto, F; Shiraishi, S; Tashiro, K; Tomiguchi, S; Toya, R; Tsujita, N; Yamashita, Y; Yoshida, M | 1 |
| Bensinger, SJ; Christofk, HR | 1 |
| Hillman, BJ | 1 |
| Coleman, RE; Duan, F; Gareen, IF; Hanna, L; Hillner, BE; Quinn, B; Shields, AF; Siegel, BA | 1 |
| Burris, HA; Camidge, DR; Chen, EX; Fingert, H; Hicks, RJ; Infante, JR; Mileshkin, LR; Pierce, KJ; Rischin, D; Roberts, WG; Shreeve, SM; Siu, LL; Xu, H | 1 |
| Czarnywojtek, A; Czepczyński, R; Janicka-Jedyńska, M; Oleksa, R; Ruchała, M; Sowiński, J; Stangierski, A | 1 |
| Dadachova, E; Jaini, S | 1 |
| Boellaard, R; Boers, M; de Langen, AJ; Hoekstra, OS; Shankar, LK; Smit, EF; Stroobants, S; van Tinteren, H; Velasquez, LM; Vincent, A; Weber, WA | 1 |
| Capala, J; Kramer-Marek, G | 1 |
| Djurić-Stefanović, A; Grozdić, I; Milovanović, A; Obradović, V; Odalović, S; Pavlović, S; Petrasinović, Z; Petrović, M; Saranović, D; Sobić-Saranović, D | 1 |
| Ceelen, W; Debergh, I; Vanhove, C | 1 |
| Allenbach, G; Boubaker, A; Fitting, JW; Letovanec, I; Mihaescu, A; Nicod Lalonde, M; Prior, JO; Ris, HB; Schmidt, S; Stupp, R | 1 |
| Guy, SD; Hicks, RJ; Lau, E; Seymour, JF; Slavin, MA; Thursky, KA; Tramontana, AR; Worth, LJ | 1 |
| Behrendt, FF; Krohn, T; Kuhl, CK; Mottaghy, FM; Palmowski, M; Pietsch, H; Rebière, M; Verburg, FA | 1 |
| Allard, M; David, S; Fernandez, P; Hatt, M; Le Rest, CC; Quellec, G; Roux, C; Visvikis, D | 1 |
| Blake, MA; Boland, GW; Cronin, CG; Daniels, GH; Halpern, EF; Kalra, MK; Palmer, EL; Prakash, P | 1 |
| Chaudhry, MA; Lodge, MA; Wahl, RL | 1 |
| Bading, JR; Cherry, SR; Colcher, D; Conti, PS; Jacobs, RE; Ng, TS; Park, R; Procissi, D; Raubitschek, AA; Sohi, H | 1 |
| Blaufox, MD; Freeman, LM | 1 |
| Bal, C; Kumar, R; Malhotra, A; Naswa, N; Nazar, AH; Sharma, P; Soundararajan, R | 1 |
| Bartenstein, P; Becker, A; Graute, V; Greil, S; Hacker, M; Jansen, N; Klein, B; Lehner, S; Pfluger, T; Schmid, I; Sohn, HY | 1 |
| Beets-Tan, RG; Groenendaal, G; Houweling, AC; Lambin, P; van der Heide, UA | 1 |
| Fathinul, F; Lau, WF; Nordin, AJ | 1 |
| Hirsch, AE; Mercier, G; Shah, B; Srivastava, N; Subramaniam, RM | 1 |
| Doot, RK; Kinahan, PE; Kurland, BF; Linden, HM; Mankoff, DA; Muzi, M; O'Sullivan, F; Pierce, LA | 1 |
| Behrendt, FF; Krohn, T; Kuhl, CK; Mottaghy, FM; Palmowski, M; Pietsch, H; Prechtel, HW; Verburg, FA | 1 |
| Daisaki, H | 1 |
| Ding, CY; Li, JY; Liu, P; Qiu, HX; Xu, J; Zhang, LJ; Zhang, SJ | 1 |
| Domeki, Y; Kato, H; Kitajima, K; Matsuura, A; Murakami, K; Yamazaki, E | 1 |
| Goto, Y; Hirata, T; Ikeda, Y; Nokihara, H; Tamura, T; Tanioka, M; Yamada, K; Yamada, Y; Yamamoto, N | 1 |
| Catalano, P; Sadow, CA; Shinagare, AB; Shyn, PB; Wasser, EJ | 1 |
| Gore, JC; Yankeelov, TE | 1 |
| Allen-Auerbach, M; Bogsrud, TV; Czernin, J; Danielson, A; Kalkanis, D; Karantanis, D; Lowe, VJ; Subramaniam, RM | 1 |
| Albert, MH; Bartenstein, P; Coppenrath, E; Melzer, HI; Mueller, WP; Pfluger, T; Schmid, I | 1 |
| Czarny, B; Dubois, A; Ducongé, F; Garofalakis, A; Tavitian, B; Thézé, B | 1 |
| Cook, GJ | 3 |
| Appenzeller, P; Crook, DW; Kuhn, FP; Mader, CE; Schmid, DT; von Schulthess, GK | 1 |
| Baselli, G; Canzi, C; Casati, R; De Bernardi, E; Gerundini, P; Soffientini, C; Zito, F | 1 |
| He, ZY; Li, CY; Xu, GZ; Zhao, L | 1 |
| Becker, M; Gariani, J; Garibotto, V; Heinzer, S; Loubeyre, P; Lovblad, K; Ratib, O; Vallée, JP; Vargas, MI | 1 |
| Arens, AI; de Geus-Oei, LF; Hutchings, M; Oyen, WJ; Vriens, D | 1 |
| Miles, K; Singh, D | 1 |
| Dimitrakopoulou-Strauss, A; Pan, L; Strauss, LG | 1 |
| Aime, J; Dauer, LT; Holahan, B; Humm, J; Quinn, B; St Germain, J | 1 |
| Chicklore, S; Cook, GJ; Goh, V; Marsden, PK; Roy, A; Siddique, M | 1 |
| Brade, J; Büsing, K; Dinter, DJ; Hausmann, D; Sadick, M; Schoenberg, SO | 1 |
| Bogsrud, TV; Eilertsen, K; Evensen, JF; Glomset, OK; Løndalen, AM; Skretting, A | 1 |
| Kim, DU; Kim, H; Kim, IJ; Kim, K; Kim, SJ; Pak, K | 1 |
| Fukuda, H; Iinuma, T; Inoue, T; Iwata, H; Jinnouchi, S; Minamimoto, R; Murano, T; Nakashima, R; Nishizawa, S; Oguchi, K; Senda, M; Terauchi, T; Tsukamoto, E; Uno, K; Yoshida, T | 1 |
| Cerci, JJ; Krauzer, C; Pereira Neto, CC; Sakamoto, DG; Vitola, JV | 1 |
| Carlier, T; Chua, S; Gleeson, F; Hugonnet, F; Kraeber-Bodéré, F; Lumbroso, J; Naegelen, VM; Nagarajah, J; Shochat, E; Stokkel, M; Tessier, J; Trampal, C | 1 |
| Kruse, V; Maes, A; Sathekge, M; Smeets, P; Van de Wiele, C | 1 |
| Korn, RL; Weiss, GJ | 1 |
| Brade, J; Büsing, KA; Schönberg, SO; Wasser, K | 1 |
| Antoch, G; Beiderwellen, K; Bockisch, A; Buchbender, C; Forsting, M; Hartung-Knemeyer, V; Heusch, P; Heusner, TA; Kühl, H; Lanzman, RS; Wittsack, HJ | 1 |
| Büther, F; Eich, HT; Ernst, I; Hamill, J; Schäfers, KP; Schäfers, M; Schober, O | 1 |
| de Lima, JM; Dick, DW; Gambhir, SS; Iagaru, A; Isidoro, J; Iyer, V; Lapa, P; Mittra, E; Mosci, C; Prakash, V; Sathekge, M | 1 |
| Appelbaum, D; Chmura, SJ; Farrey, K; Salama, JK; Solanki, AA; Weichselbaum, RR; Yenice, KM | 1 |
| Andersen, FL; Beyer, T; Holm, S; Klausen, TL; Loft, A | 1 |
| Szablewski, L | 1 |
| Higashi, T; Senda, M; Yamamoto, S | 1 |
| Biermann, M; Fasmer, KE; Johnsen, B; Reitan, BC; Rosendahl, K; Schwarzlmüller, T | 1 |
| Khong, PL; Lee, EY | 1 |
| Al-Saeedi, FJ; Luqmani, YA; Mathew, PM | 1 |
| Chan, J; Charron, M; Costantini, DL; McQuattie, S; Vali, R | 1 |
| Agrawal, A; Kulkarni, AV; Kulkarni, SS; Purandare, NC; Rangarajan, V; Roy, D; Shah, S | 1 |
| Berman, CG; Chiappori, AA; Eikman, EA; Gatenby, RA; Gillies, RJ; Kim, J; Kumar, V; Nath, K; Tanvetyanon, T | 1 |
| Berrocal, I; Canessa, J; Castro, G; Gallegos, I; Jofré, MJ; Massardo, T; Sierralta, MP | 1 |
| Alavi, A; Cheng, G; Torigian, DA; Zhuang, H | 1 |
| Coumou, AW; Kairemo, K; Kostkiewicz, M; Pauwels, EK | 1 |
| Habibollahi, P; Kuruppu, D; Loda, M; Mahmood, U; van den Berg, NS | 1 |
| Beiderwellen, KJ; Bockisch, A; Buchbender, C; Hartung-Knemeyer, V; Kuehl, H; Lauenstein, TC; Poeppel, TD | 1 |
| Buck, A; Burger, C; Goerres, G; Lonn, AH; Schoenes, S; Von Schulthess, GK | 1 |
| Coleman, RE; Turkington, TG | 1 |
| Cabrera Villegas, A; Gámez Cenzano, C; García Velloso, MJ | 1 |
| Borrego Dorado, I; Vázquez Albertino, R | 1 |
| Gambhir, SS | 1 |
| Bar-Shalom, R; Engel, A; Frenkel, A; Gaitini, D; Guralnik, L; Israel, O; Keidar, Z; Kuten, A; Mor, M | 1 |
| Cohade, C; Kohlmyer, S; Links, JM; Marshall, LT; Nakamoto, Y; Osman, M; Wahl, RL | 1 |
| Jager, PL | 1 |
| Abbruzzese, JL; Baker, C; Bucana, C; Charnsangavej, C; Davis, DW; Ellis, LM; Herbst, RS; Hess, KR; Kim, HW; Madden, TL; McConkey, DJ; Mullani, NA; O'Reilly, MS; Pluda, J; Rashid, A; Roach, J; Tran, HT | 1 |
| Forte, KF; Purnell, GL; Walker, RC; Weiss, DW | 1 |
| Antoch, G; Bockisch, A; Debatin, JF; Egelhof, T; Freudenberg, LS; Jentzen, W; Stattaus, J | 1 |
| Agoston, P; Esik, O; Fekésházy, A; Galuska, L; Kálvin, B; Lengyel, E; Lengyel, Z; Szakáll, S; Székely, J; Trón, L | 1 |
| Comans, EF; Smit, EF | 1 |
| Dupont, P; Garmyn, M; Gysen, M; Hoe, LV; Mortelmans, L; Stas, M; Stroobants, S; Wever, ID | 1 |
| Beguin, Y; Fillet, G; Hustinx, R; Jerusalem, G | 2 |
| Buck, A; Goerres, GW; Hany, TF; Steinert, HC; von Schulthess, GK | 1 |
| Bacharach, SL; Sundaram, SK | 1 |
| Bomanji, J; Costa, DC; Ell, PJ; Gopalan, D; Griffiths, D; Prvulovich, E; Townsend, C | 1 |
| Devillé, W; Haslinghuis-Bajan, LM; Hoekstra, OS; Hooft, L; Mijnhout, GS; Teule, GJ; van Lingen, A; van Tulder, M | 1 |
| Antoch, G; Bockisch, A; Debatin, JF; Freudenberg, LS; Jentzen, W; Mueller, SP; Stattaus, J | 1 |
| Boerman, O; Dierckx, RA; Goethals, I; Lahorte, C; Oyen, W; Slegers, G; Van de Wiele, C | 1 |
| Standke, R | 1 |
| Czernin, J | 1 |
| Baumert, BG; Dizendorf, EV; Lütolf, UM; Steinert, HC; von Schulthess, GK | 1 |
| Hicks, RJ; Mac Manus, MP | 1 |
| Bingham, JB | 1 |
| Schwaiger, M | 1 |
| Maisey, MN | 1 |
| Bradley, JD; Chapman, JD; Eary, JF; Haubner, R; Larson, SM; Michalski, JM; Okunieff, PG; Strauss, HW; Ung, YC; Welch, MJ | 1 |
| Cohade, C; Leal, JP; Marshall, LT; Nakamoto, Y; Osman, MM; Wahl, RL | 1 |
| Ahonen, A; Kööbi, T; Minn, H | 1 |
| Buck, A; Buehler, TC; Burger, C; Goerres, GW; Kaim, AH; Kamel, E; Seifert, B; Von Schulthess, GK | 1 |
| Hamblen, SM; Lowe, VJ | 1 |
| Bomanji, J; Costa, DC; Croasdale, I; Ell, PJ; Gacinovic, S; Lonn, AH; Visvikis, D | 1 |
| Kaim, AH; von Schulthess, GK | 1 |
| Bomanji, J; Costa, DC; Crosdale, I; Ell, PJ; Lonn, A; Pigden, I; Prvulovich, E; Townsend, C; Visvikis, D | 1 |
| Adamson, KL; Bailey, DL | 1 |
| Aerts, J; Cataldo, D; Duysinx, B; Fassotte, MF; Foidart, J; Hustinx, R; Jerusalem, G; Lemaire, C; Luxen, A; Moreau, P | 1 |
| Ino, S; Kurami, M; Minosako, Y; Nemoto, M; Shirakami, Y | 1 |
| Itoh, M; Juengling, FD; Kubota, K; Kumano, H; Moser, E; Nitzsche, EU; Reinhardt, MJ; Sasaki, H; Tashiro, M; Yanai, K | 1 |
| Laking, GR; Price, PM | 1 |
| Franzius, C; Schober, O | 1 |
| Bourguet, P | 4 |
| Lomeña Caballero, FJ; Simó Perdigó, M | 1 |
| Aboagye, EO; Barthel, H; Brady, F; Cleij, MC; Collingridge, DR; He, Q; Hutchinson, OC; Luthra, SK; Osman, S; Price, PM | 1 |
| Hatazawa, J; Higuchi, I; Nakamura, H | 1 |
| Berner, U; Diehl, M; Döbert, N; Grünwald, F; Hamscho, N; Kaufmann, R; Kriener, S; Menzel, C; Rinne, D | 1 |
| Brioschi, M; Fazio, F; Gianolli, L; Gilardi, MC; Landoni, C; Lecchi, M; Picchio, M; Rossetti, C; Savi, A | 1 |
| Weiss, RA | 1 |
| Altman, H; Bar-Shalom, R; Frenkel, A; Gaitini, D; Guralnik, L; Israel, O; Keidar, Z; Kuten, A; Yefremov, N | 1 |
| Carreras, JL; Delgado-Bolton, RC; Fernández-Pérez, C; González-Maté, A | 1 |
| Blanc-Vincent, MP; Boneu, A; Bosquet, L; Bourguet, P; Chauffert, B; Corone, C; Courbon, F; Devillers, A; Foehrenbach, H; Lumbroso, JD; Mazselin, P; Montravers, F; Moretti, JL; Talbot, JN | 1 |
| Nakamoto, Y | 1 |
| Wagner, HN | 3 |
| Chen, GJ; Chen, YK; Liao, AC; Shen, YY; Su, CT; Tsai, FS | 1 |
| Buchmann, I; Gfrörer, W; Glatting, G; Kotzerke, J; Leithäuser, F; Möller, P; Reske, SN; Schulte, M; Schultheiss, S; Vogg, AT | 1 |
| Green, MA; Laforest, R; Lewis, JS; Lewis, MR; Low, PS; Mathias, CJ; Reichert, DE; Sharp, TL; Snyder, PW; Waters, DJ; Welch, MJ; Yang, ZF | 1 |
| Bossuyt, A; Caveliers, V; Everaert, H; Franken, PR; Lahoutte, T; Muylle, K; Vanhove, C | 1 |
| Alavi, A; Chiang, SB; Johnson, GR; Khan, J; Zhuang, H | 1 |
| Bai, C; Brasse, D; Charron, M; Comtat, C; Defrise, M; Kinahan, PE; Meltzer, CC; Townsend, DW; Villemagne, V | 1 |
| Ametamey, SM; Bode, B; Buck, A; Honer, M; Kaim, AH; Späth, N; Weber, B; Westera, G; Wyss, MT | 1 |
| Hata, M; Inoue, T; Kinbara, K; Koike, I; Lee, J; Ogino, I; Ohmura, M; Oka, T; Ozawa, Y; Takahashi, N; Umezawa, T; Watai, K | 1 |
| Dimitrakopoulou-Strauss, A; Haberkorn, U; Strauss, LG | 1 |
| Granov, AM; Kostenikov, NA; Ryzhkova, DV; Savello, VE; Stanzhevskiĭ, AA; Tiushin, LA; Tlostanova, MS | 1 |
| Antoch, G; Barkhausen, J; Bockisch, A; Dahmen, G; Debatin, JF; Freudenberg, LS; Goehde, SC; Nazaradeh, F; Ruehm, SG; Vogt, FM | 1 |
| Agress, H; Cooper, BZ | 1 |
| Boellaard, R; Comans, EF; Hoekstra, OS; Joshi, U; Miller, SD; Pijpers, RJ; Raijmakers, PG; Teule, GJ; van Lingen, A | 1 |
| Alavi, A; Kung, JW; Zhuang, H | 1 |
| Antoch, G; Beyer, T; Bockisch, A; Debatin, JF; Freudenberg, LS | 1 |
| Hahn, K; Pfluger, T | 1 |
| Antoch, G; Beyer, T; Debatin, JF; Goehde, SC; Hauth, E; Jentzen, W; Kanja, J; Kuehl, H; Lauenstein, TC; Schneemann, H | 1 |
| Czernin, J; Dahlbom, M; Halpern, BS; Ratib, O; Schiepers, C; Silverman, DH; Waldherr, C; Yap, CS | 1 |
| Inoue, T; Ishida, A; Kawano, T; Lee, J; Oka, T; Suzuki, A; Takahashi, N; Tayama, Y; Yokota, S | 1 |
| Diehl, M; Döbert, N; Grünwald, F; Hamscho, N; Menzel, C; Zaplatnikov, K | 1 |
| Aktolun, C; Baum, RP; Bishof-Delaloye, A; Bombardieri, E; Buscombe, J; Chatal, JF; Maffioli, L; Moncayo, R; Mortelmans, L; Reske, SN | 1 |
| Graham, M; Kubo, A; Nishitani, H; Otsuka, H | 2 |
| Cook, GJ; Fogelman, I; Wegner, EA | 1 |
| Bonardel, G; Edeline, V; Foehrenbach, H; Neuenschwander, S | 1 |
| Conrad, EU; Farwell, DG; Krohn, KA; Mankoff, DA; Muzi, M; O'Sullivan, F; Peterson, LM; Rajendran, JG; Schwartz, DL; Spence, AM | 1 |
| Chao, K; Erdi, YE; Gonen, M; Larson, SM; Schöder, H; Yeung, HW | 1 |
| Biswal, S; Deroose, C; Gambhir, SS; Min, JJ | 1 |
| Comtat, C; Kinahan, PE; Lartizien, C | 1 |
| Ho, CL | 1 |
| Carrasquillo, JA; Chen, CC; Ilias, I; Nieman, LK; Pacak, K; Whatley, M | 1 |
| Albert, A; Foidart, J; Hustinx, R; Paquet, N | 1 |
| Czernin, J; Dahlbom, M; Halpern, BS; Quon, A; Ratib, O; Schiepers, C; Silverman, DH; Waldherr, C | 1 |
| Anaissie, E; Atoui, R; Barlogie, B; Diaz, J; Mahfouz, T; Miceli, M; Mirza, N; Tricot, G; Walker, R | 1 |
| Herz, M; Kessler, H; Poethko, T; Reubi, JC; Schottelius, M; Schwaiger, M; Wester, HJ | 1 |
| Haioun, C; Itti, E; Meignan, M; Rahmouni, A; Reyes, F | 1 |
| Laking, G; Price, P | 1 |
| Boerdijk, SM; Paans, AM; Pruim, J; Willemsen, AT | 1 |
| Hallett, WA | 1 |
| Bombardieri, E; Lucignani, G; Paganelli, G | 1 |
| Bettinardi, V; Fazio, F; Gianolli, L; Gilardi, MC; Landoni, C; Messa, C; Pelosi, E; Picchio, M | 1 |
| Allard, M; Ducassou, D; Laffon, E; Marthan, R | 1 |
| Antoch, G; Bockisch, A; Ruehm, SG; Vogt, FM | 1 |
| Barnett, M; Candler, PM; Hart, PE; Rees, JH; Weil, R | 1 |
| Erasmus, JJ; Gladish, GW; Macapinlac, HA; Marom, EM; Munden, RF; Podoloff, DA; Sabloff, BS; Truong, MT | 1 |
| Gonen, M; Larson, SM; Pandit-Taskar, N; Schöder, H; Yeung, HW | 1 |
| Boerman, O; Corstens, F; de Geus-Oei, LF; Molthoff, C; Oyen, W; van Eerd-Vismale, J | 1 |
| Alavi, A; Kung, JW; Lakhani, P; Mavi, A; Zhuang, H | 1 |
| Shiue, CY; Welch, MJ | 1 |
| Canniff, KM; Donnelly, EF; Fleischer, AC; Hallahan, DE; Niermann, KJ; Rothenberg, ME; Yankeelov, TE | 1 |
| Antoch, G; Beyer, T; Bockisch, A; Dahmen, G; Debatin, JF; Freudenberg, LS; Kuehl, H; Mueller, SP; Saoudi, N | 1 |
| Brinkmann, M; Könemann, S; Schober, O; Weckesser, M; Willich, N | 1 |
| Becker, CR; Hahn, K; Helmberger, T; Herzog, P; Reiser, MF; Scher, B | 1 |
| Chatal, JF; Couturier, O; Hustinx, R | 1 |
| Bar-Shalom, R; Epelbaum, R; Gaitini, D; Guralnik, L; Hermoni, N; Israel, O; Keidar, Z; Mor, M | 1 |
| Buell, U; Reinartz, P; Schneider, W; Wieres, FJ | 1 |
| Harris, A; Jones, T; Price, P; Wells, P; West, C | 1 |
| Gregoire, V | 1 |
| Hoekstra, OS; Mijnhout, GS; Riphagen, II | 1 |
| Inoue, T; Kawano, T | 1 |
| Deniaud-Alexandre, E; Lerouge, D; Moureau-Zabotto, L; Touboul, E | 1 |
| Avril, NE; Weber, WA | 1 |
| Chan, WS; Chu, SK; Coel, M; Tam, YM; Vernon, P; Wong, S; Yau, YY | 1 |
| Dietl, B; Marienhagen, J | 1 |
| Dietlein, M; Eschner, W; Schicha, H; Schmidt, M; Theissen, P | 1 |
| Binns, DS; Cachin, F; Hicks, RJ; Lau, WF; Pitman, AG; Ramdave, S; Ware, RE | 1 |
| Namba, Y; Oku, N | 1 |
| Schober, O; Weckesser, M | 2 |
| Ide, M; Suzuki, Y | 1 |
| Carreras Delgado, JL; Romero de Avila Y Avalos, C; Ruiz Hernández, G | 1 |
| Dimitrakopoulou-Strauss, A; Kontaxakis, G; Pavlopoulos, S; Santos, A; Strauss, LG; Thireou, T | 1 |
| Bianco, JA; Fine, JP; Jaskowiak, CJ; Perlman, SB | 1 |
| Antoch, G; Beyer, T; Bockisch, A; Stattaus, J | 1 |
| Matsumoto, K; Minato, K; Sakamoto, S; Senda, M; Tarutani, K; Yamamoto, S | 1 |
| Kang, KW; Kim, SK; Lee, ES; Park, SY; Roh, JW; Sim, JS | 1 |
| Auerbach, MA; Czernin, J; Dahlbom, M; Fueger, BJ; Halpern, BS; Ratib, O; Schiepers, C; Silverman, DH; Weber, WA | 1 |
| Burgman, P; Burnazi, E; Cai, S; Finn, RD; Humm, JL; Lewis, JS; Ling, CC; O'Donoghue, JA; Pugachev, A; Ruan, S; Smith-Jones, P; Welch, MJ; Wen, B; Zanzonico, P | 1 |
| Cheng, EY; Cheson, BD; Guyton, KZ; Hoffman, JM; Johnson, B; Kelloff, GJ; Larson, SM; Mankoff, DA; O'shaughnessy, J; Scher, HI; Schilsky, RL; Shankar, L; Siegel, BA; Sigman, CC; Sullivan, DC | 1 |
| Imam, SK | 1 |
| Campa, J; Carlin, S; Humm, JL; Larson, SM; Ling, CC; Pugachev, A; Ruan, S | 1 |
| Kawashima, H; Matsumoto, K; Minota, E; Nakamoto, Y; Okada, T; Sakamoto, S; Senda, M | 1 |
| Andersen, F; Berthelsen, AK; Holm, S; Højgaard, L; Klausen, TL; Loft, A | 1 |
| Belhocine, TZ; Jerusalem, G | 1 |
| Delbeke, D; Martin, WH; Roman, CD | 1 |
| Krause, BJ; Rota Kops, E | 1 |
| Ide, M; Yasuda, S | 1 |
| Curtwright, LA; Gelfand, MJ; Maclean, JR; O'hara, SM | 1 |
| Boerman, OC; Corstens, FH; Kok, PJ; Oyen, WJ; van Eerd, JE | 1 |
| Chihara, H; Uozumi, H | 1 |
| Grosu, AL; Jeremic, B; Molls, M; Picchio, M; Piert, M; Schratzenstaller, U; Schwaiger, M; Weber, WA; Zimmermann, FB | 1 |
| Ell, PJ | 2 |
| Donald Blaufox, M; Isasi, CR; Khandani, AH | 1 |
| Bourguet, P; Brusco, S; Carretier, J; Corone, C; Delavigne, V; Devillers, A; Fervers, B; Foehrenbach, H; Leichtnam-Dugarin, L; Lumbroso, JD; Maszelin, P; Montravers, F; Moretti, JL; Philip, T; Rain, JD; Talbot, JN | 1 |
| Abouzied, MM; Crawford, ES; Nabi, HA | 1 |
| Bautz, W; Hornegger, J; Hothorn, T; Kuwert, T; Nömayr, A; Pfahlberg, A; Römer, W | 1 |
| Gutte, H; Højgaard, L; Kjaer, A | 1 |
| Cook, G; Sharma, B; Wechalekar, K | 1 |
| Baek, CH; Choi, JY; Kim, BT; Kwon, OJ; Lee, KH; Lee, KS; Park, K; Shim, YM | 1 |
| Fujino, K; Hatazawa, J; Higuchi, I; Kawamata, M; Kitamura, K; Murase, K; Nagayoshi, M; Nakamura, Y; Oku, N; Uenishi, Y | 1 |
| Carpentier, P; Kirova, J; Kolesnikov-Gauthier, H; Levy, E; Meignan, M; Merlet, P; Piedbois, P; Syrota, A | 1 |
| Belkacémi, Y; Comet, B; Kerrou, K; Lartigau, E; Tsoutsou, PG | 1 |
| Arveux, P; Bedenne, L; Bey, P; Bismuth, MJ; Conroy, T; Faivre, J; Guillemin, F; Lejeune, C; Zanni, C | 1 |
| Beer, AJ; Fischer, M; Lordick, F; Ott, K; Rummeny, EJ; Schwaiger, M; Siewer, JR; Weber, WA; Wieder, HA; Ziegler, S | 1 |
| Chauhan, A; Kumar, R; Nadig, MR | 1 |
| de Korte, MA; de Vries, EG; Jager, PL; Koopmans, KP; Lub-de Hooge, MN; Perik, PJ; van Waarde, A | 1 |
| Avram, AM; Brown, RK; Francis, IR | 1 |
| Antoch, G; Bockisch, A; Lind, T; Rosenbaum, SJ | 1 |
| Badawi, RD; Dibos, PE; Gilbert, R; Line, BR; Lodge, MA | 1 |
| Herrmann, T | 1 |
| Czernin, J; Herschman, HR; Weber, WA | 1 |
| Cheson, BD; Juweid, ME | 1 |
| Price, P | 6 |
| Dehdashti, F; Siegel, BA | 1 |
| Kim, CK; Kim, S; Krynyckyi, BR; Machac, J | 1 |
| Aschoff, P; Bares, R; Beyer, T; Brechtel, K; Claussen, CD; Eschmann, SM; Klein, M; Mueller, M; Pfannenberg, AC; Vogel, M | 1 |
| Akpinar, AT | 1 |
| Haug, AR; Reiser, MF; Schmidt, GP; Schoenberg, SO | 1 |
| Christensen, CR; Clark, PB; Morton, KA | 1 |
| Levy, RP | 1 |
| Ide, M | 1 |
| Allouache, N; Andrieux, A; Bardet, S; Chajari, MH; Delozier, T; Gervais, R; Henry-Amar, M; Jacob, JH; Laurençon, V; Switsers, O | 1 |
| Baumert, BG; Bosmans, G; De Ruysscher, D; Gregoire, V; Lambin, P; Stroobants, S; van Baardwijk, A; van Kroonenburgh, M | 1 |
| Berard, V; Lecomte, R; van Lier, JE | 1 |
| Belhocine, T; Bourgeois, D; Bourgeois, P; Castaigne, C; Dierickx, L; Dusart, M; Flamen, P; Muylle, K; Spaepen, K | 1 |
| Beer, AJ; Goebel, M; Grosu, AL; Haubner, R; Luderschmidt, S; Martinez, MJ; Niemeyer, M; Schwaiger, M; Weber, WA; Wester, HJ; Wolf, I | 1 |
| Berland, LL; Brown, ML; Coleman, RE; Cronin, V; Delbeke, D; Guiberteau, MJ; Holbrook, S; Hubner, K; Kachelriess, M; Parker, JA; Royal, HD; Siegel, BA; Stabin, MG; Townsend, DW; Zubal, G | 1 |
| Meyer, MA | 1 |
| Gelfand, MJ | 1 |
| Amanuma, M; Endo, K; Ida, I; Kumano, H; Matsuda, H; Mikuni, M; Oriuchi, N; Oshima, A; Takahashi, K; Yuuki, N | 1 |
| Weber, WA; Wieder, H | 1 |
| Deisenhofer, S; Reske, SN | 1 |
| Belohlávek, O | 1 |
| Bacharach, SL; Carson, J; Chan, LW; English, S; Green, MV; Hapdey, S; Krishna, MC; Mitchell, JB; Seidel, J; Sowers, AL | 1 |
| Larson, SM; Schwartz, LH | 1 |
| Corstens, FH; de Geus-Oei, LF; Koenders, EB; Krabbe, PF; Oyen, WJ; Pruim, J; van Hoorn, BA; Visser, EP; Willemsen, AT | 1 |
| Bacharach, S; Graham, MM; Hoffman, JM; Karp, J; Lammertsma, AA; Larson, S; Mankoff, DA; Shankar, LK; Siegel, BA; Sullivan, D; Van den Abbeele, A; Yap, J | 1 |
| Giaccone, G; Hoekstra, CJ; Hoekstra, OS; Lammertsma, AA | 1 |
| Gwyther, SJ | 1 |
| Al-Nahhas, A; Al-Sayed, Y; Khan, S; Singh, A; Win, Z | 1 |
| Charnley, N; Price, P; Saleem, A | 1 |
| Divgi, C | 1 |
| Beaulieu, CF; Gambhir, SS; Napel, S; Quon, A | 1 |
| Bentourkia, M; Bérard, V; Cadorette, J; Hubert, L; Lecomte, R; Rousseau, JA; van Lier, JE | 1 |
| Ametamey, SM; Bettio, A; Brühlmeier, M; Groehn, V; Honer, M; Müller, C; Müller, U; Schibli, R; Schubiger, AP | 1 |
| Deng, WP; Gelovani, JG; Hwang, JJ; Lin, M; Liu, RS; Wang, HE; Wei, HJ; Yu, HM | 1 |
| Rosen, M; Schnall, M | 1 |
| Barentsz, J; De Mulder, P; Mali, W; Mus, R; Oudkerk, M; Oyen, W; Reznek, R; Takahashi, S | 1 |
| Basu, S; Nair, N | 1 |
| Hanafusa, K | 1 |
| Daghighian, F; Essner, R; Gulec, SA | 1 |
| Burger, C; Ciernik, IF; Davis, JB; Huser, M; Reiner, B; Székely, G | 1 |
| Duerk, JL; Fei, B; Feyes, DK; Flask, C; Muzic, RF; Oleinick, NL; Wang, H; Wilson, DL | 1 |
| Al-Nahhas, A; Fanti, S; Nanni, C; Rubello, D | 1 |
| Endo, K; Hanaoka, H; Higuchi, T; Iida, Y; Ishikita, T; Koyama, K; Miyakubo, M; Oriuchi, N | 1 |
| de Vries, EG; Elsinga, PH; Jager, PL; Kema, IP; Koopmans, KP; Neels, OC; Sluiter, WJ; van der Horst-Schrivers, AN | 1 |
| Oyen, WJ; van Dalen, JA; Vogel, WV | 1 |
| Bléry, M | 1 |
| Cailleux, N; Grahek, D; Gutman, F; Kerrou, K; Montravers, F; Talbot, JN | 1 |
| Al-Nahhas, A; Castellucci, P; Fanti, S; Farsad, M; Franchi, R; Gross, MD; Nanni, C; Rampin, L; Rubello, D | 1 |
| Blasberg, R; Humm, J; Ling, C; Serganova, I | 1 |
| Fukuchi, K; Ishida, Y; Matsumura, K; Ohta, H | 1 |
| Bar-Sever, Z; Bar-Shalom, R; Ben Arush, MW; Ben-Barak, A; Guralnik, L; Israel, O; Keidar, Z; Postovsky, S | 1 |
| Ebi, H; Kawada, K; Kojima, Y; Minami, H; Mukai, H; Murakami, K; Sato, T; Shimokata, K; Tahara, M | 1 |
| Alavi, A; Basu, S | 3 |
| Biehl, KJ; Bradley, JD; Dehdashti, F; El Naqa, I; Jin, JY; Kong, FM; Mutic, S; Siegel, BA | 1 |
| Kaanders, JH; Oyen, WJ; Schinagl, DA | 1 |
| Hicks, RJ; Lau, EW; Ware, RE | 1 |
| Balkay, L; Friedlander, E; Krasznai, Z; Márián, T; Németh, E; Szabó, A; Szabó-Péli, J; Trón, L; Veress, G | 1 |
| Binns, DS; Drummond, E; Hicks, RJ; Hogg, A; Hong, E; Lau, EW; Rischin, D; Shakher, R; Wang, G; Ware, RE | 1 |
| Al-Nahhas, A; Canelo, R; Habib, N; Jiao, L; Pagou, M; Szyszko, T; Tait, P; Wasan, H | 1 |
| Lin, EC | 1 |
| Cachin, F; Kelly, A; Maublant, J | 1 |
| Chung, SK; Kim, SH; O, JH; Sohn, HS; Yoo, IeR | 1 |
| Israel, O; Kuten, A | 1 |
| Figlin, R; Weber, WA | 1 |
| Geets, X; Grégoire, V; Haustermans, K; Lonneux, M; Roels, S | 1 |
| Allen-Auerbach, M; Czernin, J; Schelbert, HR | 1 |
| Grégoire, V; Hoffmann, AL; Kaanders, JH; Lee, J; Oyen, WJ; van Dalen, JA | 1 |
| Bomanji, JB; Ell, PJ; Gacinovic, S; Lai, P; Lee, SM; Mahmood, S; Nagabhushan, N; Syed, R | 1 |
| Gulec, SA | 2 |
| Jacobsson, H; Larsson, SA; Söderlund, V | 1 |
| Belkacémi, Y; Carpentier, P; Giraud, P; Kerrou, K; Lartigau, E; Taïeb, S | 1 |
| Bautz, W; Hornegger, J; Hothorn, T; Kuwert, T; Nömayr, A; Römer, W; Wolz, G | 1 |
| Ito, K; Kubota, K; Yukihiro, M | 1 |
| Aschoff, P; Bares, R; Brechtel, K; Claussen, CD; Eschmann, SM; Klein, M; Müller, M; Pfannenberg, AC | 1 |
| Kitagawa, M; Kobayashi, H; Ochiai, R; Omagari, J; Ono, K; Yamashita, Y; Yoshida, T | 1 |
| Carey, BP; Coleman, RE; Hillner, BE; Lindsay, MJ; Shields, AF; Siegel, BA; Tunis, SR | 1 |
| Bergmann, R; Haase, C; Kampfrath, T; Mäding, P; Oswald, J; Pietzsch, J; Schwenzer, B; Treite, F | 1 |
| Aquino, SL; Blake, MA; Fischman, AJ; Lee, SI; Miller, JC; Thrall, JH | 1 |
| Chen, SQ; Yu, JM | 1 |
| Hoskin, PJ; Saunders, MI; Wood, KA | 1 |
| Gerbaudo, VH; Jager, V; Mollerach, AM; Parysow, O; Racioppi, S; San Roman, J | 1 |
| Mahajan, P; Wong, CY; Yan, D | 1 |
| Agrawal, A; Jaiswar, R; Nair, N | 1 |
| Canessa, J; González, P; Humeres, P; Jofré, MJ; Massardo, T; Sierralta, P; Valdebenito, R | 1 |
| Advani, RH; Allred, C; Benson, AB; Brown, E; Burstein, HJ; Carlson, RW; Coleman, RE; Czuczman, MS; Delbeke, D; Edge, SB; Ettinger, DS; Grannis, FW; Hillner, BE; Hoffman, JM; Kiel, K; Komaki, R; Larson, SM; Mankoff, DA; Podoloff, DA; Rosenzweig, KE; Skibber, JM; Yahalom, J; Yu, JM; Zelenetz, AD | 1 |
| Gulec, SA; Hoenie, E; Hostetter, R; Schwartzentruber, D | 1 |
| Iagaru, A; Quon, A | 1 |
| Eary, JF; Krohn, KA; Link, JM; Mankoff, DA; Muzi, M; Rajendran, JG; Spence, AM | 1 |
| Adachi, I; Aga, F; Akagi, H; Komori, T; Matsuki, M; Matsumura, K; Narabayashi, I; Ogura, Y | 1 |
| Airley, RE; Mobasheri, A | 1 |
| Fukushima, M; Hara, A; Kojima, S; Kosaka, N; Matsuo, Y; Suzuki, H; Suzuki, T; Teramukai, S; Torigoe, S; Uno, K; Zhou, B | 1 |
| Boddington, SE; Coakley, FV; Franc, BL; Hawkins, RA; Purcell, DD; Yeh, BM | 1 |
| Carey, J; Clinthorne, N; Piert, M | 1 |
| Boy, C; Buell, U; Gagel, B; Kaiser, HJ; Krohn, T; Schaefer, WM; Zimny, M | 1 |
| Inoue, T; Kawamoto, M; Lee, J; Nakamoto, Y; Okumura, Y; Sato, T; Senda, M; Suzuki, A; Suzuki, Y; Takahashi, N; Terauchi, T; Uno, K | 1 |
| Mercer, JR | 1 |
| Connolly, LP; Fahey, FH; Jadvar, H; Shulkin, BL | 1 |
| Ashikaga, H; Hinohara, S; Kawada, S; Koide, S; Ono, Y; Suzuki, Y | 1 |
| Ell, PJ; Groves, AM; Haim, SB; Win, T | 1 |
| Morita, N; Nishitani, H; Otsuka, H; Yamashita, K | 1 |
| Baig, S; Begent, RH; Francis, RJ; Green, AJ | 1 |
| Asensio-del-Barrio, C; Rodríguez-Garrido, M | 1 |
| Kontaxakis, G; Pavlopoulos, S; Santos, A; Thireou, T | 1 |
| Matsumoto, K; Murase, K; Nakamoto, Y; Sakamoto, S; Senda, M | 1 |
| Vallabhajosula, S | 1 |
| Collins, CD | 1 |
| Benamor, M; Brisse, H; Moulin-Romsee, G; Neuenschwander, S; Ollivier, L; Servois, V | 1 |
| Even-Sapir, E; Lerman, H; Metser, U; Miller, E | 1 |
| Hindie, E; Moretti, JL; Vercellino, L | 1 |
| Hallett, WA; Maguire, RP; McCarthy, TJ; Schmidt, ME; Young, H | 1 |
| Bai, J; Eberl, S; Feng, DD; Jia, R; Wen, L | 1 |
| Badawi, RD; El Fakhri, G; Holdsworth, CH; Kijewski, MF; Santos, PA; Van Den Abbeele, AD | 1 |
| Michael, R | 1 |
| Linke, R; Voltz, R | 1 |
| Könemann, S; Weckesser, M | 1 |
| Bundgaard, T; Buus, S; Grau, C; Hansen, HS; Johansen, J; Keiding, S; Kirkegaard, J; Loft, A; Overgaard, J; Overgaard, M | 1 |
| Gao, N; Kurtoglu, M; Lampidis, TJ; Lane, AN; Lehrman, MA; Maher, JC; Savaraj, N; Shang, J; Wangpaichitr, M | 1 |
| Fukuda, H; Iinuma, T; Inoue, T; Ito, K; Jinnouchi, S; Kawamoto, M; Minamimoto, R; Nakashima, R; Nishio, M; Nishizawa, S; Oguchi, K; Okuyama, C; Senda, M; Suzuki, Y; Terauchi, T; Tsukamoto, E; Uno, K; Yoshida, T | 2 |
| Miller, JH; Tatsumi, M; Wahl, RL | 1 |
| Beer, AJ; Herrmann, K; Lordick, F; Lorenzen, S; Metz, S; Peschel, C; Schwaiger, M; Watzlowik, P; Wester, HJ | 1 |
| Beyer, T; Bockisch, A; Delbeke, D; Kotzerke, J; Krause, BJ; Minkov, V; Reiser, M; Willich, N | 1 |
| Hofman, MS; O'Doherty, M | 1 |
| Chua, SC; Ganatra, RH; Pearson, D; Perkins, AC | 1 |
| Hustinx, R; Jerusalem, G; Rorive, A; Withofs, N | 1 |
| Avisar, E; Molina, M | 1 |
| Brindle, K | 1 |
| Azhdarinia, A; Chanda, M; Schechter, NR; Yang, DJ | 1 |
| Alavi, A; Basu, S; Dhanpathi, H; Fanti, S; Kumar, R; Rubello, D | 1 |
| Macapinlac, HA | 1 |
| Czernin, J; Grosu, AL; Weber, WA | 1 |
| Price, P; Rembielak, A | 1 |
| Avril, N; Coleman, RE; Delbeke, D; Djulbegovic, B; Einhorn, LH; Fletcher, JW; Gorman, M; Lowe, VJ; Lyman, GH; Paschold, JC; Samson, D; Shields, AF; Siegel, BA; Soares, HP; Suh, WW; Wahl, R | 1 |
| Fujii, T; Hayabuchi, N; Ishibashi, M; Kaida, H; Kurata, S; Ogo, E; Tanaka, M | 1 |
| Digianni, L; Diller, LR; Fraumeni, JF; Garber, JE; Li, FP; Masciari, S; Rastarhuyeva, I; Schneider, K; Syngal, S; Van den Abbeele, AD; Yap, J | 1 |
| Busk, M; Bussink, J; Horsman, MR; Kristjansen, PE; Overgaard, J; van der Kogel, AJ | 1 |
| Hicks, RJ; Macmanus, MP | 1 |
| Kolodny, GM; Williams, G | 1 |
| Carneiro, MP; Domingues, RC; Gadelha, MR; Madi, K; Moraes, AB; Neto, LV; Taboada, GF; Wildemberg, LE | 1 |
| Castell, F; Cook, GJ | 1 |
| Araki, K; Ebi, H; Kawada, K; Kim, YI; Kitagawa, K; Minami, H; Mukai, H; Nakajima, H; Nakajima, K; Tahara, M | 1 |
| Bashir, H; Nunan, TO; Shabo, G | 1 |
| Bacharach, SL; Carrasquillo, JA; Hadi, M; Libutti, SK; Rao, VK; Straus, SE; Wesley, R; Whatley, M | 1 |
| Carrasquillo, JA; Larson, SM | 1 |
| Ahonen, A; Illukka, T; Johansson, R; Kiuru, A; Nordman, E; Paul, R; Roeda, D; Söderström, KO; Solin, O; Talvio, T | 1 |
| Fukuda, H; Ido, T; Kiyosawa, M; Matsuzawa, T; Sato, T; Takahashi, T; Watanuki, S; Yoshioka, S | 1 |
| Fowler, JS; Som, P | 1 |
| Darcourt, J; Lagrange, JL; Maublant, J | 1 |
| Keyes, JW | 1 |
| Knapp, WH | 2 |
| Oberhausen, E; Schaefer, A | 1 |
| Gatenby, RA | 1 |
| Delbeke, D; Hendrix, B; Kessler, RM; Martin, WH; Ohana, I; Patton, JA; Sandler, MP; Weinfeld, Z | 1 |
| Lawson, MA | 1 |
| Ackermann, RJ; Cotton, L; Ficaro, EP; Macfarlane, DJ; Minn, H; Shreve, PD; Wahl, RL | 1 |
| Castle, VP; Dole, MG; Hernandez, RJ; Hutchinson, RJ; Koeppe, RA; Mitchell, DS; Prakash, D; Shulkin, BL; Ungar, DR | 1 |
| Boland, GW; Dixon, J; Goldberg, MA; Lee, MJ; Mayo-Smith, WW; McNicholas, MM; Mueller, PR | 1 |
| Leskinen-Kallio, S | 1 |
| Arimizu, N; Imaseki, K; Itami, J; Okada, J; Oonishi, H; Uno, K; Yoshikawa, K | 1 |
| Abbott, FD; Drane, WE; Kuperus, JH; Mastin, ST; Nicole, MW | 1 |
| Alavi, A; Chandramouli, B; Gupta, NC; Kim, CK | 1 |
| Aisen, AM; Cieslak, RD; Koeppe, RA; Meyer, CR; Quint, LE; Wahl, RL | 1 |
| Glaspy, JA; Hawkins, R; Hoh, CK; Phelps, ME | 1 |
| Alpert, NM; Fischman, AJ | 1 |
| Kubota, K; Kubota, R; Yamada, S | 1 |
| Delbeke, D; Martin, WH; Patton, JA; Sandler, MP | 3 |
| Jones, T; Price, P | 1 |
| Wahl, RL; Zasadny, KR | 1 |
| Kabelitz, D; Kremer, B; Lode, H; Meinertz, T; Sauerbruch, T; Sterry, W; Strauss, LG | 1 |
| Ide, M; Kobayashi, S; Mitomi, T; Shohtsu, A; Suzuki, Y; Takagi, S; Yasuda, S | 1 |
| Bender, H; Biersack, HJ; Kozak, B; Reichel, C; Ruhlmann, J; Schomburg, A; Sommer, T | 1 |
| Pauwels, EK; Van Wyngaarden, KE | 1 |
| Kubota, K | 2 |
| Strauss, LG | 2 |
| Endo, K; Matsuzaki, H; Sugiyama, S; Suzuki, Y; Tomiyoshi, K | 1 |
| Ohana, I; Patton, JA; Sandler, MP; Weinfeld, Z | 1 |
| Lamki, LM | 1 |
| Benoit, T; Bury, T; Foidart-Willems, J; Hustinx, R; Jerusalem, G; Kaschten, BJ; Paulus, P; Rigo, P | 1 |
| Bading, JR; Conti, PS; Grafton, ST; Hawley, K; Keppler, J; Lilien, DL | 1 |
| Raylman, RR; Wahl, RL | 1 |
| Ide, M; Shohtsu, A; Takagi, S; Yasuda, S | 1 |
| Ichiya, Y | 1 |
| Kusić, Z; Lacić, M; Maisey, MN | 1 |
| Brock, CS; Meikle, SR; Price, P | 1 |
| Deloar, HM; Fujiwara, T; Hayashi, Y; Itoh, M; Kanamaru, R; Miyake, M; Nakamura, T; Takahashi, H; Watabe, H; Yoshioka, T | 1 |
| Bellemann, ME; Haberkorn, U | 1 |
| Cronin, V; Galantowicz, P; Nabi, HA | 1 |
| Hawkins, RA; Hoh, CK | 1 |
| Avril, N; Bengel, FM; Laubenbacher, C; Schwaiger, M; Weber, W; Ziegler, SI | 1 |
| Lapela, M; Leskinen, S; Lindholm, P; Minn, H | 1 |
| Dehdashti, F; Flanagan, FL; Gordon, BA | 1 |
| Carreras Delgado, JL | 1 |
| Barrington, SF; Cook, GJ; Fogelman, I; Houston, S | 1 |
| Ali, A; Alibazoglu, H; Green, A; Hollinger, EF; Lamonica, G | 1 |
| Shulkin, BL | 1 |
| Horiuchi, M; Ide, M; Shohtsu, A; Yasuda, S | 1 |
| Tamaki, N | 1 |
| Hayashi, N; Ishii, Y; Nakaumra, S; Sadato, N; Takahashi, N; Tsuchida, T; Uematsu, H; Waki, A; Yonekura, Y | 1 |
| Rigo, P | 1 |
| Bourguignon, M; Mazière, B; McCready, VR; Pauwels, EK; Ribeiro, MJ; Stoot, JH | 1 |
| Brown, M; Dahlbom, MN; Dehdashti, F; Hoh, CK; Royal, HD; Schelbert, HR; Wahl, RL | 1 |
| Altehoefer, C; Hoegerle, S; Juengling, F; Moser, EA; Nitzsche, EU; Otte, A | 1 |
| Bakheet, SM; Powe, J | 1 |
| Fujibayashi, Y; Waki, A; Yokoyama, A | 1 |
| Chen, CC; Dilsizian, V; Ferrand, SK; Neumann, RD | 1 |
| Harkness, BA; Madsen, MT | 1 |
| Hoh, CK; Schiepers, C | 1 |
| Franzius, C; Schober, O; Sciuk, J | 1 |
| Artus, JC; Herry, JY; Lumbroso, J; Maublant, J; Muratet, JP; Talbot, JN; Vuillez, JP | 1 |
| Ketchum, LE | 1 |
| Bleckmann, C; Bohuslavizki, KH; Buchert, R; Clausen, M; Lorenzen, J; Mester, J; Schulte, U | 1 |
| Boren, EL; Delbeke, D; Patton, JA; Sandler, MP | 1 |
| Fujii, H; Ide, M; Kubo, A; Shohtsu, A; Takahashi, W; Yasuda, S | 2 |
| Godwin, HA; Zuger, JH | 1 |
| Bausart, R; Bol, A; Borbath, I; Coppens, A; Defrise, M; Lonneux, M; Michel, C; Pauwels, S; Sibomana, M | 1 |
| Büll, U; Cremerius, U; Kaiser, HJ; Reinartz, P; Sabri, O; Schreckenberger, M; Zimny, M | 1 |
| Fujii, H; Ide, M; Shohtsu, A; Takagi, S; Takahashi, W; Yasuda, S | 1 |
| Buell, U; Cremerius, U; Kaiser, HJ; Reinartz, P; Sabri, O; Schreckenberger, M; Zimny, M | 1 |
| Becherer, A; Kletter, K | 1 |
| Avril, N; Schwaiger, M; Weber, WA | 2 |
| Eary, JF | 1 |
| Harolds, JA | 1 |
| Delbeke, D | 1 |
| Damhaut, P; Dusart, M; Goldman, S; Lebeau de Hemricourt, E; Vanderhoeft, A; Wikler, D | 1 |
| Amano, S; Aoki, J; Aoyagi, K; Endo, K; Inoue, T; Kunio, M; Oriuchi, N; Sato, T; Suzuki, H; Tomaru, Y; Tomiyoshi, K | 1 |
| Hanauske, AR; Schwaiger, M; Thödtmann, R; Weber, WA; Ziegler, SI | 1 |
| Biersack, HJ; Oehr, P; Ruhlmann, J | 1 |
| Bacher-Stier, C; Donnemiller, E; Erler, H; Moncayo, R; Oberladstätter, M; Riccabona, G; Zaknun, J | 1 |
| Coleman, RE; Donnelly, LF; O'Hara, SM | 1 |
| Inoue, T | 1 |
| Wahl, RL | 1 |
| Bødrogi, I; Dóczi, T; Esik, O; Fekete, S; Galuska, L; Kálvin, B; Kásler, M; Kubinyi, K; Lengyel, Z; Losonczy, H; Nyáry, I; Rácz, K; Rosta, A; Szakáll, S; Szentirmay, Z; Sziklai, I; Trón, L; Vitéz, A | 1 |
| Dopff-Kaissling, A; Schraub, S | 1 |
| Adachi, I; Kato, T; Katoh, C; Kuge, Y; Mabuchi, M; Morita, K; Shiga, T; Suginami, Y; Takano, A; Tamaki, N; Tsukamoto, E; Yoshinaga, K | 1 |
| Baum, R; Cremerius, U; Herholz, K; Hoekstra, O; Lammertsma, AA; Price, P; Pruim, J; Young, H | 1 |
| Alavi, A; Bhatnagar, A; Hustinx, R | 1 |
| Morris, JG | 1 |
| Binns, DS; Fawcett, ME; Hicks, RJ; Kalff, V; McKenzie, AF; Peters, LJ; Ware, RE; Zalcberg, JP | 1 |
| Brenner, W; Czech, N; Henze, E; Kampen, WU | 1 |
| Amols, H; Fuks, Z; Humm, J; Koutcher, JA; Larson, S; Leibel, S; Ling, CC | 1 |
| Conti, PS; Keppler, J | 1 |
| Hoekstra, CJ; Hoekstra, OS; Lammertsma, AA; Paglianiti, I; Postmus, PE; Smit, EF; Teule, GJ | 1 |
| Fazio, F; Landoni, C; Valind, S; Wollmer, P | 1 |
| Bar-Shalom, R; Blaufox, MD; Valdivia, AY | 1 |
| Bischof Delaloye, A | 1 |
| Barbet, N; Buuren, IV; Capdeville, R; Choi, L; de Vries, EG; Dumez, H; Groen, HJ; Muskiet, F; Oosterom, AT; Paridaens, R; Seeghers, M; Uges, DR; van der Graaf, WT | 1 |
| Delbeke, D; Patton, JA; Sandler, MP | 1 |
| Beyer, T; Brun, T; Byars, L; Charron, M; Jerin, J; Kinahan, PE; Nutt, R; Roddy, R; Townsend, DW; Young, J | 1 |
| Brill, AB; Gifford, HC; Judy, PF; King, MA; Licho, R; Pretorius, PH; Schneider, PB; Seldin, DW; Simkin, PH; Wells, RG | 1 |
| Comans, EF; Golding, RP; Hoekman, K; Hoekstra, OS; Teule, GJ; van der Hoeven, JJ | 1 |
| Alyafei, S; Endo, K; Ichikawa, A; Inoue, T; Matsubara, K; Oriuchi, N; Tian, M; Zhang, H | 1 |
| Hubner, KF; Smith, GT; Thie, JA | 1 |
| Bombardieri, E; Cleton, FJ; Pauwels, EK; Stokkel, MP; Sturm, EJ | 1 |
| Ak, I; Pauwels, EK; Stokkel, MP | 1 |
| Anderson, H; Price, P | 1 |
| Soepenberg, O | 1 |
| Bender, H; Biersack, HJ; Grünwald, F; Guhlke, S; Oehr, P; Ruhlmann, J | 1 |
| Picard, JD | 1 |
| Beyer, T; Bohnen, NN; Charron, M; Dachille, M; Jerin, J; Kinahan, PE; Meltzer, CC; Nutt, R; Townsend, DW; Villemagne, V | 1 |
| Huang, SC | 1 |
| Coleman, RE | 2 |
| Fujii, H; Ide, M; Mochizuki, Y; Nakahara, T; Shohtsu, A; Takahashi, W; Yasuda, S | 1 |
| Delbeke, D; Sandler, MP | 1 |
| Bar-Shalom, R | 1 |
| Bellon, JR; Mankoff, DA | 1 |
| Cave, L | 1 |
| Cachin, F; Lumbroso, J; Maublant, J; Raoul, JL; Syrota, A; Vuillez, JP | 1 |
| Eary, JF; Krohn, KA | 1 |
| Carril Carril, JM | 1 |
| Brennan, MF | 1 |
| Silberstein, EB | 1 |
| Alyafei, S; Endo, K; Inoue, T; Oriuchi, N; Tian, M; Zhang, H | 1 |
| Coel, M; Druger, G; Ko, J; McGuigan, P; Morris, P; Tucker, R | 1 |
| Altehoefer, C; Brink, I; Hoegerle, S; Moser, E; Nitzsche, EU; Reinhardt, MJ | 1 |
| Pauwels, EK; Stokkel, MP; van der Hiel, B | 1 |
| Draisma, A; Pauwels, EK; Stokkel, MP | 1 |
| Franzius, C; Schober, O; Schürmann, G; Senninger, N; Twelker, L | 1 |
| Buell, U; Cremerius, U; Kaiser, HJ; Nowak, B; Sabri, O; Wildberger, J; Zimny, M | 1 |
| Buchheimer, N; Ehrenkaufer, RL; Huang, Y; Kuhner, R; Mach, RH; Morton, TE; Wallen, CA; Wang, L; Wheeler, KT; Wu, L | 1 |
| Alyafei, S; Aoki, J; Endo, K; Inoue, T; Koyama, K; Oriuchi, N; Suzuki, H; Takeuchi, K; Tomaru, Y; Tomiyoshi, K; Yuan, Z | 1 |
| Akaizawa, T; Fukuda, H; Itoh, M; Kubota, K; Ono, S; Ozaki, K; Tashiro, M; Yamada, K; Yamaguchi, K | 1 |
| Ak, I; Blokland, JA; Pauwels, EK; Stokkel, MP | 1 |
| Aoki, J; Endo, K; Ichikawa, A; Inoue, T; Koyama, K; Matsubara, K; Oriuchi, N; Sato, N; Suzuki, H; Tomiyoshi, K | 1 |
| Lammertsma, AA | 1 |
| Coleman, RE; Czernin, J; Gambhir, SS; Phelps, ME; Schwimmer, J; Silverman, DH | 1 |
| Sasaki, M | 1 |
| Alavi, A; Albelda, SM; Lambright, ES; Lanuti, M; Li, P; Mozley, PD; Pourdehnad, M; Rossman, MD; Yamamoto, AJ; Zhuang, H | 1 |
| Adam, LE; Alavi, A; Cortés-Blanco, A; Lee, JH; Loman, JC; Martínez-Lázaro, R; Pourdehnad, M; Rossman, MD; Yamamoto, AJ; Zhuang, HM | 1 |
| Delbeke, D; Martin, WH | 1 |
| Fink, U; Ott, K; Schwaiger, M; Siewert, JR; Weber, WA | 1 |
| Haberkorn, U | 1 |
| Chan, F; Chan, WL; Freund, J; McBride, B; Pocock, NA; Sorensen, BJ; Szeto, E | 1 |
| Büll, U; Osieka, R; Schober, O | 1 |
| Totsuka, T | 1 |
| Hayes, JC | 1 |
| Fujino, K; Hashikawa, K; Nishimura, T; Paul, AK; Tatsumi, M | 1 |
| Kotzerke, J; Reske, SN | 1 |
| Baumert, B; Dizendorf, E; Luetolf, UM; Steinert, HC; von Schulthess, GK | 1 |
| Meier, N; Stumpe, KD; von Schulthess, GK | 1 |
| Erdi, YE; Larson, SM; Macapinlac, HA; Sanches, A; Squire, OD; Yeung, HW | 1 |
| Czernin, J; Phelps, ME | 1 |
| Cabrera Villegas, A; Gámez Cenzano, C; García Velloso, MJ; Sopena Monforte, R | 1 |
| Alavi, A; Reivich, M | 1 |
| Alavi, A; Bénard, F; Hustinx, R | 1 |
| Cabrera Villegas, A; Gámez Cenzano, C; Martín Urreta, JC | 1 |
| Bomanji, JB; Costa, DC; Ell, PJ | 1 |
| Beggs, AD; Curran, KM; Hain, SF; O'Doherty, MJ | 1 |
| Endo, K; Inoue, T; Oriuchi, N; Tomiyoshi, K | 1 |
| Askienazy, S; Bok, B; Grall, Y; Meignan, M; Misset, JL; Rain, JD; Talbot, JN | 1 |
| Buck, A; Burger, C; Hany, TF; Kamel, E; Lonn, AH; Treyer, V; von Schulthess, GK | 1 |
| Endo, K; Higuchi, T; Oriuchi, N; Tanada, S; Tian, M; Zhang, H | 1 |
| Scott, AM | 1 |
| D'Asseler, Y; De Winter, F; Dierckx, R; Huglo, D; Van de Wiele, C; Vandenberghe, S; Vandenbossche, B | 1 |
| Agoston, P; Esik, O; Fekésházy, A; Galuska, L; Kálvin, B; Lengyel, E; Lengyel, Z; Szakáll, S; Székely, J; Trón, L; Várady, E | 1 |
| Giorgetti, A; Mariani, G; Volterrani, D | 1 |
| Minn, H; Paul, R | 1 |
| Wilson, CB | 1 |
| Dahlbom, M; Hawkins, RA; Hoffman, EJ; Hoh, CK; Phelps, ME; Rosenqvist, G; Schiepers, C | 1 |
| Choi, Y; Hawkins, RA; Hoh, CK; Huang, SC; Messa, C; Phelps, ME | 1 |
| Chen, B; Choi, Y; Dahlbom, M; Glaspy, J; Hawkins, RA; Hoh, C; Maddahi, J; Messa, C; Slamon, D; Tse, N | 1 |
| Fukumura, T; Ichiya, Y; Jingu, K; Kuwabara, Y; Masuda, K; Otsuka, M; Tahara, T; Yoshikai, T | 1 |
| Buchsbaum, DJ; Fisher, S; Grossman, HB; Hutchins, GD; Liebert, M; Wahl, RL | 1 |
| Conti, PS; Strauss, LG | 1 |
| Fukuda, H; Matsuzawa, T; Tateno, Y | 1 |
| Fukuda, H; Ido, T; Ito, M; Maeda, S; Matsuzawa, T; Takahashi, H; Wakui, A; Yamaguchi, K; Yang, PK | 1 |
| Miraldi, F | 1 |
| Johannsen, B | 1 |
| Ahonen, A; Haaparanta, M; Johansson, R; Paul, R; Roeda, D; Sipilä, H; Solin, O | 1 |
433 review(s) available for fluorodeoxyglucose f18 and Neoplasms
| Article | Year |
|---|---|
[
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Neoplasms, Second Primary; Positron-Emission Tomography; Radiologists; Radiopharmaceuticals; Spinal Cord | 2022 |
PET/CT Ultrasound Fusion for Percutaneous Biopsy: A Retrospective Single-Center Study and Review of the Literature.
Topics: Female; Fluorodeoxyglucose F18; Humans; Image-Guided Biopsy; Male; Neoplasms; Positron Emission Tomography Computed Tomography; Retrospective Studies | 2022 |
Evidence of Clinical Impact Supports a New Petition for Medicare Coverage of 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography in the Evaluation of Staphylococcus aureus Bacteremia: A Focused Literature Review and Call to Ac
Topics: Aged; Anti-Infective Agents; Bacteremia; Fluorodeoxyglucose F18; Glucose; Humans; Medicare; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Staphylococcal Infections; Staphylococcus aureus; United States | 2022 |
Role of Fluorodeoxyglucose-PET in Interventional Radiology.
Topics: Fluorodeoxyglucose F18; Humans; Inflammation; Neoplasms; Positron-Emission Tomography; Prospective Studies; Radiology, Interventional; Radiopharmaceuticals | 2022 |
F-18-FDG PET/CT findings of paraneoplastic dermatoses.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Skin Diseases; Tomography, X-Ray Computed | 2022 |
Topics: B7-H1 Antigen; Biomarkers, Tumor; Fluorodeoxyglucose F18; Humans; Immunotherapy; Molecular Imaging; Neoplasms; Positron Emission Tomography Computed Tomography; Tumor Microenvironment | 2022 |
Monitoring of Current Cancer Therapy by Positron Emission Tomography and Possible Role of Radiomics Assessment.
Topics: Fluorodeoxyglucose F18; Humans; Multimodal Imaging; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Reproducibility of Results; Tumor Microenvironment | 2022 |
Meta-Analysis of the Test-Retest Repeatability of [18F]-Fluorodeoxyglucose Standardized Uptake Values: Implications for Assessment of Tumor Response.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results | 2023 |
Imaging endpoints for clinical trial use: a RECIST perspective.
Topics: Clinical Trials as Topic; Fluorodeoxyglucose F18; Humans; Neoplasms; Response Evaluation Criteria in Solid Tumors | 2022 |
Four-dimensional quantitative analysis using FDG-PET in clinical oncology.
Topics: Fluorodeoxyglucose F18; Humans; Medical Oncology; Neoplasms; Pilot Projects; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals | 2023 |
Metabolic factors associated with the prognosis of oligometastatic patients treated with stereotactic body radiotherapy.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Prognosis; Radiosurgery | 2023 |
[18F]FDG-PET-Based Personalized Radiotherapy Dose Prescription.
Topics: Fluorodeoxyglucose F18; Glucose; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2023 |
[
Topics: Anal Canal; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity | 2023 |
Fluorodeoxyglucose-PET for Ablation Treatment Planning, Intraprocedural Monitoring, and Response.
Topics: Bone Neoplasms; Catheter Ablation; Female; Fluorodeoxyglucose F18; Humans; Image-Guided Biopsy; Liver Neoplasms; Male; Monitoring, Physiologic; Neoplasms; Patient Care Planning; Positron-Emission Tomography; Quality Improvement; Radiation Oncology; Radiology, Interventional | 2019 |
PSMA-Targeting Positron Emission Agents for Imaging Solid Tumors Other Than Non-Prostate Carcinoma: A Systematic Review.
Topics: Animals; Antigens, Surface; Diagnosis, Differential; Fluorodeoxyglucose F18; Glutamate Carboxypeptidase II; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2019 |
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Checklist; Clinical Protocols; Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Immunotherapy; Male; Middle Aged; Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Treatment Outcome | 2020 |
PET/Computed Tomography in Treatment Response Assessment in Cancer: An Overview with Emphasis on the Evolving Role in Response Evaluation to Immunotherapy and Radiation Therapy.
Topics: Female; Fiducial Markers; Fluorodeoxyglucose F18; Humans; Immunotherapy; Male; Neoplasms; Outcome Assessment, Health Care; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Sex Characteristics; Treatment Outcome | 2020 |
RESISTing the Need to Quantify: Putting Qualitative FDG-PET/CT Tumor Response Assessment Criteria into Daily Practice.
Topics: Animals; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Image Processing, Computer-Assisted; Lymphoma; Neoplasms; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals | 2019 |
Assessing PET Parameters in Oncologic
Topics: Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Neoplasms; Positron-Emission Tomography | 2020 |
Advances in Immuno-PET for the Detection of Cancer and Assessment of Response to Therapy.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radioisotopes; Zirconium | 2021 |
Imaging and Interventional Radiology for Cancer Management.
Topics: Contrast Media; Diagnostic Imaging; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Image-Guided Biopsy; Magnetic Resonance Imaging; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Radiology, Interventional; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography | 2020 |
Chemistry Considerations for the Clinical Translation of Oncology PET Radiopharmaceuticals.
Topics: Animals; Drug Development; Drug Discovery; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiation Oncology; Radiochemistry; Radiopharmaceuticals; Treatment Outcome | 2020 |
Benefits of positron emission tomography scans for the evaluation of radiotherapy.
Topics: Chemoradiotherapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms; Radiopharmaceuticals; Radiotherapy, Adjuvant; Rectal Neoplasms; Treatment Outcome; Uterine Cervical Neoplasms | 2020 |
Non-
Topics: Child; Congenital Hyperinsulinism; Diabetes Mellitus, Type 1; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Urologic Diseases | 2020 |
Methods to delineate tumour for radiotherapy by fluorodeoxyglucose positron emission tomography.
Topics: Algorithms; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2020 |
Diagnosis and treatment of limbic encephalitis in the cancer patient.
Topics: Anticonvulsants; Autoantibodies; Fluorodeoxyglucose F18; Humans; Limbic Encephalitis; Neoplasms; Positron Emission Tomography Computed Tomography; Seizures | 2020 |
FDG PET correlates weakly with HIF-1
Topics: Correlation of Data; Fluorodeoxyglucose F18; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2021 |
Non-FDG PET/CT.
Topics: Fluorodeoxyglucose F18; Humans; Medical Oncology; Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2020 |
FDG PET Hybrid Imaging.
Topics: Fluorodeoxyglucose F18; Humans; Multimodal Imaging; Neoplasm Staging; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals | 2020 |
Clinical PET/MR.
Topics: Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Multimodal Imaging; Neoplasm Staging; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography | 2020 |
Correlation between fluorodeoxyglucose hotspots on preradiotherapy PET/CT and areas of cancer local relapse: Systematic review of literature.
Topics: Anatomic Landmarks; Esophageal Neoplasms; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Neoplasms; Patient Positioning; Positron Emission Tomography Computed Tomography; Prospective Studies; Radiopharmaceuticals; Rectal Neoplasms; Retrospective Studies | 2020 |
Does nutrition for cancer patients feed the tumour? A clinical perspective.
Topics: Diet, Ketogenic; Energy Intake; Fluorodeoxyglucose F18; Humans; Neoplasms; Nutritional Status | 2020 |
Management of FDG avid Benign Sinonasal Schneiderian Papilloma: A Case Report and Review of the Literature.
Topics: Adenoma, Oxyphilic; Aged; Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Male; Maxillary Sinus Neoplasms; Nasal Mucosa; Neoplasms; Papilloma, Inverted; Positron Emission Tomography Computed Tomography; Preoperative Care; Radiopharmaceuticals | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses | 2021 |
FDG PET/CT for Assessment of Immune Therapy: Opportunities and Understanding Pitfalls.
Topics: Fluorodeoxyglucose F18; Humans; Immunotherapy; Neoplasms; Positron Emission Tomography Computed Tomography; Prognosis | 2020 |
Abdominal immune-related adverse events: detection on ultrasonography, CT, MRI and 18F-Fluorodeoxyglucose positron emission tomography.
Topics: Digestive System Diseases; Fluorodeoxyglucose F18; Humans; Immunotherapy; Magnetic Resonance Imaging; Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Ultrasonography | 2021 |
Value of
Topics: Female; Fluorodeoxyglucose F18; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Male; Neoplasms; Positron-Emission Tomography; Programmed Cell Death 1 Receptor | 2021 |
Spectrum of [
Topics: Animals; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2021 |
Critical Role of 2-[18F]-fluoro-2-deoxy-glucose in Hormonally Active Malignancies.
Topics: Fluorodeoxyglucose F18; Glucose; Humans; Neoplasms | 2021 |
Lessons from Cancer Metabolism for Pulmonary Arterial Hypertension and Fibrosis.
Topics: Animals; Citric Acid Cycle; Fibrosis; Fluorodeoxyglucose F18; Glycolysis; Humans; Metabolic Networks and Pathways; Neoplasms; Positron-Emission Tomography; Pulmonary Arterial Hypertension | 2021 |
The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers.
Topics: Antineoplastic Agents, Immunological; Artificial Intelligence; B7-H1 Antigen; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Humans; Immune Checkpoint Inhibitors; Immunotherapy, Adoptive; Killer Cells, Natural; Neoplasms; Positron-Emission Tomography; Programmed Cell Death 1 Receptor; Radiopharmaceuticals; Signal Transduction; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Tumor Microenvironment | 2021 |
Clinical Perspectives of Theranostics.
Topics: Animals; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron Emission Tomography Computed Tomography; Radioisotopes; Therapeutics | 2021 |
Coordination and optimization of FDG PET/CT and COVID-19 vaccination; Lessons learned in the early stages of mass vaccination.
Topics: COVID-19; COVID-19 Vaccines; Diagnosis, Differential; Disease Progression; Fluorodeoxyglucose F18; Humans; Lymphadenopathy; Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; SARS-CoV-2; Vaccination | 2021 |
PET/CT metabolic patterns in systemic immune activation: A new perspective on the assessment of immunotherapy response and efficacy.
Topics: Fluorodeoxyglucose F18; Humans; Immunity; Immunotherapy; Lymphocytes; Neoplasms; Positron Emission Tomography Computed Tomography; Treatment Outcome | 2021 |
PET/CT Normal Variants and Pitfalls in Pediatric Disorders.
Topics: Adult; Child; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals | 2021 |
Likely Common Role of Hypoxia in Driving
Topics: Fluorodeoxyglucose F18; Glucose; Humans; Hypoxia; Inflammation; Myocardial Ischemia; Neoplasms; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals | 2021 |
Immune PET Imaging.
Topics: Fluorodeoxyglucose F18; Humans; Immunotherapy; Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2021 |
Metformin and Cancer Glucose Metabolism: At the Bench or at the Bedside?
Topics: AMP-Activated Protein Kinases; Animals; Biomedical Research; Carbohydrate Dehydrogenases; Cell Proliferation; Cytosol; Endoplasmic Reticulum; Fluorodeoxyglucose F18; Glucose; Humans; Hypoglycemic Agents; Metformin; NADP; Neoplasms; Oxidative Phosphorylation; Pentose Phosphate Pathway; Phosphorylation; Positron Emission Tomography Computed Tomography; Reproducibility of Results | 2021 |
Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments.
Topics: Clinical Decision-Making; Clinical Trials as Topic; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Treatment Outcome | 2017 |
EDIM-TKTL1/Apo10 Blood Test: An Innate Immune System Based Liquid Biopsy for the Early Detection, Characterization and Targeted Treatment of Cancer.
Topics: Animals; Apoptosis; Biological Evolution; Biomarkers, Tumor; Biopsy; Blood Chemical Analysis; Early Detection of Cancer; Epitopes; Fluorodeoxyglucose F18; Humans; Immunity, Innate; Lactic Acid; Macrophages; Molecular Targeted Therapy; Monocytes; Neoplasms; Oxythiamine; Positron-Emission Tomography; Recurrence; Transcriptional Activation; Transketolase | 2017 |
Metabolic PET Imaging in Oncology.
Topics: Fluorodeoxyglucose F18; Humans; Medical Oncology; Molecular Imaging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2017 |
PET Molecular Imaging-Directed Biopsy: A Review.
Topics: Fluorodeoxyglucose F18; Humans; Image-Guided Biopsy; Molecular Imaging; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2017 |
Imaging Workup of Suspected Classical Paraneoplastic Neurological Syndromes: A Systematic Review and Retrospective Analysis of
Topics: False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Paraneoplastic Syndromes, Nervous System; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Whole Body Imaging | 2017 |
Benign Bone Conditions That May Be FDG-avid and Mimic Malignancy.
Topics: Bone Diseases; Bone Neoplasms; Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Tomography, X-Ray Computed | 2017 |
Benign Cutaneous and Subcutaneous Lesions on FDG-PET/CT.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed | 2017 |
Personalized & Precision Medicine in Cancer: A Theranostic Approach.
Topics: Edetic Acid; Estradiol; Fluorodeoxyglucose F18; Gallium Isotopes; Gallium Radioisotopes; Humans; Molecular Imaging; Neoplasms; Oligopeptides; Positron Emission Tomography Computed Tomography; Precision Medicine; Radiopharmaceuticals; Theranostic Nanomedicine; Tomography, Emission-Computed, Single-Photon | 2017 |
Exploring Metabolism In Vivo Using Endogenous
Topics: Carbon Radioisotopes; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiochemistry; Radiopharmaceuticals | 2017 |
[Response evaluation in nuclear medicine : Criteria, results and pitfalls].
Topics: Fluorodeoxyglucose F18; Humans; Immunologic Factors; Neoplasms; Nuclear Medicine; Positron-Emission Tomography; Protein Kinase Inhibitors; Treatment Outcome | 2017 |
Correlation of the apparent diffusion coefficient and the standardized uptake value in neoplastic lesions: a meta-analysis.
Topics: Biological Transport; Diffusion; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Reference Standards | 2017 |
What, where and why: exploring fluorodeoxyglucose-PET's ability to localise and differentiate infection from cancer.
Topics: Bacterial Infections; Contrast Media; Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography | 2017 |
FDG-PET/CT in the Postoperative Period: Utility, Expected Findings, Complications, and Pitfalls.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasm Recurrence, Local; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postoperative Period; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed | 2017 |
How to use PET/CT in the evaluation of response to radiotherapy.
Topics: Choline; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Multimodal Imaging; Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Treatment Outcome | 2018 |
The diagnostic performance of
Topics: Female; Fluorodeoxyglucose F18; Humans; Male; Methyltyrosines; Neoplasms; Positron-Emission Tomography; Sensitivity and Specificity | 2017 |
Comparison of the morphologic criteria (RECIST) and metabolic criteria (EORTC and PERCIST) in tumor response assessments: a pooled analysis.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Outcome Assessment, Health Care; Positron-Emission Tomography | 2019 |
PET imaging for assessing tumor response to therapy.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2018 |
[Gross tumor volume (GTV) : Basics, methods, registration, limitations].
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed; Tumor Burden | 2018 |
Imaging Cancer Metabolism: Underlying Biology and Emerging Strategies.
Topics: Acetates; Fluorodeoxyglucose F18; Glucose; Humans; Magnetic Resonance Imaging; Neoplasms; Positron-Emission Tomography | 2018 |
Whole-Body MR Imaging: The Novel, "Intrinsically Hybrid," Approach to Metastases, Myeloma, Lymphoma, in Bones and Beyond.
Topics: Diffusion Magnetic Resonance Imaging; Fluorodeoxyglucose F18; Forecasting; Humans; Magnetic Resonance Imaging; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Whole Body Imaging | 2018 |
FDG PET/CT for assessing tumour response to immunotherapy : Report on the EANM symposium on immune modulation and recent review of the literature.
Topics: Congresses as Topic; Fluorodeoxyglucose F18; Humans; Immunotherapy; Neoplasms; Positron Emission Tomography Computed Tomography; Practice Guidelines as Topic; Radiopharmaceuticals; Treatment Outcome | 2019 |
Topics: Adolescent; Child; Fluorodeoxyglucose F18; Humans; Medical Oncology; Neoplasm Staging; Neoplasms; Pediatrics; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2019 |
Prognostic value of 18F-fluorodeoxyglucose bone marrow uptake in patients with solid tumors: A meta-analysis.
Topics: Biomarkers, Tumor; Bone Marrow; Disease Progression; Disease-Free Survival; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals | 2018 |
Mechanism-Based Modeling of Tumor Growth and Treatment Response Constrained by Multiparametric Imaging Data.
Topics: Combined Modality Therapy; Computer Simulation; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Multiparametric Magnetic Resonance Imaging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2019 |
PET/CT-Based Response Evaluation in Cancer-a Systematic Review of Design Issues.
Topics: Biomarkers, Tumor; Combined Modality Therapy; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Response Evaluation Criteria in Solid Tumors; Treatment Outcome | 2020 |
Associations between GLUT expression and SUV values derived from FDG-PET in different tumors-A systematic review and meta analysis.
Topics: Animals; Fluorodeoxyglucose F18; Glucose Transport Proteins, Facilitative; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2019 |
Hyperglycemia and 18F-FDG PET/CT, issues and problem solving: a literature review.
Topics: Animals; Fluorodeoxyglucose F18; Humans; Hyperglycemia; Neoplasm Staging; Neoplasms; Positron Emission Tomography Computed Tomography | 2020 |
The impact of infection and inflammation in oncologic
Topics: Animals; Fluorodeoxyglucose F18; Humans; Infections; Inflammation; Neoplasms; Positron Emission Tomography Computed Tomography | 2019 |
PET/CT in radiation oncology.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Positron Emission Tomography Computed Tomography; Radiation Oncology; Radiotherapy, Image-Guided | 2019 |
Tumour thrombosis and patterns of fluorine-18 fluorodeoxyglucose uptake: a pictorial review.
Topics: Biological Transport; Diagnosis, Differential; Diagnostic Imaging; Fluorodeoxyglucose F18; Humans; Neoplasms; Thrombosis | 2013 |
Pioneering and fundamental achievements on the development of positron emission tomography (PET) in oncology.
Topics: Carbon Radioisotopes; Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Methionine; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2013 |
Meta-analysis of the additional value of integrated 18FDG PET-CT for tumor distant metastasis staging: comparison with 18FDG PET alone and CT alone.
Topics: Fluorodeoxyglucose F18; Humans; Meta-Analysis as Topic; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Tomography, X-Ray Computed | 2013 |
Appropriate use of positron emission tomography with [(18)F]fluorodeoxyglucose for staging of oncology patients.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2014 |
The management and the diagnosis of fever of unknown origin.
Topics: Age Factors; Communicable Diseases; Diagnosis, Differential; Fever of Unknown Origin; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography | 2013 |
Predicting tumour response.
Topics: Angiogenesis Inhibitors; Cell Hypoxia; Fluorodeoxyglucose F18; Genetic Markers; Humans; Necrosis; Neoplasms; Radioisotopes | 2013 |
Identifying and distinguishing treatment effects and complications from malignancy at FDG PET/CT.
Topics: Fluorodeoxyglucose F18; Humans; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2013 |
Quantitative PET factors predictive of the response to therapy in solid tumors: which is the best?
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Treatment Outcome | 2014 |
Clinical applications of 18F-FDG PET/CT in monitoring anti-cancer therapies.
Topics: Animals; Antineoplastic Agents; Drug Monitoring; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Practice Guidelines as Topic; Tomography, X-Ray Computed | 2013 |
Diagnostic performance of PET/CT with tracers other than F-18-FDG in oncology: an evidence-based review.
Topics: Evidence-Based Medicine; Fluorodeoxyglucose F18; Humans; Medical Oncology; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2014 |
Paraneoplastic immune-mediated neurological effects of systemic cancers.
Topics: Autoantibodies; Fluorodeoxyglucose F18; Humans; Immunotherapy; Neoplasms; Paraneoplastic Syndromes, Nervous System; Positron-Emission Tomography; Reproducibility of Results; Sensitivity and Specificity | 2014 |
[Clinical application of 18F-FDG PET/CT in the treatment of sarcomas].
Topics: Biopsy; Cell Transformation, Neoplastic; Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Neoplasms; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
[Molecular imaging in oncological surgery: technical principles and importance].
Topics: Fluorodeoxyglucose F18; Glycolysis; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Molecular Imaging; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Response Evaluation Criteria in Solid Tumors; Tomography, X-Ray Computed | 2014 |
PET/CT imaging in cancer: current applications and future directions.
Topics: Apoptosis; Cell Hypoxia; Cell Proliferation; Dideoxynucleosides; Fluorodeoxyglucose F18; Humans; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Prognosis; Tomography, X-Ray Computed | 2014 |
Standardization and quantification in FDG-PET/CT imaging for staging and restaging of malignant disease.
Topics: Calibration; Equipment Failure; Fluorodeoxyglucose F18; Humans; Medical Errors; Multimodal Imaging; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Quality Control; Radiometry; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Postradiation changes in tissues: evaluation by imaging studies with emphasis on fluorodeoxyglucose-PET/computed tomography and correlation with histopathologic findings.
Topics: Bone and Bones; Brain; Brain Neoplasms; Fluorodeoxyglucose F18; Gastrointestinal Tract; Humans; Lung; Magnetic Resonance Imaging; Multimodal Imaging; Necrosis; Neoplasms; Radiation Injuries; Radionuclide Imaging; Radiopharmaceuticals; Radiotherapy; Spinal Cord; Tissue Distribution; Tomography, X-Ray Computed; Urinary Tract | 2014 |
Fluorodeoxyglucose positron emission tomography/magnetic resonance imaging: current status, future aspects.
Topics: Equipment Design; Fluorodeoxyglucose F18; Forecasting; Humans; Magnetic Resonance Imaging; Multimodal Imaging; Neoplasms; Nervous System Diseases; Positron-Emission Tomography; Radiation Injuries; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Risk Factors | 2014 |
Review of clinical practice utility of positron emission tomography with 18F-fluorodeoxyglucose in assessing tumour response to therapy.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2015 |
[Oncology PET imaging].
Topics: Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Japan; Molecular Imaging; Molecular Targeted Therapy; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2014 |
Cerenkov imaging.
Topics: Animals; Fluorodeoxyglucose F18; Humans; Luminescent Measurements; Molecular Imaging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2014 |
Assessment of treatment response using PET.
Topics: Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Treatment Outcome | 2015 |
PET-based radiation therapy planning.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiometry; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Image-Guided | 2015 |
An update on novel quantitative techniques in the context of evolving whole-body PET imaging.
Topics: Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Imaging, Three-Dimensional; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2015 |
Cost-effectiveness of PET and PET/computed tomography: a systematic review.
Topics: Cost-Benefit Analysis; Fluorodeoxyglucose F18; Health Care Costs; Humans; Internationality; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2015 |
Optimizing the use of PET with selective internal radiation therapy.
Topics: Brachytherapy; Fluorodeoxyglucose F18; Humans; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed | 2014 |
Artifacts and diagnostic pitfalls in positron emission tomography-magnetic resonance imaging.
Topics: Artifacts; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Motion; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Prostheses and Implants; Radiopharmaceuticals | 2014 |
Positron emission tomography-magnetic resonance imaging: technical review.
Topics: Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2014 |
Clinical applications of pediatric positron emission tomography-magnetic resonance imaging.
Topics: Adolescent; Child; Epilepsy; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Multimodal Imaging; Neoplasms; Pediatrics; Positron-Emission Tomography; Radiopharmaceuticals | 2014 |
Value of 18F-FDG PET and PET/CT for evaluation of pediatric malignancies.
Topics: Adolescent; Brain Neoplasms; Child; Female; Fluorodeoxyglucose F18; Humans; Lymphoma; Male; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Neuroblastoma; Pediatrics; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed; Wilms Tumor | 2015 |
Multimodality Imaging of Tumour Thrombus.
Topics: Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Multimodal Imaging; Neoplasm Invasiveness; Neoplasms; Phlebography; Positron-Emission Tomography; Radiopharmaceuticals; Thrombosis; Tomography, X-Ray Computed; Ultrasonography, Doppler, Color; Veins | 2015 |
Cancer stratification by molecular imaging.
Topics: Biomarkers, Tumor; Fluorodeoxyglucose F18; Folate Receptors, GPI-Anchored; Humans; Integrins; Magnetic Resonance Imaging; Methyltyrosines; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Receptor, ErbB-2; Tomography, X-Ray Computed | 2015 |
[New trends and novel possibilities in functional medical imaging: imaging methods].
Topics: Fluorodeoxyglucose F18; Glucose; Humans; Image Interpretation, Computer-Assisted; Iodine Radioisotopes; Magnetic Resonance Imaging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tissue Distribution; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed | 2015 |
[New trends and novel possibilities in the management of oncologic patients: clinical uses of PET/MRI].
Topics: Abdominal Neoplasms; Disease Management; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Medical Oncology; Multimodal Imaging; Neoplasms; Ovarian Neoplasms; Positron-Emission Tomography; Prostatic Neoplasms; Radiopharmaceuticals; Rectal Neoplasms; Thoracic Neoplasms | 2015 |
PET-specific parameters and radiotracers in theoretical tumour modelling.
Topics: Cell Proliferation; Coordination Complexes; Dideoxynucleosides; Diffusion; Fluorodeoxyglucose F18; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glucose; Humans; Hydrogen-Ion Concentration; Hypoxia; Misonidazole; Models, Theoretical; Multimodal Imaging; Neoplasms; Neovascularization, Pathologic; Organometallic Compounds; Oxygen; Positron-Emission Tomography; Radiopharmaceuticals; Thiosemicarbazones; Tomography, X-Ray Computed | 2015 |
The Current Role of PET/CT in Radiotherapy Planning.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed | 2015 |
The diagnostic role of (18)F fluorodeoxyglucose positron emission tomography in patients with fever of unknown origin.
Topics: Autoimmune Diseases; Epidemiologic Methods; Fever of Unknown Origin; Fluorodeoxyglucose F18; Humans; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2015 |
Hybrid PET/MR imaging: physics and technical considerations.
Topics: Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Multimodal Imaging; Neoplasms; Physics; Positron-Emission Tomography; Radiopharmaceuticals; Whole Body Imaging | 2015 |
Correlation between the Uptake of 18F-Fluorodeoxyglucose (18F-FDG) and the Expression of Proliferation-Associated Antigen Ki-67 in Cancer Patients: A Meta-Analysis.
Topics: Biological Transport; Biomarkers, Tumor; Cell Proliferation; Fluorodeoxyglucose F18; Gene Expression; Humans; Ki-67 Antigen; Neoplasms; Organ Specificity; Positron-Emission Tomography; Radiopharmaceuticals; Regression Analysis; Tomography, X-Ray Computed; Tumor Cells, Cultured | 2015 |
How to investigate multisystem disease.
Topics: Autoimmune Diseases; Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Rheumatic Diseases; Tomography, X-Ray Computed | 2014 |
Positron Emission Tomography Computed Tomography: A Guide for the General Radiologist.
Topics: Education, Medical, Continuing; Fluorodeoxyglucose F18; Humans; Multimodal Imaging; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Radiology; Sensitivity and Specificity; Tomography, X-Ray Computed | 2015 |
ADIPOSITY-RELATED CANCER AND FUNCTIONAL IMAGING OF BROWN ADIPOSE TISSUE.
Topics: Adipose Tissue, Brown; Adiposity; Diagnostic Imaging; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Neoplasms; Obesity; Positron-Emission Tomography; Tomography, X-Ray Computed; Ultrasonography | 2015 |
FDG PET/CT in cancer: comparison of actual use with literature-based recommendations.
Topics: Denmark; Fluorodeoxyglucose F18; Humans; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Practice Guidelines as Topic; Radiopharmaceuticals; Tomography, X-Ray Computed | 2016 |
Pitfalls and Artifacts in the Use of PET/CT in Oncology Imaging.
Topics: Artifacts; Choline; Contrast Media; Female; Fluorodeoxyglucose F18; Humans; Male; Metals; Motion; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Prostheses and Implants; Radiopharmaceuticals; Tomography, X-Ray Computed | 2015 |
Evidence-based medicine and clinical fluorodeoxyglucose PET/MRI in oncology.
Topics: Early Detection of Cancer; Evidence-Based Medicine; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Multimodal Imaging; Neoplasm Recurrence, Local; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2015 |
[The PET, Past and Future].
Topics: Alzheimer Disease; Brain; Cardiovascular System; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2015 |
[Technical Approaches for Quantitative Treatment Responses Using 18F-FDG PET].
Topics: Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2015 |
[Application of the PET for Radiation Therapy].
Topics: Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted | 2015 |
Facilitative glucose transporters: Implications for cancer detection, prognosis and treatment.
Topics: Animals; Fluorodeoxyglucose F18; Glucose Transport Proteins, Facilitative; Humans; Neoplasms; Prognosis | 2016 |
Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Practice Guidelines as Topic; Radiopharmaceuticals | 2016 |
New Positron-Emission Tomography/Computed Tomography Imaging for Bone Metastases
.
Topics: Bone Neoplasms; Choline; Female; Fluorodeoxyglucose F18; Humans; Male; Neoplasm Metastasis; Neoplasms; Positron Emission Tomography Computed Tomography; Radiographic Image Enhancement; Radiopharmaceuticals; Sensitivity and Specificity | 2016 |
Comparison of the RECIST and PERCIST criteria in solid tumors: a pooled analysis and review.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Response Evaluation Criteria in Solid Tumors; Treatment Outcome | 2016 |
PET-Computed Tomography in Veterinary Medicine.
Topics: Animals; Cat Diseases; Cats; Dog Diseases; Dogs; Fluorodeoxyglucose F18; Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2016 |
Pitfalls and Pearls of Wisdom in 18F-FDG PET Imaging of Tumors.
Topics: Appointments and Schedules; False Negative Reactions; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Surveys and Questionnaires | 2016 |
Imaging biomarker roadmap for cancer studies.
Topics: Biomarkers, Tumor; Clinical Decision-Making; Cost-Benefit Analysis; Fluorodeoxyglucose F18; Folic Acid; Humans; Neoplasms; Organotechnetium Compounds; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Research Design; Selection Bias | 2017 |
Molecular Imaging and Precision Medicine: PET/Computed Tomography and Therapy Response Assessment in Oncology.
Topics: Biomarkers, Tumor; Fluorodeoxyglucose F18; Humans; Molecular Imaging; Molecular Targeted Therapy; Neoplasms; Outcome Assessment, Health Care; Positron Emission Tomography Computed Tomography; Precision Medicine; Predictive Value of Tests; Prognosis; Radiopharmaceuticals | 2017 |
Radiotherapy response evaluation using FDG PET-CT-established and emerging applications.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Treatment Outcome | 2017 |
[PET/CT: Molecular Imaging and Theranostics for Radionuclide Therapy].
Topics: Evidence-Based Medicine; Fluorodeoxyglucose F18; Humans; Molecular Imaging; Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Radiotherapy, Image-Guided; Sarcoidosis; Theranostic Nanomedicine; Treatment Outcome | 2017 |
Repeatability of SUV in Oncologic
Topics: Biological Transport; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Reproducibility of Results | 2017 |
FDG uptake, a surrogate of tumour hypoxia?
Topics: Animals; Cell Hypoxia; Fluorodeoxyglucose F18; Humans; Neoplasms; Oxygen; Radionuclide Imaging; Radiopharmaceuticals | 2008 |
Causes and consequences of increased glucose metabolism of cancers.
Topics: Cell Hypoxia; Cell Transformation, Neoplastic; Evolution, Molecular; Female; Fluorodeoxyglucose F18; Game Theory; Glucose; Glycolysis; History, 19th Century; History, 20th Century; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Oncogenes; Radionuclide Imaging; Radiopharmaceuticals | 2008 |
Tumor cell metabolism imaging.
Topics: Amino Acids; Animals; Biological Transport; Cell Transformation, Neoplastic; Cellular Structures; Fluorodeoxyglucose F18; Glucose; Humans; Lipid Metabolism; Magnetic Resonance Imaging; Neoplasms; Oncogenes; Positron-Emission Tomography; Radiopharmaceuticals | 2008 |
Imaging of tumor glucose utilization with positron emission tomography.
Topics: Fluorodeoxyglucose F18; Glucose; Humans; Neoplasms; Positron-Emission Tomography | 2008 |
Review: Deoxyglucose compounds labeled with isotopes different from 18-fuoride: is there a future in clinical practice?
Topics: Animals; Deoxyglucose; Diagnostic Imaging; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Mice; Neoplasm Transplantation; Neoplasms; Pentetic Acid; Positron-Emission Tomography; Radioisotopes; Rhenium; Technetium; Tomography, Emission-Computed, Single-Photon | 2008 |
PET-associated incidental neoplasms of the thyroid.
Topics: Biopsy, Needle; Fluorodeoxyglucose F18; Humans; Incidental Findings; Magnetic Resonance Imaging; Neoplasms; Neoplasms, Second Primary; Positron-Emission Tomography; Prognosis; Risk Factors; Sensitivity and Specificity; Thyroid Gland; Thyroid Neoplasms; Thyroidectomy; Tomography, X-Ray Computed; Ultrasonography | 2008 |
Role of fluorodeoxyglucose-PET versus fluorodeoxyglucose-PET/computed tomography in detection of unknown primary tumor: a meta-analysis of the literature.
Topics: Databases, Bibliographic; False Positive Reactions; Fluorodeoxyglucose F18; Humans; Medical Oncology; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; ROC Curve; Sensitivity and Specificity; Tomography, X-Ray Computed | 2008 |
[Metabolic imaging--PET, PET/CT--in oncologic surgery].
Topics: Breast Neoplasms; Cost-Benefit Analysis; Endocrine Gland Neoplasms; Female; Fluorodeoxyglucose F18; Gastrointestinal Neoplasms; Head and Neck Neoplasms; Humans; Hungary; Lung Neoplasms; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Surgical Procedures, Operative; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed | 2008 |
Molecular imaging of tumor metabolism and apoptosis.
Topics: Amino Acids; Animals; Apoptosis; Fluorodeoxyglucose F18; Glucose; Humans; Hypoxia; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2007 |
In vivo imaging of apoptosis.
Topics: Aged; Animals; Annexin A5; Apoptosis; Autophagy; Clinical Trials as Topic; Diagnostic Imaging; Fluorodeoxyglucose F18; Humans; Male; Mitochondria; Neoplasms; Proteasome Endopeptidase Complex; Radionuclide Imaging; Radiopharmaceuticals; Signal Transduction | 2008 |
PET-CT in oncology: making the most of CT.
Topics: Contrast Media; Decision Making, Computer-Assisted; Fluorodeoxyglucose F18; Humans; Imaging, Three-Dimensional; Neoplasms; Positron-Emission Tomography; Tomography, X-Ray Computed | 2008 |
Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006-2007.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed | 2009 |
Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Diagnostic Imaging; Drug Delivery Systems; Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Magnetic Resonance Imaging; Male; Molecular Biology; Neoplasms; Positron-Emission Tomography; Sensitivity and Specificity; Tomography, X-Ray Computed | 2009 |
18F-FDG PET and PET/CT in the evaluation of cancer treatment response.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Imaging surrogates of tumor response to therapy: anatomic and functional biomarkers.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2009 |
[Molecular imaging by PET/SPECT].
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Drug Design; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Mice; Neoplasms; Neurofibrillary Tangles; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon | 2009 |
[Evaluation of therapies in oncology by positron emission tomography: towards therapeutical personalization].
Topics: Cell Count; Cell Transformation, Neoplastic; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Treatment Outcome | 2009 |
Imaging in multiple myeloma.
Topics: Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Multiple Myeloma; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Subtraction Technique; Tomography, X-Ray Computed; Whole Body Imaging | 2009 |
Radiopharmaceuticals for oncology drug development: a pharmaceutical industry perspective.
Topics: Animals; Antineoplastic Agents; Drug Design; Drug Industry; Fluorodeoxyglucose F18; Humans; Isotope Labeling; Neoplasms; Positron-Emission Tomography; Radioisotopes; Radiopharmaceuticals | 2009 |
Considerations for the use of imaging tools for phase II treatment trials in oncology.
Topics: Clinical Trials, Phase II as Topic; Endpoint Determination; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Neoplasms; Positron-Emission Tomography; Quality Assurance, Health Care; Sarcoma | 2009 |
[18F]FDG-PET-CT for early monitoring of tumor response: when and why.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Whole-body MRI and FDG PET fused images for evaluation of patients with cancer.
Topics: Contrast Media; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Whole Body Imaging | 2009 |
Monitoring response to therapeutic interventions in patients with cancer.
Topics: Cell Hypoxia; Chemotherapy, Adjuvant; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Thymidine; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Measuring response with FDG-PET: methodological aspects.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Hodgkin Disease; Humans; Lung Neoplasms; Lymphoma, Non-Hodgkin; Neoplasms; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Radiotherapy, Adjuvant; Uterine Cervical Neoplasms | 2009 |
Assessing tumor response to therapy.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Subtraction Technique; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Standards for PET image acquisition and quantitative data analysis.
Topics: Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Neoplasms; Positron-Emission Tomography; Practice Guidelines as Topic; Radiopharmaceuticals; Subtraction Technique; Treatment Outcome | 2009 |
Monitoring predominantly cytostatic treatment response with 18F-FDG PET.
Topics: Antineoplastic Agents; Cytostatic Agents; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Treatment Outcome | 2009 |
From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.
Topics: Fluorodeoxyglucose F18; Forecasting; Humans; Internationality; Neoplasms; Outcome Assessment, Health Care; Positron-Emission Tomography; Practice Guidelines as Topic; Prognosis; Radiopharmaceuticals; Treatment Outcome; World Health Organization | 2009 |
PET/CT for the staging and follow-up of patients with malignancies.
Topics: Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Subtraction Technique; Tomography, X-Ray Computed; Whole Body Imaging | 2009 |
Molecular imaging with positron emission tomography in paediatric oncology--FDG and beyond.
Topics: Child; Fluorodeoxyglucose F18; Humans; Molecular Probe Techniques; Neoplasms; Oncology Service, Hospital; Pediatrics; Positron-Emission Tomography; Radiopharmaceuticals | 2009 |
[Application and future prospect of 18F-FLT PET-CT in guiding delineation of biological target volume].
Topics: Dideoxynucleosides; False Positive Reactions; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Inflammation; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Radiotherapy, Intensity-Modulated; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
NCCN task force: clinical utility of PET in a variety of tumor types.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals | 2009 |
Monitoring cancer therapy with PET: probably effective, but more research is needed.
Topics: Clinical Trials as Topic; Endpoint Determination; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Treatment Outcome | 2009 |
PET-CT imaging in pediatric oncology.
Topics: Adolescent; Age Factors; Antineoplastic Agents; Child; Drug Monitoring; Fluorodeoxyglucose F18; Humans; Neoplasm Metastasis; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2009 |
18F-FDG PET/CT for image-guided and intensity-modulated radiotherapy.
Topics: Animals; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Tomography, X-Ray Computed | 2009 |
[Diagnosis of fever of unknown origin (FUO). Positron emission tomography/computed tomography (PET-CT)].
Topics: Citrates; Diagnosis, Differential; Fever of Unknown Origin; Fluorodeoxyglucose F18; Gallium; Humans; Indium Radioisotopes; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Sepsis | 2009 |
[Imaging in oncology and international rules for evaluation: the nuclear medicine].
Topics: Fluorodeoxyglucose F18; Humans; Lymphoma; Neoplasm, Residual; Neoplasms; Nuclear Medicine; Positron-Emission Tomography; Radiopharmaceuticals | 2009 |
[Positron emission tomography and evaluation of response to targeted therapies].
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Hypoxia; Cell Proliferation; Choline; ErbB Receptors; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lipid Metabolism; Lung Neoplasms; Neoplasms; Neovascularization, Pathologic; Piperazines; Positron-Emission Tomography; Protein Biosynthesis; Protein Kinases; Pyrimidines; Radiopharmaceuticals; Receptors, Androgen; Receptors, Estrogen; TOR Serine-Threonine Kinases | 2009 |
Visualizing cancer and immune cell function with metabolic positron emission tomography.
Topics: Cell Proliferation; Fluorodeoxyglucose F18; Humans; Immunity, Cellular; Neoplasms; Positron-Emission Tomography; Vascular Endothelial Growth Factor Receptor-1 | 2010 |
Methodological considerations in quantification of oncological FDG PET studies.
Topics: Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Neoplasms; Positron-Emission Tomography; Reproducibility of Results | 2010 |
Radionuclide imaging of tumor angiogenesis.
Topics: Alternative Splicing; Angiogenesis Inhibitors; Animals; Endothelium, Vascular; Fluorodeoxyglucose F18; Humans; Indium Radioisotopes; Integrin alphaVbeta3; Magnetic Resonance Imaging; Matrix Metalloproteinases; Mice; Neoplasm Metastasis; Neoplasms; Neoplasms, Experimental; Neovascularization, Pathologic; Oligopeptides; Positron-Emission Tomography; Receptors, Immunologic; Receptors, Peptide; Receptors, Vascular Endothelial Growth Factor | 2009 |
Imaging pharmacodynamics in oncology: the potential significance of "flares".
Topics: Animals; Biological Transport; Diagnostic Imaging; Dideoxynucleosides; Fluorodeoxyglucose F18; Humans; Neoplasms; Pharmacokinetics; Radioactive Tracers | 2010 |
Contribution of hypoxia-measuring molecular imaging techniques to radiotherapy planning and treatment.
Topics: Animals; Biomarkers, Tumor; Fluorodeoxyglucose F18; Humans; Hypoxia; Immunohistochemistry; Molecular Imaging; Neoplasms; Positron-Emission Tomography; Prognosis; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed | 2010 |
PET/CT imaging: The incremental value of assessing the glucose metabolic phenotype and the structure of cancers in a single examination.
Topics: Contrast Media; Fluorodeoxyglucose F18; Glucose; Glycolysis; Humans; Neoplasm Staging; Neoplasms; Phenotype; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Whole Body Imaging | 2010 |
Influence of chemoresistance and p53 status on fluoro-2-deoxy-D-glucose incorporation in cancer.
Topics: Animals; Biological Transport; Drug Resistance, Neoplasm; Fluorodeoxyglucose F18; Humans; Neoplasms; Prognosis; Radionuclide Imaging; Tumor Suppressor Protein p53 | 2010 |
Use of new imaging techniques to predict tumour response to therapy.
Topics: Animals; Antineoplastic Agents; Contrast Media; Diagnostic Imaging; Diffusion Magnetic Resonance Imaging; Endpoint Determination; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Spectroscopy; Neoplasms; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Treatment Outcome | 2010 |
Doctor, what does my future hold? The prognostic value of FDG-PET in solid tumours.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Prognosis; Survival Analysis | 2010 |
PET designated flouride-18 production and chemistry.
Topics: Fluorodeoxyglucose F18; Humans; Molecular Probe Techniques; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2010 |
Imaging and 'omic' methods for the molecular diagnosis of cancer.
Topics: Animals; Diagnostic Imaging; Fluorodeoxyglucose F18; Genomics; Humans; Magnetic Resonance Spectroscopy; Neoplasms; Pathology, Molecular; Positron-Emission Tomography; Proteomics | 2010 |
Evolving role of 18F-FDG-PET/CT for the body tumor and metastases in pediatrics.
Topics: Fluorodeoxyglucose F18; Forecasting; Humans; Lymphatic Metastasis; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Subtraction Technique; Tomography, X-Ray Computed; Whole Body Imaging | 2010 |
A systematic review of the factors affecting accuracy of SUV measurements.
Topics: Algorithms; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Models, Biological; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity | 2010 |
Quantitative analysis of PET studies.
Topics: Fluorodeoxyglucose F18; Glucose; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2010 |
PET/CT today and tomorrow in veterinary cancer diagnosis and monitoring: fundamentals, early results and future perspectives.
Topics: Animals; Cat Diseases; Cats; Dog Diseases; Dogs; Fluorodeoxyglucose F18; Humans; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography Scanners, X-Ray Computed | 2010 |
Personalized versus evidence-based medicine with PET-based imaging.
Topics: Disease Progression; Evidence-Based Medicine; Fluorodeoxyglucose F18; Humans; Molecular Biology; Neoadjuvant Therapy; Neoplasms; Positron-Emission Tomography; Time Factors | 2010 |
PET radiopharmaceuticals in radiation treatment planning - synthesis and biological characteristics.
Topics: Amino Acids; Biological Transport; Cell Hypoxia; Fluorodeoxyglucose F18; Glucose; Humans; Lipid Metabolism; Misonidazole; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Receptors, Somatostatin | 2010 |
FDG-PET/CT in pediatric solid tumors.
Topics: Bone Neoplasms; Brain Neoplasms; Child; Fluorodeoxyglucose F18; Hepatoblastoma; Histiocytosis, Langerhans-Cell; Humans; Liver Neoplasms; Neoplasms; Neuroblastoma; Positron-Emission Tomography; Radiopharmaceuticals; Sarcoma; Soft Tissue Neoplasms; Tomography, X-Ray Computed | 2010 |
Strategies of assessing and quantifying radiation treatment metabolic tumor response using F18 FDG Positron Emission Tomography (PET).
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Prognosis; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Tissue Distribution; Treatment Outcome; Tumor Burden | 2010 |
Added value of baseline 18F-FDG uptake in serial 18F-FDG PET for evaluation of response of solid extracerebral tumors to systemic cytotoxic neoadjuvant treatment: a meta-analysis.
Topics: Antineoplastic Agents; Fluorodeoxyglucose F18; Humans; Neoadjuvant Therapy; Neoplasms; Positron-Emission Tomography; Prognosis; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome | 2010 |
Fluorine-18 radiopharmaceuticals beyond [18F]FDG for use in oncology and neurosciences.
Topics: Animals; Fluorodeoxyglucose F18; Humans; Neoplasms; Nervous System Diseases; Radionuclide Imaging; Radiopharmaceuticals | 2010 |
Tumour response evaluation with fluorodeoxyglucose positron emission tomography: research technique or clinical tool?
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2010 |
Assessing extracranial tumors using diffusion-weighted whole-body MRI.
Topics: Adenoma, Liver Cell; Blood Glucose; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Contrast Media; Diffusion Magnetic Resonance Imaging; Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Processing, Computer-Assisted; Liver Neoplasms; Lung Neoplasms; Male; Multiple Myeloma; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Prostatic Neoplasms; Sensitivity and Specificity; Tomography, X-Ray Computed; Whole Body Imaging | 2011 |
PET imaging for pediatric oncology: an assessment of the evidence.
Topics: Child; Clinical Trials as Topic; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2010 |
Emission-guided radiation therapy: biologic targeting and adaptive treatment.
Topics: Fluorodeoxyglucose F18; Humans; Imaging, Three-Dimensional; Magnetic Resonance Imaging, Interventional; Neoplasms; Positron-Emission Tomography; Radiation Dosage; Radiography, Interventional; Radiopharmaceuticals; Radiosurgery; Radiotherapy Dosage; Stereotaxic Techniques; Tomography, X-Ray Computed | 2010 |
Positron emission tomography-computed tomography protocols for radiation therapy planning and therapy response assessment.
Topics: Fluorodeoxyglucose F18; Four-Dimensional Computed Tomography; Humans; Image Processing, Computer-Assisted; Neoplasms; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Respiratory-Gated Imaging Techniques; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Therapy response evaluation with positron emission tomography-computed tomography.
Topics: Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Neoplasm Recurrence, Local; Neoplasms; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy.
Topics: Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Best practices: consensus on performing positron emission tomography-computed tomography for radiation therapy planning and for therapy response assessment.
Topics: Benchmarking; Consensus; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Respiratory-Gated Imaging Techniques; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Positron emission tomography-computed tomography reporting in radiation therapy planning and response assessment.
Topics: Fluorodeoxyglucose F18; Humans; Information Dissemination; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Research Design; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Positron emission tomography for benign and malignant disease.
Topics: Breast Neoplasms; Colorectal Neoplasms; Dermatitis, Contact; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Melanoma; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms; Positron-Emission Tomography; Prostatic Neoplasms; Radiopharmaceuticals; Sensitivity and Specificity; Solitary Pulmonary Nodule; Tomography, X-Ray Computed | 2011 |
Molecular imaging metrics to evaluate response to preclinical therapeutic regimens.
Topics: Diagnostic Imaging; Dideoxynucleosides; Fluorodeoxyglucose F18; Humans; Molecular Imaging; Neoplasms; Neovascularization, Pathologic; Positron-Emission Tomography; Thymidine Kinase | 2011 |
A new dimension of FDG-PET interpretation: assessment of tumor biology.
Topics: Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Neoplasms; Positron-Emission Tomography | 2011 |
Clinical applications of positron emission tomography in sarcoma management.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Sarcoma | 2011 |
False-positive uptake on 2-[¹⁸F]-fluoro-2-deoxy-D-glucose (FDG) positron-emission tomography/computed tomography (PET/CT) in oncological imaging.
Topics: False Positive Reactions; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2011 |
The promise and pitfalls of positron emission tomography and single-photon emission computed tomography molecular imaging-guided radiation therapy.
Topics: Fluorodeoxyglucose F18; Humans; Molecular Imaging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Tomography, Emission-Computed, Single-Photon | 2011 |
Molecular imaging-based dose painting: a novel paradigm for radiation therapy prescription.
Topics: Fluorodeoxyglucose F18; Humans; Molecular Imaging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Tumor Burden | 2011 |
Metabolic positron emission tomography imaging in cancer detection and therapy response.
Topics: Choline; Drug Monitoring; Fluorodeoxyglucose F18; Humans; Molecular Imaging; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Tyrosine | 2011 |
Positron emission tomography imaging approaches for external beam radiation therapies: current status and future developments.
Topics: Fluorodeoxyglucose F18; Forecasting; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Tumor Burden | 2011 |
Single photon emission tomography/computed tomography (SPET/CT) and positron emission tomography/computed tomography (PET/CT) to image cancer.
Topics: Adult; Aged; Fluorodeoxyglucose F18; Humans; Middle Aged; Neoplasms; Neuroendocrine Tumors; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Thyroid Neoplasms; Tomography, Emission-Computed, Single-Photon | 2011 |
18F-fluorodeoxyglucose uptake in tumor.
Topics: Fluorodeoxyglucose F18; Glutamate Plasma Membrane Transport Proteins; Glycolysis; Hexokinase; Humans; Neoplasms; Phosphorylation; Radiopharmaceuticals | 2011 |
Transport processes of radiopharmaceuticals and -modulators.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Chemoradiotherapy; Fluorodeoxyglucose F18; Gene Expression Regulation; Humans; Neoplasms; Nuclear Medicine; Radiation-Sensitizing Agents; Radionuclide Imaging; Radiopharmaceuticals; Radiotherapy; Reactive Oxygen Species; Technetium Tc 99m Sestamibi | 2011 |
Demonstrations of AIDS-associated malignancies and infections at FDG PET-CT.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Female; Fluorodeoxyglucose F18; HIV Infections; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasms; Opportunistic Infections; Positron-Emission Tomography; Sarcoma, Kaposi; Tomography, X-Ray Computed; Tuberculosis | 2011 |
Targeted-therapy and imaging response: a new paradigm for clinical evaluation?
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Clinical Trials as Topic; Diagnostic Imaging; Fluorodeoxyglucose F18; Humans; Imatinib Mesylate; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Radiopharmaceuticals; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2011 |
[Hybrid PET/CT in cancer imaging].
Topics: Fluorodeoxyglucose F18; Humans; Neoplasm Metastasis; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2011 |
FDG PET/CT in patients with HIV.
Topics: Antiretroviral Therapy, Highly Active; Central Nervous System; Disease Progression; Fever of Unknown Origin; Fluorodeoxyglucose F18; HIV Infections; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2011 |
PET-CT in children: where is it appropriate?
Topics: Child; Fluorodeoxyglucose F18; Histiocytosis, Langerhans-Cell; Humans; Infections; Inflammation; Neoplasms; Pediatrics; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2011 |
Non-FDG PET in oncology.
Topics: Fluorodeoxyglucose F18; Humans; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2011 |
[Clinical significance of and diagnostic methods for tumoral hypoxia].
Topics: Biomarkers, Tumor; Cell Hypoxia; Coordination Complexes; Disease Progression; Drug Resistance, Neoplasm; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Neoplasms; Organometallic Compounds; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Spectrum Analysis; Thiosemicarbazones; Tomography, Emission-Computed, Single-Photon; Tomography, Optical | 2011 |
(18)F-FDG-PET/CT in evaluating response to therapy in solid tumors: where we are and where we can go.
Topics: Fluorodeoxyglucose F18; Humans; Molecular Imaging; Neoplasms; Outcome Assessment, Health Care; Positron-Emission Tomography; Radiopharmaceuticals; Subtraction Technique; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Application of metabolic PET imaging in radiation oncology.
Topics: Acetates; Carbon Radioisotopes; Carcinoma; Choline; Confounding Factors, Epidemiologic; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Glucose; Humans; Inflammation; Lymphoma; Male; Methionine; Molecular Imaging; Neoplasms; Organ Specificity; Positron-Emission Tomography; Radiation Oncology; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted | 2012 |
Cancer imaging: Gene transcription-based imaging and therapeutic systems.
Topics: Diagnostic Imaging; Fluorodeoxyglucose F18; Gene Transfer Techniques; Genes, Reporter; Genetic Therapy; Humans; Neoplasm Micrometastasis; Neoplasms; Organ Specificity; Positron-Emission Tomography; Promoter Regions, Genetic; Sensitivity and Specificity; Transcription, Genetic | 2012 |
New aspects of the Warburg effect in cancer cell biology.
Topics: Adenosine Triphosphate; Animals; Drug Resistance, Neoplasm; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Glycolysis; Humans; Isoenzymes; Mitochondria; Neoplasms; Neoplastic Stem Cells; Positron-Emission Tomography; Protein Processing, Post-Translational; Radiopharmaceuticals; Tumor Microenvironment | 2012 |
FDG for therapy of metabolically active tumors.
Topics: Animals; Fluorodeoxyglucose F18; Humans; Neoplasms; Safety | 2012 |
Repeatability of 18F-FDG uptake measurements in tumors: a metaanalysis.
Topics: Biological Transport; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Reproducibility of Results; Tumor Burden | 2012 |
Can PET imaging facilitate optimization of cancer therapies?
Topics: Animals; Biomarkers, Tumor; Fluorodeoxyglucose F18; Humans; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2012 |
Innovation in cancer imaging.
Topics: Cell Proliferation; Diffusion Magnetic Resonance Imaging; Fluorodeoxyglucose F18; Humans; Image Enhancement; Lymph Nodes; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Tomography, X-Ray Computed | 2012 |
Functional MRI for radiotherapy dose painting.
Topics: Breast Neoplasms; Diagnostic Imaging; Dose Fractionation, Radiation; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Microcirculation; Neoplasms; Oxygen; Positron-Emission Tomography; Prostatic Neoplasms; Radiation Oncology; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Computer-Assisted; Reproducibility of Results | 2012 |
18[F]FDG-PET/CT is a useful molecular marker in evaluating tumour aggressiveness: a revised understanding of an in-vivo FDG-PET imaging that alludes the alteration of cancer biology.
Topics: Biomarkers, Tumor; Cell Dedifferentiation; Early Detection of Cancer; Fluorodeoxyglucose F18; Glycolysis; Humans; Multimodal Imaging; Mutation; Neoplasm Recurrence, Local; Neoplasms; Predictive Value of Tests; Sensitivity and Specificity; Survival Analysis | 2013 |
Quantitative assessment of dynamic PET imaging data in cancer imaging.
Topics: Calibration; Clinical Trials as Topic; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Medical Oncology; Multicenter Studies as Topic; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Tomography, X-Ray Computed | 2012 |
[Quality control of PET imaging: from study to diagnosis].
Topics: Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Molecular Imaging; Neoplasms; Positron-Emission Tomography; Practice Guidelines as Topic; Quality Control; Radiopharmaceuticals; Reference Standards | 2012 |
Comparison of FDG whole-body PET/CT and gadolinium-enhanced whole-body MRI for distant malignancies in patients with malignant tumors: a meta-analysis.
Topics: Fluorodeoxyglucose F18; Humans; Likelihood Functions; Magnetic Resonance Imaging; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Tomography, X-Ray Computed | 2013 |
FDG-PET/CT based response-adapted treatment.
Topics: Adenocarcinoma; Esophageal Neoplasms; Esophagogastric Junction; Fluorodeoxyglucose F18; Humans; Lymphoma; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2012 |
Multiparametric PET/CT in oncology.
Topics: Fluorodeoxyglucose F18; Humans; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Prognosis; Tomography, X-Ray Computed | 2012 |
Quantitative approaches of dynamic FDG-PET and PET/CT studies (dPET/CT) for the evaluation of oncological patients.
Topics: Fluorodeoxyglucose F18; Humans; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2012 |
Quantifying tumour heterogeneity in 18F-FDG PET/CT imaging by texture analysis.
Topics: Fluorodeoxyglucose F18; Humans; Mathematical Computing; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Probability; Prognosis; Radiopharmaceuticals; Tomography, X-Ray Computed | 2013 |
Expression of glucose transporters in cancers.
Topics: Animals; Fluorodeoxyglucose F18; Glucose; Glucose Transport Proteins, Facilitative; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Tomography, X-Ray Computed | 2013 |
Is there a role for PET-CT and SPECT-CT in pediatric oncology?
Topics: 3-Iodobenzylguanidine; Child; Child, Preschool; Fluorodeoxyglucose F18; Humans; Infant; Neoplasms; Pediatrics; Positron-Emission Tomography; Radiation Dosage; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed | 2013 |
[Positron emission tomography with fluorine-deoxyglucose in sarcomas and non-sarcoma non-epithelial tumors].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Sarcoma; Young Adult | 2012 |
When should we recommend use of dual time-point and delayed time-point imaging techniques in FDG PET?
Topics: Fluorodeoxyglucose F18; Humans; Inflammation; Neoplasms; Positron-Emission Tomography; Time Factors | 2013 |
[¹⁸F]fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography imaging in oncology: initial staging and evaluation of cancer therapy.
Topics: Female; Fluorodeoxyglucose F18; Humans; Multimodal Imaging; Neoplasm Grading; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Clinical oncologic positron emission tomography: an introduction.
Topics: Fluorodeoxyglucose F18; Humans; Imaging, Three-Dimensional; Neoplasms; Patient Care Planning; Physical Phenomena; Physics; Radiopharmaceuticals; Reimbursement Mechanisms; Tomography, Emission-Computed | 2002 |
[Positron emission tomography (PET) in clinical oncology [Part III]].
Topics: Adult; Brain Neoplasms; Breast Neoplasms; Digestive System Neoplasms; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Neoplasms; Ovarian Neoplasms; Radiopharmaceuticals; Sensitivity and Specificity; Thyroid Neoplasms; Tomography, Emission-Computed | 2002 |
[A proposal for the rational use of the PET in oncology].
Topics: Brain Neoplasms; Colorectal Neoplasms; Consensus; Cost-Benefit Analysis; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Lung Neoplasms; Lymphoma; Melanoma; Neoplasms; Practice Guidelines as Topic; Radiopharmaceuticals; Sensitivity and Specificity; Solitary Pulmonary Nodule; Spain; Tomography, Emission-Computed | 2002 |
Molecular imaging of cancer with positron emission tomography.
Topics: Animals; Antigens, Neoplasm; Bone Remodeling; Fluorodeoxyglucose F18; Genetic Therapy; Glucose; Humans; Neoplasms; Oxygen; Pharmacokinetics; Radioactive Tracers; Tomography, Emission-Computed | 2002 |
[Cost-effective PET investigations in oncology].
Topics: Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Cost-Benefit Analysis; Diagnosis, Differential; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Hungary; Lung Neoplasms; Lymphoma; Medicare; Melanoma; Neoplasm Staging; Neoplasms; Predictive Value of Tests; Radiopharmaceuticals; Solitary Pulmonary Nodule; Tomography, Emission-Computed; Tomography, X-Ray Computed; United States | 2002 |
The value of positron emission tomography (PET) imaging in disease staging and therapy assessment.
Topics: Female; Fluorodeoxyglucose F18; Humans; Male; Neoplasm Staging; Neoplasms; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed | 2002 |
Rapid evaluation of FDG imaging alternatives using head-to-head comparisons of full ring and gamma camera based PET scanners--a systematic review.
Topics: Equipment Design; Fluorodeoxyglucose F18; Humans; Neoplasms; Radiography; Radiopharmaceuticals; Tomography, Emission-Computed | 2002 |
Nuclear medicine imaging to predict response to radiotherapy: a review.
Topics: Apoptosis; Cell Division; Cell Hypoxia; ErbB Receptors; Fluorodeoxyglucose F18; Humans; Neoplasms; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 2003 |
Clinical applications of FDG-PET in oncology.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 2002 |
Functional imaging for assessment of therapy.
Topics: Animals; Fluorodeoxyglucose F18; Humans; Mice; Molecular Probes; Neoplasm Staging; Neoplasms; Radiopharmaceuticals; Research; Sensitivity and Specificity; Tomography, Emission-Computed; Treatment Outcome | 2002 |
Overview of clinical PET.
Topics: Brain; Coronary Disease; Cost-Benefit Analysis; Epilepsy; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Myocardial Revascularization; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms; Patient Selection; Radiopharmaceuticals; Tomography, Emission-Computed | 2002 |
[Using isotopes with short half-life in the diagnostics of oncological diseases].
Topics: Cell Division; Fluorodeoxyglucose F18; Half-Life; Humans; Neoplasm Staging; Neoplasms; Radioisotopes; Radiopharmaceuticals; Tomography, Emission-Computed; Treatment Outcome | 2003 |
[Combined functional and morphological imaging with PET/CT systems].
Topics: Carcinoma, Bronchogenic; Colorectal Neoplasms; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Neoplasms; Radiopharmaceuticals; Time Factors; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2003 |
Nuclear medicine: from photons to physiology.
Topics: Fluorodeoxyglucose F18; Gamma Cameras; Humans; Magnetic Resonance Imaging; Neoplasms; Nuclear Medicine; Physiology; Radiopharmaceuticals; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 2003 |
On the development of rational standards for nuclear response evaluation.
Topics: Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Neoplasms; Radiopharmaceuticals; Reference Standards; Sensitivity and Specificity; Tomography, Emission-Computed; Treatment Outcome | 2003 |
Assessment of therapy response by FDG PET in pediatric patients.
Topics: Adolescent; Bone Neoplasms; Brain Neoplasms; Child; Child, Preschool; Female; Fluorodeoxyglucose F18; Humans; Infant; Infant, Newborn; Lymphoma; Male; Neoplasms; Osteosarcoma; Radiopharmaceuticals; Tomography, Emission-Computed; Treatment Outcome | 2003 |
[Standards, Options and Recommendations for the use of PET-FDG in cancerology. Technical bases and regulatory principles].
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Radiopharmaceuticals; Tissue Distribution; Tomography, Emission-Computed | 2003 |
[Indications of PET imaging].
Topics: Cardiovascular Diseases; Central Nervous System Diseases; Fluorodeoxyglucose F18; Humans; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 2003 |
[Positron emission tomography in oncology].
Topics: Adult; Aged; Brain Neoplasms; Breast Neoplasms; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 2003 |
PET scan imaging in oncology.
Topics: Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Neoplasm Staging; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 2003 |
Meta-analysis of the performance of 18F-FDG PET in primary tumor detection in unknown primary tumors.
Topics: False Negative Reactions; Fluorodeoxyglucose F18; Humans; Neoplasms; Neoplasms, Unknown Primary; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, Emission-Computed | 2003 |
[Clinical application of FDG-PET for cancer diagnosis].
Topics: Breast Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Lymphoma; Male; Middle Aged; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 2003 |
Implications of PET based molecular imaging on the current and future practice of medicine.
Topics: Animals; Bone Diseases; Cardiovascular Diseases; Central Nervous System; Fluorodeoxyglucose F18; Humans; Inflammation; Isotope Labeling; Neoplasms; Practice Patterns, Physicians'; Radiopharmaceuticals; Subtraction Technique; Tomography, Emission-Computed | 2004 |
To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT.
Topics: Contrast Media; Decision Making; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Neoplasm Staging; Neoplasms; Practice Patterns, Physicians'; Quality Control; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Subtraction Technique; Therapy, Computer-Assisted; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2004 |
[Positron-emission tomography in oncology].
Topics: Colorectal Neoplasms; Evidence-Based Medicine; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Lung Neoplasms; Lymphoma; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Predictive Value of Tests; Radiopharmaceuticals; Tomography, Emission-Computed | 2003 |
Clinical utility of FDG PET.
Topics: Data Interpretation, Statistical; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Tomography, Emission-Computed | 2004 |
Pitfalls and artifacts in 18FDG PET and PET/CT oncologic imaging.
Topics: Artifacts; Diagnostic Errors; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Neoplasms; Radiopharmaceuticals; Tomography Scanners, X-Ray Computed; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2004 |
[Technique and indications in pediatric oncology. Positron emission tomography with 18F-fluorodeoxyglucose].
Topics: Child; Fluorodeoxyglucose F18; Humans; Medical Oncology; Neoplasms; Pediatrics; Radiopharmaceuticals; Tomography, Emission-Computed | 2004 |
Clinical PET imaging--an Asian perspective.
Topics: Asia; Diagnostic Services; Fever of Unknown Origin; Fluorodeoxyglucose F18; Heart; Humans; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2004 |
PET scan in the therapeutic strategy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease Progression; Female; Fluorodeoxyglucose F18; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Radiopharmaceuticals; Remission Induction; Tomography, Emission-Computed; Treatment Outcome | 2004 |
Quantification in clinical fluorodeoxyglucose positron emission tomography.
Topics: Algorithms; Animals; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2004 |
The use of standardized uptake values for assessing FDG uptake with PET in oncology: a clinical perspective.
Topics: Algorithms; Antineoplastic Agents; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Neoplasms; Positron-Emission Tomography; Practice Patterns, Physicians'; Prognosis; Radiopharmaceuticals; Treatment Outcome | 2004 |
[Whole-body tumor staging: MRI or FDG-PET/CT?].
Topics: Aged; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Time Factors; Tomography, X-Ray Computed | 2004 |
PET: a revolution in medical imaging.
Topics: Fluorodeoxyglucose F18; Humans; Molecular Biology; Neoplasms; Nervous System Diseases; Patient Care Planning; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2004 |
Update on PET radiopharmaceuticals: life beyond fluorodeoxyglucose.
Topics: Brain; Carbon Radioisotopes; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2004 |
Sonographic depiction of microvessel perfusion: principles and potential.
Topics: Animals; Breast Neoplasms; Fluorodeoxyglucose F18; Humans; Image Enhancement; Magnetic Resonance Imaging; Microbubbles; Neoplasms; Neoplasms, Experimental; Neovascularization, Pathologic; Radiopharmaceuticals; Regional Blood Flow; Ultrasonography, Doppler, Color | 2004 |
[Fluorinated analogs of nucleosides and fluorinated tracers of gene expression for positron emission tomography].
Topics: Animals; Antiviral Agents; Dideoxynucleosides; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Ganciclovir; Genes, Reporter; Genetic Therapy; Guanine; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Simplexvirus | 2004 |
Measuring tumor pharmacodynamic response using PET proliferation probes: the case for 2-[(11)C]-thymidine.
Topics: Carbon Radioisotopes; Cell Proliferation; Clinical Trials as Topic; DNA Probes; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Reproducibility of Results; Thymidine | 2004 |
[The impact of integrating images of positron emission tomography with computed tomography simulation on radiation therapy planning].
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Lung Neoplasms; Neoplasms; Observer Variation; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Sensitivity and Specificity; Tomography, X-Ray Computed | 2004 |
Monitoring response to treatment in patients utilizing PET.
Topics: Fluorodeoxyglucose F18; Humans; Monitoring, Physiologic; Neoplasms; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals | 2005 |
[The value of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (18F-FDG PET) in diagnosis of neoplastic diseases].
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2005 |
Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development.
Topics: Fluorodeoxyglucose F18; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Reproducibility of Results; Sensitivity and Specificity; Survival Analysis | 2005 |
Molecular nuclear imaging: the radiopharmaceuticals (review).
Topics: Animals; Annexins; Antibodies, Monoclonal; Antigens; Apoptosis; Cysteine; Diagnostic Imaging; DNA; Fluorodeoxyglucose F18; Glycolysis; Humans; Indium Radioisotopes; Ligands; Lymphoma; Myocardial Infarction; Neoplasms; Octreotide; Organotechnetium Compounds; Positron-Emission Tomography; Radiopharmaceuticals; Technetium; Tomography, Emission-Computed, Single-Photon; Yttrium Radioisotopes | 2005 |
Use of PET for monitoring cancer therapy and for predicting outcome.
Topics: Antineoplastic Agents; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Protein Kinase Inhibitors; Radiopharmaceuticals; Treatment Outcome | 2005 |
PET and cancer screening.
Topics: Clinical Trials as Topic; Fluorodeoxyglucose F18; Humans; Incidence; Japan; Mass Screening; Neoplasms; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Risk Assessment; Risk Factors; Sensitivity and Specificity | 2005 |
[Current situation and problems of PET examinations].
Topics: Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Mass Screening; Neoplasms; Positron-Emission Tomography | 2005 |
Positron emission tomography for radiation treatment planning.
Topics: Brain Neoplasms; Female; Fluorodeoxyglucose F18; Glioma; Head and Neck Neoplasms; Humans; Lung Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Neoplasms; Neoplasms, Unknown Primary; Pilot Projects; Positron-Emission Tomography; Prospective Studies; Prostatic Neoplasms; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Randomized Controlled Trials as Topic; Sensitivity and Specificity; Tomography, X-Ray Computed; Uterine Cervical Neoplasms | 2005 |
PET/CT in oncology: a major technology for cancer care.
Topics: Brain Neoplasms; Colorectal Neoplasms; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Lung Neoplasms; Lymphoma; Neoplasms; Positron-Emission Tomography; Thyroid Neoplasms; Tomography, X-Ray Computed | 2005 |
18F-FDG imaging: pitfalls and artifacts.
Topics: Artifacts; Diagnostic Errors; Fluorodeoxyglucose F18; Humans; Neoplasms; Organ Specificity; Positron-Emission Tomography; Practice Guidelines as Topic; Practice Patterns, Physicians'; Radiopharmaceuticals; Tissue Distribution | 2005 |
PET/CT in oncology--a major advance.
Topics: Artifacts; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, X-Ray Computed | 2005 |
[Assessment of tumor radiosensitivity using functional and metabolic nuclear imaging in research and clinical practice. A review].
Topics: Cell Hypoxia; Cell Proliferation; Fluorodeoxyglucose F18; Humans; Neoplasms; Neovascularization, Pathologic; Radiation Tolerance; Radionuclide Imaging; Radiopharmaceuticals | 2006 |
Positron emission tomography: clinical applications in oncology. Part 1.
Topics: Fluorodeoxyglucose F18; Glucose; Humans; Medical Oncology; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2005 |
Molecular imaging: what can be used today.
Topics: Animals; Biochemical Phenomena; Biomarkers, Tumor; Diagnostic Imaging; Dideoxynucleosides; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Medical Oncology; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Receptor, ErbB-2; Receptors, Cell Surface | 2005 |
False-positive FDG PET uptake--the role of PET/CT.
Topics: Artifacts; Contrast Media; False Positive Reactions; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2006 |
Molecular imaging in the development of cancer therapeutics.
Topics: Drug Approval; Fluorodeoxyglucose F18; Genes, Reporter; Humans; Molecular Probe Techniques; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2006 |
The contribution of PET/CT to improved patient management.
Topics: Bone Neoplasms; Fluorodeoxyglucose F18; Humans; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted | 2006 |
Positron-emission tomography and assessment of cancer therapy.
Topics: Cost-Benefit Analysis; False Positive Reactions; Fluorodeoxyglucose F18; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Radiation Dosage | 2006 |
Oncologic PET/CT: current status and controversies.
Topics: Clinical Competence; Fluorodeoxyglucose F18; Humans; Neoplasms; Nuclear Medicine; Positron-Emission Tomography; Radiography; Radiology; Radiopharmaceuticals; Software; Tomography, Emission-Computed | 2005 |
PET-CT: evolving role in 3-D radiation therapy.
Topics: Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Tomography, X-Ray Computed | 2006 |
The current status of FDG-PET in tumour volume definition in radiotherapy treatment planning.
Topics: Fluorodeoxyglucose F18; Humans; Lymph Nodes; Neoplasm Staging; Neoplasms; Patient Care Planning; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
Positron emission tomography imaging of tumor response after photodynamic therapy.
Topics: Animals; Fluorodeoxyglucose F18; Humans; Neoplasms; Photochemotherapy; Positron-Emission Tomography; Radiopharmaceuticals | 2006 |
18FDG PET in oncology: the best and the worst (Review).
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results | 2006 |
Monitoring chemotherapy and radiotherapy of solid tumors.
Topics: Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Lung Neoplasms; Monitoring, Physiologic; Neoplasms; Radionuclide Imaging; Radiopharmaceuticals; Sarcoma; Uterine Cervical Neoplasms | 2006 |
How should we analyse FDG PET studies for monitoring tumour response?
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2006 |
The role of 18F-FDG PET in oncology: clinical and resource implications.
Topics: Fluorodeoxyglucose F18; Humans; Medical Oncology; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2006 |
Clinical molecular imaging with positron emission tomography.
Topics: Antineoplastic Agents; Dideoxynucleosides; Fluorodeoxyglucose F18; Humans; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals | 2006 |
Primer on imaging technologies for cancer.
Topics: Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Neoplasms; Optics and Photonics; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Ultrasonography | 2006 |
Commonly used imaging techniques for diagnosis and staging.
Topics: Contrast Media; Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Radiation Injuries; Tomography, X-Ray Computed; Ultrasonography | 2006 |
[PET?: comfortable whole body checkup].
Topics: Adult; Aged; Brain Diseases; Diagnosis, Differential; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Myocardial Ischemia; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Whole Body Imaging | 2006 |
PET and PET/CT using 18F-FDG in the diagnosis and management of cancer patients.
Topics: Breast Neoplasms; Carcinoma; Colorectal Neoplasms; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphoma; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Tomography, Emission-Computed; Whole Body Imaging | 2006 |
[FDG PET and its impact on patient's management in oncology].
Topics: Decision Making; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2006 |
18F-FDG PET/CT fusion imaging in paediatric solid extracranial tumours.
Topics: Child; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Lymphoma; Neoplasms; Neuroblastoma; Osteosarcoma; Positron-Emission Tomography; Tissue Distribution; Tomography, X-Ray Computed | 2006 |
Tumor hypoxia imaging.
Topics: Biomarkers; Cell Hypoxia; Fluorodeoxyglucose F18; Humans; Misonidazole; Models, Biological; Neoplasm Metastasis; Neoplasms; Oxygen; Positron-Emission Tomography | 2006 |
Benign variations and incidental abnormalities of myocardial FDG uptake in the fasting state as encountered during routine oncology positron emission tomography studies.
Topics: Fasting; Fluorodeoxyglucose F18; Heart Diseases; Humans; Incidental Findings; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2007 |
The role of PET scanning in determining pharmacoselective doses in oncology drug development.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Dose-Response Relationship, Drug; Drug Design; Fluorodeoxyglucose F18; Humans; Models, Chemical; Neoplasms; Perfusion; Positron-Emission Tomography; Technology, Pharmaceutical; Time Factors | 2007 |
[Evaluation of the therapeutic response: role of isotopic imaging].
Topics: Diphosphonates; Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Monitoring, Physiologic; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Technetium Compounds; Technetium Tc 99m Sestamibi; Thallium Radioisotopes; Tomography, Emission-Computed; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
Early detection of cancer recurrence: 18F-FDG PET/CT can make a difference in diagnosis and patient care.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasm Recurrence, Local; Neoplasms; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Risk Assessment; Risk Factors; Sensitivity and Specificity; Subtraction Technique; Systems Integration; Technology Assessment, Biomedical; Tomography, X-Ray Computed; Treatment Outcome; Whole Body Imaging | 2007 |
Monitoring cancer treatment with PET/CT: does it make a difference?
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Outcome Assessment, Health Care; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Risk Assessment; Risk Factors; Sensitivity and Specificity; Subtraction Technique; Systems Integration; Technology Assessment, Biomedical; Tomography, X-Ray Computed; Treatment Outcome; Whole Body Imaging | 2007 |
PET-based treatment planning in radiotherapy: a new standard?
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Practice Guidelines as Topic; Practice Patterns, Physicians'; Prognosis; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Computer-Assisted; Radiotherapy, Conformal; Risk Assessment; Risk Factors | 2007 |
Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006.
Topics: Clinical Trials as Topic; Evidence-Based Medicine; Fluorodeoxyglucose F18; Neoplasm Staging; Neoplasms; Periodicals as Topic; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Whole Body Imaging | 2007 |
[The contribution of PET to radiation treatment planning].
Topics: Bronchial Neoplasms; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiobiology; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2007 |
[Perspective for imaging of tumor metabolism].
Topics: Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography | 2007 |
FDG-PET CT for tumor imaging.
Topics: Fluorodeoxyglucose F18; Humans; Image Enhancement; Neoplasms; Positron-Emission Tomography; Practice Guidelines as Topic; Practice Patterns, Physicians'; Radiopharmaceuticals; Subtraction Technique; Tomography, X-Ray Computed; United States | 2007 |
[Advances in research on biological target volume and conformal intensity-modulated radiotherapy].
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasms; Positron-Emission Tomography; Radiotherapy, Intensity-Modulated; Tomography, X-Ray Computed; Tumor Burden | 2006 |
Positron emission tomography in oncology: a review.
Topics: Evidence-Based Medicine; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2007 |
[Chilean experience with the use of 18F-deoxyglucose positron emission tomography].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Chile; Female; Fluorodeoxyglucose F18; Humans; Infant; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies | 2007 |
Advances in metabolic imaging for surgical oncology.
Topics: Diagnostic Imaging; Fluorodeoxyglucose F18; Humans; Medical Oncology; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2007 |
Tumor-specific positron emission tomography imaging in patients: [18F] fluorodeoxyglucose and beyond.
Topics: Animals; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2007 |
Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics.
Topics: Anaerobiosis; Animals; Biological Transport; Fluorodeoxyglucose F18; Glucose; Glucose Transport Proteins, Facilitative; Glucose Transporter Type 1; Glucose Transporter Type 3; Glycolysis; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Neoplasms; Neovascularization, Pathologic; Positron-Emission Tomography | 2007 |
Probe-guided localization of cancer deposits using [18F]fluorodeoxyglucose.
Topics: Fluorodeoxyglucose F18; Health Personnel; Humans; Intraoperative Period; Neoplasms; Operating Rooms; Positron-Emission Tomography; Radiation Dosage; Radiopharmaceuticals | 2008 |
Molecular imaging agents for clinical positron emission tomography in oncology other than fluorodeoxyglucose (FDG): applications, limitations and potential.
Topics: Animals; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2007 |
PET and PET/CT in pediatric oncology.
Topics: Child; Fluorodeoxyglucose F18; Humans; Medical Oncology; Neoplasms; Pediatrics; Positron-Emission Tomography; Radiopharmaceuticals; Subtraction Technique; Tomography, X-Ray Computed | 2007 |
[Cancer screening with PET: advantages and limitations].
Topics: Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Tomography, X-Ray Computed | 2007 |
PET probe-guided surgery.
Topics: Clinical Trials as Topic; Fluorodeoxyglucose F18; Gamma Cameras; Humans; Iodine Radioisotopes; Neoplasms; Positron-Emission Tomography; Radioimmunodetection; Radiopharmaceuticals; Sensitivity and Specificity; Surgery, Computer-Assisted | 2007 |
Non-[18F]FDG PET in clinical oncology.
Topics: Antibodies; Choline; Dideoxynucleosides; Dihydroxyphenylalanine; Fluorodeoxyglucose F18; Medical Oncology; Neoplasms; Oxygen; Positron-Emission Tomography; Radiopharmaceuticals; Receptors, Estrogen; Receptors, Somatostatin | 2007 |
FDG-PET/CT for cancer management.
Topics: Aged; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2007 |
(18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization.
Topics: Amino Acids; Animals; Bone and Bones; Cell Hypoxia; Choline; Dideoxynucleosides; Dihydroxyphenylalanine; Estradiol; Fluorine Radioisotopes; Fluoroacetates; Fluorodeoxyglucose F18; Glucose; Humans; Membrane Lipids; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2007 |
PET/CT in oncology: for which tumours is it the reference standard?
Topics: Breast Neoplasms; Colorectal Neoplasms; Contrast Media; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Lung Neoplasms; Lymphoma; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms; Radiopharmaceuticals; Reference Standards; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2007 |
PET/CT imaging: what radiologists need to know.
Topics: Contrast Media; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Whole Body Imaging | 2007 |
Considerations for generic oncology FDG-PET/CT protocol preparation in drug development.
Topics: Clinical Trials as Topic; Drug Design; Fluorodeoxyglucose F18; Humans; Models, Statistical; Neoplasms; Patient Selection; Positron-Emission Tomography; Radiopharmaceuticals; Research Design; Tomography, X-Ray Computed | 2007 |
Radiopharmacy.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radioisotopes; Radiopharmaceuticals; Tomography, X-Ray Computed | 2008 |
FDG-pet in paraneoplastic syndromes.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Paraneoplastic Syndromes; Positron-Emission Tomography; Radiopharmaceuticals | 2008 |
PET and PET/CT in radiotherapy.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Radiation Oncology; Radiation Tolerance; Radiopharmaceuticals; Radiotherapy; Tomography, X-Ray Computed | 2008 |
Mobile PET in the UK: legislative, regulatory and cost-effectiveness considerations.
Topics: Cost-Benefit Analysis; Fluorodeoxyglucose F18; Hospitals; Humans; Magnetic Resonance Imaging; Mobile Health Units; Neoplasms; Positron-Emission Tomography; Radiology; Time Factors; Tomography, X-Ray Computed; United Kingdom | 2008 |
[Positron emission tomography in oncology: an update].
Topics: Fluorodeoxyglucose F18; Humans; Neoplasm Recurrence, Local; Neoplasms; Patient Selection; Positron-Emission Tomography; Radiopharmaceuticals | 2007 |
New approaches for imaging tumour responses to treatment.
Topics: Animals; Clinical Trials as Topic; Diagnostic Imaging; Fluorodeoxyglucose F18; Glycolysis; Humans; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Neoplasms; Neovascularization, Pathologic; Positron-Emission Tomography; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; Ultrasonography | 2008 |
Technologies for translational imaging using generators in oncology.
Topics: Animals; Diagnostic Imaging; Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Neoplasms; Patents as Topic; Positron-Emission Tomography; Radiopharmaceuticals; Technetium; Tomography, Emission-Computed, Single-Photon | 2007 |
Oncologic PET tracers beyond [(18)F]FDG and the novel quantitative approaches in PET imaging.
Topics: Carbon Radioisotopes; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2008 |
Clinical applications of positron emission tomography/computed tomography treatment planning.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Imaging, Three-Dimensional; Lung Neoplasms; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed | 2008 |
Technology Insight: advances in molecular imaging and an appraisal of PET/CT scanning.
Topics: Drug Monitoring; Fluorodeoxyglucose F18; Humans; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Radiotherapy Planning, Computer-Assisted; Sensitivity and Specificity; Systems Integration; Tomography, X-Ray Computed | 2008 |
The role of PET in target localization for radiotherapy treatment planning.
Topics: Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Lymphatic Irradiation; Lymphoma; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Radiation Injuries; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
18F-PET-CT in extracranial paediatric oncology: when and for whom is it useful?
Topics: Child; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2008 |
Quantitative techniques in 18FDG PET scanning in oncology.
Topics: Breast Neoplasms; Data Interpretation, Statistical; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Lymphoma; Male; Medical Oncology; Neoplasms; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Radiopharmaceuticals; Regression Analysis; Solitary Pulmonary Nodule; Stomach Neoplasms | 2008 |
Positron emission tomography scanning is coming to a hospital near you soon!
Topics: Colorectal Neoplasms; Diagnosis, Differential; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphoma; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms; Outcome and Process Assessment, Health Care; Radiopharmaceuticals; Tomography, Emission-Computed; Tomography, X-Ray Computed; United Kingdom | 2008 |
Nuclear oncology 1984.
Topics: Antibodies, Monoclonal; Antigens, Neoplasm; Bleomycin; Brain Neoplasms; Deoxyglucose; Fluorodeoxyglucose F18; Gallium Radioisotopes; Glioma; Humans; Liver Neoplasms; Male; Melanoma; Melanoma-Specific Antigens; Middle Aged; Neoplasm Proteins; Neoplasms; Tomography, Emission-Computed | 1984 |
[Positron-emission tomography: role of 18F-fluorodeoxyglucose (18FDG) imaging in oncology].
Topics: Cell Transformation, Neoplastic; Deoxyglucose; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Gamma Cameras; Humans; Lymphatic Metastasis; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms; Predictive Value of Tests; Tomography, Emission-Computed | 1995 |
Positron emission tomographic oncology.
Topics: Deoxyglucose; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Neoplasms; Tomography, Emission-Computed | 1994 |
Positron emission tomography in oncology.
Topics: Carbon Radioisotopes; Deoxyglucose; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Methionine; Neoplasms; Tomography, Emission-Computed | 1994 |
Use of positron emission tomography in oncology.
Topics: Brain Neoplasms; Breast Neoplasms; Deoxyglucose; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasms; Tomography, Emission-Computed | 1993 |
Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy? The EC PET Oncology Concerted Action and the EORTC PET Study Group.
Topics: Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxyglucose; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Fluorodeoxyglucose F18; Humans; Neoplasms; Sensitivity and Specificity; Tomography, Emission-Computed; Treatment Outcome | 1995 |
[Cancer diagnosis with positron emission tomography (PET)].
Topics: Carbon Radioisotopes; Clinical Trials as Topic; Deoxyglucose; Diagnosis, Differential; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Methionine; Neoplasms; Tomography, Emission-Computed | 1996 |
Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients.
Topics: Artifacts; Deoxyglucose; False Positive Reactions; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Neoplasms; Sensitivity and Specificity; Tomography, Emission-Computed | 1996 |
Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose.
Topics: Deoxyglucose; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Neoplasms; Tomography, Emission-Computed | 1996 |
PET and [18F]-FDG in oncology: a clinical update.
Topics: Deoxyglucose; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Neoplasms; Tomography, Emission-Computed | 1996 |
[Diagnosis of cancers by FDG-PET].
Topics: Deoxyglucose; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Neoplasm Staging; Neoplasms; Prognosis; Tomography, Emission-Computed | 1997 |
Does fluorine-18 fluorodeoxyglucose metabolic imaging of tumours benefit oncology?
Topics: Deoxyglucose; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Medical Oncology; Neoplasms; Tomography, Emission-Computed | 1997 |
[Positron emission tomography].
Topics: Animals; Blood Glucose; Brain Diseases; Deoxyglucose; Energy Metabolism; Fluorodeoxyglucose F18; Humans; Neoplasms; Pharmacokinetics; Receptors, Neurotransmitter; Tomography, Emission-Computed | 1997 |
Metabolic imaging by positron emission tomography in oncology.
Topics: Brain Neoplasms; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasms; Radiography; Tomography, Emission-Computed | 1997 |
PET applications in pediatrics.
Topics: Central Nervous System Diseases; Child; Child, Preschool; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Heart Defects, Congenital; Humans; Infant; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 1997 |
FDG uptake, tumour characteristics and response to therapy: a review.
Topics: Animals; Fluorodeoxyglucose F18; Glucose; Glycolysis; Humans; Monosaccharide Transport Proteins; Neoplasms; Prognosis; Radiopharmaceuticals; Tomography, Emission-Computed | 1998 |
[New functional imaging technique "positron emission tomography"].
Topics: Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 1998 |
FDG accumulation and tumor biology.
Topics: Fluorodeoxyglucose F18; Glucose; Glycolysis; Humans; Mutagenesis; Neoplasms; Radionuclide Imaging; Radiopharmaceuticals | 1998 |
Benign causes of 18-FDG uptake on whole body imaging.
Topics: Artifacts; False Positive Reactions; Fluorodeoxyglucose F18; Humans; Neoplasms; Radionuclide Imaging; Radiopharmaceuticals; Tissue Distribution | 1998 |
Recent advances in the analyses of the characteristics of tumors on FDG uptake.
Topics: Animals; Biological Transport; Fluorodeoxyglucose F18; Humans; Neoplasms; Neoplasms, Experimental | 1998 |
What is new in nuclear medicine imaging?
Topics: Fluorodeoxyglucose F18; Humans; Indium Radioisotopes; Intraoperative Care; Neoplasms; Radiology, Interventional; Radionuclide Angiography; Radiopharmaceuticals; Somatostatin; Technetium Tc 99m Sestamibi; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 1999 |
Positron emission tomography as a diagnostic tool in oncology.
Topics: Biomarkers, Tumor; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Male; Medical Oncology; Neoplasms; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, Emission-Computed | 1998 |
[Role of 18F-FDG positron emission tomography in surgical evaluation].
Topics: Carcinoma, Bronchogenic; Colorectal Neoplasms; Fluorodeoxyglucose F18; Glycolysis; Humans; Lung Neoplasms; Neoplasms; Pancreatic Neoplasms; Sensitivity and Specificity; Tomography, Emission-Computed | 1998 |
Positron emission tomography (PET) in the evaluation of patients with cancer.
Topics: Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 1999 |
[PET evaluation of glucose metabolism in cancer].
Topics: Cancer Care Facilities; Costs and Cost Analysis; Evaluation Studies as Topic; Fluorodeoxyglucose F18; Glucose; Humans; Japan; Neoplasms; Thyroid Neoplasms; Tomography, Emission-Computed | 1999 |
[FDG-PET in oncology. Methodological principles and clinical applications].
Topics: Fluorodeoxyglucose F18; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms; Sensitivity and Specificity; Tomography, Emission-Computed | 1999 |
Relevance of positron emission tomography (PET) in oncology.
Topics: Carbon Radioisotopes; Fluorides; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Magnetic Resonance Imaging; Methionine; Misonidazole; Neoplasm Staging; Neoplasms; Radioisotopes; Radiopharmaceuticals; Sensitivity and Specificity; Thymidine; Tomography, Emission-Computed; Tomography, X-Ray Computed | 1999 |
Nuclear medicine in cancer diagnosis.
Topics: Female; Fluorodeoxyglucose F18; Humans; Male; Neoplasm Staging; Neoplasms; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 1999 |
18-Fluorodeoxyglucose imaging in oncology.
Topics: Biophysical Phenomena; Biophysics; Fluorodeoxyglucose F18; Humans; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 1999 |
Oncological applications of FDG PET imaging.
Topics: Breast Neoplasms; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Lymphatic Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms; Pancreatic Neoplasms; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed | 1999 |
FDG-PET in clinical oncology: review of the literature and report of one institution's experience.
Topics: Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Medical Oncology; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 1999 |
[Present status of PET images: clinical FDG PET in oncology].
Topics: Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 1999 |
Nuclear imaging methods for non-invasive drug monitoring.
Topics: Drug Monitoring; Fluorodeoxyglucose F18; Humans; Neoplasms; Radioimmunodetection; Radioimmunotherapy; Radionuclide Imaging; Receptors, Cell Surface; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 2000 |
Positron emission tomography (PET) in diagnostic oncology: is it a necessary tool today?
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 2000 |
[Diagnostic value of positron emission tomography (PET) in clinical oncology].
Topics: Brain Neoplasms; Breast Neoplasms; Diagnosis, Differential; Digestive System Neoplasms; Evaluation Studies as Topic; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Lung Neoplasms; Lymphoma; Male; Melanoma; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed; Urogenital Neoplasms | 2000 |
Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality.
Topics: Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Neoplasms; Prostatic Neoplasms; Radiobiology; Radiopharmaceuticals; Radiotherapy, Conformal; Tomography, Emission-Computed | 2000 |
Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-D-glucose and positron emission tomography: an overview of different analytical methods.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Regression Analysis; Reproducibility of Results; Tomography, Emission-Computed | 2000 |
Changes in 18F-FDG uptake measured by PET as a pharmacodynamic end-point in anticancer therapy. How far have we got?
Topics: Antineoplastic Agents; Europe; Fluorodeoxyglucose F18; Glucose; Humans; Neoplasms; Pancreatic Neoplasms; Practice Guidelines as Topic; Predictive Value of Tests; Radiopharmaceuticals; Sensitivity and Specificity; Tissue Distribution; Tomography, Emission-Computed | 2000 |
PET imaging in oncology.
Topics: Colonic Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphoma; Male; Melanoma; Neoplasms; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed; United States | 2000 |
Radioimmunoimaging and radioimmunotherapy: will these be routine procedures?
Topics: Antibodies, Monoclonal; Fluorodeoxyglucose F18; Humans; Neoplasms; Radioimmunodetection; Radioimmunotherapy; Radiopharmaceuticals; Tomography, Emission-Computed | 2000 |
[Added value of positron emission tomography with fluoro-18-deoxyglucose as the tracer (FDG-PET) in clinical problem cases in oncology].
Topics: Adult; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed | 2000 |
The diagnostic utility of the lognormal behavior of PET standardized uptake values in tumors.
Topics: Biomarkers, Tumor; Fluorodeoxyglucose F18; Humans; Neoplasms; Radiopharmaceuticals; ROC Curve; Tomography, Emission-Computed | 2000 |
Positron-emission tomography with [18F]fluorodeoxyglucose. Part I. Biochemical uptake mechanism and its implication for clinical studies.
Topics: Citric Acid Cycle; Fluorodeoxyglucose F18; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glycolysis; Hexokinase; Humans; Mitochondria; Monosaccharide Transport Proteins; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed; Up-Regulation | 2000 |
Positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose in oncology. Part II. The clinical value in detecting and staging primary tumours.
Topics: Breast Neoplasms; Colorectal Neoplasms; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Melanoma; Neoplasm Staging; Neoplasms; Ovarian Neoplasms; Radiopharmaceuticals; Skin Neoplasms; Tomography, Emission-Computed | 2000 |
What does positron emission tomography offer oncology?
Topics: Antineoplastic Agents; Fluorodeoxyglucose F18; Gene Expression; History, 20th Century; Humans; Neoplasms; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed | 2000 |
Quantitative assessment of tumor metabolism using FDG-PET imaging.
Topics: Fluorodeoxyglucose F18; Glucose; Humans; Neoplasms; Radiopharmaceuticals; Reproducibility of Results; Tomography, Emission-Computed | 2000 |
The role of hybrid cameras in oncology.
Topics: Fluorodeoxyglucose F18; Gamma Cameras; Humans; Image Processing, Computer-Assisted; Lymphoma, AIDS-Related; Magnetic Resonance Imaging; Neoplasms; Radiopharmaceuticals; Reproducibility of Results; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed | 2000 |
Positron-emission tomographic imaging of cancer: glucose metabolism and beyond.
Topics: Adult; Animals; Female; Fluorodeoxyglucose F18; Glucose; Humans; Neoplasms; Tomography, Emission-Computed | 2001 |
The rate-limiting step for tumor [18F]fluoro-2-deoxy-D-glucose (FDG) incorporation.
Topics: Animals; Fluorodeoxyglucose F18; Hexokinase; Humans; Mice; Monosaccharide Transport Proteins; Neoplasms; Radiopharmaceuticals; Rats; Tomography, Emission-Computed; Tumor Cells, Cultured | 2001 |
[Nuclear medicine in oncology: new diagnostic and therapeutic methods].
Topics: Carcinoma, Hepatocellular; Contraindications; Contrast Media; Fluorodeoxyglucose F18; Humans; Iodine Radioisotopes; Iodized Oil; Liver Neoplasms; Lymphatic Metastasis; Medical Oncology; Neoplasms; Nuclear Medicine; Radioimmunotherapy; Radiopharmaceuticals; Tomography, Emission-Computed | 2001 |
Positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose in oncology. Part IIIa: Therapy response monitoring in breast cancer, lymphoma and gliomas.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Central Nervous System Neoplasms; Evaluation Studies as Topic; Female; Fluorodeoxyglucose F18; Glioma; Humans; Lymphoma; Male; Neoplasm Metastasis; Neoplasms; Outcome Assessment, Health Care; Rats; Tomography, Emission-Computed | 2001 |
Positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose in oncology. Part IIIb: Therapy response monitoring in colorectal and lung tumours, head and neck cancer, hepatocellular carcinoma and sarcoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Hepatocellular; Colorectal Neoplasms; Evaluation Studies as Topic; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Metastasis; Neoplasms; Outcome Assessment, Health Care; Sarcoma; Soft Tissue Neoplasms; Tomography, Emission-Computed | 2001 |
The clinical value of 18F-FDG detection with a dual-head coincidence camera: a review.
Topics: Animals; Fluorodeoxyglucose F18; Humans; Neoplasms; Radionuclide Imaging; Radiopharmaceuticals | 2001 |
A tabulated summary of the FDG PET literature.
Topics: Bibliometrics; Brain; Coronary Disease; Dementia; Fluorodeoxyglucose F18; Humans; Myocardium; Neoplasms; Radiopharmaceuticals; Seizures; Tissue Survival; Tomography, Emission-Computed | 2001 |
[Clinical usefulness of FDG-PET in oncology].
Topics: Fluorodeoxyglucose F18; Glucose; Humans; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 2001 |
Positron emission tomography imaging in oncology.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 2001 |
[Monitoring of response to neoadjuvant therapy by positron emission tomography (PET)].
Topics: Female; Fluorodeoxyglucose F18; Humans; Male; Neoadjuvant Therapy; Neoplasms; Prognosis; Radiopharmaceuticals; Radiotherapy Dosage; Time Factors; Tomography, Emission-Computed; Tomography, X-Ray Computed; Treatment Outcome | 2001 |
[The role of diagnostic PET in treatment planning before tumor surgery].
Topics: Breast Neoplasms; Carcinoma, Bronchogenic; Clinical Trials as Topic; Colorectal Neoplasms; Combined Modality Therapy; Diagnosis, Differential; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Glucose; Humans; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Neoplasms; Prognosis; Prospective Studies; Radiopharmaceuticals; Sarcoma; Soft Tissue Neoplasms; Thyroid Neoplasms; Time Factors; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2001 |
[Meta-analysis on the diagnostic efficacy of FDG-PET].
Topics: Coronary Disease; Epilepsy; Fluorodeoxyglucose F18; Humans; Neoplasms; Radiopharmaceuticals; Sensitivity and Specificity; Tissue Survival; Tomography, Emission-Computed | 2001 |
FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III", 21 July and 19 September 2000.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 2001 |
Positron emission tomography scanning: current and future applications.
Topics: Energy Metabolism; Fluorodeoxyglucose F18; Forecasting; Humans; Neoplasm Staging; Neoplasms; Tomography, Emission-Computed; United States | 2002 |
[Positron emission tomography (PET) in oncology (Part I)].
Topics: Abdomen; Animals; Bone and Bones; Carbon Radioisotopes; Diagnosis, Differential; Energy Metabolism; Fasting; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Glucose Transporter Type 1; Head; Humans; Image Processing, Computer-Assisted; Methionine; Mice; Monosaccharide Transport Proteins; Muscles; Neoplasm Proteins; Neoplasms; Pelvis; Radiopharmaceuticals; Thorax; Thyroid Gland; Tissue Distribution; Tomography, Emission-Computed | 2002 |
From tumor biology to clinical Pet: a review of positron emission tomography (PET) in oncology.
Topics: Amino Acids; Cell Hypoxia; Fluorodeoxyglucose F18; Glucose; Humans; Methionine; Models, Chemical; Neoplasm Recurrence, Local; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed; Treatment Outcome; Whole-Body Counting | 2001 |
Whole-body FDG-PET imaging in the management of patients with cancer.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms; Radionuclide Imaging; Radiopharmaceuticals; Whole-Body Counting | 2002 |
[Positron emission tomography (PET) in clinical oncology. Part II].
Topics: Adult; Aged; Colorectal Neoplasms; False Negative Reactions; False Positive Reactions; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphoma; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms; Predictive Value of Tests; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2002 |
Clinical role of positron emission tomography in oncology.
Topics: Colorectal Neoplasms; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Lung Neoplasms; Lymphoma; Melanoma; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 2001 |
A shifting landscape: what will be next FDG in PET oncology?
Topics: Adult; Amino Acids; DNA; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 2002 |
Current status of positron emission tomography in oncology.
Topics: Australia; Fluorodeoxyglucose F18; Humans; Neoplasm Metastasis; Neoplasms; Tomography, Emission-Computed | 2002 |
[Cost-effective PET scans in oncology].
Topics: Breast Neoplasms; Colorectal Neoplasms; Cost-Benefit Analysis; Diagnosis, Differential; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Hungary; Lung Neoplasms; Lymphoma; Medicare; Melanoma; Neoplasm Staging; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed; United States | 2002 |
Clinical oncological applications of Positron Emission Tomography (PET) using fluorine-18-fluoro-2-deoxy-D-glucose.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasm Staging; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 2002 |
PET scanning in oncology.
Topics: Deoxyglucose; Fluorodeoxyglucose F18; Humans; Methionine; Neoplasms; Tomography, Emission-Computed | 1992 |
The applications of PET in clinical oncology.
Topics: Brain Neoplasms; Colorectal Neoplasms; Deoxyglucose; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasms; Tomography, Emission-Computed | 1991 |
[Positron emitters for the study of tumor metabolism].
Topics: Deoxyglucose; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Fluorouracil; Humans; Neoplasms; Tomography, Emission-Computed | 1989 |
[Potential use of positron-emission tomography in clinical oncology].
Topics: Carbon Radioisotopes; Deoxyglucose; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Fucose; Humans; Methionine; Neoplasms; Tomography, Emission-Computed | 1988 |
Potential of NMR and PET for determining tumor metabolism.
Topics: Brain Neoplasms; Cerebrovascular Circulation; Deoxyglucose; Fluorodeoxyglucose F18; Glucose; Humans; Magnetic Resonance Spectroscopy; Neoplasms; Oxygen Consumption; Tomography, Emission-Computed | 1986 |
70 trial(s) available for fluorodeoxyglucose f18 and Neoplasms
| Article | Year |
|---|---|
SUVfdg: A standard-uptake-value (SUV) body habitus normalizer specific to fluorodeoxyglucose (FDG) in humans.
Topics: Adult; Body Height; Body Surface Area; Child; Cohort Studies; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2022 |
Ten-year prospective evaluation of whole-body cancer screening with multiple modalities including [
Topics: Adult; Aged; Early Detection of Cancer; Female; Fluorodeoxyglucose F18; Healthy Volunteers; Humans; Male; Mass Screening; Middle Aged; Neoplasms; Positron-Emission Tomography; Prospective Studies; Whole Body Imaging | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses | 2021 |
Comparison of CT and PET/CT for biopsy guidance in oncological patients.
Topics: Aged; Biological Transport; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Image-Guided Biopsy; Male; Middle Aged; Neoplasms; Positron Emission Tomography Computed Tomography | 2017 |
Polymyalgia rheumatica and giant cell arteritis-three challenges-consequences of the vasculitis process, osteoporosis, and malignancy: A prospective cohort study protocol.
Topics: Biopsy; Denmark; Fluorodeoxyglucose F18; Giant Cell Arteritis; Humans; Middle Aged; Neoplasms; Osteoporosis; Patient Selection; Polymyalgia Rheumatica; Positron Emission Tomography Computed Tomography; Prednisolone; Prevalence; Radiopharmaceuticals; Single-Blind Method; Steroids; Temporal Arteries; Vasculitis | 2017 |
Pilot study of propranolol premedication to reduce FDG uptake in brown adipose tissue on PET scans of adolescent and young adult oncology patients.
Topics: Adipose Tissue, Brown; Adolescent; Adult; Blood Glucose; Blood Pressure; Female; Fluorodeoxyglucose F18; Heart Rate; Humans; Male; Neoplasms; Pilot Projects; Positron-Emission Tomography; Propranolol; Prospective Studies; Young Adult | 2017 |
Quality assessment of positron emission tomography scans: recommendations for future multicentre trials.
Topics: Dose-Response Relationship, Radiation; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Neoplasms; Positron-Emission Tomography; Practice Guidelines as Topic; Quality Assurance, Health Care; Quality Control; Radiopharmaceuticals | 2017 |
Effect of the types of pretreatment imaging modalities on the treatment response to palliative radiation for painful bone metastases from solid cancer: a single-center retrospective analysis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Bone Neoplasms; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Neoplasms; Palliative Care; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Retrospective Studies; Tomography, X-Ray Computed; Young Adult | 2019 |
A prospective clinical trial of tumor hypoxia imaging with 18F-fluoromisonidazole positron emission tomography and computed tomography (F-MISO PET/CT) before and during radiation therapy.
Topics: Adult; Aged; Aged, 80 and over; Cell Hypoxia; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Misonidazole; Molecular Imaging; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2013 |
A phase 1, dose-escalation, pharmacokinetic and pharmacodynamic study of BIIB021 administered orally in patients with advanced solid tumors.
Topics: Adenine; Administration, Oral; Antineoplastic Agents; Biopsy; Drug Administration Schedule; Fluorodeoxyglucose F18; HSP90 Heat-Shock Proteins; Humans; Insulin-Like Growth Factor Binding Protein 2; Intracellular Space; Leukocytes, Mononuclear; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Pyridines; Receptor, ErbB-2 | 2014 |
Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Dose-Response Relationship, Drug; Everolimus; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Radionuclide Imaging; Radiopharmaceuticals; Sirolimus; TOR Serine-Threonine Kinases | 2014 |
A partial volume effect correction tailored for 18F-FDG-PET oncological studies.
Topics: Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiography; Radiopharmaceuticals | 2013 |
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer.
Topics: Activin Receptors, Type II; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Female; Fluorodeoxyglucose F18; Humans; Immunoglobulin Fc Fragments; Ligands; Male; Middle Aged; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Recombinant Fusion Proteins; Telangiectasis; Treatment Outcome | 2014 |
Tumor texture analysis in 18F-FDG PET: relationships between texture parameters, histogram indices, standardized uptake values, metabolic volumes, and total lesion glycolysis.
Topics: Adult; Aged; Aged, 80 and over; Biological Transport; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Reference Standards; Tumor Burden | 2014 |
Diazepam and Jacobson's progressive relaxation show similar attenuating short-term effects on stress-related brain glucose consumption.
Topics: Adult; Anti-Anxiety Agents; Anxiety; Brain; Diazepam; Female; Fluorodeoxyglucose F18; Glucose; Humans; Male; Neoplasms; Positron-Emission Tomography; Prefrontal Cortex; Relaxation Therapy | 2015 |
Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Dose-Response Relationship, Drug; Female; Fluorodeoxyglucose F18; Humans; Hydroxychloroquine; Male; Melanoma; Middle Aged; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Protein Kinase Inhibitors; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome; Vacuoles | 2014 |
18F-fluoride PET used for treatment monitoring of systemic cancer therapy: results from the National Oncologic PET Registry.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Databases, Factual; Female; Fluorodeoxyglucose F18; Humans; Male; Neoplasm Metastasis; Neoplasms; Positron-Emission Tomography; Prognosis; Prospective Studies; Prostatic Neoplasms; Registries; Sodium Fluoride; Treatment Outcome | 2015 |
Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Nanoparticles; Neoplasms; Paclitaxel; Positron-Emission Tomography; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome | 2015 |
(18)F-fluorodeoxyglucose positron-emission tomography-computed tomography to diagnose recurrent cancer.
Topics: Adult; Aged; Aged, 80 and over; Canada; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasm Recurrence, Local; Neoplasms; Positron-Emission Tomography; Radiography | 2015 |
Pilot Prospective Evaluation of (18)F-Alfatide II for Detection of Skeletal Metastases.
Topics: Adult; Aged; Bone Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Peptides, Cyclic; Pilot Projects; Positron-Emission Tomography; Radiopharmaceuticals | 2015 |
First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Mutation; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Radiopharmaceuticals; Treatment Outcome; Young Adult | 2016 |
Variations in target volume definition and dose to normal tissue using anatomic versus biological imaging (
Topics: Aged; Bone Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiology, Interventional; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted | 2017 |
Reproducibility of standardized uptake value measurements determined by 18F-FDG PET in malignant tumors.
Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Reproducibility of Results; Time Factors; Tomography, X-Ray Computed | 2008 |
PET-CT-guided interventions in the management of FDG-positive lesions in patients suffering from solid malignancies: initial experiences.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Pilot Projects; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Subtraction Technique; Surgery, Computer-Assisted; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2009 |
[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy.
Topics: Animals; Antibiotics, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Disease Progression; Female; Fluorodeoxyglucose F18; Glucose Transporter Type 1; Humans; Mice; Mice, Nude; Neoplasms; Patient Selection; Phosphorylation; Positron-Emission Tomography; Predictive Value of Tests; Protein Kinases; Proto-Oncogene Proteins c-akt; Radiopharmaceuticals; Sirolimus; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Treatment Outcome; Xenograft Model Antitumor Assays | 2009 |
[Positron emission tomography in the diagnosis of atherosclerotic plaques in cancer patients].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Atherosclerosis; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Sex Factors | 2010 |
Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours.
Topics: Aged; Aurora Kinase A; Aurora Kinase B; Aurora Kinases; Belgium; Biopsy; Dose-Response Relationship, Drug; Female; Fluorodeoxyglucose F18; Heterocyclic Compounds, 3-Ring; Histones; Humans; Immunohistochemistry; Linear Models; Male; Maximum Tolerated Dose; Middle Aged; Mitosis; Models, Biological; Molecular Targeted Therapy; Neoplasms; Phosphorylation; Positron-Emission Tomography; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrimidines; Radiopharmaceuticals; Tennessee; Treatment Outcome | 2011 |
Multimodal imaging and detection approach to 18F-FDG-directed surgery for patients with known or suspected malignancies: a comprehensive description of the specific methodology utilized in a single-institution cumulative retrospective experience.
Topics: Adult; Aged; Aged, 80 and over; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Neoplasm Recurrence, Local; Neoplasms; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Whole Body Imaging | 2011 |
Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Australia; Canada; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Fluorodeoxyglucose F18; Focal Adhesion Kinase 1; Focal Adhesion Kinase 2; Humans; Male; Maximum Tolerated Dose; Midazolam; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Neoplasms; Nonlinear Dynamics; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyrimidines; Radiopharmaceuticals; Sulfonamides; Treatment Outcome; United States | 2012 |
Use of FDG PET/CT for investigation of febrile neutropenia: evaluation in high-risk cancer patients.
Topics: Adult; Aged; Female; Fever; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasms; Neutropenia; Positron-Emission Tomography; Risk; Tomography, X-Ray Computed | 2012 |
Multiphase CT scanning and different intravenous contrast media concentrations in combined F-18-FDG PET/CT: Effect on quantitative and clinical assessment.
Topics: Contrast Media; Dose-Response Relationship, Drug; Female; Fluorodeoxyglucose F18; Humans; Infusions, Intravenous; Iohexol; Male; Middle Aged; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed | 2012 |
Effects of a proton pump inhibitor on the physiological accumulation of fluoro-2-deoxy-D-glucose (FDG) in FDG-positron emission tomography.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Colon; Drug Administration Schedule; Female; Fluorodeoxyglucose F18; Gastric Mucosa; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Proton Pump Inhibitors; Rabeprazole; Radiopharmaceuticals; Stomach; Tissue Distribution; Tomography, X-Ray Computed | 2012 |
A phase I study of BMS-690514 in Japanese patients with advanced or metastatic solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Piperidines; Positron-Emission Tomography; Pyrroles; Triazines | 2012 |
Discrimination and anatomical mapping of PET-positive lesions: comparison of CT attenuation-corrected PET images with coregistered MR and CT images in the abdomen.
Topics: Abdomen; Adult; Aged; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Whole Body Imaging | 2013 |
Impact of cytokines on diffuse splenic 18F-fluorodeoxyglucose uptake during positron emission tomography/computed tomography.
Topics: Aged; Biological Transport; Cytokines; Female; Fluorodeoxyglucose F18; Hematologic Tests; Humans; Liver; Male; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Spleen; Tomography, X-Ray Computed | 2013 |
Combined 18F-fluoride and 18F-FDG PET/CT scanning for evaluation of malignancy: results of an international multicenter trial.
Topics: Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Neoplasms; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Glucose; Humans; Image Processing, Computer-Assisted; International Cooperation; Male; Medical Oncology; Middle Aged; Neoplasm Metastasis; Neoplasms; Nuclear Medicine; Pilot Projects; Positron-Emission Tomography; Prospective Studies; Reproducibility of Results; Tomography, X-Ray Computed | 2013 |
Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Apoptosis; Biomarkers; CD3 Complex; Collagen; Dose-Response Relationship, Drug; Endostatins; Endothelium; Female; Fluorodeoxyglucose F18; Humans; In Situ Nick-End Labeling; Lasers; Male; Middle Aged; Neoplasms; Neovascularization, Pathologic; Peptide Fragments; Prospective Studies; Recombinant Proteins; Tomography, Emission-Computed | 2002 |
Impact of whole-body 18F-FDG PET on staging and managing patients for radiation therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Palliative Care; Patient Care Management; Prognosis; Radiopharmaceuticals; Radiotherapy; Reproducibility of Results; Sensitivity and Specificity; Tomography, Emission-Computed; Treatment Outcome; Whole-Body Counting | 2003 |
Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG.
Topics: Aged; Aged, 80 and over; Feasibility Studies; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Lung Neoplasms; Lymphoma; Male; Middle Aged; Neoplasms; Organ Specificity; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tissue Distribution; Tomography, Emission-Computed; Whole-Body Counting | 2003 |
Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Image Enhancement; Male; Middle Aged; Neoplasms; Quality Control; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Subtraction Technique; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2003 |
Shortened PET data acquisition protocol for the quantification of 18F-FDG kinetics.
Topics: Computer Simulation; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Kinetics; Metabolic Clearance Rate; Models, Biological; Neoplasms; Radioisotope Dilution Technique; Radiopharmaceuticals; Sample Size; Statistics as Topic; Tomography, Emission-Computed | 2003 |
Initial experience with a prototype dual-crystal (LSO/NaI) dual-head coincidence camera in oncology.
Topics: Adult; Aged; Aged, 80 and over; Equipment Design; Equipment Failure Analysis; Feasibility Studies; Female; Fluorodeoxyglucose F18; Gamma Cameras; Humans; Lutetium; Male; Middle Aged; Neoplasms; Pilot Projects; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Silicates; Sodium Iodide; Transducers; Whole-Body Counting | 2004 |
Dual-modality PET/CT scanning with negative oral contrast agent to avoid artifacts: introduction and evaluation.
Topics: Administration, Oral; Adult; Aged; Artifacts; Barium Sulfate; Blood Glucose; Contrast Media; Digestive System; Female; Fluorodeoxyglucose F18; Galactans; Humans; Image Enhancement; Male; Mannans; Mannitol; Middle Aged; Neoplasms; Phantoms, Imaging; Plant Gums; Polysaccharides; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2004 |
Clinical implications of different image reconstruction parameters for interpretation of whole-body PET studies in cancer patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Male; Middle Aged; Neoplasms; Phantoms, Imaging; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, Emission-Computed; Whole-Body Counting | 2004 |
Application of intravenous contrast in PET/CT: does it really introduce significant attenuation correction error?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Artifacts; Contrast Media; Diagnostic Errors; Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Injections, Intravenous; Iopamidol; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Subtraction Technique; Tomography, X-Ray Computed | 2005 |
Optimized intravenous contrast administration for diagnostic whole-body 18F-FDG PET/CT.
Topics: Contrast Media; Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Injections, Intravenous; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Subtraction Technique; Tomography, X-Ray Computed; Whole-Body Counting | 2005 |
Optimizing imaging protocols for overweight and obese patients: a lutetium orthosilicate PET/CT study.
Topics: Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Lutetium; Male; Middle Aged; Neoplasms; Obesity; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Severity of Illness Index; Silicates; Subtraction Technique; Tomography, X-Ray Computed | 2005 |
PET/CT with intravenous contrast can be used for PET attenuation correction in cancer patients.
Topics: Adult; Aged; Artifacts; Contrast Media; Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Injections, Intravenous; Iothalamic Acid; Male; Middle Aged; Neoplasms; Phantoms, Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Single-Blind Method; Subtraction Technique; Tomography, X-Ray Computed | 2005 |
Incremental value of fusion imaging with integrated PET-CT in oncology.
Topics: Fluorodeoxyglucose F18; Humans; Image Enhancement; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Subtraction Technique; Tomography, X-Ray Computed | 2005 |
Usefulness of noise adaptive non-linear gaussian filter in FDG-PET study.
Topics: Adult; Aged; Algorithms; Computer Simulation; Female; Filtration; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Male; Middle Aged; Models, Biological; Models, Statistical; Neoplasms; Normal Distribution; Phantoms, Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Signal Processing, Computer-Assisted; Stochastic Processes | 2005 |
Optimized contrast-enhanced CT protocols for diagnostic whole-body 18F-FDG PET/CT: technical aspects of single-phase versus multiphase CT imaging.
Topics: Artifacts; Biotechnology; Contrast Media; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Iohexol; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Reproducibility of Results; Respiration; Sensitivity and Specificity; Subtraction Technique; Tomography, X-Ray Computed; Whole Body Imaging | 2006 |
Cancer screening with FDG-PET.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Incidence; Japan; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Risk Assessment; Risk Factors; Sensitivity and Specificity; Whole Body Imaging | 2006 |
Clinical impact of fluorine-18 fluorodeoxyglucose positron emission tomography in cancer patients. A comparative study between dedicated camera and dual-head coincidence gamma camera.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Equipment Design; Equipment Failure Analysis; Female; Fluorodeoxyglucose F18; France; Gamma Cameras; Humans; Incidence; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Practice Patterns, Physicians'; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity | 2006 |
Comparison of image-derived and arterial input functions for estimating the rate of glucose metabolism in therapy-monitoring 18F-FDG PET studies.
Topics: Adult; Aged; Arteries; Blood Glucose; Female; Fluorodeoxyglucose F18; Glucose; Humans; Male; Middle Aged; Neoplasms; Outcome Assessment, Health Care; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Therapy, Computer-Assisted; Treatment Outcome | 2006 |
Prospective study of positron emission tomography for evaluation of the activity of lapatinib, a dual inhibitor of the ErbB1 and ErbB2 tyrosine kinases, in patients with advanced tumors.
Topics: Adult; Aged; Antineoplastic Agents; ErbB Receptors; Female; Fluorodeoxyglucose F18; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Receptor, ErbB-2; Tomography, X-Ray Computed; Treatment Outcome | 2007 |
Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Extracellular Signal-Regulated MAP Kinases; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2008 |
Standardized uptake values of FDG: body surface area correction is preferable to body weight correction.
Topics: Body Surface Area; Body Weight; Deoxyglucose; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Male; Neoplasms; Tomography, Emission-Computed | 1994 |
[Cancer detection with whole-body FDG PET images without attenuation correction].
Topics: Adult; Aged; Deoxyglucose; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Sensitivity and Specificity; Tomography, Emission-Computed | 1996 |
[Tumor diagnosis using 18F-FDG SPECT].
Topics: Deoxyglucose; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Gamma Cameras; Humans; Neoplasms; Tomography, Emission-Computed, Single-Photon | 1996 |
Performance study of a miniature gamma ray scintillation vivo probe for tumor localization.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Citrates; Deoxyglucose; Endoscopes; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Gallium; Gallium Radioisotopes; Gamma Cameras; Humans; Lung Neoplasms; Lymphatic Metastasis; Lymphoma; Male; Middle Aged; Neoplasms; Phantoms, Imaging; Tomography, Emission-Computed | 1997 |
Combined FDG and [F-18]fluoride whole-body PET: a feasible two-in-one approach to cancer imaging?
Topics: Adolescent; Adult; Aged; Bone and Bones; Bone Neoplasms; Feasibility Studies; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Observer Variation; Prospective Studies; Radiopharmaceuticals; Tomography, Emission-Computed; Whole-Body Counting | 1998 |
Comparison of FDG PET and positron coincidence detection imaging using a dual-head gamma camera with 5/8-inch NaI(Tl) crystals in patients with suspected body malignancies.
Topics: Adult; Aged; Algorithms; Female; Fluorodeoxyglucose F18; Gamma Cameras; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Neoplasms; Radiopharmaceuticals; Sodium Iodide; Tomography, Emission-Computed | 1999 |
Accuracy of standardized uptake value measured by simultaneous emission and transmission scanning in PET oncology.
Topics: Algorithms; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Models, Anatomic; Neoplasms; Radiopharmaceuticals; Reference Standards; Tomography, Emission-Computed; Tomography, X-Ray | 1999 |
Reproducibility of metabolic measurements in malignant tumors using FDG PET.
Topics: Antineoplastic Agents; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Radiopharmaceuticals; Reproducibility of Results; Tomography, Emission-Computed | 1999 |
One year's clinical experience of 18F-FDG PET with a modified SPET camera using molecular coincidence detection.
Topics: Coronary Disease; Epilepsy; Evaluation Studies as Topic; Fluorodeoxyglucose F18; Gamma Cameras; Humans; Neoplasms; Nerve Degeneration; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon | 1999 |
A phase I study of a new polyamine biosynthesis inhibitor, SAM486A, in cancer patients with solid tumours.
Topics: Adenosylmethionine Decarboxylase; Adult; Aged; Agranulocytosis; Amidines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Area Under Curve; Dose-Response Relationship, Drug; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Indans; Male; Middle Aged; Neoplasms; Polyamines; Radiopharmaceuticals; Time Factors; Tomography, Emission-Computed | 2000 |
Value of iterative reconstruction, attenuation correction, and image fusion in the interpretation of FDG PET images with an integrated dual-head coincidence camera and X-ray-based attenuation maps.
Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Neoplasms; Radionuclide Imaging; Radiopharmaceuticals; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2001 |
Detection of malignant tumors: whole-body PET with fluorine 18 alpha-methyl tyrosine versus FDG--preliminary study.
Topics: Adult; Aged; Aged, 80 and over; alpha-Methyltyrosine; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Male; Methyltyrosines; Middle Aged; Neoplasms; Probability; Reference Values; Sensitivity and Specificity; Tomography, Emission-Computed; Whole-Body Irradiation | 2001 |
Advantage of delayed whole-body FDG-PET imaging for tumour detection.
Topics: Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Mesothelioma; Neoplasms; Radiopharmaceuticals; Sarcoidosis; Time Factors; Tissue Distribution; Tomography, Emission-Computed; Whole-Body Counting | 2001 |
CT vs 68Ge attenuation correction in a combined PET/CT system: evaluation of the effect of lowering the CT tube current.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Calibration; Female; Fluorodeoxyglucose F18; Germanium; Humans; Image Enhancement; Male; Middle Aged; Neoplasm Staging; Neoplasms; Radiographic Image Enhancement; Radioisotopes; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2002 |
915 other study(ies) available for fluorodeoxyglucose f18 and Neoplasms
| Article | Year |
|---|---|
Synthesis and biological evaluation of novel F-18 labeled pyrazolo[1,5-a]pyrimidine derivatives: potential PET imaging agents for tumor detection.
Topics: Animals; Fluorine Radioisotopes; Mice; Molecular Conformation; Neoplasms; Positron-Emission Tomography; Pyrazoles; Pyrimidines; Stereoisomerism; Tissue Distribution | 2011 |
Temporal metabolic response to mRNA COVID-19 vaccinations in oncology patients.
Topics: Adult; Aged; Aged, 80 and over; Axilla; COVID-19; COVID-19 Vaccines; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Male; Middle Aged; mRNA Vaccines; Neoplasms; Pectoralis Muscles; Positron Emission Tomography Computed Tomography; Time Factors; Vaccines, Synthetic | 2021 |
Changes of [
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Bayes Theorem; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Sensitivity and Specificity | 2021 |
ER Imaging for Estrogen-Related Tumors Is Bothersome but Useful.
Topics: Breast Neoplasms; Estrogens; Female; Fluorodeoxyglucose F18; Humans; Neoplasms; Receptors, Progesterone | 2022 |
Qualitative study of nuclear medicine physicians' perceptions of positron emission tomography/computed tomography in pregnant patients with cancer.
Topics: Female; Fluorodeoxyglucose F18; Humans; Neoplasm Staging; Neoplasms; Nuclear Medicine; Perception; Physicians; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Pregnancy; Radiopharmaceuticals | 2021 |
A Case of Brown Tumor on 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT.
Topics: Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radionuclide Imaging | 2022 |
[
Topics: Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Hyperparathyroidism, Primary; Neoplasms; Positron Emission Tomography Computed Tomography; Quinolines | 2022 |
First results on kinetic modelling and parametric imaging of dynamic
Topics: Fluorodeoxyglucose F18; Humans; Kinetics; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Whole Body Imaging | 2022 |
Duodenal Ulcer-Induced Gastric Outlet Obstruction Showing Pyloric Wall Thickening and Abnormal FDG Uptake Mimicking Malignancy.
Topics: Duodenal Ulcer; Fluorodeoxyglucose F18; Gastric Outlet Obstruction; Humans; Neoplasms; Positron Emission Tomography Computed Tomography; Pylorus | 2022 |
68Ga-FAPI and 18F-FDG PET/CT Findings in a Patient With Pancreatic Tuberculosis Mimicking Malignant Tumor.
Topics: Adult; Fluorodeoxyglucose F18; Humans; Male; Neoplasms; Positron Emission Tomography Computed Tomography; Quinolines; Tuberculosis; Young Adult | 2022 |
Deep learning-based attenuation correction for whole-body PET - a multi-tracer study with
Topics: Deep Learning; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radionuclide Imaging; Radiopharmaceuticals | 2022 |
Abbreviated scan protocols to capture
Topics: Fluorodeoxyglucose F18; Humans; Kinetics; Neoplasms; Positron-Emission Tomography; Radionuclide Imaging | 2022 |
Cancer and immune-mediated necrotizing myopathy: a longitudinal referral case-controlled outcomes evaluation.
Topics: Autoantibodies; Autoimmune Diseases; Fluorodeoxyglucose F18; Humans; Immunoglobulin G; Muscle, Skeletal; Muscular Diseases; Myositis; Necrosis; Neoplasms; Positron Emission Tomography Computed Tomography | 2022 |
A Paradigm of Cancer Immunotherapy Based on 2-[18F]FDG and Anti-PD-L1 mAb Combination to Enhance the Antitumor Effect.
Topics: Animals; B7-H1 Antigen; Cell Line, Tumor; Fluorodeoxyglucose F18; Immunologic Factors; Immunotherapy; Mice; Neoplasms; Positron-Emission Tomography; Tumor Microenvironment | 2022 |
18F-FDG PET/CT May Predict Tumor Type and Risk Score in Gestational Trophoblastic Disease.
Topics: Female; Fluorodeoxyglucose F18; Gestational Trophoblastic Disease; Humans; Neoplasms; Positron Emission Tomography Computed Tomography; Pregnancy; Prognosis; Retrospective Studies; Risk Factors; Tumor Burden | 2022 |
Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [
Topics: Australia; Fluorodeoxyglucose F18; Humans; Molecular Imaging; Neoplasms; Nuclear Medicine; Positron Emission Tomography Computed Tomography; Societies | 2022 |
Superiority of 11 C-Choline PET/CT in the Delineation of a Rare Intracranial Diffuse Embryonic Tumor.
Topics: Adult; Choline; Female; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography | 2022 |
Solitary Chest Wall Tuberculosis Mimicking a Malignancy Demonstrated on FDG PET/CT.
Topics: Adult; Female; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Thoracic Wall; Tomography, X-Ray Computed; Tuberculosis | 2022 |
Ultrafast 30-s total-body PET/CT scan: a preliminary study.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Retrospective Studies; Whole Body Imaging | 2022 |
Renal Pelvis Immunoglobulin G4-Related Disease Mimicking Malignant Tumor: A Case of 18 F-FDG and 68 Ga-FAPI PET/CT Imaging.
Topics: Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Immunoglobulin G4-Related Disease; Kidney Pelvis; Male; Middle Aged; Neoplasms; Positron Emission Tomography Computed Tomography | 2022 |
A spatiotemporal multi-scale computational model for FDG PET imaging at different stages of tumor growth and angiogenesis.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Neovascularization, Pathologic; Positron-Emission Tomography; Radiopharmaceuticals; Tumor Microenvironment | 2022 |
Performance of digital PET/CT compared with conventional PET/CT in oncologic patients: a prospective comparison study.
Topics: Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography | 2022 |
[PET Research in Clinical Oncology].
Topics: Fluorodeoxyglucose F18; Humans; Medical Oncology; Neoplasm Staging; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals | 2022 |
18F-FDG PET/CT Did Not Increase the Risk of Cataract Occurrence in Oncology Patients: A Nationwide Population-Based Cohort Study.
Topics: Cataract; Cohort Studies; Fluorodeoxyglucose F18; Humans; Neoplasms; Propensity Score | 2022 |
18 F-FDG PET/CT findings in a patient with cerebral schistosomiasis mimicking the metastatic tumor.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Schistosomiasis | 2023 |
EARL compliance and imaging optimisation on the Biograph Vision Quadra PET/CT using phantom and clinical data.
Topics: Biomarkers; Fluorodeoxyglucose F18; Humans; Neoplasms; Phantoms, Imaging; Positron Emission Tomography Computed Tomography | 2022 |
Intelligent Labeling of Tumor Lesions Based on Positron Emission Tomography/Computed Tomography.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography | 2022 |
It's Not What You Take Up, It's What You Keep: How Discoveries from Diverse Disciplines Directed the Development of the FDG PET/CT Scan.
Topics: Fluorodeoxyglucose F18; Glucose; Humans; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2022 |
Accurate total-body K
Topics: Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Whole Body Imaging | 2023 |
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Animals; Antibodies, Bispecific; Antibody Formation; Astrocytes; Betacoronavirus; Brucellosis; Calcium; Carps; Cell Survival; Computational Biology; Coronavirus; Coronavirus Infections; Epitopes, B-Lymphocyte; Epitopes, T-Lymphocyte; Fish Diseases; Fish Proteins; Fluorodeoxyglucose F18; Glial Fibrillary Acidic Protein; Guanidines; HEK293 Cells; Humans; Immunity, Innate; Inflammation; Intestines; Keto Acids; Lymphocyte Activation; Mammals; Mice; Mitochondria; Molecular Docking Simulation; Neoplasms; NF-kappa B; Phylogeny; Proteome; Reactive Oxygen Species; Receptors, Antigen, T-Cell; Sodium-Calcium Exchanger; Spinal Cord; T-Lymphocytes; Toll-Like Receptor 3; Transaminases; Transcription Factor AP-1; Vaccines, Subunit | 2022 |
Glucose-Thymidine Ratio as a Metabolism Index Using
Topics: Animals; Biomarkers; Dideoxynucleosides; Fluorodeoxyglucose F18; Glucose; Immune Checkpoint Inhibitors; Mice; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Thymidine | 2022 |
Spatiotemporal multi-scale modeling of radiopharmaceutical distributions in vascularized solid tumors.
Topics: Diffusion; Fluorodeoxyglucose F18; Humans; Neoplasms; Radiopharmaceuticals; Tumor Microenvironment | 2022 |
[18F]FDG PET/CT in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Sodium Fluoride | 2022 |
Feasibility of using abbreviated scan protocols with population-based input functions for accurate kinetic modeling of [
Topics: Arteries; Feasibility Studies; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography | 2023 |
Umbilical Endometriosis Mimicking Malignancy on 18 F-FDG PET/CT.
Topics: Adult; Diagnosis, Differential; Endometriosis; Female; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron Emission Tomography Computed Tomography; Umbilicus | 2023 |
Standardized uptake value of normal organs on routine clinical [18F]FDG PET/CT: impact of tumor metabolism and patient-related factors.
Topics: Creatinine; Female; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies | 2023 |
Abnormal [
Topics: Biomarkers; Fluorodeoxyglucose F18; Humans; Liver; Neoplasms; Obesity; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Retrospective Studies; Weight Loss | 2023 |
Cancer photodynamic therapy with chlorin e6-loaded, goat milk-derived extracellular vesicles: [
Topics: Animals; Cell Line, Tumor; Fluorodeoxyglucose F18; Goats; Milk; Neoplasms; Photochemotherapy | 2023 |
Modification of [18F]-FDG PET/CT imaging protocols in obese oncology patients: A nationwide survey.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Obesity; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography | 2023 |
Unilateral Reduction of 18F-FDG Accumulation in Brown Adipose Tissue by Sympathectomy for Hyperhidrosis.
Topics: Adipose Tissue, Brown; Adult; Female; Fluorodeoxyglucose F18; Humans; Hyperhidrosis; Neoplasms; Positron Emission Tomography Computed Tomography; Sympathectomy | 2023 |
Clinical significance of incidental
Topics: Aged; Clinical Relevance; Female; Fluorodeoxyglucose F18; Gastrointestinal Tract; Humans; Incidental Findings; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed | 2023 |
Brown adipose tissue is not associated with cachexia or increased mortality in a retrospective study of patients with cancer.
Topics: Adipose Tissue, Brown; Animals; Cachexia; Diabetes Mellitus, Type 2; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Retrospective Studies | 2023 |
18F-FDG PET/CT Imaging of G-CSF-Producing Inflammatory Myofibroblastic Tumor of the Pleura.
Topics: Aged; Fluorodeoxyglucose F18; Granulocyte Colony-Stimulating Factor; Humans; Male; Neoplasms; Pleura; Positron Emission Tomography Computed Tomography | 2023 |
Calvarial Tumors: A Retrospective Analysis and Clinical Experience.
Topics: Adult; Child; Female; Fluorodeoxyglucose F18; Humans; Male; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies | 2023 |
Generalized Muscular Hypermetabolism Caused by Mitochondrial Myopathy Shown on 18 F-FDG PET/CT.
Topics: Adolescent; Fluorodeoxyglucose F18; Humans; Male; Mitochondrial Myopathies; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography | 2023 |
A Combined Scoring Method Based on 18F-FDG PET/CT for Distinguishing Spinal Infection From Malignancy.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Research Design; Retrospective Studies | 2023 |
Incidence of incidental positron emission tomography and computed tomography signs of COVID-19 in asymptomatic cancer patients in Egypt.
Topics: COVID-19; Egypt; Fluorodeoxyglucose F18; Humans; Incidence; Neoplasms; Pandemics; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals | 2023 |
Solitary Malignant Peripheral Nerve Sheath Tumor of Lumbar Vertebra Mimicking Metastatic Malignancy.
Topics: Aged; Fluorodeoxyglucose F18; Humans; Lumbar Vertebrae; Male; Neoplasms; Neoplasms, Second Primary; Nerve Sheath Neoplasms; Neurofibrosarcoma; Positron Emission Tomography Computed Tomography | 2023 |
Tracheobronchial Tuberculosis Mimicking Malignancy on Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography.
Topics: Bronchi; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron Emission Tomography Computed Tomography; Trachea; Tuberculosis | 2023 |
Direct co-registration of [
Topics: Feasibility Studies; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals | 2023 |
Findings from Positron Emission Tomography-Computed Tomography with 18F-Fluorodeoxyglucose Uncover a Potential Marker of Nutritional Status in Cancer Patients: A Cross-Sectional Pilot Study.
Topics: Adult; Cross-Sectional Studies; Fluorodeoxyglucose F18; Humans; Neoplasms; Nutritional Status; Pilot Projects; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2023 |
Quantitative and visual analyses of the effect of activity reduction on image metrics and quality in 18F-FDG PET/MRI in pediatric oncology.
Topics: Child; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies | 2023 |
Design of a generic method for single dual-tracer PET imaging acquisition in clinical routine.
Topics: Fluorodeoxyglucose F18; Humans; Kinetics; Neoplasms; Positron-Emission Tomography; Time Factors | 2023 |
FDG PET/CT-based Response Assessment in Malignancies.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals | 2023 |
Liver adenomatosis mimics metastatic liver involvement on FDG-PET/ CT.
Topics: Female; Fluorodeoxyglucose F18; Humans; Liver; Middle Aged; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2023 |
In vivo imaging of acute physiological responses after treatment of cancer with near-infrared photoimmunotherapy.
Topics: Animals; Cell Line, Tumor; Fluorodeoxyglucose F18; Immunoconjugates; Immunotherapy; Mice; Neoplasms; Phototherapy; Xenograft Model Antitumor Assays | 2023 |
Postoperative Spinal 18 F-FDG PET Pseudoprogression Mimicking Malignancy.
Topics: Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Gliosis; Humans; Middle Aged; Neoplasms; Spine | 2023 |
Multiple-Organ Involvement of Malakoplakia Mimicking Malignant Neoplasms on 18 F-FDG PET/CT.
Topics: Fluorodeoxyglucose F18; Humans; Malacoplakia; Male; Middle Aged; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography | 2023 |
Multimodality imaging in marantic endocarditis associated with cancer: a multicentric cohort study.
Topics: Aged; Cohort Studies; Endocarditis; Endocarditis, Non-Infective; Fluorodeoxyglucose F18; Heart Valve Prosthesis; Humans; Middle Aged; Multimodal Imaging; Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Retrospective Studies | 2023 |
Optimal Management of Insulin in Patients Undergoing 18F-Fluorodeoxyglucose Positron Emission Tomography Scans.
Topics: Diabetes Mellitus; Fluorodeoxyglucose F18; Humans; Insulin; Insulin, Regular, Human; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals | 2023 |
Patient centered radiology: investigating 3 Tesla whole body MRI acceptance in cancer patients.
Topics: Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Neoplasm Staging; Neoplasms; Patient-Centered Care; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prospective Studies; Radiology; Whole Body Imaging | 2023 |
Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms.
Topics: Adult; Fluorodeoxyglucose F18; Humans; Mitogen-Activated Protein Kinase Kinases; Neoplasms; Positron-Emission Tomography; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Recurrence | 2023 |
FDG PET Scans in Cancer Care.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies | 2023 |
Letter to the Editor: The theoretical challenges of routinely using [
Topics: Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals | 2023 |
Clinical application of real-time PET/CT guided targeted retroperitoneal masses biopsy in diagnosing malignant tumors.
Topics: Aged; Biopsy; Biopsy, Needle; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Positron Emission Tomography Computed Tomography | 2023 |
Evaluation of post-chemotherapy residual seminomatous masses by 18F-fluorodeoxyglucose PET/CT using tumor-to-liver ratio - conundrum or solution?
Topics: Fluorodeoxyglucose F18; Humans; Liver; Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity | 2023 |
18F-FDG PET/CT helps rule out malignancy in lipomatous hypertrophy of the interatrial septum with atypical MRI manifestations, to avoid unnecessary surgical treatment.
Topics: Atrial Septum; Fluorodeoxyglucose F18; Humans; Hypertrophy; Magnetic Resonance Imaging; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Predictive Value of Tests | 2022 |
18F-FDG-PET/CT imaging of aseptic abscess syndrome mimicking metastatic disease or granulomatosis.
Topics: Abscess; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography | 2023 |
Evaluation of 18-FDG PET diagnostic capabilities for cancer screening in heart transplant patients, a retrospective study.
Topics: Early Detection of Cancer; Female; Fluorodeoxyglucose F18; Heart Transplantation; Humans; Male; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Tomography, X-Ray Computed | 2023 |
Imaging Tumor-Targeting Bacteria Using 18F-Fluorodeoxysorbitol Positron Emission Tomography.
Topics: Animals; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Mice; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2023 |
Bone Echinococcosis Mimicking Malignancy on FDG PET.
Topics: Adult; Echinococcosis; Female; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Thoracic Vertebrae | 2023 |
Impact of Tracer Dose Reduction in [18 F]-Labelled Fluorodeoxyglucose-Positron Emission Tomography ([18 F]-FDG)-PET) on Texture Features and Histogram Indices: A Study in Homogeneous Tissues of Phantom and Patient.
Topics: Drug Tapering; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2023 |
[Inflammatory Polyp due to Peanut Aspiration, Needed to Differentiate from Malignant Tumor: Report of a Case].
Topics: Arachis; Bronchi; Bronchoscopy; Fluorodeoxyglucose F18; Humans; Male; Neoplasms | 2023 |
Guidance on the use of PET for treatment planning in radiotherapy clinical trials.
Topics: Clinical Protocols; Clinical Trials as Topic; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Quality Assurance, Health Care; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Image-Guided; Tumor Burden | 2019 |
Combined thermo-chemotherapy of cancer using 1 MHz ultrasound waves and a cisplatin-loaded sonosensitizing nanoplatform: an in vivo study.
Topics: Alginates; Animals; Cell Line, Tumor; Cisplatin; Combined Modality Therapy; Drug Carriers; Drug Compounding; Fluorodeoxyglucose F18; Gold; Humans; Hyperthermia, Induced; Male; Metal Nanoparticles; Mice; Mice, Inbred BALB C; Neoplasms; Positron-Emission Tomography; Treatment Outcome; Ultrasonic Therapy; Xenograft Model Antitumor Assays | 2019 |
ADC on Diffusion Imaging: The MR Analog of SUV on FDG-PET: Perfect Is the Enemy of Good.
Topics: Diffusion Magnetic Resonance Imaging; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2020 |
Brown adipose tissue and cancer progression.
Topics: Adipose Tissue, Brown; Adult; Aged; Aged, 80 and over; Disease Progression; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Retrospective Studies; Young Adult | 2020 |
Does 2-FDG PET Accurately Reflect Quantitative In Vivo Glucose Utilization?
Topics: Blood-Brain Barrier; Brain; Fluorodeoxyglucose F18; Glucose; Glucose Transporter Type 1; Glycolysis; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Sodium-Glucose Transport Proteins | 2020 |
Characterization of continuous bed motion effects on patient breathing and respiratory motion correction in PET/CT imaging.
Topics: Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Movement; Neoplasms; Positron Emission Tomography Computed Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Respiration; Respiratory-Gated Imaging Techniques | 2020 |
Design and evaluation of an accurate CNR-guided small region iterative restoration-based tumor segmentation scheme for PET using both simulated and real heterogeneous tumors.
Topics: Algorithms; Computer Simulation; Contrast Media; Entropy; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Neoplasm Staging; Neoplasms; Phantoms, Imaging; Positron-Emission Tomography; Tumor Burden | 2020 |
Positron emission tomography as an adjuvant diagnostic test in the evaluation of checkpoint inhibitor-associated acute interstitial nephritis.
Topics: Acute Disease; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Neoplasms; Nephritis, Interstitial; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography | 2019 |
The QIBA Profile for FDG PET/CT: Improving the Value of PET.
Topics: Biomarkers; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals | 2020 |
Examining Immunotherapy Response Using Multiple Radiotracers.
Topics: Anilides; Animals; Cell Line, Tumor; Flow Cytometry; Fluorodeoxyglucose F18; Granzymes; Humans; Immunotherapy; Macrophages; Mice; Neoplasms; Organometallic Compounds; Pyridines; Radiopharmaceuticals; T-Lymphocytes; Treatment Outcome | 2020 |
Interobserver agreement of
Topics: Early Detection of Cancer; Fluorodeoxyglucose F18; Humans; Neoplasms; Observer Variation; Positron-Emission Tomography; Radiopharmaceuticals; Venous Thromboembolism | 2020 |
Discrepancies between positron emission tomography/magnetic resonance imaging and positron emission tomography/computed tomography in a cohort of oncological patients.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Young Adult | 2020 |
Clinical usefulness of FDG-PET/CT for identification of abnormal extra-cardiac foci in patients with infective endocarditis.
Topics: Aged; Aged, 80 and over; Clinical Decision-Making; Colonic Polyps; Denmark; Discitis; Endocarditis, Bacterial; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Prognosis; Radiopharmaceuticals; Retrospective Studies; Risk Factors; Whole Body Imaging | 2020 |
Pretreatment tumor-related leukocytosis misleads positron emission tomography-computed tomography during lymph node staging in gynecological malignancies.
Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Female; Fluorodeoxyglucose F18; Humans; Leukocytosis; Lymph Nodes; Middle Aged; Neoplasms; Positron Emission Tomography Computed Tomography; Uterine Cervical Neoplasms | 2020 |
A critical appraisal of the quality of
Topics: Europe; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron Emission Tomography Computed Tomography; Practice Guidelines as Topic; Radiopharmaceuticals | 2020 |
FDG uptake in cancer: a continuing debate.
Topics: Cell Line; Drug Resistance, Neoplasm; Fluorodeoxyglucose F18; Glycolysis; Humans; Neoplasms; Oxygen; Positron-Emission Tomography; Radiopharmaceuticals; Tumor Microenvironment; Warburg Effect, Oncologic | 2020 |
[Nuclear Medicine for Optimized Treatment Strategy and Real-Time Therapy Imaging].
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Nuclear Medicine; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon | 2020 |
Heterotopic pancreas mimicking primary gastric malignant tumour on
Topics: Child; Fluorodeoxyglucose F18; Humans; Multimodal Imaging; Neoplasms; Pancreas; Positron-Emission Tomography; Radiopharmaceuticals | 2020 |
Implications of radiation microdosimetry for accelerator-based boron neutron capture therapy: a radiobiological perspective.
Topics: Boranes; Boron Compounds; Boron Neutron Capture Therapy; Fluorodeoxyglucose F18; Humans; Monte Carlo Method; Neoplasms; Phenylalanine; Radiobiology; Relative Biological Effectiveness | 2020 |
[PET-based measurements in oncology: PET/CT and PET/MRI applications].
Topics: Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2020 |
COVID-19: Incidental Diagnosis by 18F-FDG PET/CT.
Topics: Aged; Betacoronavirus; Coronavirus Infections; COVID-19; Fluorodeoxyglucose F18; Humans; Male; Neoplasms; Pandemics; Pneumonia, Viral; Positron Emission Tomography Computed Tomography; Pulmonary Disease, Chronic Obstructive; SARS-CoV-2 | 2020 |
Multi-cancer blood testing combined with PET-CT: road for hope to screen for cancer and guide intervention.
Topics: Feasibility Studies; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron Emission Tomography Computed Tomography | 2020 |
Unknown SARS-CoV-2 pneumonia detected by PET/CT in patients with cancer.
Topics: Betacoronavirus; Contrast Media; Coronavirus Infections; COVID-19; Disease Outbreaks; Female; Fluorodeoxyglucose F18; Gallium Isotopes; Gallium Radioisotopes; Humans; Italy; Lung; Male; Membrane Glycoproteins; Neoplasms; Organometallic Compounds; Pandemics; Pneumonia; Pneumonia, Viral; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; SARS-CoV-2 | 2020 |
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; Fluorodeoxyglucose F18; Humans; Lung; Male; Middle Aged; Neoplasms; Pandemics; Pneumonia, Viral; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; SARS-CoV-2 | 2020 |
Traumatic myositis ossificans: multifocal lesions suggesting malignancy on FDG-PET/CT-a case report.
Topics: Adult; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Myositis Ossificans; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography | 2021 |
How fast can we scan patients with modern (digital) PET/CT systems?
Topics: Child; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Positron Emission Tomography Computed Tomography; Time Factors | 2020 |
Combining liquid biopsies and PET-CT for early cancer detection.
Topics: Feasibility Studies; Fluorodeoxyglucose F18; Humans; Liquid Biopsy; Neoplasms; Positron Emission Tomography Computed Tomography | 2020 |
Simultaneous use of FDG-18 and
Topics: Adenocarcinoma; Aged; Anthracosis; Biopsy; Bronchoscopy; Citrates; Colonic Neoplasms; Diagnosis, Differential; Fluorodeoxyglucose F18; Gallium; Humans; Lung; Male; Neoplasms; Positron Emission Tomography Computed Tomography; Sarcoidosis | 2020 |
Weight loss as primary indication for FDG-PET/CT.
Topics: Adult; Aged; False Positive Reactions; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasms; Positron Emission Tomography Computed Tomography; Weight Loss | 2020 |
Will FAPI PET/CT Replace FDG PET/CT in the Next Decade? Counterpoint-No, Not So Fast!
Topics: Biomarkers; Endopeptidases; Fluorodeoxyglucose F18; Gelatinases; Humans; Membrane Proteins; Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Serine Endopeptidases | 2021 |
Will FAPI PET/CT Replace FDG PET/CT in the Next Decade? Point-An Important Diagnostic, Phenotypic, and Biomarker Role.
Topics: Biomarkers; Endopeptidases; Fluorodeoxyglucose F18; Gelatinases; Humans; Membrane Proteins; Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Serine Endopeptidases | 2021 |
Images of COVID-19 Infection Cases in Asymptomatic or Paucisymptomatic Patients With Neoplastic Diseases on 18F-FDG PET/CT.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Pandemics; Pneumonia, Viral; Positron Emission Tomography Computed Tomography; Retrospective Studies; SARS-CoV-2 | 2020 |
Incidental findings suggestive of COVID-19 in asymptomatic cancer patients undergoing 18F-FDG PET/CT in a low prevalence region.
Topics: Aged; Asymptomatic Infections; COVID-19; Female; Fluorodeoxyglucose F18; Humans; Incidental Findings; Lung; Male; Middle Aged; Neoplasms; Positron Emission Tomography Computed Tomography; Prevalence; Radiopharmaceuticals | 2021 |
Case report: a nonfunctioning juxtaglomerular cell tumor mimicking renal cell carcinoma.
Topics: Adult; Aftercare; Carcinoma, Renal Cell; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Juxtaglomerular Apparatus; Kidney Neoplasms; Laparoscopy; Neoplasms; Nephrectomy; Positron Emission Tomography Computed Tomography; Robotic Surgical Procedures; Treatment Outcome | 2020 |
Assessment of extra-parenchymal lung involvement in asymptomatic cancer patients with COVID-19 pneumonia detected on
Topics: Common Bile Duct Neoplasms; COVID-19; COVID-19 Testing; Female; Fluorodeoxyglucose F18; Humans; Lung; Male; Neoplasms; Pneumonia; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; SARS-CoV-2 | 2021 |
[
Topics: Asymptomatic Infections; COVID-19; Female; Fluorodeoxyglucose F18; Humans; Male; Neoplasms; Pandemics; Positron Emission Tomography Computed Tomography; SARS-CoV-2; Spain | 2021 |
68Ga-FAPI and 18F-FDG PET/CT Images in a Patient With Extrapulmonary Tuberculosis Mimicking Malignant Tumor.
Topics: Aged; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron Emission Tomography Computed Tomography; Quinolines; Tuberculosis | 2020 |
[Expert consensus on assessing tumor response to immune checkpoint inhibitors by PET/CT (2020 Edition)].
Topics: China; Consensus; Fluorodeoxyglucose F18; Humans; Immune Checkpoint Inhibitors; Neoplasms; Positron Emission Tomography Computed Tomography | 2020 |
Molecular imaging of tumor-specific markers and their expression in other organs.
Topics: Animals; Biomarkers, Tumor; Cardiology; Diastole; Fibroblasts; Fluorodeoxyglucose F18; Heart; Humans; Inflammation; Ligands; Molecular Imaging; Neoplasms; Nuclear Medicine; Regeneration; Systole; Ventricular Dysfunction, Left | 2021 |
Brown fat does not cause cachexia in cancer patients: A large retrospective longitudinal FDG-PET/CT cohort study.
Topics: Adipose Tissue, Brown; Adult; Aged; Body Mass Index; Body Temperature; Cachexia; Cohort Studies; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasms; Positron Emission Tomography Computed Tomography; Retrospective Studies | 2020 |
Effect of Propranolol on 18F-Fluorodeoxyglucose Uptake in Brown Adipose Tissue in Children and Young Adults with Neoplastic Diseases.
Topics: Adipose Tissue, Brown; Administration, Oral; Adolescent; Adrenergic beta-Antagonists; Child; Child, Preschool; Cold Temperature; Female; Fluorodeoxyglucose F18; Humans; Infant; Infant, Newborn; Male; Neoplasms; Positron Emission Tomography Computed Tomography; Propranolol; Radiopharmaceuticals; Tissue Distribution; Young Adult | 2021 |
Incidental findings of COVID-19 in F18-FDG PET/CT from asymptomatic patients with cancer in two healthcare institutions in Bogotá, Colombia
Topics: Adult; Aged; Asymptomatic Diseases; Betacoronavirus; Carcinoma, Signet Ring Cell; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Testing; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Incidental Findings; Lymphatic Metastasis; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasms; Pandemics; Pleural Effusion; Pneumonia, Viral; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Reverse Transcriptase Polymerase Chain Reaction; SARS-CoV-2; Seminoma; Stomach Neoplasms | 2020 |
Quantitative CT Detects Undiagnosed Low Bone Mineral Density in Oncologic Patients Imaged With 18F-FDG PET/CT.
Topics: Adult; Aged; Bone Density; Female; Femur Neck; Fluorodeoxyglucose F18; Humans; Lumbar Vertebrae; Male; Middle Aged; Neoplasms; Positron Emission Tomography Computed Tomography; Retrospective Studies | 2021 |
The role of histogram analysis of grayscale sonograms to differentiate thyroid nodules identified by 18F-FDG PET-CT.
Topics: Adult; Aged; Aged, 80 and over; Biopsy, Fine-Needle; Biopsy, Large-Core Needle; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Positron Emission Tomography Computed Tomography; Retrospective Studies; Thyroid Gland; Thyroid Nodule; Ultrasonography | 2020 |
Prognostic importance of coincidental coronary artery calcification on FDG-PET/CT oncology studies.
Topics: Aged; Coronary Artery Disease; Female; Fluorodeoxyglucose F18; Humans; Incidental Findings; Male; Middle Aged; Neoplasms; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Prevalence; Prognosis; Radiopharmaceuticals; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Vascular Calcification | 2021 |
FAPI PET/CT: Will It End the Hegemony of
Topics: Blood Proteins; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron Emission Tomography Computed Tomography | 2021 |
Glucose-Functionalized Liposomes for Reducing False Positives in Cancer Diagnosis.
Topics: Animals; Fluorodeoxyglucose F18; Glucose; Liposomes; Mice; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity | 2021 |
Predictive factors for dental inflammation with exacerbation during cancer therapy with FDG-PET/CT imaging.
Topics: Aged; Female; Fluorodeoxyglucose F18; Humans; Inflammation; Male; Middle Aged; Neoplasms; Positron Emission Tomography Computed Tomography; Risk Factors | 2021 |
Spleen glucose metabolism on [
Topics: Biomarkers; Fluorodeoxyglucose F18; Glucose; Humans; Neoplasms; Positron Emission Tomography Computed Tomography; Spleen | 2021 |
Digital PET/CT allows for shorter acquisition protocols or reduced radiopharmaceutical dose in [
Topics: Body Weight; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Signal-To-Noise Ratio | 2021 |
Correlation between contrast enhancement, standardized uptake value (SUV), and diffusion restriction (ADC) with tumor grading in patients with therapy-naive neuroendocrine neoplasms using hybrid
Topics: Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Magnetic Resonance Imaging; Multimodal Imaging; Neoplasm Grading; Neoplasms; Octreotide; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals | 2021 |
Axillary Lymph Nodes Hypermetabolism After BNT162b2 mRNA COVID-19 Vaccination in Cancer Patients Undergoing 18F-FDG PET/CT: A Cohort Study.
Topics: Adult; Aged; Axilla; BNT162 Vaccine; Cohort Studies; COVID-19 Vaccines; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Male; Middle Aged; Neoplasms; Positron Emission Tomography Computed Tomography; Retrospective Studies; RNA, Messenger; Vaccination | 2021 |
A comparison between 18F-FDG PET/CT and classical physical examination package for cancer screening in asymptomatic Chinese patients.
Topics: China; Early Detection of Cancer; Fluorodeoxyglucose F18; Humans; Neoplasms; Physical Examination; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity | 2021 |
Comparison of
Topics: Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Neoplasm Staging; Neoplasms; Positron Emission Tomography Computed Tomography; Quinolines | 2021 |
Reducing Radiation Exposure to Paediatric Patients Undergoing [18F]FDG-PET/CT Imaging.
Topics: Adolescent; Child, Preschool; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Male; Neoplasms; Positron Emission Tomography Computed Tomography; Radiation Dosage; Signal-To-Noise Ratio | 2021 |
Total-body
Topics: Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Neoplasms; Phantoms, Imaging; Positron Emission Tomography Computed Tomography; Tomography, X-Ray Computed | 2021 |
Ultra-short time imaging of total-body PET/CT for cancer pain-induced untenable body position.
Topics: Cancer Pain; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Multimodal Imaging; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Whole Body Imaging | 2021 |
Different Appearances of 3 Malignancies in 68Ga-PSMA-11 Versus 18F-FDG PET/CT.
Topics: Aged; Edetic Acid; Fluorodeoxyglucose F18; Gallium Isotopes; Gallium Radioisotopes; Humans; Male; Neoplasms; Oligopeptides; Positron Emission Tomography Computed Tomography | 2021 |
Predictors of Diagnostic Contributions and Spontaneous Remission of Symptoms Associated with Positron Emission Tomography with Fluorine-18-Fluorodeoxy Glucose Combined with Computed Tomography in Classic Fever or Inflammation of Unknown Origin: a Retrospe
Topics: Adult; Fever of Unknown Origin; Fluorodeoxyglucose F18; Humans; Infections; Inflammation; Male; Middle Aged; Neoplasms; Positron Emission Tomography Computed Tomography; Remission, Spontaneous; Retrospective Studies; Tomography, X-Ray Computed | 2021 |
Early Changes in [
Topics: Animals; Fluorodeoxyglucose F18; Heterografts; Mice; Mice, Nude; Neoplasms; Pharmaceutical Preparations; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases | 2021 |
A case of periosteal fasciitis located in the mandible in a child.
Topics: Child; Fasciitis; Female; Fluorodeoxyglucose F18; Humans; Mandible; Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2022 |
Assessing immune response upon systemic RNA vaccination on [18F]-FDG PET/CT for COVID-19 vaccine and then for immuno-oncology?
Topics: COVID-19; COVID-19 Vaccines; Fluorodeoxyglucose F18; Humans; Immunity; Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; RNA; SARS-CoV-2; Vaccination | 2021 |
Radiopharmaceutical and Eu
Topics: Animals; Female; Fluorodeoxyglucose F18; Gadolinium; Luminescence; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Imaging; Nanoparticles; Neoplasms; Optical Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Surgery, Computer-Assisted | 2021 |
Tumor Thrombus on 18F-FDG PET/CT in Stage IV Plasmablastic Lymphoma.
Topics: Aged; Female; Fluorodeoxyglucose F18; Humans; Neoplasms; Plasmablastic Lymphoma; Positron Emission Tomography Computed Tomography; Thrombosis | 2022 |
Patterns of [18F]FDG myocardial uptake in oncology patients as a predictor of myocardial ischaemia on stress myocardial perfusion imaging.
Topics: Coronary Artery Disease; Fluorodeoxyglucose F18; Humans; Myocardial Ischemia; Myocardial Perfusion Imaging; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon | 2021 |
Targeting personalized medicine in a non-Hodgkin lymphoma patient with 18F-FDG and 18F-choline PET/CT.
Topics: Choline; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Skin Neoplasms; Sternum | 2017 |
Incidental spade-shaped FDG uptake in the left ventricular apex suggests apical hypertrophic cardiomyopathy.
Topics: Aged; Biological Transport; Cardiomyopathy, Hypertrophic; Female; Fluorodeoxyglucose F18; Heart Ventricles; Humans; Incidental Findings; Male; Neoplasms; Positron Emission Tomography Computed Tomography; Prognosis; Retrospective Studies | 2017 |
Automated synthesis of N-(2-[
Topics: Automation; Chemistry Techniques, Synthetic; Fluorodeoxyglucose F18; Glutamates; Hydrolysis; Kinetics; Neoplasms; Positron-Emission Tomography; Radioactive Tracers | 2017 |
Reproducibility and repeatability of same-day two sequential FDG PET/MR and PET/CT.
Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Reproducibility of Results; Tumor Burden | 2017 |
Quantitative comparison between regularized time-of-flight and OSEM PET reconstructions for small 18F-FDG-avid lesions.
Topics: Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Retrospective Studies; Time Factors | 2017 |
Revisit 18F-fluorodeoxyglucose oncology positron emission tomography: "systems molecular imaging" of glucose metabolism.
Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Female; Fluorodeoxyglucose F18; Glucose; Humans; Hypoxia; Mice; Molecular Imaging; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Oxygen; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography | 2017 |
18F-FDG PET/CT-based early treatment response evaluation of nanoparticle-assisted photothermal cancer therapy.
Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Female; Fluorodeoxyglucose F18; Humans; Metal Nanoparticles; Mice; Mice, Nude; Neoplasms; Photochemotherapy; Positron Emission Tomography Computed Tomography; Treatment Outcome; Xenograft Model Antitumor Assays | 2017 |
Performance of 18F-fluorodesoxyglucose positron-emission tomography combined with low-dose computed tomography for cancer screening in patients with unprovoked venous thromboembolism.
Topics: Aged; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Tomography, X-Ray Computed; Venous Thromboembolism | 2017 |
Intense Muscle Activity Due to Polymyositis Incidentally Detected in a Patient Evaluated for Possible Malignancy by FDG PET/CT Imaging.
Topics: Adult; Female; Fluorodeoxyglucose F18; Humans; Incidental Findings; Muscles; Neoplasms; Polymyositis; Positron Emission Tomography Computed Tomography | 2017 |
Can the combined administration of labelled fluoro-2 deoxy d glucose and insulin or chrome increase the diagnostic sensitivity of Positron Emission Tomography (PET)?
Topics: Fluorodeoxyglucose F18; Glycolysis; Humans; Insulin; Models, Theoretical; Neoplasms; Positron-Emission Tomography; Reproducibility of Results; Sensitivity and Specificity | 2017 |
Detection of unexpected emergency diseases using FDG-PET/CT in oncology patients.
Topics: Acute Disease; Aged; Aged, 80 and over; Chronic Disease; Comorbidity; Emergencies; Female; Fluorodeoxyglucose F18; Humans; Incidental Findings; Male; Middle Aged; Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Retrospective Studies | 2017 |
Hunting for abscopal and bystander effects: clinical exploitation of non-targeted effects induced by partial high-single-dose irradiation of the hypoxic tumour segment in oligometastatic patients.
Topics: Aged; Bystander Effect; Cell Hypoxia; Cell Line, Tumor; Fatal Outcome; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Positron Emission Tomography Computed Tomography; Radiation Dosage; Radiosurgery; Radiotherapy Planning, Computer-Assisted; Treatment Outcome | 2017 |
18F-fluoro-deoxy-glucose positron emission tomography combined with computed tomography can reliably rule-out infection and cancer in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis suspected of disease relapse.
Topics: Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; False Negative Reactions; False Positive Reactions; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Infections; Male; Middle Aged; Neoplasms; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Recurrence; Retrospective Studies; Sensitivity and Specificity; Whole Body Imaging | 2017 |
The Incidence of Totally Implantable Venous Access Devices Insertion and the Associated Abnormalities in Patients With Cancer Revealed in
Topics: Catheter-Related Infections; Catheterization, Central Venous; Catheters, Indwelling; Equipment Failure; Female; Fluorodeoxyglucose F18; Foreign-Body Migration; Humans; Male; Middle Aged; Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Retrospective Studies | 2017 |
Appropriate Use Criteria for
Topics: Fluorodeoxyglucose F18; Humans; Neoplasm Staging; Neoplasms; Positron Emission Tomography Computed Tomography; Treatment Outcome | 2017 |
Dielectric imaging for differentiation between cancer and inflammation in vivo.
Topics: Animals; Cell Line, Tumor; Female; Fluorodeoxyglucose F18; Inflammation; Magnetic Resonance Imaging; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Neoplasms; Positron-Emission Tomography | 2017 |
A clinical evaluation of the impact of the Bayesian penalized likelihood reconstruction algorithm on PET FDG metrics.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Bayes Theorem; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Likelihood Functions; Male; Middle Aged; Neoplasms; Positron Emission Tomography Computed Tomography; Signal-To-Noise Ratio; Young Adult | 2017 |
The Warburg effect: persistence of stem-cell metabolism in cancers as a failure of differentiation.
Topics: Cell Differentiation; Fluorodeoxyglucose F18; Glucose; Glycolysis; Humans; Models, Biological; Neoplasms; Neoplastic Stem Cells; Oxidative Phosphorylation; Positron-Emission Tomography; Radiopharmaceuticals | 2018 |
Quantitative PET/CT in clinical practice: assessing the agreement of PET tumor indices using different clinical reading platforms.
Topics: Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Neoplasms; Positron Emission Tomography Computed Tomography; Reproducibility of Results; Retrospective Studies | 2018 |
The clinical utility of fluorodeoxyglucose-positron emission tomography for investigation of fever in immunocompromised children.
Topics: Adolescent; Anti-Infective Agents; Antineoplastic Agents; Child; Child, Preschool; Female; Fever of Unknown Origin; Fluorodeoxyglucose F18; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Immunosuppressive Agents; Infant; Infections; Male; Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Retrospective Studies | 2018 |
Whole-body PET/MRI of Pediatric Patients: The Details That Matter.
Topics: Child; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Sarcoma; Tumor Stem Cell Assay; Whole Body Imaging | 2017 |
Diagnosis and staging of solid pseudopapillary neoplasms of the pancreas: The role of
Topics: Fluorodeoxyglucose F18; Humans; Neoplasm Staging; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2018 |
A Voice From the Past: Rediscovering the Virchow Node With Prostate-specific Membrane Antigen-targeted
Topics: Antigens, Surface; Clavicle; Fluorodeoxyglucose F18; Germany; Glutamate Carboxypeptidase II; History, 19th Century; Humans; Lymph Nodes; Lymphatic Metastasis; Neoplasms; Pathology; Positron-Emission Tomography; Radiopharmaceuticals | 2018 |
Effects of hyperglycemia on fluorine-18-fluorodeoxyglucose biodistribution in a large oncology clinical practice.
Topics: Artifacts; Blood Glucose; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron Emission Tomography Computed Tomography; Retrospective Studies; Tissue Distribution | 2018 |
Role of 18F-FDG PET/CT in patients without known primary malignancy with skeletal lesions suspicious for cancer metastasis.
Topics: Aged; Bone and Bones; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, X-Ray Computed | 2018 |
Optimal monochromatic color combinations for fusion imaging of FDG-PET and diffusion-weighted MR images.
Topics: Analysis of Variance; Color; Diffusion Magnetic Resonance Imaging; Fluorodeoxyglucose F18; Humans; Multimodal Imaging; Neoplasms; Phantoms, Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Spectrophotometry | 2018 |
Combined hyperpolarized
Topics: Animals; Carbon Isotopes; Cross-Sectional Studies; Disease Models, Animal; Dogs; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Magnetic Resonance Spectroscopy; Male; Neoplasms; Positron-Emission Tomography; Pyruvic Acid; Radiopharmaceuticals; Whole Body Imaging | 2018 |
answer for the "Diagnosis and staging of solid pseudopapillary neoplasms of the pancreas: the role of 18 1 F-FDG PET/CT scan".
Topics: Fluorodeoxyglucose F18; Humans; Neoplasm Staging; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2018 |
LIFEx: A Freeware for Radiomic Feature Calculation in Multimodality Imaging to Accelerate Advances in the Characterization of Tumor Heterogeneity.
Topics: Fluorodeoxyglucose F18; Genetic Heterogeneity; Humans; Image Processing, Computer-Assisted; Multimodal Imaging; Neoplasms; Positron Emission Tomography Computed Tomography; Radiometry; Software | 2018 |
Pericardial mass in a 71-year-old man.
Topics: Abscess; Aged; Aortic Valve; Chronic Disease; Diagnosis, Differential; Diagnostic Errors; Fluorodeoxyglucose F18; Heart Valve Prosthesis Implantation; Hematoma; Humans; Magnetic Resonance Imaging, Cine; Male; Neoplasms; Pericardium; Positron-Emission Tomography; Radiopharmaceuticals; Remission, Spontaneous; Tomography, X-Ray Computed | 2018 |
Combined Inhibition of PI3Kβ and mTOR Inhibits Growth of PTEN-null Tumors.
Topics: Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Chromones; Female; Fluorodeoxyglucose F18; Forkhead Box Protein O3; Glucose; Humans; Mice, Nude; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Protein Transport; PTEN Phosphohydrolase; TOR Serine-Threonine Kinases | 2018 |
Preliminary investigation of brown adipose tissue assessed by PET/CT and cancer activity.
Topics: Adipose Tissue, Brown; Adult; Aged; Aged, 80 and over; Body Composition; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Retrospective Studies | 2019 |
A smart and operator independent system to delineate tumours in Positron Emission Tomography scans.
Topics: Algorithms; Brain Neoplasms; Diagnosis, Computer-Assisted; False Positive Reactions; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Neoplasm Metastasis; Neoplasms; Observer Variation; Pattern Recognition, Automated; Phantoms, Imaging; Positron-Emission Tomography; Predictive Value of Tests; Radiotherapy Planning, Computer-Assisted; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity; Software; Tomography, X-Ray Computed | 2018 |
Textural analysis demonstrates heterogeneous [
Topics: Aged; Aged, 80 and over; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Idiopathic Pulmonary Fibrosis; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2018 |
Impact of image reconstruction methods on quantitative accuracy and variability of FDG-PET volumetric and textural measures in solid tumors.
Topics: Adult; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Male; Neoplasms; Phantoms, Imaging; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Tumor Burden | 2019 |
Usefulness of both PET/CT with F18-FDG and whole-body diffusion-weighted imaging in cancer screening: a preliminary report.
Topics: Aged; Aged, 80 and over; Diffusion Magnetic Resonance Imaging; Female; Fluorodeoxyglucose F18; Humans; Male; Mass Screening; Middle Aged; Neoplasms; Positron Emission Tomography Computed Tomography; Whole Body Imaging | 2019 |
Clinical evaluation of CT radiation dose in whole-body
Topics: Aged; Arm; Female; Fluorodeoxyglucose F18; Humans; Male; Neoplasms; Patient Positioning; Positron Emission Tomography Computed Tomography; Radiation Dosage; Radiopharmaceuticals; Whole Body Imaging | 2019 |
[Nuclear medical diagnostic and cancer precision medicine].
Topics: Fluorodeoxyglucose F18; Humans; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Precision Medicine; Radiopharmaceuticals | 2018 |
Multimodal imaging of cardiac-calcified amorphous tumor.
Topics: Aged; Contrast Media; Echocardiography; Fluorodeoxyglucose F18; Heart; Heart Neoplasms; Humans; Inflammation; Magnetic Resonance Imaging; Male; Multimodal Imaging; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Tomography, X-Ray Computed | 2020 |
Prediction of Lymph Node Maximum Standardized Uptake Value in Patients With Cancer Using a 3D Convolutional Neural Network: A Proof-of-Concept Study.
Topics: Adult; Aged; Aged, 80 and over; Fluorodeoxyglucose F18; Humans; Imaging, Three-Dimensional; Lymphatic Metastasis; Middle Aged; Neoplasms; Neural Networks, Computer; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Proof of Concept Study; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Young Adult | 2019 |
Clinical Value of Positron Emission Tomography-Computed Tomography Combined with Ultrasound in Detection of Primary Tumors in Patients with Malignant Ascites.
Topics: Ascites; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Radiopharmaceuticals; Sensitivity and Specificity; Ultrasonography | 2019 |
A thermo-responsive alginate nanogel platform co-loaded with gold nanoparticles and cisplatin for combined cancer chemo-photothermal therapy.
Topics: Alginates; Animals; Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Combined Modality Therapy; Fluorodeoxyglucose F18; Gold; Hyperthermia, Induced; Lasers; Male; Metal Nanoparticles; Mice, Inbred BALB C; Nanogels; Neoplasms; Photochemotherapy; Radiopharmaceuticals | 2019 |
Gender-disease interaction on brain cerebral metabolism in cancer patients with depressive symptoms.
Topics: Adult; Aged; Brain; Depression; Female; Fluorodeoxyglucose F18; Glucose; Humans; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Psychiatric Status Rating Scales; Sex Characteristics | 2019 |
Comparison of image quality and lesion detection between digital and analog PET/CT.
Topics: Aged; Aged, 80 and over; Diagnosis, Computer-Assisted; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Neoplasms; Observer Variation; Positron Emission Tomography Computed Tomography; Prospective Studies; Radiopharmaceuticals | 2019 |
Prevalence of clinically significant incidental findings by whole-body fludeoxyglucose F 18 positron emission tomography/computed tomography scanning in moderate-to-severe psoriasis patients participating in clinical trials.
Topics: Adult; Aged; Asymptomatic Diseases; Clinical Trials as Topic; Comorbidity; Cross-Sectional Studies; Ethnicity; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Incidental Findings; Male; Middle Aged; Neoplasms; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Prevalence; Psoriasis; Radiopharmaceuticals; Severity of Illness Index; Smoking; Whole Body Imaging | 2019 |
18F-FDG PET/CT versus conventional investigations for cancer screening in autoimmune inflammatory myopathy in the era of novel myopathy classifications.
Topics: Aged; Autoimmune Diseases; Cohort Studies; Early Detection of Cancer; Female; Fluorodeoxyglucose F18; Humans; Inflammation; Male; Mass Screening; Middle Aged; Muscular Diseases; Neoplasms; Positron Emission Tomography Computed Tomography; Retrospective Studies | 2019 |
Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT.
Topics: Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Immunotherapy; Lymphocytes; Male; Middle Aged; Neoplasms; Positron Emission Tomography Computed Tomography; Retrospective Studies; Treatment Outcome; Young Adult | 2019 |
Glucose-6-phosphatase Expression-Mediated [
Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Fluorodeoxyglucose F18; Glucose; Glucose-6-Phosphatase; Humans; Inflammation; Macrophages; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; RAW 264.7 Cells | 2019 |
L-[Methyl-
Topics: Cell Line, Tumor; Fluorodeoxyglucose F18; Humans; Methionine; Neoplasms; Positron-Emission Tomography | 2019 |
Imaging Cancer Metabolism with Positron Emission Tomography (PET).
Topics: Animals; Biomarkers; Carbon Radioisotopes; Disease Models, Animal; Energy Metabolism; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Metabolic Networks and Pathways; Mice; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals | 2019 |
Treatment response assessment in [
Topics: Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Neoplasms; Positron Emission Tomography Computed Tomography; Treatment Outcome | 2019 |
Inflammatory Activity of Tumoral Calcinosis in a Patient With Fever of Unknown Origin.
Topics: Calcinosis; Fever of Unknown Origin; Fluorodeoxyglucose F18; Humans; Inflammation; Male; Middle Aged; Neoplasms; Positron Emission Tomography Computed Tomography | 2019 |
The Distribution Volume of
Topics: Albumins; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Female; Fluorodeoxyglucose F18; Humans; Mice; Mice, Nude; Neoplasms; Neovascularization, Pathologic; Positron-Emission Tomography; Radiopharmaceuticals; Sunitinib; Tissue Distribution; Treatment Outcome; Xenograft Model Antitumor Assays | 2019 |
The forgotten right ventricle in cardio-oncology.
Topics: Cardiotoxicity; Fluorodeoxyglucose F18; Heart Ventricles; Humans; Myocardium; Neoplasms | 2020 |
Clinical value of FDG-PET/CT in bacteremia of unknown origin with catalase-negative gram-positive cocci or Staphylococcus aureus.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacteremia; Catalase; Female; Fluorodeoxyglucose F18; Gram-Positive Bacteria; Humans; Male; Middle Aged; Neoplasms; Positron Emission Tomography Computed Tomography; Reference Values; Retrospective Studies; Staphylococcal Infections; Staphylococcus aureus; Young Adult | 2019 |
Cardiac molecular pathways influenced by doxorubicin treatment in mice.
Topics: Animals; Annexin A5; Apoptosis; Cardiotoxins; Caspase 3; Disease Models, Animal; Doxorubicin; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Heart; Humans; Mice; Neoplasms; Organotechnetium Compounds; Proto-Oncogene Proteins c-bcl-2; Radiopharmaceuticals | 2019 |
Whole-Body [18F]-FDG-PET/MRI for Oncology: A Consensus Recommendation.
Topics: Consensus; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Quality Control; Research Design; Safety; Whole Body Imaging | 2019 |
Whole-Body [18F]-FDG-PET/MRI for Oncology: A Consensus Recommendation.
Topics: Artifacts; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Neoplasms; Patient Education as Topic; Positron-Emission Tomography; Quality Control; Radiology Information Systems; Whole Body Imaging; Workflow | 2019 |
Topics: Adipose Tissue, Brown; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals | 2019 |
Intratumoral heterogeneity as measured using the tumor-stroma ratio and PET texture analyses in females with lung adenocarcinomas differs from that of males with lung adenocarcinomas or squamous cell carcinomas.
Topics: Adenocarcinoma of Lung; Aged; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Retrospective Studies; Sex Factors | 2019 |
Development and Evaluation of an
Topics: Animals; Cell Line, Tumor; Chemokine CXCL12; Female; Fluorodeoxyglucose F18; Gene Knockdown Techniques; Heterocyclic Compounds; Heterografts; Humans; Inhibitory Concentration 50; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Neoplasms; Organic Cation Transport Proteins; Positron-Emission Tomography; Pyridines; Radiopharmaceuticals; Receptors, CXCR4; Renal Elimination; Tissue Distribution | 2019 |
Comparison of FDG PET/MRI and FDG PET/CT in Pediatric Oncology in Terms of Anatomic Correlation of FDG-positive Lesions.
Topics: Adolescent; Child; Child, Preschool; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Infant; Magnetic Resonance Imaging; Male; Medical Oncology; Multimodal Imaging; Neoplasms; Pediatrics; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals | 2019 |
The Value of 18F-FDG PET/CT in Detecting Bone Marrow Involvement in Childhood Cancers.
Topics: Adolescent; Bone Marrow Neoplasms; Child; Child, Preschool; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Infant; Male; Neoplasms; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies | 2019 |
Prognostic and diagnostic value of [18F]FDG-PET/CT in restaging patients with small cell lung carcinoma: an Italian multicenter study.
Topics: Adult; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Italy; Kaplan-Meier Estimate; Male; Neoplasm Staging; Neoplasms; Positron Emission Tomography Computed Tomography; Retrospective Studies; Small Cell Lung Carcinoma | 2019 |
Diffusely Decreased Liver Uptake on FDG PET and Cancer-Associated Cachexia With Reduced Survival.
Topics: Adult; Aged; Aged, 80 and over; Biological Transport; Cachexia; Female; Fluorodeoxyglucose F18; Humans; Liver; Male; Middle Aged; Neoplasms; Positron Emission Tomography Computed Tomography; Prognosis; Retrospective Studies; Young Adult | 2019 |
Image quality evaluation in a modern PET system: impact of new reconstructions methods and a radiomics approach.
Topics: Abdomen; Adult; Aged; Aged, 80 and over; Algorithms; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Retrospective Studies; Young Adult | 2019 |
Frequency and clinical implications of incidental new primary cancers detected on true whole-body 18F-FDG PET/CT studies.
Topics: Cohort Studies; Fluorodeoxyglucose F18; Humans; Incidental Findings; Multimodal Imaging; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Retrospective Studies; Tomography, X-Ray Computed; Whole Body Imaging | 2013 |
Predicting future morphological changes of lesions from radiotracer uptake in 18F-FDG-PET images.
Topics: Adult; Aged; Algorithms; Artificial Intelligence; Cluster Analysis; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Male; Markov Chains; Middle Aged; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Software; Tissue Distribution; Tomography, X-Ray Computed | 2013 |
The additional diagnostic value of contemporary evaluation of FDG PET/CT scan and contrast enhanced CT imaging both acquired by a last generation PET/CT system in oncologic patients.
Topics: Contrast Media; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasms; Radionuclide Imaging; Radiopharmaceuticals | 2013 |
Integrated whole-body PET/MR hybrid imaging: clinical experience.
Topics: Adult; Aged; Artifacts; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Neoplasms; Observer Variation; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed; Whole Body Imaging; Young Adult | 2013 |
Value of true whole-body FDG-PET/CT scanning protocol in oncology: optimization of its use based on primary diagnosis.
Topics: Diagnostic Errors; Female; Fluorodeoxyglucose F18; Humans; Male; Multimodal Imaging; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Radiographic Image Interpretation, Computer-Assisted; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Whole Body Imaging | 2013 |
Improvement in clinical evaluation of PET/CT images with high resolution algorithms.
Topics: Algorithms; Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Imaging, Three-Dimensional; Male; Middle Aged; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed | 2013 |
Using PET/CT imaging to characterize 18 F-fluorodeoxyglucose utilization in fish.
Topics: Animals; Disease Models, Animal; Fluorodeoxyglucose F18; Glucose; Neoplasms; Positron-Emission Tomography; Tomography, X-Ray Computed | 2013 |
Intraoperative detection of ¹⁸F-FDG-avid tissue sites using the increased probe counting efficiency of the K-alpha probe design and variance-based statistical analysis with the three-sigma criteria.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Pilot Projects; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals | 2013 |
Low positive yield from routine inclusion of the brain in whole-body 18F-FDG PET/CT imaging for noncerebral malignancies: results from a large population study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Brain; Child; Child, Preschool; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Neoplasms; Positron-Emission Tomography; Retrospective Studies; Tomography, X-Ray Computed; Whole Body Imaging; Young Adult | 2013 |
Midbrain encephalitis associated with neoplasia.
Topics: Encephalitis; Fluorodeoxyglucose F18; Humans; Male; Mesencephalon; Middle Aged; Neoplasms; Positron-Emission Tomography | 2013 |
[Cancer treatment response evaluation based on imaging modalities, such as computed tomography, magnetic resonance imaging and FDG-PET].
Topics: Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Neoplasms; Positron-Emission Tomography; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Ascites metabolism measurement enhanced the diagnostic value and accuracy of prognostic evaluation in 18F-FDG PET/CT studies in malignant ascites patients.
Topics: Adult; Aged; Aged, 80 and over; Ascites; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Prognosis; Retrospective Studies; ROC Curve; Survival Analysis; Tomography, X-Ray Computed; Young Adult | 2013 |
Area under the cumulative SUV-volume histogram is not a viable metric of intratumoral metabolic heterogeneity.
Topics: Algorithms; Area Under Curve; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Probability; Reproducibility of Results; Treatment Outcome | 2013 |
Acute cytotoxic effects of photoimmunotherapy assessed by 18F-FDG PET.
Topics: Animals; Fluorodeoxyglucose F18; Immunotherapy; Light; Mice; Neoplasms; NIH 3T3 Cells; Positron-Emission Tomography | 2013 |
Combining multiple FDG-PET radiotherapy target segmentation methods to reduce the effect of variable performance of individual segmentation methods.
Topics: Algorithms; Fluorodeoxyglucose F18; Image Enhancement; Image Interpretation, Computer-Assisted; Neoplasms; Pattern Recognition, Automated; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy, Image-Guided; Reproducibility of Results; Sensitivity and Specificity | 2013 |
Split-dose technique for FDG PET/CT-guided percutaneous ablation: a method to facilitate lesion targeting and to provide immediate assessment of treatment effectiveness.
Topics: Adult; Aged; Aged, 80 and over; Catheter Ablation; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed | 2013 |
Reporting guidance for oncologic 18F-FDG PET/CT imaging.
Topics: Fluorodeoxyglucose F18; Humans; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Quality Control; Research Design; Tomography, X-Ray Computed | 2013 |
PET/US fusion as a problem-solving tool in oncology imaging: differentiation of hernia repair mesh plugs from malignancy suspected on PET/CT.
Topics: Adult; Diagnosis, Differential; Fluorodeoxyglucose F18; Herniorrhaphy; Humans; Image Processing, Computer-Assisted; Male; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Tomography, X-Ray Computed; Ultrasonography | 2014 |
Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antibodies; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Demography; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Receptors, TNF-Related Apoptosis-Inducing Ligand | 2014 |
Physiological (18)F-FDG uptake patterns in female reproductive organs before and after chemotherapy treatments: assessment by PET/CT.
Topics: Adolescent; Adult; Chi-Square Distribution; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Multimodal Imaging; Neoplasms; Ovary; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Uterus | 2013 |
Prevalence of vocal cord paralysis in patients with incidentally discovered enlarged lymph nodes along the expected course of the recurrent laryngeal nerve.
Topics: Cohort Studies; Fluorodeoxyglucose F18; Humans; Incidental Findings; Lymphatic Diseases; Lymphatic Metastasis; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Prevalence; Radiopharmaceuticals; Recurrent Laryngeal Nerve; Retrospective Studies; Sarcoidosis; Tomography, X-Ray Computed; United States; Vocal Cord Paralysis | 2013 |
Improved PET imaging of tumors in mice using a novel (18) F-folate conjugate with an albumin-binding entity.
Topics: Albumins; Animals; Cell Line, Tumor; Female; Fluorodeoxyglucose F18; Folic Acid; Humans; Mice; Mice, Nude; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tissue Distribution | 2013 |
SUVmax of 2.5 should not be embraced as a magic threshold for separating benign from malignant lesions.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Predictive Value of Tests; Protein Binding; Radiopharmaceuticals; Reference Standards | 2013 |
In vivo imaging of glucose uptake and metabolism in tumors.
Topics: Amino Acids; Animals; Autoradiography; Carbon Isotopes; Cell Hypoxia; Female; Fluorodeoxyglucose F18; Glucose; Humans; Magnetic Resonance Imaging; Mice; Microscopy, Fluorescence; Neoplasms; Perfusion; Xenograft Model Antitumor Assays | 2013 |
Automated biological target volume delineation for radiotherapy treatment planning using FDG-PET/CT.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Automation; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed; Tumor Burden | 2013 |
Monitoring of tumor response to cisplatin with simultaneous fluorescence and positron emission tomography: a feasibility study.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Disease Progression; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Injections, Intraperitoneal; Luminescent Proteins; Mice; Mice, Inbred BALB C; Microscopy, Fluorescence; Molecular Imaging; Neoplasm Transplantation; Neoplasms; Positron-Emission Tomography; Red Fluorescent Protein | 2014 |
Imaging-guided biopsy of (18)F-FDG-avid extrapulmonary lesions: do lesion location and morphologic features on CT affect the positive predictive value for malignancy?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biopsy; Chi-Square Distribution; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Predictive Value of Tests; Radiography, Interventional; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed | 2013 |
Diagnostic value of 18F-FDG PET/CT in comparison to bone scintigraphy, CT and 18F-FDG PET for the detection of bone metastasis.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Prognosis; Radionuclide Imaging; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed | 2013 |
The promise and limits of PET texture analysis.
Topics: Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Neoplasms; Positron-Emission Tomography | 2013 |
Four-dimensional (4D) motion detection to correct respiratory effects in treatment response assessment using molecular imaging biomarkers.
Topics: Algorithms; Biomarkers; Calibration; Datasets as Topic; Fluorodeoxyglucose F18; Four-Dimensional Computed Tomography; Humans; Lung Neoplasms; Molecular Imaging; Motion; Neoplasms; Phantoms, Imaging; Positron-Emission Tomography | 2014 |
Clinical impact of PET/MR imaging in patients with cancer undergoing same-day PET/CT: initial experience in 134 patients--a hypothesis-generating exploratory study.
Topics: Contrast Media; Female; Fluorodeoxyglucose F18; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed | 2013 |
[(18)F]-fluorodeoxyglucose positron emission tomography and computed tomography in response evaluation of oncolytic adenovirus treatments of patients with advanced cancer.
Topics: Adenoviridae; Animals; Cricetinae; Fluorodeoxyglucose F18; Genetic Therapy; Humans; Neoplasms; Oncolytic Viruses; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, Emission-Computed | 2013 |
FDG-avid venous malformation could mimic malignancy on 18F-FDG PET/CT.
Topics: Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms; Phlebography; Positron-Emission Tomography; Tomography, X-Ray Computed; Veins | 2013 |
Defining gross tumor volume using positron emission tomography/computed tomography phantom studies.
Topics: Algorithms; Fluorodeoxyglucose F18; Humans; Neoplasms; Phantoms, Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Tumor Burden | 2013 |
Correlation between standardized uptake value and apparent diffusion coefficient of neoplastic lesions evaluated with whole-body simultaneous hybrid PET/MRI.
Topics: Aged; Diffusion Magnetic Resonance Imaging; Female; Fluorodeoxyglucose F18; Humans; Male; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Whole Body Imaging | 2013 |
Molecular imaging of tumors and metastases using chemical exchange saturation transfer (CEST) MRI.
Topics: Animals; Cell Line, Tumor; Contrast Media; Disease Models, Animal; Female; Fluorine-19 Magnetic Resonance Imaging; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Mice; Molecular Imaging; Neoplasms | 2013 |
Chemistry. Expanding the scope of fluorine tags for PET imaging.
Topics: Alzheimer Disease; Aniline Compounds; Celecoxib; Ethylene Glycols; Fluorescent Dyes; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Fluoxetine; Glucose; Halogenation; Humans; Melanoma; Neoplasms; Patient Selection; Plaque, Amyloid; Positron-Emission Tomography; Pyrazoles; Radiopharmaceuticals; Sulfonamides | 2013 |
Assessment of early changes in 3H-fluorothymidine uptake after treatment with gefitinib in human tumor xenograft in comparison with Ki-67 and phospho-EGFR expression.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Models, Animal; ErbB Receptors; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Ki-67 Antigen; Mice; Neoplasms; Phosphorylation; Quinazolines; Radiopharmaceuticals; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Dose escalation to high-risk sub-volumes based on non-invasive imaging of hypoxia and glycolytic activity in canine solid tumors: a feasibility study.
Topics: Algorithms; Animals; Coordination Complexes; Copper Radioisotopes; Dogs; Dose-Response Relationship, Radiation; Fluorodeoxyglucose F18; Glycolysis; Hypoxia; Multimodal Imaging; Neoplasms; Normal Distribution; Organometallic Compounds; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Thiosemicarbazones; Tomography, X-Ray Computed | 2013 |
A pilot study using next-generation sequencing in advanced cancers: feasibility and challenges.
Topics: Adult; Aged; DNA Copy Number Variations; Female; Fluorodeoxyglucose F18; Gene Expression Profiling; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Pilot Projects; Positron-Emission Tomography; Tomography, X-Ray Computed; Transcriptome; Young Adult | 2013 |
[18F-Nsodiumfluorid/18F-FDG-PET/CT shows promising results].
Topics: Female; Fluorodeoxyglucose F18; Humans; Male; Neoplasms; Positron-Emission Tomography; Tomography, X-Ray Computed | 2013 |
Effect of varying number of OSEM subsets on PET lesion detectability.
Topics: Algorithms; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Neoplasms; Positron-Emission Tomography | 2013 |
(18)F-alfatide II and (18)F-FDG dual-tracer dynamic PET for parametric, early prediction of tumor response to therapy.
Topics: Albumin-Bound Paclitaxel; Albumins; Animals; Antineoplastic Agents; Doxorubicin; Female; Fluorodeoxyglucose F18; Humans; Mice; Mice, Nude; Neoplasms; Oligopeptides; Paclitaxel; Peptides, Cyclic; Positron-Emission Tomography; Radiopharmaceuticals; Time Factors | 2014 |
Comparative effectiveness research for molecular imaging.
Topics: Comparative Effectiveness Research; Fluorodeoxyglucose F18; Humans; Molecular Imaging; Neoplasms; Positron-Emission Tomography; Precision Medicine; Radiopharmaceuticals; Sensitivity and Specificity | 2012 |
The role of response evaluation criteria in solid tumour in anticancer treatment evaluation: results of a survey in the oncology community.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Outcome Assessment, Health Care; Positron-Emission Tomography; Practice Guidelines as Topic; Surveys and Questionnaires | 2014 |
How to assess background activity: introducing a histogram-based analysis as a first step for accurate one-step PET quantification.
Topics: Algorithms; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Neoplasms; Phantoms, Imaging; Positron-Emission Tomography; Retrospective Studies | 2014 |
Quantitative FDG PET/CT in the community: experience from interpretation of outside oncologic PET/CT exams in referred cancer patients.
Topics: Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Referral and Consultation; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity; Tertiary Care Centers; Tomography, X-Ray Computed | 2014 |
Normal cerebral FDG uptake during childhood.
Topics: Adolescent; Brain; Child; Child, Preschool; Female; Fluorodeoxyglucose F18; Humans; Infant; Male; Neoplasms; Radionuclide Imaging; Radiopharmaceuticals; Tissue Distribution | 2014 |
Heavy PETting: reducing radiation exposure from intradepartment positron emission tomography scans.
Topics: Fluorodeoxyglucose F18; Half-Life; Humans; Neoplasms; Occupational Exposure; Positron-Emission Tomography; Radiology Department, Hospital; Radiopharmaceuticals | 2014 |
Computed tomography automatic exposure control techniques in 18F-FDG oncology PET-CT scanning.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Automation; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasms; Phantoms, Imaging; Positron-Emission Tomography; Radiation Dosage; Tomography, X-Ray Computed; Young Adult | 2014 |
Interreader agreement and variability of FDG PET volumetric parameters in human solid tumors.
Topics: Aged; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Tumor Burden | 2014 |
Diagnostic accuracy of FDG-PET cancer screening in asymptomatic individuals: use of record linkage from the Osaka Cancer Registry.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Early Detection of Cancer; Female; Fluorodeoxyglucose F18; Humans; Japan; Magnetic Resonance Imaging; Male; Mass Screening; Middle Aged; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Registries; Sensitivity and Specificity; Whole Body Imaging; Young Adult | 2014 |
An alternative approach to histopathological validation of PET imaging for radiation therapy image-guidance: a proof of concept.
Topics: Animals; Autoradiography; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Imaging, Three-Dimensional; Mice; Mice, Nude; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Image-Guided | 2014 |
Clinical impact of "true whole-body" (18)F-FDG PET/CT: lesion frequency and added benefit in distal lower extremities.
Topics: Adult; Aged; Aged, 80 and over; Child; Female; Fluorodeoxyglucose F18; Foot; Head; Humans; Lower Extremity; Male; Middle Aged; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Time; Tomography, X-Ray Computed; Whole Body Imaging; Young Adult | 2014 |
[Cancer Diagnosis - 18F-sodiumfluorid/18F-FDG-PET/CT shows promising results. ].
Topics: Female; Fluorodeoxyglucose F18; Humans; Male; Neoplasms; Positron-Emission Tomography; Tomography, X-Ray Computed | 2013 |
Whole-body-MR-diffusion weighted imaging in oncology.
Topics: Adult; Aged; Diffusion Magnetic Resonance Imaging; Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Imaging, Three-Dimensional; Magnetic Resonance Spectroscopy; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Positron-Emission Tomography; Reference Values; Sensitivity and Specificity; Tomography, X-Ray Computed; Whole Body Imaging | 2013 |
Frequency and clinical relevance of PET/CT incidentalomas.
Topics: Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Incidental Findings; Male; Middle Aged; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Young Adult | 2014 |
Can whole-body MRI replace (18)F-fluorodeoxyglucose PET/CT?
Topics: Diffusion Magnetic Resonance Imaging; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Whole Body Imaging | 2014 |
Ionising radiation-free whole-body MRI versus (18)F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective, non-randomised, single-centre study.
Topics: Adolescent; Adult; Child; Diffusion Magnetic Resonance Imaging; Fluorodeoxyglucose F18; Humans; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Tomography, X-Ray Computed; Whole Body Imaging; Young Adult | 2014 |
Clinical value of dual-phase 18F-FDG SPECT with serum procalcitonin for identification of etiology in tumor patients with fever of unknown origin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Calcitonin; Calcitonin Gene-Related Peptide; Female; Fever of Unknown Origin; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Infections; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Prognosis; Prospective Studies; Protein Precursors; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon; Young Adult | 2014 |
Imaging: reducing ionizing radiation in children and adolescents.
Topics: Diffusion Magnetic Resonance Imaging; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Whole Body Imaging | 2014 |
A novel radiotracer to image glycogen metabolism in tumors by positron emission tomography.
Topics: Cell Cycle Checkpoints; Cell Line, Tumor; Fluorodeoxyglucose F18; G1 Phase; Glycogen; Humans; Neoplasms; Positron-Emission Tomography; rab GTP-Binding Proteins; Radiopharmaceuticals; Resting Phase, Cell Cycle | 2014 |
Does the novel integrated PET/MRI offer the same diagnostic performance as PET/CT for oncological indications?
Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, X-Ray Computed | 2014 |
The Neurobiological Basis of the Distress Thermometer: A PET Study in Cancer Patients.
Topics: Adult; Aged; Anxiety Disorders; Brain; Depressive Disorder; Female; Fluorodeoxyglucose F18; Humans; Linear Models; Logistic Models; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Stress, Psychological; Surveys and Questionnaires | 2015 |
FDG PET metabolic tumor volume segmentation and pathologic volume of primary human solid tumors.
Topics: Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Tumor Burden | 2014 |
Unexpected FDG-PET uptake in the gastrointestinal tract: endoscopic and histopathological correlations.
Topics: Adult; Aged; Aged, 80 and over; Endoscopy; Endoscopy, Digestive System; Female; Fluorodeoxyglucose F18; Gastrointestinal Tract; Humans; Incidental Findings; Inflammation; Lymphatic Diseases; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Inferior glucose metabolism and chemosensitivity of post-radiotherapy local recurrence in comparison with distant metastases as assessed by sequential (18)F-FDG PET/CT imaging.
Topics: Adult; Aged; Biological Transport; Female; Fluorodeoxyglucose F18; Glucose; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms; Positron-Emission Tomography; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Low-dose radiation from 18F-FDG PET does not increase cancer frequency or shorten latency but reduces kidney disease in cancer-prone Trp53+/- mice.
Topics: Animals; Dose-Response Relationship, Radiation; Fluorodeoxyglucose F18; Gamma Rays; Kidney Diseases; Lymphoma; Male; Mice; Neoplasms; Organ Specificity; Osteosarcoma; Positron-Emission Tomography; Survival Analysis; Tumor Suppressor Protein p53 | 2014 |
(18)F-FDG PET/CT scans for children and adolescents.
Topics: Diffusion Magnetic Resonance Imaging; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Whole Body Imaging | 2014 |
(18)F-FDG PET/CT scans for children and adolescents - authors' reply.
Topics: Diffusion Magnetic Resonance Imaging; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Whole Body Imaging | 2014 |
Defining key signaling nodes and therapeutic biomarkers in NF1-mutant cancers.
Topics: Antineoplastic Agents; Biomarkers; Class Ia Phosphatidylinositol 3-Kinase; Fluorodeoxyglucose F18; Glucose Transporter Type 1; Humans; Mechanistic Target of Rapamycin Complex 1; Molecular Targeted Therapy; Multiprotein Complexes; Neoplasms; Neoplasms, Nerve Tissue; Nerve Sheath Neoplasms; Neurofibromin 1; Positron-Emission Tomography; Protein Kinase Inhibitors; Signal Transduction; TOR Serine-Threonine Kinases | 2014 |
The role of 18F-FDG PET/CT in differentiating malignant from benign portal vein thrombosis.
Topics: Adult; Aged; Aged, 80 and over; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasms; Portal Vein; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; ROC Curve; Sensitivity and Specificity; Tomography, X-Ray Computed; Venous Thrombosis; Young Adult | 2014 |
18F-FDG PET/CT oncologic imaging at extended injection-to-scan acquisition time intervals derived from a single-institution 18F-FDG-directed surgery experience: feasibility and quantification of 18F-FDG accumulation within 18F-FDG-avid lesions and backgro
Topics: Adult; Aged; Aged, 80 and over; Databases, Factual; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Postoperative Period; Preoperative Period; Retrospective Studies; Tomography, X-Ray Computed | 2014 |
Positron emission tomography: the ideal tool in polymyalgia rheumatica?
Topics: Fluorodeoxyglucose F18; Giant Cell Arteritis; Humans; Neoplasms; Polymyalgia Rheumatica; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2014 |
Fever of unknown origin in the 2000s: evaluation of 103 cases over eleven years.
Topics: Adult; Aged; Aged, 80 and over; DNA, Bacterial; DNA, Viral; Female; Ferritins; Fever of Unknown Origin; Fluorodeoxyglucose F18; Humans; Infections; Inflammation; Male; Middle Aged; Neoplasms; Polymerase Chain Reaction; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Young Adult | 2014 |
Generation of prescriptions robust against geometric uncertainties in dose painting by numbers.
Topics: Algorithms; Carcinoma, Squamous Cell; Confidence Intervals; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Neoplasms; Normal Distribution; Positron-Emission Tomography; Prescriptions; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Uncertainty | 2015 |
Tumor thrombus: ancillary findings on FDG PET/CT in an oncologic population.
Topics: Adolescent; Adult; Aged; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Child; Female; Fluorodeoxyglucose F18; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasms; Portal Vein; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Thrombosis; Tomography, X-Ray Computed; Veins; Vena Cava, Inferior; Venous Thromboembolism; Young Adult | 2014 |
Evaluation of clinical contributions provided by addition of the brain, calvarium, and scalp to the limited whole body imaging area in FDG-PET/CT tumor imaging.
Topics: Adult; Aged; Brain; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Prognosis; Scalp; Skull; Tomography, X-Ray Computed | 2014 |
Reduction of patient anxiety in PET/CT imaging by improving communication between patient and technologist.
Topics: Anxiety; Attitude to Health; Communication; Female; Fluorodeoxyglucose F18; Humans; Male; Medical Laboratory Personnel; Multimodal Imaging; Neoplasms; Patient Satisfaction; Positron-Emission Tomography; Professional-Patient Relations; Surveys and Questionnaires; Tomography, X-Ray Computed | 2014 |
Dynamic metabolic changes during the first 3 months after 90Y-ibritumomab tiuxetan radioimmunotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Radioimmunotherapy; Time Factors | 2014 |
Metformin may be associated with false-negative cancer detection in the gastrointestinal tract on PET/CT.
Topics: Diabetes Mellitus, Type 2; False Negative Reactions; Fluorodeoxyglucose F18; Humans; Metformin; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2014 |
Performance of intra-procedural 18-fluorodeoxyglucose PET/CT-guided biopsies for lesions suspected of malignancy but poorly visualized with other modalities.
Topics: Abdomen; Adolescent; Adult; Aged; Bone and Bones; Child; Female; Fluorodeoxyglucose F18; Humans; Image-Guided Biopsy; Liver; Lung; Male; Middle Aged; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Subcutaneous Tissue; Tomography, X-Ray Computed | 2014 |
Diagnostic accuracy of whole-body PET/MRI and whole-body PET/CT for TNM staging in oncology.
Topics: Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Reference Standards; Sensitivity and Specificity; Tomography, X-Ray Computed; Whole Body Imaging | 2015 |
¹⁸FDG a PET tumor diagnostic tracer is not a substrate of the ABC transporter P-glycoprotein.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line; Flow Cytometry; Fluorodeoxyglucose F18; Humans; Mice; Neoplasms; NIH 3T3 Cells; Positron-Emission Tomography; Rhodamine 123; Substrate Specificity | 2014 |
[18F]FDG-PET/CT for the diagnosis of patients with fever of unknown origin.
Topics: Adult; Aged; Aged, 80 and over; Female; Fever of Unknown Origin; Fluorodeoxyglucose F18; Hospitalization; Humans; Infections; Inflammation; Male; Middle Aged; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Young Adult | 2015 |
Comparison of two threshold detection criteria methodologies for determination of probe positivity for intraoperative in situ identification of presumed abnormal 18F-FDG-avid tissue sites during radioguided oncologic surgery.
Topics: Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Intraoperative Care; Male; Middle Aged; Models, Statistical; Neoplasms; Radionuclide Imaging; Radiopharmaceuticals; Sensitivity and Specificity; Surgery, Computer-Assisted | 2014 |
Modeling the relationship between fluorodeoxyglucose uptake and tumor radioresistance as a function of the tumor microenvironment.
Topics: Blood Glucose; Cell Proliferation; Fluorodeoxyglucose F18; Glucose; Humans; Neoplasms; Oxygen; Positron-Emission Tomography; Probability; Radiopharmaceuticals; Reproducibility of Results; Tumor Microenvironment | 2014 |
A multifractal approach to space-filling recovery for PET quantification.
Topics: Algorithms; Computer Simulation; Fluorodeoxyglucose F18; Fractals; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Models, Theoretical; Neoplasms; Normal Distribution; Positron-Emission Tomography; Reproducibility of Results; Software; Tumor Burden | 2014 |
The effect of PPAR-γ agonist on (18)F-FDG PET imaging for differentiating tumors and inflammation lesions.
Topics: Anilides; Animals; Biological Transport; Cell Line, Tumor; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Glucose; Glucose Transporter Type 1; Glucose Transporter Type 3; Humans; Inflammation; Macrophages; Mice; Neoplasms; Pioglitazone; Positron-Emission Tomography; PPAR gamma; Thiazolidinediones; Tissue Distribution | 2015 |
Segmentation of heterogeneous or small FDG PET positive tissue based on a 3D-locally adaptive random walk algorithm.
Topics: Algorithms; Data Interpretation, Statistical; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Imaging, Three-Dimensional; Neoplasms; Phantoms, Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity | 2014 |
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0.
Topics: Fluorodeoxyglucose F18; Humans; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2015 |
Perceived misinterpretation rates in oncologic 18F-FDG PET/CT studies: a survey of referring physicians.
Topics: Diagnostic Errors; Fluorodeoxyglucose F18; Health Care Surveys; Humans; Internet; Medical Oncology; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Referral and Consultation; Surveys and Questionnaires | 2014 |
Using SUV as a guide to 18F-FDG dose reduction.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Dose-Response Relationship, Drug; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Reference Values; Retrospective Studies; Tomography, X-Ray Computed; Young Adult | 2014 |
2014 Cassen Lecture: What have we learned from the National Oncologic PET Registry?
Topics: Fluorodeoxyglucose F18; Humans; Insurance, Health, Reimbursement; Neoplasms; Nuclear Medicine; Positron-Emission Tomography; Radiopharmaceuticals; Registries; United States | 2014 |
Is the standard uptake value (SUV) appropriate for quantification in clinical PET imaging? - Variability induced by different SUV measurements and varying reconstruction methods.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Image Processing, Computer-Assisted; Male; Middle Aged; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Tomography, X-Ray Computed; Whole Body Imaging | 2015 |
[Usefulness of (18)FDG PET-CT scan as a diagnostic tool of fever of unknown origin].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Diagnosis, Differential; Female; Fever of Unknown Origin; Fluorodeoxyglucose F18; Humans; Infections; Inflammation; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Tomography, X-Ray Computed; Young Adult | 2015 |
18F-FDG PET uptake characterization through texture analysis: investigating the complementary nature of heterogeneity and functional tumor volume in a multi-cancer site patient cohort.
Topics: Biological Transport; Cohort Studies; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Prognosis; Retrospective Studies; Survival Analysis; Tumor Burden | 2015 |
[New challenges and perspectives in nuclear medicine imaging].
Topics: Contrast Media; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Multimodal Imaging; Neoplasms; Nuclear Medicine; Positron-Emission Tomography; Radiation Dosage; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed | 2014 |
[New trends in functional medical imaging: quantitative methods].
Topics: Fluorodeoxyglucose F18; Glucose; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Kinetics; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2014 |
High 18F-FDG uptake in a systemic right ventricle after atrial switch.
Topics: Cardiac Surgical Procedures; False Positive Reactions; Female; Fluorodeoxyglucose F18; Heart Ventricles; Humans; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Young Adult | 2015 |
Feasibility study of novel endoscopic Cerenkov luminescence imaging system in detecting and quantifying gastrointestinal disease: first human results.
Topics: Adult; Animals; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Luminescence; Male; Mice, Nude; Middle Aged; Neoplasms; Phantoms, Imaging; Pilot Projects; Positron-Emission Tomography; Proctoscopy; Radiopharmaceuticals; Rectal Neoplasms | 2015 |
Endoscopic ultrasound - fine needle aspiration of 2-deoxy-2-[18F] fluoro-D-glucose avid lymph nodes seen on positron emission tomography- computed tomography -what looks like cancer may not always be so.
Topics: Adolescent; Adult; Aged; Biopsy, Fine-Needle; Child; Child, Preschool; Endosonography; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed | 2014 |
Contrast-enhanced [18 F] fluorodeoxyglucose-positron emission tomography/computed tomography in clinical oncology: tumor-, site-, and question-based comparison with standard positron emission tomography/computed tomography.
Topics: Adult; Aged; Contrast Media; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasms; Patient Selection; Positron-Emission Tomography; Radiographic Image Enhancement; Radiopharmaceuticals; Tomography, X-Ray Computed | 2014 |
Multiparametric analysis of bone marrow in cancer patients using simultaneous PET/MR imaging: Correlation of fat fraction, diffusivity, metabolic activity, and anthropometric data.
Topics: Adipose Tissue; Adiposity; Adolescent; Adult; Aged; Aged, 80 and over; Anthropometry; Body Weight; Bone Marrow; Child; Child, Preschool; Contrast Media; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Imaging, Three-Dimensional; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Reproducibility of Results; Sensitivity and Specificity; Young Adult | 2015 |
Comparison of Single-fraction and Multi-fraction Stereotactic Radiotherapy for Patients with 18F-fluorodeoxyglucose Positron Emission Tomography-staged Pulmonary Oligometastases.
Topics: Aged; Dose Fractionation, Radiation; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Radiosurgery; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Retrospective Studies; Survival Rate; Tissue Distribution | 2015 |
Low-order non-spatial effects dominate second-order spatial effects in the texture quantifier analysis of 18F-FDG-PET images.
Topics: Algorithms; Computer Simulation; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Image Processing, Computer-Assisted; Neoplasms; Positron-Emission Tomography; ROC Curve; Tomography, X-Ray Computed | 2015 |
Multimodality functional imaging in radiation therapy planning: relationships between dynamic contrast-enhanced MRI, diffusion-weighted MRI, and 18F-FDG PET.
Topics: Area Under Curve; Contrast Media; Diffusion Magnetic Resonance Imaging; Fluorodeoxyglucose F18; Humans; Hypoxia; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Radiotherapy Planning, Computer-Assisted; Reproducibility of Results | 2015 |
Optimising delineation accuracy of tumours in PET for radiotherapy planning using blind deconvolution.
Topics: Algorithms; Fluorodeoxyglucose F18; Humans; Imaging, Three-Dimensional; Neoplasms; Pattern Recognition, Automated; Phantoms, Imaging; Positron-Emission Tomography; Radiographic Image Interpretation, Computer-Assisted; Radiotherapy Planning, Computer-Assisted; Reproducibility of Results; Tomography, X-Ray Computed | 2015 |
Patient doses from PET-CT procedures.
Topics: Bulgaria; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Radiation Dosage; Radiation Protection; Radiometry; Radiopharmaceuticals; Retrospective Studies; Software; Tomography, X-Ray Computed; Whole Body Imaging | 2015 |
Detecting residual fluorine 18 from a medical PET-CT procedure during population whole body counter screening in Fukushima.
Topics: Fluorodeoxyglucose F18; Fukushima Nuclear Accident; Humans; Japan; Male; Mass Screening; Middle Aged; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Whole-Body Counting | 2014 |
Summary of the UPICT Protocol for 18F-FDG PET/CT Imaging in Oncology Clinical Trials.
Topics: Clinical Trials as Topic; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Medical Oncology; Motion; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Quality Control; Reproducibility of Results; Research Design; Respiration; Risk Management; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Quantitative Evaluation of Segmentation- and Atlas-Based Attenuation Correction for PET/MR on Pediatric Patients.
Topics: Adolescent; Adult; Aged; Algorithms; Bone and Bones; Child; Child, Preschool; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Reproducibility of Results; Tomography, X-Ray Computed; Whole Body Imaging | 2015 |
Tumor growth prediction with reaction-diffusion and hyperelastic biomechanical model by physiological data fusion.
Topics: Algorithms; Biomechanical Phenomena; Contrast Media; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Predictive Value of Tests; Radiographic Image Interpretation, Computer-Assisted; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, X-Ray Computed | 2015 |
Feasibility of FDG-PET/CT for the initial diagnosis of papillary thyroid cancer.
Topics: Adult; Aged; Carcinoma, Papillary; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Incidental Findings; Lymphatic Metastasis; Male; Middle Aged; Neck Dissection; Neoplasms; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Sensitivity and Specificity; Thyroid Diseases; Thyroid Neoplasms | 2016 |
Oncological whole-body staging in integrated (18)F-FDG PET/MR: Value of different MR sequences for simultaneous PET and MR reading.
Topics: Diffusion Magnetic Resonance Imaging; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Tomography, X-Ray Computed; Whole Body Imaging | 2015 |
Variability of [18F]FDG administered activities among patients undergoing PET examinations: an international multicenter survey.
Topics: Communicable Diseases; Fluorodeoxyglucose F18; Health Care Surveys; Humans; Inflammation; International Agencies; Neoplasms; Nuclear Medicine; Positron-Emission Tomography; Practice Guidelines as Topic; Radiopharmaceuticals | 2016 |
Comparative Oncology: Evaluation of 2-Deoxy-2-[18F]fluoro-D-glucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) for the Staging of Dogs with Malignant Tumors.
Topics: Animals; Disease Models, Animal; Dog Diseases; Dogs; Female; Fluorodeoxyglucose F18; Male; Neoplasms; Positron-Emission Tomography; Tomography, X-Ray Computed | 2015 |
Fetal Radiation Dose from 18F-FDG in Pregnant Patients Imaged with PET, PET/CT, and PET/MR.
Topics: Adult; Diagnostic Imaging; Female; Fetus; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Maternal Exposure; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Pregnancy; Pregnancy Complications, Neoplastic; Radiation Dosage; Radiometry; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Urinary Bladder; Young Adult | 2015 |
A limited overlap between intratumoral distribution of 1-(5-fluoro-5-deoxy-α-D-arabinofuranosyl)-2-nitroimidazole and copper-diacetyl-bis[N(4)-methylthiosemicarbazone].
Topics: Animals; Biomarkers, Tumor; Cell Hypoxia; Cell Line, Tumor; Cell Tracking; Coordination Complexes; Fluorodeoxyglucose F18; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Mice; Neoplasms; Nitroimidazoles; Organometallic Compounds; Positron-Emission Tomography; Radiography; Thiosemicarbazones; Xenograft Model Antitumor Assays | 2015 |
Beyond 18F-FDG: Characterization of PET/CT and PET/MR Scanners for a Comprehensive Set of Positron Emitters of Growing Application--18F, 11C, 89Zr, 124I, 68Ga, and 90Y.
Topics: Carbon Radioisotopes; Contrast Media; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Image Processing, Computer-Assisted; Iodine Radioisotopes; Magnetic Resonance Imaging; Multimodal Imaging; Neoplasms; Phantoms, Imaging; Positron-Emission Tomography; Radioisotopes; Radiopharmaceuticals; Tomography, X-Ray Computed; Yttrium Radioisotopes; Zirconium | 2015 |
[18F-Berberine Derivatives: a Potential Molecular Imaging Agent for Tumor Targeting by PET/CT Tumor].
Topics: Berberine; Fluorodeoxyglucose F18; Humans; Molecular Imaging; Neoplasms; Positron-Emission Tomography; Tissue Distribution; Tomography, X-Ray Computed | 2015 |
Clinical importance of re-interpretation of PET/CT scanning in patients referred to a tertiary care medical centre.
Topics: Adult; Aged; Aged, 80 and over; Denmark; Double-Blind Method; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Observer Variation; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Referral and Consultation; Reproducibility of Results; Tertiary Care Centers; Young Adult | 2017 |
Feasibility of using respiration-averaged MR images for attenuation correction of cardiac PET/MR imaging.
Topics: Algorithms; Computer Simulation; Feasibility Studies; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Models, Statistical; Multimodal Imaging; Neoplasms; Phantoms, Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Dosage; Respiratory-Gated Imaging Techniques | 2015 |
Impact of Image Reconstruction Settings on Texture Features in 18F-FDG PET.
Topics: Aged; Aged, 80 and over; Algorithms; Data Interpretation, Statistical; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Whole Body Imaging | 2015 |
STatistically Assigned Response Criteria in Solid Tumors (STARCIST).
Topics: Algorithms; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Glucose; Humans; Lung Neoplasms; Neoplasms; Normal Distribution; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Robust PET-guided intensity-modulated radiation therapy.
Topics: Computer Simulation; Datasets as Topic; Fluorodeoxyglucose F18; Four-Dimensional Computed Tomography; Humans; Motion; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Probability; Radiation Dosage; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Image-Guided; Radiotherapy, Intensity-Modulated; Respiration; Respiratory-Gated Imaging Techniques; Uncertainty | 2015 |
Influence of Statistical Fluctuation on Reproducibility and Accuracy of SUVmax and SUVpeak: A Phantom Study.
Topics: Computer Simulation; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Models, Biological; Models, Statistical; Neoplasms; Phantoms, Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Whole Body Imaging | 2015 |
Comparative study of ¹⁸F-FDG-PET/CT imaging and serum hTERT mRNA quantification in cancer diagnosis.
Topics: Early Detection of Cancer; Female; Fluorodeoxyglucose F18; Humans; Male; Multimodal Imaging; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms; Positron-Emission Tomography; Prospective Studies; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sensitivity and Specificity; Telomerase; Tomography, X-Ray Computed | 2015 |
Preclinical Assessment of Efficacy of Radiation Dose Painting Based on Intratumoral FDG-PET Uptake.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Radiation; Fluorodeoxyglucose F18; Humans; Male; Neoplasms; Positron-Emission Tomography; Radiation Dosage; Rats; Rhabdomyosarcoma; Tumor Burden | 2015 |
Comprehensive Oncologic Imaging in Infants and Preschool Children With Substantially Reduced Radiation Exposure Using Combined Simultaneous ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging: A Direct Comparison to ¹⁸F-Fluorode
Topics: Child; Child, Preschool; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Infant; Magnetic Resonance Imaging; Male; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Prospective Studies; Radiation Exposure; Radiopharmaceuticals; Tomography, X-Ray Computed | 2016 |
Simultaneous Hyperpolarized 13C-Pyruvate MRI and 18F-FDG PET (HyperPET) in 10 Dogs with Cancer.
Topics: Animals; Dog Diseases; Dogs; Fluorodeoxyglucose F18; Image Processing, Computer-Assisted; Lactic Acid; Magnetic Resonance Imaging; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Prognosis; Pyruvic Acid; Radiopharmaceuticals | 2015 |
Clinical Impact of Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Carried Out for Non-Medicare Eligible Indications in Australia: A Prospective Study.
Topics: Australia; Fluorodeoxyglucose F18; Humans; Medicare; Neoplasms; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Tomography, X-Ray Computed; United States | 2015 |
FDG PET and Split-Bolus Multi-Detector Row CT Fusion Imaging in Oncologic Patients: Preliminary Results.
Topics: Adult; Aged; Aged, 80 and over; Contrast Media; Female; Fluorodeoxyglucose F18; Humans; Iohexol; Iopamidol; Male; Middle Aged; Multidetector Computed Tomography; Multimodal Imaging; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies | 2016 |
Molecular Imaging of Post-Src Inhibition Tumor Signatures for Guiding Dasatinib Combination Therapy.
Topics: Animals; Antineoplastic Agents; Dasatinib; Drug Therapy, Combination; Fluorodeoxyglucose F18; Genes, src; Integrin alphaVbeta3; Luminescence; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Imaging; Neoplasms; Radioligand Assay; Radiopharmaceuticals; Ranibizumab; Tomography, Emission-Computed, Single-Photon; Vascular Endothelial Growth Factor A | 2016 |
Using PET and CT imaging to define the radiotherapy target for tumours that move with respiration.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Respiration; Tomography, X-Ray Computed | 2015 |
Comparison of positron emission tomography diffusion-weighted imaging (PET/DWI) registration quality in a PET/MR scanner: Zoomed DWI vs. Conventional DWI.
Topics: Aged; Artifacts; Diffusion Magnetic Resonance Imaging; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results | 2016 |
Progressing Toward a Cohesive Pediatric 18F-FDG PET/MR Protocol: Is Administration of Gadolinium Chelates Necessary?
Topics: Adolescent; Chelating Agents; Child; Child, Preschool; Contrast Media; Female; Fluorodeoxyglucose F18; Gadolinium; Humans; Infant; Magnetic Resonance Imaging; Male; Multimodal Imaging; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Retrospective Studies; Sensitivity and Specificity; Young Adult | 2016 |
Impact of Point-Spread Function Modeling on PET Image Quality in Integrated PET/MR Hybrid Imaging.
Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Models, Theoretical; Multimodal Imaging; Neoplasms; Phantoms, Imaging; Positron-Emission Tomography | 2016 |
Regarding "Segmentation of heterogeneous or small FDG PET positive tissue based on a 3D-locally adaptive random walk algorithm" By DP. Onoma et al.
Topics: Algorithms; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Imaging, Three-Dimensional; Neoplasms; Positron-Emission Tomography | 2015 |
The value of F-18 fluorodeoxyglucose positron emission tomography/computed tomography in asymptomatic examinees with unexplained elevated blood carcinoembryonic antigen levels.
Topics: Adult; Aged; Asymptomatic Diseases; Carcinoembryonic Antigen; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2016 |
Evaluation of a new motion correction algorithm in PET/CT: combining the entire acquired PET data to create a single three-dimensional motion-corrected PET/CT image.
Topics: Aged; Algorithms; Artifacts; Biological Transport; Female; Fluorodeoxyglucose F18; Humans; Imaging, Three-Dimensional; Male; Movement; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Respiratory-Gated Imaging Techniques; Tomography, X-Ray Computed; Tumor Burden | 2016 |
Appropriate indications for positron emission tomography/computed tomography: College of Nuclear Physicians of the Colleges of Medicine of South Africa.
Topics: Fluorodeoxyglucose F18; Heart Diseases; Humans; Infections; Inflammation; Neoplasms; Nervous System Diseases; Positron-Emission Tomography; South Africa; Tomography, X-Ray Computed | 2015 |
Impact of point spread function reconstruction on quantitative 18F-FDG-PET/CT imaging parameters and inter-reader reproducibility in solid tumors.
Topics: Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Multimodal Imaging; Neoplasms; Observer Variation; Positron-Emission Tomography; Reproducibility of Results; Retrospective Studies; Tomography, X-Ray Computed | 2016 |
Additional Heparin Preadministration Improves Cardiac Glucose Metabolism Suppression over Low-Carbohydrate Diet Alone in ¹⁸F-FDG PET Imaging.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Diet; Diet, Carbohydrate-Restricted; Endocarditis; Female; Fluorodeoxyglucose F18; Glucose; Heart; Heparin; Humans; Inflammation; Male; Middle Aged; Myocardium; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Sarcoidosis; Young Adult | 2016 |
A Population-Based Gaussian Mixture Model Incorporating 18F-FDG PET and Diffusion-Weighted MRI Quantifies Tumor Tissue Classes.
Topics: Animals; Diffusion Magnetic Resonance Imaging; Disease Progression; Fluorodeoxyglucose F18; Humans; Imaging, Three-Dimensional; Mice; Mitosis; Multimodal Imaging; Necrosis; Neoplasm Transplantation; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tumor Microenvironment | 2016 |
Potential influence of Gadolinium contrast on image segmentation in MR-based attenuation correction with Dixon sequences in whole-body 18F-FDG PET/MR.
Topics: Adult; Aged; Contrast Media; Female; Fluorodeoxyglucose F18; Gadolinium; Humans; Image Enhancement; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Whole Body Imaging | 2016 |
Growth Hormone Protects the Intestine Preserving Radiotherapy Efficacy on Tumors: A Short-Term Study.
Topics: Animals; Apoptosis; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Fluorodeoxyglucose F18; Growth Hormone; Ileum; Immunohistochemistry; Intestinal Mucosa; Intestines; Neoplasms; Positron-Emission Tomography; Protective Agents; Rats; Receptors, Somatotropin; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Comparison of integrated whole-body PET/MR and PET/CT: Is PET/MR alternative to PET/CT in routine clinical oncology?
Topics: Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Medical Oncology; Middle Aged; Multimodal Imaging; Neoplasms; Positron Emission Tomography Computed Tomography; Systems Integration; Whole Body Imaging; Young Adult | 2016 |
Characterization of brown adipose tissue ¹⁸F-FDG uptake in PET/CT imaging and its influencing factors in the Chinese population.
Topics: Adipose Tissue, Brown; Adolescent; Adult; Aged; Aged, 80 and over; Asian People; Biological Transport; Blood Glucose; Body Mass Index; Child; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Multivariate Analysis; Neoplasms; Positron-Emission Tomography; Retrospective Studies; Sex Characteristics; Tomography, X-Ray Computed; Young Adult | 2016 |
Effects of curcumin on cancer cell mitochondrial function and potential monitoring with ¹⁸F-FDG uptake.
Topics: Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Curcumin; Fluorodeoxyglucose F18; Humans; Membrane Potential, Mitochondrial; Mitochondria; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Reactive Oxygen Species; Signal Transduction | 2016 |
Comparison of three ¹⁸F-labeled carboxylic acids with ¹⁸F-FDG of the differentiation tumor from inflammation in model mice.
Topics: Animals; Benzoates; Carboxylic Acids; Diagnosis, Differential; Disease Models, Animal; Fluoroacetates; Fluorocarbons; Fluorodeoxyglucose F18; Humans; Inflammation; Mice; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tissue Distribution | 2016 |
First Experience with Chemokine Receptor CXCR4-Targeted PET Imaging of Patients with Solid Cancers.
Topics: Aged; Aged, 80 and over; Biological Transport; Coordination Complexes; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Peptides, Cyclic; Positron-Emission Tomography; Receptors, CXCR4 | 2016 |
Impact of Oxygenation Status on 18F-FDG Uptake in Solid Tumors.
Topics: Animals; Cell Line, Tumor; Electron Spin Resonance Spectroscopy; Fluorodeoxyglucose F18; Humans; Mice; Neoplasms; Oxygen; Positron-Emission Tomography | 2016 |
18F-FDG, as a single imaging agent in assessing cancer, shows the ongoing biological phenomena in many domains: do we need additional tracers for clinical purposes?
Topics: Cell Proliferation; Diagnostic Imaging; Fluorodeoxyglucose F18; Humans; Neoplasms; Neovascularization, Pathologic; Positron-Emission Tomography; Radioactive Tracers | 2016 |
Positron emission tomography response criteria in solid tumours criteria for quantitative analysis of [18F]-fluorodeoxyglucose positron emission tomography with integrated computed tomography for treatment response assessment in metastasised solid tumours
Topics: Fluorodeoxyglucose F18; Humans; Multimodal Imaging; Neoplasm Metastasis; Neoplasms; Positron-Emission Tomography; Predictive Value of Tests; Radiographic Image Interpretation, Computer-Assisted; Radiopharmaceuticals; Reproducibility of Results; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Optimization of oncological ¹⁸F-FDG PET/CT imaging based on a multiparameter analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Fluorodeoxyglucose F18; Humans; Imaging, Three-Dimensional; Middle Aged; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Radiation Dosage; Reproducibility of Results; Retrospective Studies; Signal-To-Noise Ratio; Tomography, X-Ray Computed; Young Adult | 2016 |
Characterization of F-18 Fluorodeoxyglucose PET/CT in Granulomatosis with Polyangiitis.
Topics: Aged; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Granulomatosis with Polyangiitis; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Differentiating Between Cancer and Inflammation: A Metabolic-Based Method for Functional Computed Tomography Imaging.
Topics: Animals; Cell Line, Tumor; Contrast Media; Fluorodeoxyglucose F18; Glucose; Gold; Humans; Inflammation; Metal Nanoparticles; Mice; Neoplasms; Positron-Emission Tomography; Tomography, X-Ray Computed | 2016 |
The influence of respiratory motion on the cumulative SUV-volume histogram and fractal analyses of intratumoral heterogeneity in PET/CT imaging.
Topics: Artifacts; Biological Transport; Fluorodeoxyglucose F18; Fractals; Image Processing, Computer-Assisted; Movement; Neoplasms; Phantoms, Imaging; Positron Emission Tomography Computed Tomography; Respiration | 2016 |
Experimental Approach to Evaluate the 11C Perfusion and Diffusion in Small Animal Tissues for HadronPET Applications.
Topics: Animals; Brain; Carbon Radioisotopes; Fluorodeoxyglucose F18; Heterografts; Humans; Muscle, Skeletal; Neoplasms; Perfusion; Positron-Emission Tomography; Rats; Tissue Distribution | 2016 |
Impact of Data-driven Respiratory Gating in Clinical PET.
Topics: Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Positron Emission Tomography Computed Tomography; Prospective Studies; Radiopharmaceuticals; Reproducibility of Results; Respiratory-Gated Imaging Techniques; Whole Body Imaging | 2016 |
Variability in the amount of fluorine-18 fluorodeoxyglucose excreted in urine measured from oncology patients during PET/computed tomography imaging.
Topics: Blood Glucose; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Male; Neoplasms; Positron Emission Tomography Computed Tomography; Radiation Dosage; Radiopharmaceuticals | 2016 |
Image quality and variability for routine diagnostic FDG-PET scans in a Japanese community hospital: current status and possibility of improvement.
Topics: Adult; Aged; Aged, 80 and over; Body Mass Index; Female; Fluorodeoxyglucose F18; Hospitals, Community; Humans; Japan; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies | 2016 |
Selecting radiomic features from FDG-PET images for cancer treatment outcome prediction.
Topics: Algorithms; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Reproducibility of Results; Treatment Outcome | 2016 |
Effect of (18)F-fluorodeoxyglucose extravasation on time taken for tumoral uptake to reach a plateau: animal and clinical PET analyses.
Topics: Aged; Animals; Biological Transport; Female; Fluorodeoxyglucose F18; Humans; Kinetics; Male; Mice; Neoplasms; Positron Emission Tomography Computed Tomography | 2016 |
Commentary to 'Evaluation of a new motion correction algorithm in PET/CT: combining the entire acquired PET data to create a single three-dimensional motion-corrected PET/CT image'.
Topics: Aged; Algorithms; Artifacts; Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Imaging, Three-Dimensional; Male; Movement; Neoplasms; Positron Emission Tomography Computed Tomography; Reproducibility of Results; Sensitivity and Specificity | 2016 |
Response to 'Commentary to "Evaluation of a new motion correction algorithm in PET/CT: combining the entire acquired PET data to create a single three-dimensional motion-corrected PET/CT image."'.
Topics: Aged; Algorithms; Artifacts; Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Imaging, Three-Dimensional; Male; Movement; Neoplasms; Positron Emission Tomography Computed Tomography; Reproducibility of Results; Sensitivity and Specificity | 2016 |
Oncological Patient Anxiety in Imaging Studies: the PET/CT Example.
Topics: Anxiety; Cross-Sectional Studies; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Positron Emission Tomography Computed Tomography; Radiation Oncology; Self Report; Surveys and Questionnaires | 2017 |
Impact on Patient Management of [18F]-Fluorodeoxyglucose-Positron Emission Tomography (PET) Used for Cancer Diagnosis: Analysis of Data From the National Oncologic PET Registry.
Topics: Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Neoplasms, Unknown Primary; Paraneoplastic Syndromes; Positron-Emission Tomography; Registries; Tomography, X-Ray Computed | 2016 |
The potential of positron emission tomography/computerized tomography (PET/CT) scanning as a detector of high-risk patients with oral infection during preoperative staging.
Topics: Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Pericoronitis; Periodontitis; Positron Emission Tomography Computed Tomography; Preoperative Period; Radiopharmaceuticals | 2016 |
Single Particle and PET-based Platform for Identifying Optimal Plasmonic Nano-Heaters for Photothermal Cancer Therapy.
Topics: Animals; Benchmarking; Cell Line, Tumor; Fluorodeoxyglucose F18; Gold; Heterografts; Hot Temperature; Humans; Hyperthermia, Induced; Metal Nanoparticles; Mice; Neoplasm Transplantation; Neoplasms; Phototherapy; Positron-Emission Tomography | 2016 |
Significantly Low Effective Dose from 18FDG PET/CT Scans Using Dose Reducing Strategies: "Lesser is Better".
Topics: Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prospective Studies; Radiation Dosage; Tomography, X-Ray Computed; Whole Body Imaging | 2016 |
Optimized workflow and imaging protocols for whole-body oncologic PET/MRI.
Topics: Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Whole Body Imaging; Workflow | 2016 |
PET and MRI: Is the Whole Greater than the Sum of Its Parts?
Topics: Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography | 2016 |
Clinical evaluation of a block sequential regularized expectation maximization reconstruction algorithm in 18F-FDG PET/CT studies.
Topics: Algorithms; Artifacts; Cohort Studies; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Likelihood Functions; Multivariate Analysis; Neoplasms; Observer Variation; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Signal-To-Noise Ratio | 2017 |
The clinical utility of FDG PET/CT among solid organ transplant recipients suspected of malignancy or infection.
Topics: Adult; Female; Fluorodeoxyglucose F18; Humans; Infections; Male; Middle Aged; Neoplasms; Organ Transplantation; Positron Emission Tomography Computed Tomography; Postoperative Complications; Radiopharmaceuticals | 2017 |
Spatiotemporal distribution modeling of PET tracer uptake in solid tumors.
Topics: Algorithms; Computer Simulation; Diffusion; Fluorodeoxyglucose F18; Humans; Models, Biological; Neoplasms; Neovascularization, Pathologic; Positron-Emission Tomography; Pressure; Radiopharmaceuticals | 2017 |
Correlation of PET/CT and Image-Guided Biopsies of Pediatric Malignancies.
Topics: Adolescent; Child; Child, Preschool; Female; Fluorodeoxyglucose F18; Humans; Image-Guided Biopsy; Male; Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity; Statistics as Topic | 2017 |
Concordance of 18F-FDG PET Uptake in Tumor and Normal Tissues on PET/MRI and PET/CT.
Topics: Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Liver; Magnetic Resonance Imaging; Male; Mediastinum; Middle Aged; Multimodal Imaging; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Young Adult | 2017 |
Conspicuity of Malignant Lesions on PET/CT and Simultaneous Time-Of-Flight PET/MRI.
Topics: Adult; Aged; Aged, 80 and over; Diagnostic Errors; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Retrospective Studies | 2017 |
A PET for All Seasons:
Topics: Fluorodeoxyglucose F18; Humans; Inflammation; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Retroperitoneal Fibrosis; Tomography, X-Ray Computed | 2017 |
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Clinical Decision-Making; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Patient Selection; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Retrospective Studies; Tumor Burden; Young Adult | 2018 |
Value of second-opinion review of outside institution PET-CT examinations.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Diagnostic Errors; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Nuclear Medicine; Positron Emission Tomography Computed Tomography; Prospective Studies; Radiopharmaceuticals; Referral and Consultation; Young Adult | 2017 |
[Individualised radiotherapy on the basis of functional imaging with FMISO PET].
Topics: Diagnostic Imaging; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Image Processing, Computer-Assisted; Kinetics; Neoplasms; Positron-Emission Tomography; Radiation-Sensitizing Agents; Radiotherapy | 2008 |
Guidelines for 18F-FDG PET and PET-CT imaging in paediatric oncology.
Topics: Child; Europe; Fluorodeoxyglucose F18; Humans; Medical Oncology; Neoplasms; Pediatrics; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2008 |
Functional mapping of pattern and probability of locoregional and distant metastases: can FDG-PET/CT imaging data be the basis for multidimensional scaling in patients with cancer?
Topics: Fluorodeoxyglucose F18; Humans; Neoplasm Metastasis; Neoplasms; Positron-Emission Tomography; Probability; Tomography, X-Ray Computed | 2008 |
Usefulness of automatic quantification of immunochemical staining on whole tumor sections for correlation with oncological small animal PET studies: an example with cell proliferation, glucose transporter 1 and FDG.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cyclin A; Fluorodeoxyglucose F18; Glucose Transporter Type 1; Humans; Male; Neoplasms; Positron-Emission Tomography; Rats; Xenograft Model Antitumor Assays | 2008 |
The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Diagnosis, Differential; Digestive System Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, X-Ray Computed | 2008 |
Effective radiotherapy of primary tumors and metastasis with 18F-2-deoxy-2-fluoro-D-glucose in C57BL/6 mice.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Female; Fluorodeoxyglucose F18; Gentian Violet; Humans; Lung Neoplasms; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Neoplasms; Positron-Emission Tomography; Radiation Oncology; Radiopharmaceuticals | 2008 |
Evaluation of whole-body cancer screening using 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography: a preliminary report.
Topics: Female; Fluorodeoxyglucose F18; Humans; Male; Mass Screening; Middle Aged; Neoplasms; Pilot Projects; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Whole Body Imaging | 2008 |
Impact of whole-body 18F-FDG PET on diagnostic and therapeutic management of Medical Oncology patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Treatment Outcome; Whole Body Imaging | 2008 |
Radiation dose to surgical staff from positron-emitter-based localization and radiosurgery of tumors.
Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Male; Medical Staff, Hospital; Middle Aged; Neoplasms; Occupational Exposure; Positron-Emission Tomography; Radiation Dosage; Radiation Protection; Radiopharmaceuticals; Radiosurgery | 2008 |
Assessment of tumour response with (18)F-fluorodeoxyglucose positron emission tomography using three-dimensional measures compared to SUVmax--a phantom study.
Topics: Algorithms; Fluorodeoxyglucose F18; Image Enhancement; Image Interpretation, Computer-Assisted; Imaging, Three-Dimensional; Neoplasms; Phantoms, Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity | 2008 |
Cellular uptake of PET tracers of glucose metabolism and hypoxia and their linkage.
Topics: Animals; Binding, Competitive; Biological Transport; Cell Count; Cell Line, Tumor; Female; Fluorodeoxyglucose F18; Glucose; Humans; Hypoxia; Mice; Neoplasms; Nitroimidazoles; Oxygen; Positron-Emission Tomography; Time Factors | 2008 |
Molecular imaging and targeted therapies in oncology: new concepts in treatment response assessment. a collection of cases.
Topics: Aged; Antineoplastic Agents; Carbon Radioisotopes; Choline; Clinical Trials as Topic; Female; Fluorodeoxyglucose F18; Humans; Male; Methionine; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2008 |
Contouring carcinomas by FDG-PET: is the role of tumor biology underestimated? In regard to MacManus et al. (Int J Radiat Oncol Biol Phys 2008;71:2-4).
Topics: Cell Survival; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Stromal Cells; Tumor Burden | 2008 |
Time and again, children resemble their parents.
Topics: Diagnostic Imaging; Fluorodeoxyglucose F18; Humans; Inflammation; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2008 |
Quantitative assessment of FDG uptake in brown fat using standardized uptake value and dual-time-point scanning.
Topics: Adipose Tissue, Brown; Adolescent; Adult; Aged; Child; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Organ Specificity; Radionuclide Imaging; Radiopharmaceuticals; Tissue Distribution | 2008 |
[Risk-benefit analysis of 18FDG PET cancer screening].
Topics: Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiation Dosage; Risk Assessment; Software | 2008 |
Combined imaging modalities: PET/CT and SPECT/CT.
Topics: Fluorodeoxyglucose F18; Half-Life; Humans; Image Processing, Computer-Assisted; Neoplasms; Nuclear Medicine; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Technetium; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; Whole-Body Irradiation | 2008 |
Noninvasive diagnosis of solitary pulmonary lesions in cancer patients based on 2-fluoro-2-deoxy-D-glucose avidity on positron emission tomography/computed tomography.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Retrospective Studies; Sensitivity and Specificity; Solitary Pulmonary Nodule | 2008 |
cis-4-[(18)F]-Fluoro-l-proline fails to detect peripheral tumors in humans.
Topics: Adult; Aged; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Proline; Radionuclide Imaging | 2008 |
CMS and PET for solid tumors.
Topics: Centers for Medicare and Medicaid Services, U.S.; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; United States | 2008 |
Cancer-associated stroma affects FDG uptake in experimental carcinomas. Implications for FDG-PET delineation of radiotherapy target.
Topics: Animals; Carcinoma; Cell Line, Tumor; Fluorodeoxyglucose F18; Glucose Transporter Type 1; Homozygote; Humans; Image Processing, Computer-Assisted; Immunohistochemistry; Mice; Mice, Nude; Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Positron-Emission Tomography; Radiography; Radiopharmaceuticals | 2009 |
Validation of fast-RAMLA in clinical PET.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Imaging, Three-Dimensional; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Whole Body Imaging | 2008 |
Abnormal FDG uptake on 18F-fluorodeoxyglucose positron emission tomography in patients with cancer diagnosis: case reports of tuberculous lymphadenitis.
Topics: Antitubercular Agents; Breast Neoplasms; Colonic Neoplasms; Diagnosis, Differential; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Lymphatic Metastasis; Lymphoma; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Stomach Neoplasms; Tuberculosis, Lymph Node | 2009 |
Retrospective analysis of radiation load during examination of cancer patients by (68)Ga-DOTATOC and (18)F-FDG positron emission tomography.
Topics: Fluorine Radioisotopes; Fluorodeoxyglucose F18; Gadolinium; Humans; Neoplasms; Octreotide; Organometallic Compounds; Positron-Emission Tomography; Radiation Dosage; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed | 2008 |
Impact of intravenous insulin on 18F-FDG PET in diabetic cancer patients.
Topics: Aged; Blood Glucose; Clinical Protocols; Diabetes Complications; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Injections, Intravenous; Insulin; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2009 |
Lesion detection in dynamic FDG-PET using matched subspace detection.
Topics: Algorithms; Breast; Breast Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Image Processing, Computer-Assisted; Monte Carlo Method; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; ROC Curve | 2009 |
A novel approach for reduction of brown fat uptake on FDG PET.
Topics: Adipose Tissue, Brown; Adolescent; Adrenergic beta-Antagonists; Adult; Female; Fluorodeoxyglucose F18; Humans; Male; Neoplasms; Positron-Emission Tomography; Propranolol; Prospective Studies; Radiopharmaceuticals; Whole Body Imaging; Young Adult | 2009 |
SUV and segmentation: pressing challenges in tumour assessment and treatment.
Topics: Algorithms; Automation; Computer Simulation; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Medical Oncology; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2009 |
Strategies for biologic image-guided dose escalation: a review.
Topics: Cell Hypoxia; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Neoplasms; Positron-Emission Tomography; Radiation Tolerance; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2009 |
A novel method for direct site-specific radiolabeling of peptides using [18F]FDG.
Topics: Animals; Cell Line, Tumor; Fluorodeoxyglucose F18; Humans; Integrin alphaVbeta3; Mice; Mice, Nude; Neoplasms; Oligopeptides; Positron-Emission Tomography; Radiopharmaceuticals | 2009 |
Prospective evaluation of whole-body cancer screening with multiple modalities including [18F]fluorodeoxyglucose positron emission tomography in a healthy population: a preliminary report.
Topics: Adult; Aged; Biomarkers, Tumor; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Mass Screening; Middle Aged; Neoplasms; Occult Blood; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Tomography, X-Ray Computed | 2009 |
Cancer drug development using glucose metabolism radiopharmaceuticals.
Topics: Animals; Antineoplastic Agents; Drug Design; Fluorodeoxyglucose F18; Glucose; Humans; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon | 2009 |
Novel strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation of malignancy: results of the pilot-phase study.
Topics: Adult; Aged; Animals; Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Male; Mice; Middle Aged; Neoplasms; Pilot Projects; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Subtraction Technique; Tomography, X-Ray Computed; Young Adult | 2009 |
Spectrum of focal benign musculoskeletal 18F-FDG uptake at PET/CT of the shoulder and pelvis.
Topics: Aged; Aged, 80 and over; Contrast Media; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Iothalamate Meglumine; Male; Middle Aged; Musculoskeletal Diseases; Neoplasms; Pelvis; Positron-Emission Tomography; Radiopharmaceuticals; Shoulder; Tomography, X-Ray Computed | 2009 |
Comparison of 2D and 3D performance for FDG PET with different acquisition times in oncological patients.
Topics: Body Mass Index; Fluorodeoxyglucose F18; Humans; Imaging, Three-Dimensional; Neoplasms; Positron-Emission Tomography; Time Factors | 2009 |
Molecular imaging of proliferation in vivo: positron emission tomography with [18F]fluorothymidine.
Topics: Animals; Cell Proliferation; Clinical Trials as Topic; Diagnosis, Differential; Dideoxynucleosides; Disease Models, Animal; Fluorodeoxyglucose F18; Humans; Molecular Diagnostic Techniques; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2009 |
The effect of PPAR-gamma agonist on (18)F-FDG uptake in tumor and macrophages and tumor cells.
Topics: Animals; Biological Transport; Cell Line, Tumor; Dimethyl Sulfoxide; Fluorodeoxyglucose F18; Gene Expression Regulation; Glucose; Glucose Transport Proteins, Facilitative; Hexokinase; Humans; Inflammation; Macrophages; Mice; Neoplasms; Positron-Emission Tomography; PPAR gamma; Rosiglitazone; Thiazolidinediones; Tomography, X-Ray Computed | 2009 |
FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo.
Topics: Animals; Antineoplastic Agents; Biomarkers; Carrier Proteins; Cell Line, Tumor; Enzyme Inhibitors; Everolimus; Female; Fluorodeoxyglucose F18; Humans; Mice; Mice, Nude; Neoplasms; Phosphotransferases (Alcohol Group Acceptor); Positron-Emission Tomography; Sirolimus; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2009 |
Sarcoid-like reaction to malignancy on whole-body integrated (18)F-FDG PET/CT: prevalence and disease pattern.
Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Granuloma; Humans; Lung Diseases; Male; Mediastinal Diseases; Middle Aged; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Prevalence; Radiopharmaceuticals; Retrospective Studies; Sarcoidosis; Tomography, X-Ray Computed | 2009 |
Doxorubicin-polyphosphazene conjugate hydrogels for locally controlled delivery of cancer therapeutics.
Topics: Animals; Cell Line, Tumor; Doxorubicin; Drug Delivery Systems; Fluorodeoxyglucose F18; Humans; Hydrogels; Hydrolysis; Magnetic Resonance Spectroscopy; Mice; Mice, Nude; Neoplasms; Organophosphorus Compounds; Phase Transition; Polymers; Positron-Emission Tomography; Spectrophotometry, Ultraviolet; Temperature; Xenograft Model Antitumor Assays | 2009 |
Inflammation of unknown origin versus fever of unknown origin: two of a kind.
Topics: Adult; Aged; C-Reactive Protein; Databases, Factual; Diagnosis-Related Groups; Female; Fever of Unknown Origin; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Infections; Inflammation; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Rheumatic Diseases | 2009 |
Brown fat in humans: turning up the heat on obesity.
Topics: Adipose Tissue, Brown; Adult; Body Weight; Cold Temperature; Disease Outbreaks; Energy Intake; Energy Metabolism; Exercise; Fluorodeoxyglucose F18; Homeostasis; Humans; Infant, Newborn; Neoplasms; Obesity; Overweight; Reference Values; Weight Loss | 2009 |
[Business administration of PET facilities: a cost analysis of three facilities utilizing delivery FDG].
Topics: Cost-Benefit Analysis; Costs and Cost Analysis; Fluorodeoxyglucose F18; Health Facilities; Humans; Japan; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2008 |
[Statistical study on the self-selection bias in FDG-PET cancer screening by a questionnaire survey].
Topics: Adult; Aged; Aged, 80 and over; Attitude to Health; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Surveys and Questionnaires | 2008 |
Synthesis and evaluation of novel F-18 labeled fluoroarylvaline derivatives: potential PET imaging agents for tumor detection.
Topics: Animals; Benzamides; Butyrates; Cell Line, Tumor; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Mice; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tissue Distribution; Tyrosine | 2009 |
Application of 18F-fluorodeoxyglucose positron emission tomography in diagnosis of malignant diseases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Neoplasms, Unknown Primary; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Young Adult | 2009 |
Brown fat: atypical locations and appearances encountered in PET/CT.
Topics: Adipose Tissue, Brown; Adult; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Male; Middle Aged; Muscle, Skeletal; Neck; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2009 |
A bone marrow F-18 FDG uptake exceeding the liver uptake may indicate bone marrow hyperactivity.
Topics: Age Factors; Bone Marrow; Fluorodeoxyglucose F18; Hematology; Humans; Inflammation; Liver; Middle Aged; Neoplasms; Regression Analysis; Retrospective Studies | 2009 |
Comparison of 18F-FDG, 18F-FET and 18F-FLT for differentiation between tumor and inflammation in rats.
Topics: Animals; Diagnosis, Differential; Dideoxynucleosides; Feasibility Studies; Female; Fluorodeoxyglucose F18; Inflammation; Neoplasms; Positron-Emission Tomography; Rats; Thymidine Phosphorylase; Tissue Distribution; Tyrosine | 2009 |
Cancer screening using 18F-FDG PET/CT in Korean asymptomatic volunteers: a preliminary report.
Topics: Adult; Aged; Asian People; Delivery of Health Care; False Negative Reactions; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; In Vitro Techniques; Male; Mass Screening; Middle Aged; Neoplasms; Positron-Emission Tomography; Retrospective Studies; Tomography, X-Ray Computed | 2009 |
Significance of chronic marked hyperglycemia on FDG-PET: is it really problematic for clinical oncologic imaging?
Topics: Adult; Aged; Blood Glucose; Chronic Disease; Diabetes Complications; False Negative Reactions; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Hyperglycemia; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Retrospective Studies | 2009 |
[Utility of FDG-PET and diffusion weighted MRI for the management of cancer patients and medical cancer checkup].
Topics: Diffusion Magnetic Resonance Imaging; Fluorodeoxyglucose F18; Humans; Mass Screening; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity | 2008 |
Lesion quantification in oncological positron emission tomography: a maximum likelihood partial volume correction strategy.
Topics: Algorithms; Fluorodeoxyglucose F18; Image Interpretation, Computer-Assisted; Likelihood Functions; Neoplasms; Phantoms, Imaging; Positron-Emission Tomography; Radiography | 2009 |
[PTV--PET traced volume?].
Topics: Brain Neoplasms; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography | 2009 |
18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease.
Topics: Aged; Arteries; Atherosclerosis; Calcinosis; Cardiovascular Diseases; Cerebrovascular Disorders; Cohort Studies; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Incidental Findings; Inflammation; Male; Middle Aged; Neoplasms; Nuclear Medicine; Positron-Emission Tomography; Prognosis; Radiology; Risk; Sex Characteristics; Survival Analysis; Tomography, X-Ray Computed; Vascular Diseases | 2009 |
Molecular imaging of solid tumors: exploiting the potential.
Topics: Clinical Trials as Topic; Drug Administration Schedule; Fluorodeoxyglucose F18; Humans; Neoplasms; Outcome Assessment, Health Care; Patient Selection; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Risk Factors; Treatment Outcome | 2009 |
Impact of F-18 fluorodeoxyglucose positron emission tomography-computed tomography on oncologic patient management: first 2 years' experience at a single Canadian cancer center.
Topics: British Columbia; Decision Making; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Patient Care Planning; Positron-Emission Tomography; Radiopharmaceuticals; Surveys and Questionnaires; Tomography, X-Ray Computed | 2010 |
Assessment of interobserver reproducibility in quantitative 18F-FDG PET and CT measurements of tumor response to therapy.
Topics: Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Observer Variation; Positron-Emission Tomography; Reproducibility of Results; Retrospective Studies; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
The clinical value of incidental 18F-fluorodeoxyglucose-avid foci detected on positron emission tomography/computed tomography.
Topics: Adult; Aged; Aged, 80 and over; Biological Transport; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Incidental Findings; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Retrospective Studies; Tomography, X-Ray Computed; Young Adult | 2010 |
Development of a generic thresholding algorithm for the delineation of 18FDG-PET-positive tissue: application to the comparison of three thresholding models.
Topics: Algorithms; Artificial Intelligence; Computer Simulation; Differential Threshold; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Models, Biological; Neoplasms; Pattern Recognition, Automated; Phantoms, Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity | 2009 |
Cutaneous and subcutaneous imaging on FDG-PET: benign and malignant findings.
Topics: Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Postoperative Care; Skin; Tomography, X-Ray Computed; Whole Body Imaging; Wound Healing | 2009 |
A curve-fitting approach to estimate the arterial plasma input function for the assessment of glucose metabolic rate and response to treatment.
Topics: Adult; Aged; Arteries; Blood Glucose; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Models, Biological; Neoplasms; Positron-Emission Tomography; Reference Values; Reproducibility of Results; Treatment Outcome | 2009 |
FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0.
Topics: Europe; Fluorodeoxyglucose F18; Humans; Neoplasms; Nuclear Medicine; Positron-Emission Tomography; Practice Guidelines as Topic; Radiopharmaceuticals; Subtraction Technique; Tomography, X-Ray Computed | 2010 |
Intra-operative use of PET probe for localization of FDG avid lesions.
Topics: Breast Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lymphoma; Melanoma; Neoplasms; Positron-Emission Tomography; Stomach Neoplasms | 2009 |
Perioperative (18)F-fluorodeoxyglucose-guided imaging using the becquerel as a quantitative measure for optimizing surgical resection in patients with advanced malignancy.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Postoperative Period; Preoperative Period; Radiometry; Radiopharmaceuticals; Retrospective Studies; Surgical Procedures, Operative | 2009 |
Combined (18)F-FDG and fluoride approach in PET/CT imaging: is there a clinical future?
Topics: Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2010 |
Combined (18)F-FDG and fluoride approach in PET/CT imaging: is there a clinical future?
Topics: Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Muscle, Skeletal; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2010 |
Correlation analysis of measurement result between accelerator mass spectrometry and gamma counter.
Topics: Animals; Carbon Radioisotopes; Cell Line, Tumor; Female; Fluorodeoxyglucose F18; Gamma Rays; Humans; Mass Spectrometry; Mice; Neoplasms; Positron-Emission Tomography | 2010 |
Investigation of 18F-FDG 3D mode PET image quality versus acquisition time.
Topics: Equipment Design; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Likelihood Functions; Male; Neoplasms; Phantoms, Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Time Factors; Tomography, X-Ray Computed | 2010 |
Performance of a 99mTc-labelled 1-thio-beta-D-glucose 2,3,4,6-tetra-acetate analogue in the detection of infections and tumours in mice: a comparison with [18F]FDG.
Topics: Acetates; Animals; Cell Line, Tumor; Fluorodeoxyglucose F18; Glucose; Glucose Transporter Type 1; Humans; Male; Mice; Mice, Inbred C57BL; Neoplasms; Organotechnetium Compounds; Radionuclide Imaging; Radiopharmaceuticals; Rats; Staphylococcus aureus; Technetium; Thioglucosides; Tissue Distribution | 2010 |
Comparative assessment of methods for estimating tumor volume and standardized uptake value in (18)F-FDG PET.
Topics: Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Liver Neoplasms; Lung Neoplasms; Monte Carlo Method; Neoplasms; Phantoms, Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Software | 2010 |
SUV: from silly useless value to smart uptake value.
Topics: Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2010 |
The clinical significance of 18F-FDG-PET/CT in early detection of second primary malignancy in cancer patients.
Topics: Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Incidence; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Neoplasms, Second Primary; Positron-Emission Tomography; Prognosis; Rectal Neoplasms; Retrospective Studies; Tomography, X-Ray Computed | 2010 |
Posterior parahepatic cyst as an incidental finding--review of 40 cases.
Topics: Aged; Aged, 80 and over; Cysts; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Incidental Findings; Liver Diseases; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed | 2010 |
Accurate automatic delineation of heterogeneous functional volumes in positron emission tomography for oncology applications.
Topics: Algorithms; Bayes Theorem; Fluorodeoxyglucose F18; Fuzzy Logic; Humans; Markov Chains; Medical Oncology; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Tumor Burden | 2010 |
CT Hounsfield units of brown adipose tissue increase with activation: preclinical and clinical studies.
Topics: Adipose Tissue, Brown; Adolescent; Adult; Animals; Cold Temperature; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; In Vitro Techniques; Lipid Metabolism; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Rats; Rats, Inbred Lew; Retrospective Studies; Tomography, X-Ray Computed; Young Adult | 2010 |
The twilight saga of insulin administration in hyperglycemic patients undergoing (18)F-FDG PET.
Topics: Diabetes Complications; Fluorodeoxyglucose F18; Humans; Hyperglycemia; Insulin; Neoplasms; Positron-Emission Tomography | 2010 |
[18F]Fluorodeoxyglucose positron emission tomography for outcome prediction of mammalian target of rapamycin inhibitor therapy.
Topics: Antibiotics, Antineoplastic; Disease Progression; Disease-Free Survival; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Intracellular Signaling Peptides and Proteins; Neoplasms; Positron-Emission Tomography; Protein Serine-Threonine Kinases; Radiopharmaceuticals; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome | 2010 |
FDG uptake in axillary lymph nodes after vaccination against pandemic (H1N1).
Topics: Adult; Aged; Axilla; Disease Outbreaks; False Positive Reactions; Female; Fluorodeoxyglucose F18; Greece; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2010 |
The reproducibility of deep-inspiration breath-hold (18)F-FDG PET/CT technique in diagnosing various cancers affected by respiratory motion.
Topics: Adult; Aged; Artifacts; Female; Fluorodeoxyglucose F18; Humans; Inhalation; Male; Middle Aged; Movement; Neoplasms; Phantoms, Imaging; Positron-Emission Tomography; Reproducibility of Results; Tomography, X-Ray Computed | 2010 |
Gold nanocages as photothermal transducers for cancer treatment.
Topics: Animals; Cell Line, Tumor; Fluorodeoxyglucose F18; Gold; Humans; Injections, Intravenous; Light; Metal Nanoparticles; Mice; Neoplasms; Polyethylene Glycols; Positron-Emission Tomography; Spectrophotometry, Ultraviolet; Spectroscopy, Near-Infrared; Temperature; Tissue Distribution; Tomography, X-Ray Computed; Transducers; Xenograft Model Antitumor Assays | 2010 |
[Whole-body MRI and FDG-PET/CT imaging diagnostics in oncology].
Topics: Fluorodeoxyglucose F18; Germany; Humans; Magnetic Resonance Imaging; Medical Oncology; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Subtraction Technique; Tomography, X-Ray Computed; Whole Body Imaging | 2010 |
Evaluation of the risk of radiation exposure from new 18FDG PET/CT plans versus conventional X-ray plans in patients with pediatric cancers.
Topics: Child; Environmental Exposure; Female; Fluorodeoxyglucose F18; Humans; Longevity; Male; Neoplasms; Positron-Emission Tomography; Radiation Dosage; Radiation Injuries; Risk; Tomography, X-Ray Computed | 2010 |
Association of inflammation of the left anterior descending coronary artery with cardiovascular risk factors, plaque burden and pericardial fat volume: a PET/CT study.
Topics: Adipose Tissue; Adolescent; Adult; Aged; Aged, 80 and over; Atherosclerosis; Biological Transport; Biomarkers; Cardiovascular Diseases; Coronary Angiography; Coronary Vessels; Female; Fluorodeoxyglucose F18; Humans; Inflammation; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Reproducibility of Results; Retrospective Studies; Risk Factors; Tomography, X-Ray Computed; Young Adult | 2010 |
Is (18)F-FDG a surrogate tracer to measure tumor hypoxia? Comparison with the hypoxic tracer (14)C-EF3 in animal tumor models.
Topics: Animals; Carbon Radioisotopes; Disease Models, Animal; Fiducial Markers; Fluorodeoxyglucose F18; Hypoxia; Male; Mice; Neoplasms; Nitroimidazoles; Radionuclide Imaging | 2010 |
Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a 68Ga- and 18F-labeled hapten peptide in mice with human tumor xenografts.
Topics: Animals; Antibodies, Bispecific; Carcinoembryonic Antigen; Dose-Response Relationship, Drug; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Gallium Radioisotopes; Haptens; Heterocyclic Compounds, 1-Ring; Humans; Mice; Mice, Inbred BALB C; Neoplasms; Oligopeptides; Positron-Emission Tomography; Tissue Distribution; Tomography, X-Ray Computed; Xenograft Model Antitumor Assays | 2010 |
Japanese guideline for the oncology FDG-PET/CT data acquisition protocol: synopsis of Version 1.0.
Topics: Fluorodeoxyglucose F18; Humans; Japan; Neoplasms; Phantoms, Imaging; Positron-Emission Tomography; Quality Control; Tomography, X-Ray Computed | 2010 |
PET imaging for the quantification of biologically heterogeneous tumours: measuring the effect of relative position on image-based quantification of dose-painting targets.
Topics: Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Image Processing, Computer-Assisted; Models, Biological; Neoplasms; Positron-Emission Tomography; Radiation Dosage; Tomography, X-Ray Computed; Uncertainty; Whole Body Imaging | 2010 |
Partial volume correction strategies for quantitative FDG PET in oncology.
Topics: Artifacts; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Neoplasms; Phantoms, Imaging; Positron-Emission Tomography; Reproducibility of Results; Tumor Burden; Whole Body Imaging | 2010 |
Noninvasive assessment of regulable transferred-p53 gene expression and evaluation of therapeutic response with FDG-PET in tumor model.
Topics: Animals; Cell Line, Tumor; Cells, Cultured; Fluorodeoxyglucose F18; Genetic Therapy; Genetic Vectors; Humans; Luminescent Proteins; Mice; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Red Fluorescent Protein; Tumor Suppressor Protein p53 | 2010 |
Comment on: "FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging, version 1.0".
Topics: Europe; Fluorodeoxyglucose F18; Humans; Neoplasms; Nuclear Medicine; Positron-Emission Tomography; Practice Guidelines as Topic; Tomography, X-Ray Computed | 2010 |
[Preliminary study on the validity of whole body diffusion-weighted imaging for the detection of malignant lesions].
Topics: Adolescent; Adult; Aged; Carcinoma, Hepatocellular; Diffusion Magnetic Resonance Imaging; Female; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Stomach Neoplasms; Whole Body Imaging; Young Adult | 2010 |
FDG PET/CT in oncology: "raising the bar".
Topics: Fluorodeoxyglucose F18; Humans; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Practice Guidelines as Topic; Radiopharmaceuticals; Tomography, X-Ray Computed; United Kingdom | 2010 |
Prevalence of positive FDG-PET findings in patients with high CEA levels.
Topics: Adult; Aged; Aged, 80 and over; Carcinoembryonic Antigen; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Retrospective Studies | 2010 |
Do hyperglycemia and diabetes affect the incidence of false-negative 18F-FDG PET/CT studies in patients evaluated for infection or inflammation and cancer? A Comparative analysis.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus; False Negative Reactions; Female; Fluorodeoxyglucose F18; Humans; Hyperglycemia; Image Processing, Computer-Assisted; Infections; Inflammation; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Tomography, Emission-Computed; Young Adult | 2010 |
FDG for dose painting: a rational choice.
Topics: Dose-Response Relationship, Radiation; Drug Administration Routes; Fluorodeoxyglucose F18; Humans; Neoplasms; Radiopharmaceuticals | 2010 |
Two decades at the cross-roads of biology, physics and epidemiology: lessons learned in [18F-]FDG positron emission tomography in oncology.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Practice Guidelines as Topic; Radiopharmaceuticals; Sensitivity and Specificity | 2010 |
18F-FDG uptake and calcifications in the thoracic aorta on positron emission tomography/computed tomography examinations: frequency and stability on serial scans.
Topics: Adult; Aged; Aged, 80 and over; Aorta, Thoracic; Drug Stability; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Observer Variation; Plaque, Atherosclerotic; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Risk Factors; Tomography, Emission-Computed | 2011 |
Diagnostic value of CT density in patients with diffusely increased FDG uptake in the thyroid gland on PET/CT images.
Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Thyroid Function Tests; Thyroid Gland; Tomography, X-Ray Computed | 2010 |
[Procedure guidelines for whole-body 18F-FDG PET and PET/CT in children with malignant diseases].
Topics: Body Weight; Child; Fluorodeoxyglucose F18; Germany; Humans; Neoplasms; Pediatrics; Positron-Emission Tomography; Practice Guidelines as Topic; Radiopharmaceuticals; Tomography, X-Ray Computed | 2010 |
PET imaging of norepinephrine transporter-expressing tumors using 76Br-meta-bromobenzylguanidine.
Topics: Animals; Biological Transport; Bromobenzenes; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Guanidines; Mice; Neoplasms; PC12 Cells; Positron-Emission Tomography; Rats; Receptors, Adrenergic | 2010 |
Clinical use of PET-CT data for radiotherapy planning: what are we looking for?
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Precision Medicine; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed | 2010 |
PET/CT may change diagnosis and treatment in cancer patients.
Topics: Denmark; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Whole Body Imaging | 2010 |
Preclinical dynamic 18F-FDG PET - tumor characterization and radiotherapy response assessment by kinetic compartment analysis.
Topics: Animals; Biological Availability; Body Fluid Compartments; Feasibility Studies; Fluorodeoxyglucose F18; Humans; Kinetics; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Positron-Emission Tomography; Prognosis; Tissue Distribution; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2010 |
Variability of textural features in FDG PET images due to different acquisition modes and reconstruction parameters.
Topics: Diagnostic Errors; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Image Processing, Computer-Assisted; Neoplasms; Observer Variation; Positron-Emission Tomography; Retrospective Studies; Tomography, Emission-Computed | 2010 |
The clinical implication and prediction of diffuse splenic FDG uptake during cancer surveillance.
Topics: Biological Transport; Bone Marrow; Diffusion; Female; Fluorodeoxyglucose F18; Hematologic Tests; Humans; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Retrospective Studies; Spleen; Tomography, X-Ray Computed | 2010 |
Dual phase FDG-PET imaging of brain metastases provides superior assessment of recurrence versus post-treatment necrosis.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Necrosis; Neoplasm Recurrence, Local; Neoplasms; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies | 2011 |
[Fluorodeoxyglucose F18(FDG)-probe guided biopsy].
Topics: Biopsy; Fluorodeoxyglucose F18; Humans; Inflammation; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2010 |
Analysis of various malignant neoplasms detected by FDG-PET cancer screening program: based on a Japanese Nationwide Survey.
Topics: Adult; Aged; Aged, 80 and over; Data Collection; Early Detection of Cancer; Female; Fluorodeoxyglucose F18; Humans; Japan; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Tomography, X-Ray Computed; Young Adult | 2011 |
Phenotyping of tumor biology in patients by multimodality multiparametric imaging: relationship of microcirculation, alphavbeta3 expression, and glucose metabolism.
Topics: Aged; Aged, 80 and over; Biological Transport; Diagnostic Imaging; Female; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Glucose; Humans; Integrin alphaVbeta3; Magnetic Resonance Imaging; Male; Microcirculation; Middle Aged; Neoplasms; Phenotype; Positron-Emission Tomography; Tumor Burden | 2010 |
Segmental acquisition method for stationary objects in (18)F-fluorodeoxyglucose positron emission tomography tests.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Back; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Muscle, Skeletal; Neoplasms; Phantoms, Imaging; Positron-Emission Tomography; Radiographic Image Interpretation, Computer-Assisted; Radiopharmaceuticals; Reproducibility of Results; Time Factors; Tomography, X-Ray Computed | 2010 |
Restaging: should we percist without pattern recognition?
Topics: Algorithms; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Inflammation; Neoplasm Staging; Neoplasms; Pattern Recognition, Automated; Pattern Recognition, Visual; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, Emission-Computed | 2010 |
18F-FDG PET/CT of patients with cancer: comparison of whole-body and limited whole-body technique.
Topics: Aged; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Whole Body Imaging | 2010 |
Beyond 18F-fluorodeoxyglucose: making the next generation of PET radiotracers available for oncology research in the UK.
Topics: Biomedical Research; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radioactive Tracers; United Kingdom | 2011 |
FDG uptake in lymph-nodes of HIV+ and tuberculosis patients: implications for cancer staging.
Topics: Adult; Female; Fluorodeoxyglucose F18; HIV Infections; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tuberculosis | 2010 |
FDG PET/CT in cancer therapy monitoring: computer-assisted analysis of baseline together with up to two follow-ups.
Topics: Adult; Aged; Algorithms; Artificial Intelligence; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Information Storage and Retrieval; Male; Middle Aged; Neoplasms; Pattern Recognition, Automated; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Beyond FDG: Many Molecular Imaging Agents Are in Development.
Topics: Biomarkers, Tumor; Breast Neoplasms; Dihydrotestosterone; Drug Design; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Glucose; Humans; Male; Neoplasms; Nuclear Medicine; Positron-Emission Tomography; Prostatic Neoplasms; Radiology; Radiopharmaceuticals; Receptor, ErbB-2; Receptors, Androgen; Sensitivity and Specificity; Tomography, X-Ray Computed | 2011 |
Measuring response to therapy using FDG PET: semi-quantitative and full kinetic analysis.
Topics: Area Under Curve; Female; Fluorodeoxyglucose F18; Humans; Kinetics; Male; Neoplasms; Nonlinear Dynamics; Positron-Emission Tomography; Regression Analysis; Reproducibility of Results; Retrospective Studies; Treatment Outcome | 2011 |
Arterial foci of F-18 fluorodeoxyglucose are associated with an enhanced risk of subsequent ischemic stroke in cancer patients: a case-control pilot study.
Topics: Aged; Arteries; Biological Transport; Brain Ischemia; Case-Control Studies; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasms; Pilot Projects; Positron-Emission Tomography; Retrospective Studies; Risk; Stroke; Tomography, X-Ray Computed | 2011 |
Comparison of two region of interest definition methods for metabolic response evaluation with [¹⁸F]FDG-PET.
Topics: Adult; Aged; Antineoplastic Agents; Computer Simulation; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Middle Aged; Models, Biological; Neoplasms; Netherlands; Positron-Emission Tomography; Prevalence; Prognosis; Proportional Hazards Models; Radiopharmaceuticals; Reproducibility of Results; Risk Assessment; Risk Factors; Sensitivity and Specificity; Survival Analysis; Survival Rate; Treatment Outcome | 2010 |
Variations in PET/CT methodology for oncologic imaging at U.S. academic medical centers: an imaging response assessment team survey.
Topics: Academic Medical Centers; Blood Glucose; Conscious Sedation; Diet, Carbohydrate-Restricted; Fluorodeoxyglucose F18; Health Care Surveys; Humans; Image Processing, Computer-Assisted; Medical Records; National Institutes of Health (U.S.); Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Software; Surveys and Questionnaires; Tomography, Emission-Computed; United States | 2011 |
PET based volume segmentation with emphasis on the iterative TrueX algorithm.
Topics: Algorithms; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Multimodal Imaging; Neoplasms; Phantoms, Imaging; Positron-Emission Tomography; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Software; Tomography, X-Ray Computed | 2012 |
A rare case of pemphigus vegetans mimicking malignancy on F-18 FDG PET/CT.
Topics: Adult; Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Male; Neoplasms; Pemphigus; Positron-Emission Tomography; Tomography, X-Ray Computed; Whole Body Imaging | 2011 |
Pattern of 18F-FDG uptake in the spinal cord in patients with non-central nervous system malignancy.
Topics: Adult; Aged; Analysis of Variance; California; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Spinal Cord; Tissue Distribution; Tomography, X-Ray Computed; Whole Body Imaging | 2011 |
Volume-of-interest assessment of oncologic response using 18F-FDG PET/CT: a phantom study.
Topics: Fluorodeoxyglucose F18; Image Interpretation, Computer-Assisted; Necrosis; Neoplasms; Phantoms, Imaging; Positron-Emission Tomography; Software; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Shortened acquisition protocols for the quantitative assessment of the 2-tissue-compartment model using dynamic PET/CT 18F-FDG studies.
Topics: Algorithms; Computer Simulation; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Models, Biological; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Time Factors; Tomography, X-Ray Computed | 2011 |
Improvement in lesion detection with whole-body oncologic time-of-flight PET.
Topics: Algorithms; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Imaging, Three-Dimensional; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Whole Body Imaging | 2011 |
[Usefulness of metabolic volume and total lesion glycolysis for predicting therapeutic response in cancer therapy by 18F-FDG PET/CT].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2010 |
Searching for alternatives to full kinetic analysis in 18F-FDG PET: an extension of the simplified kinetic analysis method.
Topics: Algorithms; Area Under Curve; Artificial Intelligence; Carcinoma, Renal Cell; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Infusions, Intravenous; Kidney Neoplasms; Kinetics; Lymphatic Metastasis; Magnetic Resonance Imaging; Models, Statistical; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Tomography, X-Ray Computed | 2011 |
Atlas of confounding factors in head and neck PET/CT imaging.
Topics: Artifacts; Biological Transport; Fluorodeoxyglucose F18; Head; Humans; Image Interpretation, Computer-Assisted; Inflammation; Male; Neck; Neoplasms; Positron-Emission Tomography; Tomography, X-Ray Computed | 2011 |
Radiologists urge FDA to accept PET-based tumor response criteria in clinical trials.
Topics: Biomarkers, Tumor; Clinical Trials as Topic; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphoma; Molecular Targeted Therapy; Neoplasms; Nuclear Medicine; Positron-Emission Tomography; Radiopharmaceuticals; Treatment Outcome; United States; United States Food and Drug Administration; Workforce | 2011 |
Dual-modality monitoring of tumor response to cyclophosphamide therapy in mice with bioluminescence imaging and small-animal positron emission tomography.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cyclophosphamide; Fluorodeoxyglucose F18; Humans; Luminescence; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Random Allocation; Treatment Outcome | 2011 |
Fluorodeoxyglucose positron emission tomography/computed tomography standardized uptake value in discriminating benign versus malignant lesions: an open and debated issue.
Topics: Biological Transport; Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Tomography, X-Ray Computed | 2011 |
Synthesis and radioluminescence of PEGylated Eu(3+) -doped nanophosphors as bioimaging probes.
Topics: Animals; Contrast Media; Europium; Fluorodeoxyglucose F18; Mice; Mice, Nude; Nanostructures; Neoplasms; Polyethylene Glycols; Positron-Emission Tomography; Spectroscopy, Near-Infrared | 2011 |
[Usefulness of positron emission tomography in oncology].
Topics: Fluorodeoxyglucose F18; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Prognosis | 2011 |
Nuclear medicine imaging of infection in cancer patients (with emphasis on FDG-PET).
Topics: Adolescent; Adult; Aged; Female; Fluorodeoxyglucose F18; Humans; Infections; Male; Middle Aged; Neoplasms; Nuclear Medicine; Positron-Emission Tomography; Radiopharmaceuticals; Young Adult | 2011 |
Evaluation of optimal acquisition duration or injected activity for pediatric 18F-FDG PET/CT.
Topics: Adolescent; Body Weight; Child; Child, Preschool; Fluorodeoxyglucose F18; Humans; Infant; Injections; Male; Neoplasms; Positron-Emission Tomography; Radiation Dosage; Sensitivity and Specificity; Time Factors; Tomography, X-Ray Computed; Young Adult | 2011 |
Focal fluorine-18 fluorodeoxyglucose-avid lesions without computed tomography correlate at whole-body positron emission tomography-computed tomography in oncology patients: how often are they malignant?
Topics: Aged; Biological Transport; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Image Interpretation, Computer-Assisted; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Retrospective Studies; Tomography, X-Ray Computed; Whole Body Imaging | 2011 |
Radiation exposure and risk-benefit analysis in cancer screening using FDG-PET: results of a Japanese nationwide survey.
Topics: Adult; Aged; Aged, 80 and over; Data Collection; Early Detection of Cancer; Environmental Exposure; Female; Fluorodeoxyglucose F18; Humans; Japan; Life Expectancy; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiation Dosage; Risk Assessment; Young Adult | 2011 |
Whole-body MR-DWIBS vs. [18F]-FDG-PET/CT in the study of malignant tumors: a retrospective study.
Topics: Diffusion Magnetic Resonance Imaging; Double-Blind Method; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Whole Body Imaging | 2012 |
Shortened dynamic (18)F-FDG PET.
Topics: Algorithms; Computer Simulation; Data Interpretation, Statistical; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Time Factors | 2011 |
Clinical significance of incidental finding of focal activity in the breast at 18F-FDG PET/CT.
Topics: Aged; Breast Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Incidental Findings; Middle Aged; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Regression Analysis; Retrospective Studies; Statistics, Nonparametric; Tomography, X-Ray Computed; Ultrasonography, Mammary | 2011 |
Quantifying the effects of iodine contrast media on standardised uptake values of FDG PET/CT images: an anthropomorphic phantom study.
Topics: Contrast Media; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Iodine; Multimodal Imaging; Neoplasms; Phantoms, Imaging; Positron-Emission Tomography; Tomography, X-Ray Computed | 2011 |
18F-FDG PET-CT in the diagnosis of tumor thrombus: can it be differentiated from benign thrombus?
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Retrospective Studies; Tomography, X-Ray Computed; Venous Thromboembolism; Young Adult | 2011 |
A pilot study utilizing whole body 18 F-FDG-PET/CT as a comprehensive screening strategy for occult malignancy in patients with unprovoked venous thromboembolism.
Topics: Adult; Aged; Cost-Benefit Analysis; Early Detection of Cancer; Feasibility Studies; Female; Fluorodeoxyglucose F18; Health Care Costs; Humans; Insurance, Health, Reimbursement; Male; Mass Screening; Medicare; Middle Aged; Multimodal Imaging; Neoplasms; Pilot Projects; Positron-Emission Tomography; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Time Factors; Tomography, X-Ray Computed; United States; Utah; Venous Thromboembolism; Whole Body Imaging | 2012 |
Incidental diagnosis of thrombus within an aneurysm on 18F-FDG PET/CT: frequency in 926 patients.
Topics: Aged; Aged, 80 and over; Aneurysm; Aortic Aneurysm, Abdominal; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Incidental Findings; Jugular Veins; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Thrombosis | 2011 |
FDG PET/CT imaging of NUT midline carcinoma.
Topics: Adolescent; Anatomic Landmarks; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Multimodal Imaging; Neoplasms; Nuclear Proteins; Oncogene Proteins, Fusion; Positron-Emission Tomography; Tomography, X-Ray Computed; Torso | 2011 |
MRI-based attenuation correction for whole-body PET/MRI: quantitative evaluation of segmentation- and atlas-based methods.
Topics: Aged; Algorithms; Atlases as Topic; Data Interpretation, Statistical; Databases, Factual; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Metals; Middle Aged; Neoplasms; Positron-Emission Tomography; Prostheses and Implants; Radiopharmaceuticals; Whole Body Imaging | 2011 |
Are we ready for dual-time point FDG PET imaging?
Topics: Fluorodeoxyglucose F18; Humans; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2011 |
Dual-time-point (18)F-FDG-PET/CT imaging in the assessment of suspected malignancy.
Topics: Adult; Aged; Aged, 80 and over; Chi-Square Distribution; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Male; Middle Aged; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, X-Ray Computed; Whole Body Imaging | 2011 |
Impact of [¹⁸F]FDG PET imaging parameters on automatic tumour delineation: need for improved tumour delineation methodology.
Topics: Algorithms; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Neoplasms; Pattern Recognition, Automated; Phantoms, Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity | 2011 |
Imaging-guided preoperative hookwire localization of nonpalpable extramammary lesions.
Topics: Adult; Aged; Algorithms; Contrast Media; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiography, Interventional; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Ultrasonography, Interventional | 2011 |
Fever of unknown origin: a retrospective study of 52 cases with evaluation of the diagnostic utility of FDG-PET/CT.
Topics: Adult; Aged; Female; Fever of Unknown Origin; Fluorodeoxyglucose F18; Humans; Infections; Inflammation; Male; Middle Aged; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed | 2012 |
Role of combined DWIBS/3D-CE-T1w whole-body MRI in tumor staging: Comparison with PET-CT.
Topics: Adult; Aged; Diffusion Magnetic Resonance Imaging; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed; Whole Body Imaging | 2012 |
Cancer screening by FDG-PET: benefit or risk?
Topics: Data Collection; Early Detection of Cancer; Environmental Exposure; Female; Fluorodeoxyglucose F18; Humans; Male; Neoplasms; Positron-Emission Tomography | 2011 |
Oncology.
Topics: Biomarkers, Tumor; Fluorodeoxyglucose F18; Humans; Molecular Imaging; Molecular Probes; Molecular Targeted Therapy; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Radioimmunotherapy; Tomography, X-Ray Computed | 2011 |
Prospective comparison of combined 18F-FDG and 18F-NaF PET/CT vs. 18F-FDG PET/CT imaging for detection of malignancy.
Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Sodium Fluoride; Tomography, X-Ray Computed | 2012 |
Multimodality functional imaging of spontaneous canine tumors using 64Cu-ATSM and 18FDG PET/CT and dynamic contrast enhanced perfusion CT.
Topics: Animals; Contrast Media; Coordination Complexes; Copper Radioisotopes; Dog Diseases; Dogs; Fluorodeoxyglucose F18; Multimodal Imaging; Neoplasms; Organometallic Compounds; Perfusion Imaging; Positron-Emission Tomography; Radiographic Image Enhancement; Radiopharmaceuticals; Thiosemicarbazones; Tomography, X-Ray Computed | 2012 |
Synthesis and biodistribution of a new (99m) Tc-oxo complex with deoxyglucose dithiocarbamate for tumor imaging.
Topics: Animals; Carbamates; Cell Line, Tumor; Coordination Complexes; Deoxyglucose; Fluorodeoxyglucose F18; Mice; Mice, Nude; Neoplasms; Organotechnetium Compounds; Radiopharmaceuticals; Tissue Distribution; Tomography, Emission-Computed, Single-Photon | 2012 |
Technical feasibility vs. clinical utility: a question of "can we?" vs. "should we?".
Topics: Female; Fluorodeoxyglucose F18; Humans; Male; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Tomography, X-Ray Computed | 2012 |
The relationship between brown adipose tissue activity and neoplastic status: an (18)F-FDG PET/CT study in the tropics.
Topics: Adipose Tissue, Brown; Adolescent; Adult; Aged; Body Fat Distribution; Child; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Multivariate Analysis; Neoplasms; Positron-Emission Tomography; Retrospective Studies; Taiwan; Tomography, X-Ray Computed; Tropical Climate; Young Adult | 2011 |
A brief evaluation of tumor imaging in mice with 99mTc-glucarate including a comparison with 18F-FDG.
Topics: Animals; Female; Fluorodeoxyglucose F18; Glucaric Acid; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Organotechnetium Compounds; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon; Transplantation, Heterologous; Tumor Cells, Cultured | 2011 |
Supraclavicular lymph nodes detected by 18F-FDG PET/CT in cancer patients: assessment with 18F-FDG PET/CT and sonography.
Topics: Adult; Aged; Biopsy, Fine-Needle; Clavicle; Contrast Media; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Iohexol; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; ROC Curve; Tomography, X-Ray Computed; Ultrasonography, Interventional | 2012 |
Imaging thrombus in cancer patients with FDG PET-CT.
Topics: Adolescent; Adult; Child; Child, Preschool; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasms; Neoplastic Cells, Circulating; Positron-Emission Tomography; Radiopharmaceuticals; Thrombosis; Tomography, X-Ray Computed; Vena Cava, Inferior; Venous Thromboembolism; Young Adult | 2012 |
Tumor perfusion using first-pass F-18 FDG PET images.
Topics: Fluorodeoxyglucose F18; Humans; Multimodal Imaging; Neoplasms; Perfusion; Positron-Emission Tomography; Tomography, X-Ray Computed | 2012 |
Evaluation of deuterated 18F- and 11C-labeled choline analogs for cancer detection by positron emission tomography.
Topics: Animals; Carbon Radioisotopes; Cell Line, Tumor; Choline; Deuterium; Disease Models, Animal; Fluorodeoxyglucose F18; Humans; Kidney; Kinetics; Male; Melanoma; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Oxidation-Reduction; Positron-Emission Tomography; Prostatic Neoplasms; Radioactive Tracers | 2012 |
Highlights of the EANM Congress 2011: Birmingham, UK.
Topics: Algorithms; Animals; Biopsy; Diagnostic Imaging; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Neoplasms; Nuclear Medicine; Positron-Emission Tomography; Societies, Medical; United Kingdom | 2012 |
Physiological ¹⁸F-FDG uptake by the spinal cord: is it a point of consideration for cancer patients?
Topics: Adult; Aged; Aged, 80 and over; Cervical Vertebrae; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Lumbar Vertebrae; Male; Middle Aged; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Radioisotopes; Seasons; Spinal Cord; Tomography, X-Ray Computed; Young Adult | 2012 |
Delineation of FDG-PET tumors from heterogeneous background using spectral clustering.
Topics: Algorithms; Artifacts; Artificial Intelligence; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Neoplasms; Pattern Recognition, Automated; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity | 2012 |
Kinetic analysis of 18F-FLT PET in lung tumors.
Topics: Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Imaging, Three-Dimensional; Lung Neoplasms; Male; Models, Biological; Neoplasms; Positron-Emission Tomography; Radioisotope Dilution Technique; Thoracic Neoplasms; Thymidine Kinase; Tomography, Emission-Computed | 2012 |
[11C]GSK2126458 and [18F]GSK2126458, the first radiosynthesis of new potential PET agents for imaging of PI3K and mTOR in cancers.
Topics: Carbon Radioisotopes; Fluorodeoxyglucose F18; Humans; Molecular Structure; Neoplasms; Phosphatidylinositol 3-Kinases; Positron-Emission Tomography; Pyridazines; Quinolines; Radiopharmaceuticals; Sulfonamides; TOR Serine-Threonine Kinases | 2012 |
Thyroid incidentalomas in FDG-PET/CT: prevalence and clinical impact.
Topics: Adult; Aged; Aged, 80 and over; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Incidental Findings; Male; Middle Aged; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Thyroid Diseases; Thyroid Neoplasms; Thyroid Nodule; Thyroiditis, Autoimmune; Tomography, X-Ray Computed | 2012 |
Parameters related to a positive test result for FDG PET(/CT) for large vessel vasculitis: a multicenter retrospective study.
Topics: Aged; Early Diagnosis; Female; Fluorodeoxyglucose F18; Giant Cell Arteritis; Humans; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies | 2012 |
Quantitative assessment of heterogeneity in tumor metabolism using FDG-PET.
Topics: Adult; Aged; Blood Volume; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Female; Fluorodeoxyglucose F18; Glucose; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Phosphorylation; Positron-Emission Tomography; Radiopharmaceuticals | 2012 |
Understanding and fighting cancer cachexia syndrome: can PET help?
Topics: Adipose Tissue, Brown; Cachexia; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2012 |
FDG-PET/CT-based gross tumor volume contouring for radiation therapy planning: an experimental phantom study.
Topics: Fluorodeoxyglucose F18; Humans; Imaging, Three-Dimensional; Neoplasms; Phantoms, Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Image-Guided; Reproducibility of Results; Sensitivity and Specificity; Subtraction Technique; Tomography, X-Ray Computed; Tumor Burden | 2012 |
A broader importance of NOPR to the future of nuclear imaging.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Registries | 2012 |
Impact of 18F-FDG PET used after initial treatment of cancer: comparison of the National Oncologic PET Registry 2006 and 2009 cohorts.
Topics: Cohort Studies; Fluorodeoxyglucose F18; Humans; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Prognosis; Recurrence; Registries; Treatment Outcome | 2012 |
[[Practice guidelines for FDG PET, PET/CT].
Topics: Epilepsy; Fluorodeoxyglucose F18; Humans; Myocardial Ischemia; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Safety Management; Tomography, X-Ray Computed | 2010 |
Incidental ¹⁸F-FDG uptake in the thyroid in patients diagnosed with PET/CT for other malignancies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Cohort Studies; Female; Fluorodeoxyglucose F18; Humans; Incidental Findings; Infant; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Thyroid Neoplasms; Tomography, X-Ray Computed | 2011 |
Preliminary experience with 18f-fluoro-deoxy-glucose positron emission tomography/computed tomography in pediatric oncology patients.
Topics: Adolescent; Child; Child, Preschool; Female; Fluorodeoxyglucose F18; Humans; Male; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Young Adult | 2011 |
¹⁸F-fluorodeoxyglucose PET/CT findings in pleural effusions of patients with known cancer. A cytopathological correlation.
Topics: Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasms; Pleural Effusion; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed | 2012 |
Image change detection using paradoxical theory for patient follow-up quantitation and therapy assessment.
Topics: Algorithms; Computer Simulation; Databases, Factual; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Image Processing, Computer-Assisted; Medical Oncology; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Tumor Burden | 2012 |
Brown fat at PET/CT: correlation with patient characteristics.
Topics: Adipose Tissue, Brown; Analysis of Variance; Barium Sulfate; Case-Control Studies; Chi-Square Distribution; Female; Fluorodeoxyglucose F18; Humans; Iopamidol; Male; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Prevalence; Radiopharmaceuticals; Sex Factors; Tomography, X-Ray Computed | 2012 |
Noise considerations for PET quantification using maximum and peak standardized uptake value.
Topics: Algorithms; Data Interpretation, Statistical; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Neoplasms; Phantoms, Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Reference Standards; Reproducibility of Results | 2012 |
Quantitative, simultaneous PET/MRI for intratumoral imaging with an MRI-compatible PET scanner.
Topics: Algorithms; Animals; Antibodies; Autoradiography; Calibration; Copper Radioisotopes; Fluorodeoxyglucose F18; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Mice; Mice, Inbred C57BL; Neoplasms; Phantoms, Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results | 2012 |
Letter from the Editors: low-sensitivity FDG-PET studies.
Topics: Fluorodeoxyglucose F18; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Sensitivity and Specificity | 2012 |
Spectrum of 18F-FDG PET/CT findings in patients presenting with fever of unknown origin.
Topics: Causality; Comorbidity; Fever of Unknown Origin; Fluorodeoxyglucose F18; Global Health; Humans; Infections; Inflammation; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, X-Ray Computed | 2012 |
Diagnostic role of whole-body [18F]-FDG positron emission tomography in patients with symptoms suspicious for malignancy after heart transplantation.
Topics: Adolescent; Adult; Aged; Child, Preschool; Female; Fluorodeoxyglucose F18; Heart Transplantation; Humans; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Postoperative Complications; Radiopharmaceuticals; Retrospective Studies | 2012 |
Intra-reader reliability of FDG PET volumetric tumor parameters: effects of primary tumor size and segmentation methods.
Topics: Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Neoplasms; Observer Variation; Positron-Emission Tomography; Reproducibility of Results; Retrospective Studies; Tumor Burden | 2012 |
Different intravenous contrast media concentrations do not affect clinical assessment of 18F-fluorodeoxyglucose positron emission tomography/computed tomography scans in an intraindividual comparison.
Topics: Contrast Media; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Iodine; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Statistics, Nonparametric; Tomography, X-Ray Computed | 2012 |
The significance of 18F-FDG PET/CT in secondary hemophagocytic lymphohistiocytosis.
Topics: Adolescent; Adult; Aged; Diagnosis, Differential; Epstein-Barr Virus Infections; Female; Fluorodeoxyglucose F18; Herpesvirus 4, Human; Humans; Lymphohistiocytosis, Hemophagocytic; Male; Middle Aged; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Tomography, X-Ray Computed; Young Adult | 2012 |
A segmentation framework towards automatic generation of boost subvolumes for FDG-PET tumors: a digital phantom study.
Topics: Algorithms; Computer Simulation; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Models, Biological; Neoplasms; Pattern Recognition, Automated; Phantoms, Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity | 2012 |
Incidence, appropriateness, and consequences of recommendations for additional imaging tests in oncological PET/CT reports.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Female; Fluorodeoxyglucose F18; Humans; Incidence; Male; Middle Aged; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Quality Control; Radiation Dosage; Retrospective Studies; Risk Assessment; Sensitivity and Specificity; Tomography, X-Ray Computed | 2013 |
Preface to the special issue on quantitative imaging in cancer.
Topics: Diagnostic Imaging; Fluorodeoxyglucose F18; Humans; Medical Oncology; Neoplasms; Positron-Emission Tomography; Tomography, Emission-Computed, Single-Photon | 2012 |
Oncologic 18F-FDG PET/CT: referring physicians' point of view.
Topics: Communication; Data Collection; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Multimodal Imaging; Neoplasms; Physicians; Positron-Emission Tomography; Referral and Consultation; Research Report; Tomography, X-Ray Computed | 2012 |
Diagnostic value of combined ¹⁸F-FDG PET/MRI for staging and restaging in paediatric oncology.
Topics: Adolescent; Child; Child, Preschool; Female; Fluorodeoxyglucose F18; Humans; Infant; Magnetic Resonance Imaging; Male; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2012 |
Fusion of [(18)F]FDG PET with fluorescence diffuse optical tomography to improve validation of probes and tumor imaging.
Topics: Animals; Cathepsins; Cell Line, Tumor; Diffusion; Fluorescent Dyes; Fluorodeoxyglucose F18; Humans; Mice; Molecular Probes; Neoplasms; Oligopeptides; Positron-Emission Tomography; Reproducibility of Results; Tissue Distribution; Tomography, Optical | 2013 |
PET/CT in oncology.
Topics: Fluorodeoxyglucose F18; Gastrointestinal Neoplasms; Humans; Lung Neoplasms; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2012 |
The use of zeolites to generate PET phantoms for the validation of quantification strategies in oncology.
Topics: Adsorption; Algorithms; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Multimodal Imaging; Neoplasms; Phantoms, Imaging; Porosity; Positron-Emission Tomography; Tomography, X-Ray Computed; Zeolites | 2012 |
Approaches for the optimization of MR protocols in clinical hybrid PET/MRI studies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Artifacts; Brain Diseases; Child; Clinical Protocols; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Neoplasms; Patient Positioning; Positron-Emission Tomography; Radiopharmaceuticals; Time Factors; Whole Body Imaging | 2013 |
Measured dose rate constant from oncology patients administered 18F for positron emission tomography.
Topics: Adult; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiometry | 2012 |
The impact of acquisition time on image quality in whole-body 18F-FDG PET/CT for cancer staging.
Topics: Adult; Aged; Aged, 80 and over; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Neoplasms; Observer Variation; Positron-Emission Tomography; Quality Control; Time Factors; Tomography, X-Ray Computed; Tumor Burden; Whole Body Imaging | 2012 |
A gel tumour phantom for assessment of the accuracy of manual and automatic delineation of gross tumour volume from FDG-PET/CT.
Topics: Algorithms; Carcinoma, Squamous Cell; Fluorodeoxyglucose F18; Gels; Head and Neck Neoplasms; Humans; Image Interpretation, Computer-Assisted; Imaging, Three-Dimensional; Models, Anatomic; Models, Biological; Multimodal Imaging; Neoplasms; Pattern Recognition, Automated; Phantoms, Imaging; Positron-Emission Tomography; Radiotherapy Planning, Computer-Assisted; Squamous Cell Carcinoma of Head and Neck; Tomography, X-Ray Computed; Tumor Burden | 2013 |
The current status of an FDG-PET cancer screening program in Japan, based on a 4-year (2006-2009) nationwide survey.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Data Collection; Early Detection of Cancer; Female; Fluorodeoxyglucose F18; Humans; Japan; Male; Middle Aged; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Predictive Value of Tests; Tomography, X-Ray Computed; Young Adult | 2013 |
The impact of coaxial core biopsy guided by FDG PET/CT in oncological patients.
Topics: Biopsy, Needle; Female; Fluorodeoxyglucose F18; Humans; Image-Guided Biopsy; Male; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2013 |
Differences in the biologic activity of 2 novel MEK inhibitors revealed by 18F-FDG PET: analysis of imaging data from 2 phase I trials.
Topics: Adult; Aged; Benzamides; Clinical Trials, Phase I as Topic; Coumarins; Extracellular Signal-Regulated MAP Kinases; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Neoplasms; Oxazines; Phosphoproteins; Positron-Emission Tomography; Protein Kinase Inhibitors; Treatment Failure; Young Adult | 2012 |
Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours.
Topics: Carcinoma, Squamous Cell; Disease-Free Survival; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Genital Neoplasms, Female; Glycolysis; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Medical Oncology; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Treatment Outcome; Tumor Burden | 2013 |
Interpretation of PET scans: do not take SUVs at face value.
Topics: Algorithms; Antineoplastic Agents; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2012 |
Impact of blood glucose, diabetes, insulin, and obesity on standardized uptake values in tumors and healthy organs on 18F-FDG PET/CT.
Topics: Biological Transport; Blood Glucose; Diabetes Complications; Female; Fluorodeoxyglucose F18; Humans; Insulin; Kidney; Liver; Male; Middle Aged; Multimodal Imaging; Neoplasms; Obesity; Positron-Emission Tomography; Reference Standards; Retrospective Studies; Tomography, X-Ray Computed | 2013 |
Does positron emission tomography data acquisition impact simultaneous diffusion-weighted imaging in a whole-body PET/MRI system?
Topics: Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Subtraction Technique; Whole Body Imaging | 2013 |
External radioactive markers for PET data-driven respiratory gating in positron emission tomography.
Topics: Aged; Aged, 80 and over; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Respiratory-Gated Imaging Techniques; Sodium Radioisotopes; Tomography, X-Ray Computed | 2013 |
The utility of FDG-PET for assessing outcomes in oligometastatic cancer patients treated with stereotactic body radiotherapy: a cohort study.
Topics: Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Neoplasm Metastasis; Neoplasms; Positron-Emission Tomography; Prospective Studies; Radiosurgery; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Clinical evaluation of PET image reconstruction using a spatial resolution model.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Computer Simulation; Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Imaging, Three-Dimensional; Male; Middle Aged; Models, Biological; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Whole Body Imaging; Young Adult | 2013 |
A GSO tweezers-type coincidence detector for tumor detection.
Topics: Equipment Design; Fluorodeoxyglucose F18; Humans; Neoplasms; Phantoms, Imaging; Photons; Positron-Emission Tomography; Silicates; Transducers | 2013 |
Combined 18F-Fluoride and 18F-FDG PET/CT scanning for evaluation of malignancy: results of an international multicenter trial.
Topics: Female; Fluorodeoxyglucose F18; Humans; Male; Neoplasms; Positron-Emission Tomography; Tomography, X-Ray Computed | 2013 |
The value of 18F-FDG PET/contrast-enhanced CT in detection of tumor thrombus.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Contrast Media; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Retrospective Studies; ROC Curve; Thrombosis; Tomography, X-Ray Computed | 2013 |
Assessment of tracer 99mTc(V)-DMSA uptake as a measure of tumor cell proliferation in vitro.
Topics: Benzamides; Biomarkers; Cell Line, Tumor; Cell Proliferation; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; MCF-7 Cells; Neoplasms; Piperazines; Pyrimidines; Radiopharmaceuticals; S Phase; Technetium Tc 99m Dimercaptosuccinic Acid | 2013 |
Dual-time-point FDG PET/CT for the evaluation of pediatric tumors.
Topics: Adolescent; Child; Child, Preschool; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Infant; Male; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, X-Ray Computed | 2013 |
18F-FDG PET/CT-directed biopsy: does it offer incremental benefit?
Topics: Adolescent; Adult; Aged; Biopsy; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lymph Nodes; Male; Middle Aged; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Research Design; Tomography, X-Ray Computed; Young Adult | 2013 |
Variance of SUVs for FDG-PET/CT is greater in clinical practice than under ideal study settings.
Topics: Adult; Aged; Analysis of Variance; Biological Transport; Female; Fluorodeoxyglucose F18; Guideline Adherence; Humans; Image Interpretation, Computer-Assisted; Male; Middle Aged; Multicenter Studies as Topic; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Retrospective Studies; Tomography, X-Ray Computed | 2013 |
Metformin--an adjunct antineoplastic therapy--divergently modulates tumor metabolism and proliferation, interfering with early response prediction by 18F-FDG PET imaging.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fluorodeoxyglucose F18; Humans; Metformin; Mice; Mice, Nude; Models, Biological; Neoplasms; Positron-Emission Tomography; Time Factors | 2013 |
Optimizing positron emission tomography image acquisition protocols in integrated positron emission tomography/magnetic resonance imaging.
Topics: Contrast Media; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms; Observer Variation; Organometallic Compounds; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Signal-To-Noise Ratio; Time Factors | 2013 |
PET attenuation coefficients from CT images: experimental evaluation of the transformation of CT into PET 511-keV attenuation coefficients.
Topics: Calibration; Fluorodeoxyglucose F18; Humans; Image Enhancement; Models, Biological; Neoplasms; Phantoms, Imaging; Protons; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2002 |
Combined functional and structural evaluation of cancer patients with a hybrid camera-based PET/CT system using (18)F-FDG.
Topics: Female; Fluorodeoxyglucose F18; Gamma Cameras; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2002 |
PET/CT: comparison of quantitative tracer uptake between germanium and CT transmission attenuation-corrected images.
Topics: Algorithms; Female; Fluorodeoxyglucose F18; Germanium; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Neoplasms; Radioisotopes; Radiopharmaceuticals; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2002 |
Improving amino acid imaging: hungry or stuffed?
Topics: Amino Acids; Animals; Fasting; Fluorodeoxyglucose F18; Humans; Iodine Radioisotopes; Methyltyrosines; Neoplasms; Radionuclide Imaging; Radiopharmaceuticals; Rats | 2002 |
Positron emission tomography scanning: a primer.
Topics: Arkansas; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Medicare Assignment; Neoplasms; Radiopharmaceuticals; Robotics; Tomography, Emission-Computed | 2002 |
Focal tracer uptake: a potential artifact in contrast-enhanced dual-modality PET/CT scans.
Topics: Artifacts; Body Surface Area; Contrast Media; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Iohexol; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2002 |
[Positron emission tomography in the Netherlands: need to expand the capacity].
Topics: Cost-Benefit Analysis; Fluorodeoxyglucose F18; Humans; Neoplasm Staging; Neoplasms; Netherlands; Outcome and Process Assessment, Health Care; Practice Guidelines as Topic; Radiopharmaceuticals; Tomography, Emission-Computed | 2002 |
18-FDG PET scan in the staging of recurrent melanoma: additional value and therapeutic impact.
Topics: Adult; Aged; Aged, 80 and over; False Negative Reactions; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasms; Radiopharmaceuticals; Recurrence; Sensitivity and Specificity; Skin Neoplasms; Time Factors; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2002 |
PET diagnostic accuracy: improvement with in-line PET-CT system: initial results.
Topics: Abdominal Neoplasms; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Male; Microcomputers; Middle Aged; Neoplasm Staging; Neoplasms; Otorhinolaryngologic Neoplasms; Sensitivity and Specificity; Software; Tomography, Emission-Computed; Tomography, Spiral Computed | 2002 |
18F-FDG in cardiology and oncology: the bitter with the sweet.
Topics: Animals; Brain; Energy Metabolism; Fluorodeoxyglucose F18; Glucose; Humans; Myocardium; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 2002 |
Fluorodeoxyglucose positron emission tomography in clinical oncology: the referrer's perspective.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Attitude of Health Personnel; Child; Decision Making; Disease Management; Female; Fluorodeoxyglucose F18; Health Care Surveys; Humans; Male; Medical Oncology; Middle Aged; Neoplasm Staging; Neoplasms; Practice Patterns, Physicians'; Prospective Studies; Radiopharmaceuticals; Referral and Consultation; Tomography, Emission-Computed; United Kingdom | 2002 |
Whole-body positron emission tomography-CT: optimized CT using oral and IV contrast materials.
Topics: Administration, Oral; Adult; Aged; Barium Sulfate; Contrast Media; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2002 |
[Basic principles of 18F-fluorodeoxyglucose positron emission tomography].
Topics: Biological Transport; Fluorodeoxyglucose F18; Humans; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 2002 |
18F-FDG PET in candidates for radiation therapy: is it important and how do we validate its impact?
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Patient Care Management; Patient Selection; Predictive Value of Tests; Radiopharmaceuticals; Radiotherapy; Tomography, Emission-Computed | 2003 |
Where can FDG-PET contribute most to anatomical imaging problems?
Topics: Brain Neoplasms; Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2002 |
Molecular (functional) imaging for radiotherapy applications: an RTOG symposium.
Topics: Animals; Biomarkers, Tumor; Cell Hypoxia; Fluorodeoxyglucose F18; Humans; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Radiation Tolerance; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Receptors, Cell Surface; Research; Tomography Scanners, X-Ray Computed; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed | 2003 |
Clinically significant inaccurate localization of lesions with PET/CT: frequency in 300 patients.
Topics: Adult; Aged; Breast Neoplasms; Colonic Neoplasms; Diagnostic Errors; False Negative Reactions; False Positive Reactions; Female; Fluorodeoxyglucose F18; Germanium; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasms; Radioisotopes; Radiopharmaceuticals; Rectal Neoplasms; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity; Subtraction Technique; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2003 |
Respiration-induced attenuation artifact at PET/CT: technical considerations.
Topics: Adult; Analysis of Variance; Artifacts; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Radiopharmaceuticals; Respiration; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2003 |
Clinical 18F-FDG oncology patient preparation techniques.
Topics: Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Neoplasms; Patient Care; Radiopharmaceuticals; Tomography, Emission-Computed | 2003 |
CT-based attenuation correction in the calculation of semi-quantitative indices of [18F]FDG uptake in PET.
Topics: Algorithms; Artifacts; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Liver Neoplasms; Lung Neoplasms; Mediastinal Neoplasms; Neoplasms; Quality Control; Reproducibility of Results; Sensitivity and Specificity; Subtraction Technique; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2003 |
Positron emission and computed X-ray tomography: a coming together.
Topics: Equipment Design; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Male; Neoplasms; Quality Control; Radiopharmaceuticals; Subtraction Technique; Technology Assessment, Biomedical; Tomography, Emission-Computed; Tomography, X-Ray Computed; United Kingdom | 2003 |
[Uptake of FDG (2-fluoro-2-deoxy-D-glucose) as a tumor imaging agent into erythrocytes and accumulation of FDG in tumor cells].
Topics: Animals; Erythrocytes; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Glucose-6-Phosphate; Hexokinase; Monosaccharide Transport Proteins; Neoplasms; Phosphorylation; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Tomography, Emission-Computed | 2003 |
High social desirability and prefrontal cortical activity in cancer patients: a preliminary study.
Topics: Adult; Aged; Anxiety; Depression; Female; Fluorodeoxyglucose F18; Gyrus Cinguli; Humans; Male; Middle Aged; Neoplasms; Pilot Projects; Prefrontal Cortex; Social Desirability; Temporal Lobe; Tomography, Emission-Computed | 2003 |
[Standards, Options and Recommendations 2002 for the use of Positron Emission Tomography with [18F]-FDG (PET-FDG in cancerology (integral connection].
Topics: Fluorodeoxyglucose F18; France; Humans; Neoplasms; Practice Guidelines as Topic; Radiopharmaceuticals; Societies, Medical; Tomography, Emission-Computed | 2003 |
[2002 Standards, Options and Recommendations for the use of [18F]-FDG (PET-FDG) in cancerology].
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 2003 |
3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography.
Topics: Adenosine Triphosphate; Animals; Dideoxynucleosides; Drug Monitoring; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Fluorouracil; Humans; Mice; Mice, Inbred C3H; Mice, Nude; Neoplasms; Neoplasms, Experimental; Radiopharmaceuticals; Tissue Distribution; Tomography, Emission-Computed; Transplantation, Heterologous | 2003 |
Paraneoplastic syndromes: detection of malignant tumors using [(18)F]FDG-PET.
Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Paraneoplastic Syndromes; Radiography; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity; Tomography, Emission-Computed | 2003 |
Evaluation of the clinical performances of a large NaI(Tl) crystal 3D PET scanner.
Topics: Adult; Aged; Equipment Failure Analysis; Fluorodeoxyglucose F18; Humans; Imaging, Three-Dimensional; Middle Aged; Neoplasms; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Sodium Iodide; Tomography, Emission-Computed; Transducers | 2003 |
The oncologists' and radiologists' PET.
Topics: Cost-Benefit Analysis; Decision Making; Fluorodeoxyglucose F18; Health Policy; Humans; Neoplasms; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed | 2003 |
Summary of the Standards, Options and Recommendations for the use of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose (FDP-PET scanning) in oncology (2002).
Topics: Fluorodeoxyglucose F18; Health Planning Guidelines; Humans; Medical Oncology; Neoplasm Staging; Neoplasms; Reference Standards; Research; Tomography, Emission-Computed | 2003 |
2003 SNM Highlights Lecture: From proof of principle to proof of value.
Topics: Drug Design; Female; Fluorodeoxyglucose F18; Humans; Male; Neoplasms; Radioisotopes; Radiopharmaceuticals; Tomography, Emission-Computed | 2003 |
The value of 18F-fluorodeoxyglucose positron emission tomography with the additional help of tumor markers in cancer screening.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; CA-125 Antigen; False Negative Reactions; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Male; Mass Screening; Middle Aged; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 2003 |
[18F]5-fluoro-2-deoxyuridine-PET for imaging of malignant tumors and for measuring tissue proliferation.
Topics: Adult; Aged; Bone and Bones; Cell Division; Female; Fluorodeoxyglucose F18; Gastrointestinal Neoplasms; Humans; Ki-67 Antigen; Kidney; Liver; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Neoplasms; Prospective Studies; Radiopharmaceuticals; Sarcoma; Tissue Distribution; Tomography, Emission-Computed; Urinary Bladder | 2003 |
Preparation of 66Ga- and 68Ga-labeled Ga(III)-deferoxamine-folate as potential folate-receptor-targeted PET radiopharmaceuticals.
Topics: Animals; Autoradiography; Carrier Proteins; Deferoxamine; Feasibility Studies; Fluorodeoxyglucose F18; Folate Receptors, GPI-Anchored; Folic Acid; Gallium Radioisotopes; Humans; Isotope Labeling; KB Cells; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Radiopharmaceuticals; Receptors, Cell Surface; Tomography, Emission-Computed | 2003 |
Optimal dose of 18F-FDG required for whole-body PET using an LSO PET camera.
Topics: Dose-Response Relationship, Drug; Equipment Failure Analysis; Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Lutetium; Male; Middle Aged; Neoplasms; Quality Control; Radiation Protection; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity; Silicates; Tomography, Emission-Computed; Whole-Body Counting | 2003 |
Roles of positron emission tomography with fluorine-18-deoxyglucose in the detection of local recurrent and distant metastatic sarcoma.
Topics: Adolescent; Adult; Aged; Child; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Sarcoma; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
An analytic study of the effects of attenuation on tumor detection in whole-body PET oncology imaging.
Topics: Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Neoplasms; Phantoms, Imaging; Tomography, Emission-Computed | 2003 |
18F-choline in experimental soft tissue infection assessed with autoradiography and high-resolution PET.
Topics: Animals; Autoradiography; Choline; Fluorodeoxyglucose F18; Metabolic Clearance Rate; Muscle, Skeletal; Myositis; Neoplasms; Organ Specificity; Positron-Emission Tomography; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sensitivity and Specificity; Soft Tissue Infections; Staphylococcal Infections; Tissue Distribution | 2004 |
FDG-PET scanning after radiation can predict tumor regrowth three months later.
Topics: Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Neoplasms; Predictive Value of Tests; Radiopharmaceuticals; Tomography, Emission-Computed | 2003 |
[The role of positron emission tomography with C18-Fluorodeoxyglucose in clinical oncology].
Topics: Brain Neoplasms; Breast Neoplasms; Carbon Radioisotopes; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Lung Neoplasms; Lymphoma; Male; Medical Oncology; Neoplasms; Outcome Assessment, Health Care; Pancreatic Neoplasms; Radiopharmaceuticals; Sensitivity and Specificity; Testicular Neoplasms; Tomography, Emission-Computed | 2003 |
Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology.
Topics: Adult; Aged; Aged, 80 and over; Contrast Media; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Neoplasms; Prospective Studies; Radiopharmaceuticals; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2003 |
Detection of clinically unexpected malignant and premalignant tumors with whole-body FDG PET: histopathologic comparison.
Topics: Aged; Aged, 80 and over; Biopsy; Blood Glucose; Energy Metabolism; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Incidental Findings; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Neoplasms, Multiple Primary; Precancerous Conditions; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2004 |
Has PET become an important clinical tool in paediatric imaging?
Topics: Cardiovascular Diseases; Child; Child, Preschool; Fluorodeoxyglucose F18; Humans; Infant; Infant, Newborn; Neoplasms; Neuromuscular Diseases; Pediatrics; Positron-Emission Tomography; Radiopharmaceuticals | 2004 |
Cardiac pacemakers and central venous lines can induce focal artifacts on CT-corrected PET images.
Topics: Aged; Artifacts; Catheterization, Central Venous; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Neoplasms; Pacemaker, Artificial; Radiopharmaceuticals; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2004 |
The clinical relevance of thymic fluorodeoxyglucose uptake in pediatric patients after chemotherapy.
Topics: Adolescent; Child; Child, Preschool; Diagnosis, Differential; Diagnostic Errors; Female; Fluorodeoxyglucose F18; Humans; Infant; Infant, Newborn; Male; Neoplasms; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity; Thymus Gland; Thymus Neoplasms | 2004 |
FDG-PET: procedure guidelines for tumour imaging.
Topics: Europe; Fluorodeoxyglucose F18; Humans; Neoplasms; Nuclear Medicine; Patient Care Management; Practice Guidelines as Topic; Practice Patterns, Physicians'; Radiopharmaceuticals; Societies, Medical; Tomography, Emission-Computed | 2003 |
Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging.
Topics: Cell Line, Tumor; Fluorodeoxyglucose F18; Glucose; Glycolysis; Humans; Hypoxia; Image Processing, Computer-Assisted; Neoplasm Metastasis; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2004 |
Tetraphenylphosphonium as a novel molecular probe for imaging tumors.
Topics: Animals; Cell Line, Tumor; Diagnosis, Differential; Fluorodeoxyglucose F18; Inflammation; Male; Mice; Mice, Nude; Molecular Probes; Neoplasms; Onium Compounds; Organ Specificity; Organophosphorus Compounds; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sensitivity and Specificity; Tissue Distribution; Tomography, Emission-Computed; Tuberculosis, Cutaneous | 2004 |
A lesion detection observer study comparing 2-dimensional versus fully 3-dimensional whole-body PET imaging protocols.
Topics: Algorithms; Computer Simulation; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Imaging, Three-Dimensional; Models, Biological; Neoplasms; Observer Variation; Phantoms, Imaging; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, Emission-Computed; Whole-Body Counting | 2004 |
The role of [(18)F]fluorodeoxyglucose positron emission tomography and [(111)In]-diethylenetriaminepentaacetate-D-Phe-pentetreotide scintigraphy in the localization of ectopic adrenocorticotropin-secreting tumors causing Cushing's syndrome.
Topics: ACTH Syndrome, Ectopic; Adult; Aged; Cushing Syndrome; Female; Fluorodeoxyglucose F18; Humans; Indium Radioisotopes; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms; Pentetic Acid; Radiopharmaceuticals; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2004 |
Within-patient variability of (18)F-FDG: standardized uptake values in normal tissues.
Topics: Body Height; Body Weight; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Liver; Lung; Male; Mediastinum; Middle Aged; Muscle, Skeletal; Neoplasms; Radiopharmaceuticals; Reference Values; Reproducibility of Results; Tomography, Emission-Computed | 2004 |
Impact of patient weight and emission scan duration on PET/CT image quality and lesion detectability.
Topics: Body Weight; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Lutetium; Male; Middle Aged; Neoplasms; Posture; Prospective Studies; Radiopharmaceuticals; Silicates; Time Factors; Tomography Scanners, X-Ray Computed; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2004 |
Diagnosis of deep septic thrombophlebitis in cancer patients by fluorine-18 fluorodeoxyglucose positron emission tomography scanning: a preliminary report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Thrombophlebitis; Tomography, Emission-Computed | 2004 |
First (18)F-labeled tracer suitable for routine clinical imaging of sst receptor-expressing tumors using positron emission tomography.
Topics: Animals; Cell Line, Tumor; CHO Cells; Chromatography, High Pressure Liquid; Cricetinae; Dose-Response Relationship, Drug; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Glucose; Glycosylation; Inhibitory Concentration 50; Kinetics; Magnetic Resonance Spectroscopy; Models, Chemical; Neoplasms; Oximes; Peptides; Positron-Emission Tomography; Radiopharmaceuticals; Rats; Receptors, Somatostatin; Time Factors; Tissue Distribution; Transfection | 2004 |
How should we introduce clinical PET in the UK? The oncologists need to have a view.
Topics: Fluorodeoxyglucose F18; Health Care Costs; Humans; Medical Oncology; Neoplasms; Physician's Role; Practice Patterns, Physicians'; Radiopharmaceuticals; Tomography, Emission-Computed; United Kingdom | 2004 |
Source of impaired image quality in 3D whole-body FDG PET scanning.
Topics: Artifacts; Dose-Response Relationship, Drug; Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Imaging, Three-Dimensional; Lutetium; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Quality Control; Radiation Protection; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity; Silicates; Whole-Body Counting | 2004 |
PET/CT in diagnostic oncology.
Topics: Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Neoplasm Staging; Neoplasms; Radiopharmaceuticals; Tomography Scanners, X-Ray Computed; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2004 |
A method to quantify the uptake rate of 2-[18F]fluoro-2-deoxy-D-glucose in tissues.
Topics: Algorithms; Animals; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Metabolic Clearance Rate; Models, Biological; Neoplasms; Positron-Emission Tomography; Radioisotope Dilution Technique; Radiopharmaceuticals | 2004 |
A follow up study of patients with paraneoplastic neurological disease in the United Kingdom.
Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Antibodies; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms; Paraneoplastic Syndromes, Nervous System; Prognosis; Radiopharmaceuticals; Sex Factors; Tomography, Emission-Computed; United Kingdom | 2004 |
Focal FDG uptake in mediastinal brown fat mimicking malignancy: a potential pitfall resolved on PET/CT.
Topics: Adipose Tissue, Brown; Adolescent; Adult; Aged; Chi-Square Distribution; Child; Child, Preschool; Diagnosis, Differential; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Male; Mediastinum; Middle Aged; Neoplasms; Radiopharmaceuticals; Retrospective Studies; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2004 |
Clinical significance of unexplained abnormal focal FDG uptake in the abdomen during whole-body PET.
Topics: Abdomen; Aged; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 2004 |
Tracers to monitor the response to chemotherapy: in vitro screening of four radiopharmaceuticals.
Topics: DNA; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluorodeoxyglucose F18; Humans; Idoxuridine; Iodine Radioisotopes; Male; Methyltyrosines; Neoplasms; Organophosphorus Compounds; Organotechnetium Compounds; Radiopharmaceuticals; Verapamil | 2004 |
The relationship between standard uptake value (SUV) and Hounsfield Unit (HU) of oral contrast agent for FDG-PET/CT study.
Topics: Administration, Oral; Adult; Aged; Contrast Media; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2004 |
Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Tomography, X-Ray Computed | 2004 |
[PET/CT in radiotherapy].
Topics: Blood Glucose; Carcinoma, Bronchogenic; Equipment Design; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Lung Neoplasms; Lymphatic Metastasis; Neoplasms; Positron-Emission Tomography; Prognosis; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed | 2004 |
[PET-CT interventional tumour therapy].
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Equipment Design; Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Processing, Computer-Assisted; Male; Middle Aged; Neoplasm Staging; Neoplasms; Palliative Care; Positron-Emission Tomography; Radiology, Interventional; Sensitivity and Specificity; Therapy, Computer-Assisted; Tomography, X-Ray Computed | 2004 |
Is 18F-FDG PET/CT useful for imaging and management of patients with suspected occult recurrence of cancer?
Topics: Adult; Aged; Biomarkers; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Positron-Emission Tomography; Tomography, Emission-Computed | 2004 |
18FDG-PET in 733 consecutive patients with or without side-by-side CT evaluation: analysis of 921 lesions.
Topics: Female; Fluorodeoxyglucose F18; Humans; Male; Neoplasms; Radionuclide Imaging; Radiopharmaceuticals; Recurrence; Reproducibility of Results; Tomography, X-Ray Computed | 2004 |
Is there any future in radiotherapy planning without the use of PET: unraveling the myth...
Topics: Dose Fractionation, Radiation; Fluorodeoxyglucose F18; Humans; Neoplasms; Patient Care Planning; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy | 2004 |
Update of the FDG PET search strategy.
Topics: Abstracting and Indexing; Databases, Bibliographic; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Information Storage and Retrieval; Melanoma; Neoplasms; Positron-Emission Tomography; PubMed; Software; Subject Headings | 2004 |
[Fundamental knowledge for understanding FDG-PET].
Topics: Early Diagnosis; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2004 |
[Practice guidelines for PDG-PET cancer screening].
Topics: Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Japan; Magnetic Resonance Imaging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Ultrasonography | 2004 |
[The therapeutic impact of (18)F-FDG whole body PET. A radiooncologist's view].
Topics: Biopsy; Fluorodeoxyglucose F18; Humans; Neoplasm Recurrence, Local; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Whole-Body Irradiation | 2005 |
[Established nuclear medicine techniques for tumour diagnosis (tumour SPECT): can they still compete with (18)F-FDG-PET?].
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Nuclear Medicine; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Tomography, Emission-Computed, Single-Photon | 2005 |
Clinical experience with the first combined positron emission tomography/computed tomography scanner in Australia.
Topics: Australia; Fluorodeoxyglucose F18; Humans; Insurance, Health, Reimbursement; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Tomography Scanners, X-Ray Computed; Tomography, Spiral Computed | 2005 |
Glucuronate-modified, long-circulating liposomes for the delivery of anticancer agents.
Topics: Antineoplastic Agents; Cell Line; Doxorubicin; Drug Stability; Fluorodeoxyglucose F18; Glucuronates; Humans; Liposomes; Macrophages; Neoplasms; Positron-Emission Tomography | 2005 |
Is whole-body FDG-PET valuable for health screening? Against.
Topics: Fluorodeoxyglucose F18; Humans; Mass Screening; Neoplasms; Positron-Emission Tomography; Practice Guidelines as Topic; Practice Patterns, Physicians'; Radiopharmaceuticals; Whole-Body Counting | 2005 |
Is whole-body FDG-PET valuable for health screening? For.
Topics: Fluorodeoxyglucose F18; Humans; Japan; Mass Screening; Neoplasms; Positron-Emission Tomography; Practice Guidelines as Topic; Practice Patterns, Physicians'; Radiopharmaceuticals; Whole-Body Counting | 2005 |
Feasibility study of the use of similarity maps in the evaluation of oncological dynamic positron emission tomography images.
Topics: Colorectal Neoplasms; Feasibility Studies; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Neoplasm Recurrence, Local; Neoplasms; Phantoms, Imaging; Positron-Emission Tomography; Radiopharmaceuticals | 2005 |
Influence of reconstruction iterations on 18F-FDG PET/CT standardized uptake values.
Topics: Algorithms; Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Male; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Subtraction Technique; Tomography, X-Ray Computed | 2005 |
An intra-operative positron probe with background rejection capability for FDG-guided surgery.
Topics: Background Radiation; Equipment Design; Equipment Failure Analysis; Fluorodeoxyglucose F18; Humans; Neoplasms; Phantoms, Imaging; Positron-Emission Tomography; Radiation Dosage; Radiometry; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Surgery, Computer-Assisted; Transducers | 2005 |
Incidental ovarian 18F-FDG accumulation on PET: correlation with the menstrual cycle.
Topics: Adult; Breast Neoplasms; Colorectal Neoplasms; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Spectroscopy; Menopause; Menstrual Cycle; Middle Aged; Neoplasm Metastasis; Neoplasms; Ovarian Neoplasms; Ovary; Positron-Emission Tomography; Radiopharmaceuticals; Time Factors; Uterine Cervical Neoplasms | 2005 |
Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent mic
Topics: Animals; Autoradiography; Benzimidazoles; Cell Hypoxia; Coordination Complexes; Fluorodeoxyglucose F18; Humans; Immunohistochemistry; Male; Microscopy, Fluorescence; Misonidazole; Neoplasms; Nitroimidazoles; Organometallic Compounds; Positron-Emission Tomography; Radiation-Sensitizing Agents; Radiopharmaceuticals; Rats; Rats, Nude; Thiosemicarbazones; Transplantation, Heterologous | 2005 |
Dependence of FDG uptake on tumor microenvironment.
Topics: Animals; Autoradiography; Benzimidazoles; Bromodeoxyuridine; Cell Hypoxia; Cell Proliferation; Coloring Agents; Fluorodeoxyglucose F18; Glucose; Male; Mice; Mice, Nude; Neoplasms; Nitroimidazoles; Prostatic Neoplasms; Radiopharmaceuticals | 2005 |
Accuracy of image fusion using a fixation device for whole-body cancer imaging.
Topics: Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Immobilization; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Technology, Radiologic; Tomography, X-Ray Computed; Vacuum | 2005 |
Metabolic monitoring of chemosensitivity with 18FDG PET.
Topics: Body Weight; Brain; Drug Screening Assays, Antitumor; Female; Fluorodeoxyglucose F18; Glucose; Humans; Linear Models; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Time Factors; Uterine Cervical Neoplasms | 2005 |
The influence of filtered back-projection and iterative reconstruction on partial volume correction in PET.
Topics: Algorithms; Brain; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Neoplasms; Phantoms, Imaging; Positron-Emission Tomography | 2005 |
Pre-medication to block [(18)F]FDG uptake in the brown adipose tissue of pediatric and adolescent patients.
Topics: Adipose Tissue, Brown; Administration, Oral; Adolescent; Adult; Age Factors; Analgesics, Opioid; Child; Child, Preschool; Diazepam; Female; Fentanyl; Fluorodeoxyglucose F18; Humans; Hypnotics and Sedatives; Infant; Injections, Intravenous; Male; Neoplasms; Positron-Emission Tomography; Premedication; Radiopharmaceuticals; Retrospective Studies; Thorax | 2005 |
Biodistribution and imaging of FDG in rats with LS174T carcinoma xenografts and focal Escherichia coli infection.
Topics: Animals; Cell Line, Tumor; Escherichia coli; Escherichia coli Infections; Fluorodeoxyglucose F18; Humans; Neoplasm Transplantation; Neoplasms; Positron-Emission Tomography; Rats; Rats, Nude; Tissue Distribution | 2005 |
Intra-individual variability of cardiac uptake on serial whole-body 18F-FDG PET.
Topics: Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Heart; Humans; Male; Middle Aged; Myocardium; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity; Tissue Distribution; United States; Whole-Body Counting | 2005 |
[Understanding positon emission tomography (PET) with [18F]-FDG in clinical oncology. Informations dedicated to patients and relatives].
Topics: Decision Making; Documentation; Fluorodeoxyglucose F18; Humans; Neoplasms; Patient Education as Topic; Positron-Emission Tomography; Radiopharmaceuticals | 2005 |
[Anatomical accuracy of lesion localization. Retrospective interactive rigid image registration between 18F-FDG-PET and X-ray CT].
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Observer Variation; Positron-Emission Tomography; Radioisotopes; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed | 2005 |
Early clinical experience and impact of 18F-FDG PET.
Topics: Data Collection; Denmark; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Practice Patterns, Physicians'; Radiopharmaceuticals; Referral and Consultation | 2005 |
Improved detection of second primary cancer using integrated [18F] fluorodeoxyglucose positron emission tomography and computed tomography for initial tumor staging.
Topics: Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Neoplasms, Second Primary; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2005 |
FDG PET in patients with cancer of an unknown primary.
Topics: Adenocarcinoma; Adult; Aged; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Neoplasms, Unknown Primary; Positron-Emission Tomography; Prospective Studies; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Whole-Body Counting | 2005 |
Use of a decision analysis model to assess the cost-effectiveness of 18F-FDG PET in the management of metachronous liver metastases of colorectal cancer.
Topics: Colorectal Neoplasms; Cost-Benefit Analysis; Decision Support Techniques; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Sensitivity and Specificity; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2005 |
Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Time Factors; Tomography, X-Ray Computed | 2005 |
The clinical role of CT/PET in oncology: an update.
Topics: Colonic Neoplasms; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Lung Neoplasms; Lymphoma; Melanoma; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Radiation Oncology; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed | 2005 |
Comparison of 2-dimensional and 3-dimensional acquisition for 18F-FDG PET oncology studies performed on an LSO-based scanner.
Topics: Equipment Design; Equipment Failure Analysis; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Imaging, Three-Dimensional; Lutetium; Male; Medical Oncology; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Silicates; Whole Body Imaging | 2006 |
Radiation oncology and functional imaging.
Topics: Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2005 |
Molecular imaging to improve radiotherapy.
Topics: Fluorodeoxyglucose F18; Humans; Imaging, Three-Dimensional; Molecular Probe Techniques; Neoplasms; Positron-Emission Tomography; Radiometry; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Computer-Assisted; Radiotherapy, Conformal | 2006 |
Concomitant paravertebral FDG uptake helps differentiate supraclavicular and suprarenal brown fat uptake from malignant uptake when CT coregistration is not available.
Topics: Adipose Tissue, Brown; Clavicle; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Kidney; Male; Middle Aged; Neoplasms; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity; Spine; Subtraction Technique; Tomography, X-Ray Computed | 2006 |
Early clinical experience and impact of [18F]fluorodeoxyglucose positron emission tomography.
Topics: Bias; Data Collection; Denmark; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Practice Patterns, Physicians'; Radiopharmaceuticals; Referral and Consultation | 2006 |
Whole-body MRI and PET-CT in the management of cancer patients.
Topics: Early Diagnosis; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Processing, Computer-Assisted; Lymphatic Metastasis; Magnetic Resonance Imaging; Mass Screening; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Radiation Dosage; Radiopharmaceuticals; Tomography, Spiral Computed; Tomography, X-Ray Computed; Treatment Outcome; Whole Body Imaging | 2006 |
Reversal of hypermetabolic brown adipose tissue in F-18 FDG PET imaging.
Topics: Adipose Tissue, Brown; Adolescent; Adult; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 2006 |
PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression.
Topics: Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Integrin alphaVbeta3; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Oligopeptides; Positron-Emission Tomography; Radiometry; Radiopharmaceuticals | 2006 |
Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0.
Topics: Adult; Child; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Quality Control; Radiopharmaceuticals | 2006 |
Positron-emission tomography in cancer therapy.
Topics: Fluorodeoxyglucose F18; Glioma; Humans; Neoplasms; Positron-Emission Tomography | 2006 |
Multiagency effort to focus on PET as biomarker.
Topics: Biomarkers, Tumor; Cooperative Behavior; Fluorodeoxyglucose F18; Humans; Lymphoma, Non-Hodgkin; Neoplasms; Positron-Emission Tomography; Radioimmunotherapy; Radiopharmaceuticals; United States; United States Dept. of Health and Human Services | 2006 |
Q&A: perspective on pediatric nuclear medicine: an interview with Michael J. Gelfand.
Topics: Child; Fluorodeoxyglucose F18; Humans; Neoplasms; Nuclear Medicine; Positron-Emission Tomography; Radiopharmaceuticals; Technology, Radiologic; United States | 2006 |
Brain metabolic changes associated with predispotion to onset of major depressive disorder and adjustment disorder in cancer patients--a preliminary PET study.
Topics: Adjustment Disorders; Adolescent; Adult; Aged; Blood Glucose; Brain; Cerebral Cortex; Depressive Disorder, Major; Disease Progression; Energy Metabolism; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Male; Middle Aged; Neoplasms; Nerve Net; Personality Inventory; Positron-Emission Tomography; Sensitivity and Specificity | 2007 |
Is 3'-deoxy-3'-(18)F-fluorothymidine a better marker for tumour response than (18)F-fluorodeoxyglucose?
Topics: Animals; Antineoplastic Agents; Dideoxynucleosides; Disease Models, Animal; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Mice; Neoplasms; Radionuclide Imaging; Reproducibility of Results | 2006 |
[PET--options and limitations].
Topics: Fluorodeoxyglucose F18; Humans; Multiple Myeloma; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2006 |
The influence of tumor oxygenation on (18)F-FDG (fluorine-18 deoxyglucose) uptake: a mouse study using positron emission tomography (PET).
Topics: Air; Animals; Female; Fluorodeoxyglucose F18; Hypoxia; Mice; Mice, Inbred C3H; Models, Statistical; Neoplasms; Oxygen; Pilot Projects; Positron-Emission Tomography; Temperature; Time Factors | 2006 |
18F-FDG PET as a candidate for "qualified biomarker": functional assessment of treatment response in oncology.
Topics: Biomarkers, Tumor; Fluorodeoxyglucose F18; Humans; Neoplasms; Outcome Assessment, Health Care; Positron-Emission Tomography; Practice Guidelines as Topic; Practice Patterns, Physicians'; Prognosis; Radiopharmaceuticals; Treatment Outcome; United States | 2006 |
Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.
Topics: Clinical Trials as Topic; Fluorodeoxyglucose F18; Humans; National Institutes of Health (U.S.); Neoplasms; Outcome Assessment, Health Care; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Treatment Outcome; United States | 2006 |
Current standards for response evaluation by imaging techniques.
Topics: Clinical Trials, Phase II as Topic; Fluorodeoxyglucose F18; Humans; Neoplasms; Radionuclide Imaging; Radiopharmaceuticals; Tomography, X-Ray Computed | 2006 |
Instant gratification must wait.
Topics: Cell Line, Tumor; Cell Proliferation; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Thymidine; Tritium | 2006 |
"Flying through" and "flying around" a PET/CT scan: Pilot study and development of 3D integrated 18F-FDG PET/CT for virtual bronchoscopy and colonoscopy.
Topics: Adult; Aged; Aged, 80 and over; Bronchoscopy; Colonoscopy; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Male; Middle Aged; Models, Anatomic; Neoplasms; Pilot Projects; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Whole Body Imaging | 2006 |
Dynamic imaging of transient metabolic processes by small-animal PET for the evaluation of photosensitizers in photodynamic therapy of cancer.
Topics: Animals; Disease Models, Animal; Female; Fluorodeoxyglucose F18; Image Processing, Computer-Assisted; Indoles; Isoindoles; Models, Chemical; Neoplasms; Photochemotherapy; Photosensitizing Agents; Positron-Emission Tomography; Rats; Rats, Inbred F344; Time Factors | 2006 |
Synthesis and preclinical evaluation of a folic acid derivative labeled with 18F for PET imaging of folate receptor-positive tumors.
Topics: Animals; Carrier Proteins; Cell Line, Tumor; Chromatography, High Pressure Liquid; Fluorodeoxyglucose F18; Folate Receptors, GPI-Anchored; Folic Acid; Humans; KB Cells; Mice; Mice, Nude; Models, Chemical; Neoplasms; Positron-Emission Tomography; Protein Binding; Radiopharmaceuticals; Receptors, Cell Surface | 2006 |
Molecular imaging with 123I-FIAU, 18F-FUdR, 18F-FET, and 18F-FDG for monitoring herpes simplex virus type 1 thymidine kinase and ganciclovir prodrug activation gene therapy of cancer.
Topics: Animals; Antiviral Agents; Arabinofuranosyluracil; Cell Line, Tumor; Female; Floxuridine; Fluorodeoxyglucose F18; Ganciclovir; Genetic Therapy; Herpesvirus 1, Human; Humans; Iodine Radioisotopes; Mice; Neoplasms; Prodrugs; Thymidine Kinase; Tyrosine | 2006 |
"Cold" vertebrae on F-18 FDG PET: Causes and characteristics.
Topics: Adenocarcinoma; Adult; Breast Neoplasms; Female; Fluorodeoxyglucose F18; Hemangioma; Hodgkin Disease; Humans; Liver Neoplasms; Lung Neoplasms; Male; Mediastinal Neoplasms; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Spine | 2006 |
PET-Probe: Evaluation of Technical Performance and Clinical Utility of a Handheld High-Energy Gamma Probe in Oncologic Surgery.
Topics: Adolescent; Adult; Aged; Female; Fluorodeoxyglucose F18; Gamma Rays; Humans; Intraoperative Period; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms; Positron-Emission Tomography; Prospective Studies; Radiometry; Radiopharmaceuticals; Young Adult | 2016 |
Assessment of 18F PET signals for automatic target volume definition in radiotherapy treatment planning.
Topics: Automation; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Neoplasms; Phantoms, Imaging; Positron-Emission Tomography; Radiation Oncology; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Software; Tomography, X-Ray Computed | 2006 |
Deformable and rigid registration of MRI and microPET images for photodynamic therapy of cancer in mice.
Topics: Animals; Automation; Disease Models, Animal; Fluorodeoxyglucose F18; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Kidney; Magnetic Resonance Imaging; Mice; Neoplasms; Photochemotherapy; Positron-Emission Tomography; Radiography; Reproducibility of Results; Sensitivity and Specificity; Time Factors; Urinary Bladder; Whole-Body Counting | 2006 |
Clinical PET in oncology: not only FDG.
Topics: Acetates; Carbon Radioisotopes; Choline; Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Medical Oncology; Methionine; Neoplasms; Organometallic Compounds; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity | 2006 |
Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study.
Topics: Adult; Aged; Carcinoid Tumor; Dihydroxyphenylalanine; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Receptors, Somatostatin; Reproducibility of Results; Somatostatin; Tomography, X-Ray Computed | 2006 |
[Use of PET for evaluation of treatment response in oncology].
Topics: Fluorodeoxyglucose F18; Humans; Lymphoma; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Treatment Outcome | 2006 |
Adequate evaluation of image registration in hybrid PET/CT.
Topics: Artifacts; Biotechnology; Contrast Media; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Iohexol; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Reproducibility of Results; Respiration; Sensitivity and Specificity; Subtraction Technique; Tomography, X-Ray Computed; Whole Body Imaging | 2006 |
[Functional cellular imaging: revolution for oncology].
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2006 |
The incremental value of 18F-FDG PET/CT in paediatric malignancies.
Topics: Adolescent; Adult; Child; Child, Preschool; Diagnostic Imaging; Female; Fluorodeoxyglucose F18; Humans; Lymphoma; Male; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2007 |
Defining co-related parameters between 'metabolic' flare and 'clinical', 'biochemical', and 'osteoblastic' flare and establishing guidelines for assessing response to treatment in cancer.
Topics: Antineoplastic Agents; Artifacts; Fluorodeoxyglucose F18; Humans; Inflammation; Neoplasms; Osteoblasts; Positron-Emission Tomography; Practice Guidelines as Topic; Prognosis; Radiopharmaceuticals; Radiotherapy; Time Factors; Treatment Outcome | 2007 |
18F-FDG PET definition of gross tumor volume for radiotherapy of non-small cell lung cancer: is a single standardized uptake value threshold approach appropriate?
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Linear Models; Lung Neoplasms; Neoplasms; Positron-Emission Tomography; Radiation Oncology; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed | 2006 |
From anatomical to biological target volumes: the role of PET in radiation treatment planning.
Topics: Cell Hypoxia; Clinical Trials as Topic; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Misonidazole; Neoplasms; Observer Variation; Patient Care Planning; Positron-Emission Tomography; Radiation Tolerance; Radiopharmaceuticals; Radiotherapy; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed; Tumor Burden | 2006 |
PET/CT: will it change the way that we use CT in cancer imaging?
Topics: Adenocarcinoma; Biomarkers, Tumor; Carcinoembryonic Antigen; Case Management; Colorectal Neoplasms; Diagnostic Errors; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Liver Neoplasms; Lymphatic Metastasis; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Predictive Value of Tests; Prevalence; Probability; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, X-Ray Computed | 2006 |
Na+/Ca2+ exchanger inhibitors modify the accumulation of tumor-diagnostic PET tracers in cancer cells.
Topics: Bepridil; Calcium; Carbon Radioisotopes; Cell Line, Tumor; Choline; Flow Cytometry; Fluorodeoxyglucose F18; Humans; Microscopy, Confocal; Microscopy, Fluorescence; Neoplasms; Positron-Emission Tomography; Radioactive Tracers; Sodium; Sodium-Calcium Exchanger; Thapsigargin | 2007 |
How do oncologists deal with incidental abnormalities on whole-body fluorine-18 fluorodeoxyglucose PET/CT?
Topics: Adult; Aged; Aged, 80 and over; Diagnosis, Differential; False Positive Reactions; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasms; Neoplasms, Multiple Primary; Positron-Emission Tomography; Tomography, X-Ray Computed | 2007 |
Assessment of response to treatment of unresectable liver tumours with 90Y microspheres: value of FDG PET versus computed tomography.
Topics: Adult; Colorectal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Male; Microspheres; Middle Aged; Neoplasm Metastasis; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome; Yttrium Radioisotopes | 2007 |
Isolated papillary muscle uptake on FDG PET/CT.
Topics: Diagnosis, Differential; Fluorodeoxyglucose F18; Heart; Humans; Incidental Findings; Neoplasms; Papillary Muscles; Positron-Emission Tomography; Thrombosis; Tomography, X-Ray Computed | 2007 |
Clinical significance of small pulmonary nodules with little or no 18F-FDG uptake on PET/CT images of patients with nonthoracic malignancies.
Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Models, Statistical; Neoplasm Metastasis; Neoplasms; Positron-Emission Tomography; Retrospective Studies; Tomography, X-Ray Computed | 2007 |
Regarding Davis et al.: Assessment of (18)F PET signals for automatic target volume definition in radiotherapy treatment planning.
Topics: Computer Simulation; Fluorodeoxyglucose F18; Humans; Models, Theoretical; Neoplasms; Phantoms, Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted | 2007 |
Detection of tumour thrombus by 18F-FDG-PET/CT imaging.
Topics: Adult; Fatal Outcome; Female; Fluorodeoxyglucose F18; Heart Atria; Humans; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Thrombosis; Tomography, X-Ray Computed | 2007 |
A surgical perspective on positron emission tomography.
Topics: Breast Neoplasms; Colorectal Neoplasms; Female; Fluorodeoxyglucose F18; Glucose Transporter Type 1; Humans; Image Enhancement; Melanoma; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Sentinel Lymph Node Biopsy; Thyroid Neoplasms; Tomography, X-Ray Computed | 2007 |
Reduction of FDG uptake in brown adipose tissue in clinical patients by a single dose of propranolol.
Topics: Adipose Tissue, Brown; Adult; Artifacts; Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Propranolol; Radionuclide Imaging | 2007 |
Anatomical accuracy of interactive and automated rigid registration between X-ray CT and FDG-PET.
Topics: Adolescent; Adult; Aged; Automation; Female; Fluorodeoxyglucose F18; Humans; Lymphoma; Male; Melanoma; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Tomography, X-Ray Computed; Treatment Outcome | 2007 |
Value of contrast-enhanced multiphase CT in combined PET/CT protocols for oncological imaging.
Topics: Adult; Aged; Aged, 80 and over; Clinical Protocols; Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed | 2007 |
The detection rates and tumor clinical/pathological stages of whole-body FDG-PET cancer screening.
Topics: Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Male; Mass Screening; Middle Aged; Neoplasms; Positron-Emission Tomography; Severity of Illness Index; Whole Body Imaging | 2007 |
The National Oncologic PET Registry: expanded medicare coverage for PET under coverage with evidence development.
Topics: Fluorodeoxyglucose F18; Insurance Coverage; Medicare; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Records; Registries; United States | 2007 |
Experimental hypoxia is a potent stimulus for radiotracer uptake in vitro: comparison of different tumor cells and primary endothelial cells.
Topics: Cell Hypoxia; Cell Line; Cell Line, Tumor; Cells, Cultured; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Gene Expression; HT29 Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Misonidazole; Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors; Vascular Endothelial Growth Factor A | 2007 |
Low-dose oral propranolol could reduce brown adipose tissue F-18 FDG uptake in patients undergoing PET scans.
Topics: Adipose Tissue; Administration, Oral; Adolescent; Adrenergic beta-Antagonists; Adult; Cohort Studies; Drug Interactions; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Propranolol | 2007 |
Dynamic threshold for radiation target volume by PET/CT.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Linear Models; Lung Neoplasms; Neoplasms; Positron-Emission Tomography; Radiation Oncology; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed | 2007 |
Substitution of oral (18)F-FDG for intravenous (18)F-FDG in PET scanning.
Topics: Administration, Oral; Adolescent; Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Injections, Intravenous; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity | 2007 |
NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer.
Topics: Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Fluorodeoxyglucose F18; Humans; Lymphoma; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Prognosis; Tomography, X-Ray Computed | 2007 |
Partial volume correction of standardized uptake values and the dual time point in FDG-PET imaging: should these be routinely employed in assessing patients with cancer?
Topics: Artifacts; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Imaging, Three-Dimensional; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity | 2007 |
PET probe-guided surgery: applications and clinical protocol.
Topics: Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Surgery, Computer-Assisted; Young Adult | 2007 |
2-[Fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography versus whole-body diffusion-weighted MRI for detection of malignant lesions: initial experience.
Topics: Adult; Aged; Contrast Media; Diffusion; Diffusion Magnetic Resonance Imaging; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2007 |
Cancer screening of healthy volunteers using whole-body 18F-FDG-PET scans: The Nishidai clinic study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Male; Mass Screening; Middle Aged; Neoplasms; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals | 2007 |
Anterior layering of excreted 18F-FDG in the bladder on PET/CT: frequency and cause.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Contrast Media; Female; Fluorodeoxyglucose F18; Humans; Injections, Intravenous; Iohexol; Male; Middle Aged; Neoplasms; Phantoms, Imaging; Positron-Emission Tomography; Radiography; Radiopharmaceuticals; Retrospective Studies; Tomography, Emission-Computed; Urinary Bladder; Urinary Bladder Neoplasms | 2007 |
[3D volume and SUV analysis of oncological PET studies: a voxel-based image processing tool with NSCLC as example].
Topics: Algorithms; Computer Simulation; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Neoplasms; Phantoms, Imaging; Positron-Emission Tomography; Radiopharmaceuticals | 2007 |
Inter-observer variations in FDG-PET interpretation for cancer screening.
Topics: Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Observer Variation; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2007 |
Staging with PET and the "Will Rogers" effect: redefining prognosis and survival in patients with cancer.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Prognosis; Survival Rate; Treatment Outcome | 2008 |
Semiautomatic volume of interest drawing for (18)F-FDG image analysis-method and preliminary results.
Topics: Algorithms; Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Imaging, Three-Dimensional; Male; Middle Aged; Neoplasms; Pattern Recognition, Automated; Pilot Projects; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity | 2008 |
Multicentre assessment and monitored use of [(18)F]FDG-PET in oncology: the Spanish experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Spain | 2008 |
Analysis and interpretation of dynamic FDG PET oncological studies using data reduction techniques.
Topics: Algorithms; Artificial Intelligence; Data Interpretation, Statistical; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Neoplasms; Positron-Emission Tomography; Principal Component Analysis; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity | 2007 |
[Feasibility of diagnostic contrast-enhanced CT for attenuation correction of whole body PET images].
Topics: Aged; Contrast Media; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Whole Body Imaging | 2007 |
Benign nonphysiologic lesions with increased 18F-FDG uptake on PET/CT: characterization and incidence.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Female; Fluorodeoxyglucose F18; Humans; Infant; Israel; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Prevalence; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Risk Assessment; Risk Factors; Sensitivity and Specificity; Tomography, X-Ray Computed | 2007 |
[Therapeutic response evaluation by nuclear functional imaging].
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Treatment Outcome | 2007 |
Optimal dual time point for FDG-PET in the differentiation of benign from malignant lung lesions: a simulation study.
Topics: Computer Simulation; Fluorodeoxyglucose F18; Humans; Models, Biological; Neoplasms; Positron-Emission Tomography; Radiography; Radiopharmaceuticals; Reproducibility of Results; Time Factors | 2007 |
Impact of acquisition geometry, image processing, and patient size on lesion detection in whole-body 18F-FDG PET.
Topics: Body Mass Index; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Whole Body Imaging | 2007 |
Prospective study of 18FDG-PET in the detection and management of patients with lymph node metastases to the neck from an unknown primary tumor. Results from the DAHANCA-13 study.
Topics: Adult; Aged; Carcinoma; Endoscopy; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Middle Aged; Neck Dissection; Neoplasms; Neoplasms, Unknown Primary; Positron-Emission Tomography; Practice Guidelines as Topic; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Radiotherapy, Adjuvant; Sensitivity and Specificity | 2008 |
Under normoxia, 2-deoxy-D-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation.
Topics: Adenosine Triphosphate; Aerobiosis; Anaerobiosis; Cell Death; Cell Line, Tumor; Cell Survival; Deoxyglucose; Fluorodeoxyglucose F18; Glycolysis; Glycosylation; Humans; Mannose; Models, Biological; Neoplasms; Oligosaccharides; Oxygen; Oxygen Consumption; Protein Folding; Transcription Factor CHOP; Up-Regulation | 2007 |
Performance profile of FDG-PET and PET/CT for cancer screening on the basis of a Japanese Nationwide Survey.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; False Positive Reactions; Female; Fluorodeoxyglucose F18; Health Care Surveys; Humans; Image Processing, Computer-Assisted; Japan; Male; Middle Aged; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Predictive Value of Tests; Program Evaluation; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Tomography, X-Ray Computed | 2007 |
18F-FDG PET/CT in evaluating non-CNS pediatric malignancies.
Topics: Adolescent; Adult; Child; Child, Preschool; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed | 2007 |
Comparison of integrin alphaVbeta3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG.
Topics: Aged; Aged, 80 and over; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Galactose; Humans; Integrin alphaVbeta3; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Peptides, Cyclic; Positron-Emission Tomography; Radiopharmaceuticals | 2008 |
[FDG-PET/CT in oncology. German Guideline].
Topics: Documentation; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2007 |
How do we best balance optimal timing of FDG PET-CT imaging?
Topics: Fluorodeoxyglucose F18; Humans; Image Enhancement; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Time Factors; Tomography, X-Ray Computed | 2007 |
Use of PET probe in surgical oncology.
Topics: Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lymphatic Metastasis; Neoplasm Recurrence, Local; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Surgery, Computer-Assisted | 2008 |
[Performance profile of FDG-PET and PET/CT for cancer screening based on a Japanese nationwide survey].
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Child; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Japan; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Surveys and Questionnaires; Tomography, X-Ray Computed | 2007 |
Recommendations on the use of 18F-FDG PET in oncology.
Topics: Fluorodeoxyglucose F18; Humans; Medical Oncology; Neoplasms; Nuclear Medicine; Positron-Emission Tomography; Practice Guidelines as Topic; Radiopharmaceuticals | 2008 |
Improved detection of breast cancer on FDG-PET cancer screening using breast positioning device.
Topics: Adult; Aged; Aged, 80 and over; Breast; Breast Neoplasms; Clinical Protocols; Equipment Failure Analysis; Female; Fluorodeoxyglucose F18; Humans; Male; Mass Screening; Middle Aged; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Prone Position; Radiopharmaceuticals; Reproducibility of Results; Supine Position; Whole Body Imaging | 2008 |
F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome.
Topics: Adult; Feasibility Studies; Female; Fluorodeoxyglucose F18; Genes, p53; Heterozygote; Humans; Li-Fraumeni Syndrome; Male; Mutation; Neoplasms; Pilot Projects; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, Spiral Computed; Whole Body Imaging | 2008 |
Aerobic glycolysis in cancers: implications for the usability of oxygen-responsive genes and fluorodeoxyglucose-PET as markers of tissue hypoxia.
Topics: Aerobiosis; Animals; Cell Line, Tumor; Fluorodeoxyglucose F18; Glycolysis; Humans; Hypoxia; Immunohistochemistry; Lactic Acid; Mice; Neoplasms; Oxygen; Positron-Emission Tomography | 2008 |
Where do we draw the line? Contouring tumors on positron emission tomography/computed tomography.
Topics: Algorithms; Fluorodeoxyglucose F18; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Tumor Burden; Visual Perception | 2008 |
Method for decreasing uptake of 18F-FDG by hypermetabolic brown adipose tissue on PET.
Topics: Adipose Tissue, Brown; Adult; Aged; Blood Glucose; Cohort Studies; Diet; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies | 2008 |
Utility of [(18)F] fluoro-2-deoxy-D: -glucose positron emission tomography in the localization of ectopic ACTH-secreting tumors.
Topics: Adult; Carcinoid Tumor; Carcinoma, Small Cell; Female; Fluorodeoxyglucose F18; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms; Positron-Emission Tomography | 2009 |
Glucose and insulin variations in patients during the time course of a FDG-PET study and implications for the "glucose-corrected" SUV.
Topics: Biological Transport; Blood Glucose; Fluorodeoxyglucose F18; Glucose; Humans; Insulin; Neoplasms; Observer Variation; Positron-Emission Tomography; Reference Standards; Tissue Distribution | 2008 |
Imaging of canine cancers with 18F-2-fluoro-2-deoxy-D-glucose (FDG) suggests further applications for cancer imaging in man.
Topics: Animals; Deoxy Sugars; Deoxyglucose; Dog Diseases; Dogs; Female; Fluorine; Fluorodeoxyglucose F18; Male; Mammary Glands, Animal; Neoplasms; Osteosarcoma; Radioisotopes; Radionuclide Imaging | 1984 |
[Experimental study for cancer diagnosis with 18FDG: differential diagnosis of inflammation from malignant tumor].
Topics: Animals; Deoxy Sugars; Deoxyglucose; Diagnosis, Differential; Fluorine; Fluorodeoxyglucose F18; Inflammation; Neoplasms; Rabbits; Radioisotopes; Radionuclide Imaging | 1983 |
Differential uptake of 2-fluoro-2-deoxy-D-glucose.
Topics: Animals; Cells, Cultured; Chick Embryo; Deoxy Sugars; Deoxyglucose; Fibroblasts; Fluorodeoxyglucose F18; Humans; Mice; Neoplasms | 1983 |
SUV: standard uptake or silly useless value?
Topics: Blood Glucose; Deoxyglucose; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Neoplasms; Reference Standards; Tissue Distribution; Tomography, Emission-Computed | 1995 |
Highlights of the annual meeting of the European Association of Nuclear Medicine, Düsseldorf 1994.
Topics: Bone and Bones; Brain; Deoxyglucose; Europe; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Heart; Humans; Infections; Joints; Neoplasms; Nuclear Medicine; Radioimmunodetection; Radiotherapy; Societies, Medical; Technetium Tc 99m Sestamibi; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 1995 |
[Performance of a multispect 2 gamma camera for imaging 511-keV gamma rays].
Topics: Deoxyglucose; Electrons; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Gamma Rays; Humans; Models, Structural; Neoplasms; Nitrilotriacetic Acid; Organometallic Compounds; Organophosphonates; Organophosphorus Compounds; Sensitivity and Specificity; Tomography, Emission-Computed, Single-Photon | 1995 |
Potential role of FDG-PET imaging in understanding tumor-host interaction.
Topics: Deoxyglucose; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Glucose; Models, Biological; Neoplasms; Tomography, Emission-Computed | 1995 |
FDG-SPECT: correlation with FDG-PET.
Topics: Adult; Aged; Brain; Deoxyglucose; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Heart; Humans; Male; Middle Aged; Neoplasms; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 1995 |
Triple-head SPECT with 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG): initial evaluation in oncology and comparison with FDG PET.
Topics: Deoxyglucose; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Gamma Cameras; Humans; Models, Structural; Neoplasms; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 1995 |
Neoplasms in a pediatric population: 2-[F-18]-fluoro-2-deoxy-D-glucose PET studies.
Topics: Adolescent; Child; Deoxyglucose; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Infant; Lymphoma; Neoplasms; Neuroblastoma; Sarcoma, Ewing; Tomography, Emission-Computed | 1995 |
Cancer or inflammation? A Holy Grail for nuclear medicine.
Topics: Citrates; Citric Acid; Deoxyglucose; Diagnosis, Differential; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Inflammation; Lymphoma; Neoplasms; Sarcoidosis; Sensitivity and Specificity; Tomography, Emission-Computed | 1994 |
Indeterminate adrenal mass in patients with cancer: evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose.
Topics: Adrenal Gland Diseases; Adrenal Gland Neoplasms; Aged; Deoxyglucose; Diagnosis, Differential; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Tomography, Emission-Computed | 1995 |
FDG-PET for the evaluation of tumor viability after anticancer therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxyglucose; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasms; Radiotherapy, High-Energy; Tomography, Emission-Computed | 1994 |
Technology for FDG SPECT with a relatively inexpensive gamma camera. Work in progress.
Topics: Adult; Brain; Costs and Cost Analysis; Deoxyglucose; Feasibility Studies; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Gamma Cameras; Heart; Humans; Male; Middle Aged; Models, Structural; Neoplasms; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 1994 |
"Anatometabolic" tumor imaging: fusion of FDG PET with CT or MRI to localize foci of increased activity.
Topics: Adult; Algorithms; Deoxyglucose; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Neoplasms; Tomography, Emission-Computed; Tomography, X-Ray Computed | 1993 |
FDG-PET in oncology: there's more to it than looking at pictures.
Topics: Deoxyglucose; Fluorodeoxyglucose F18; Glucose; Humans; Neoplasms; Tomography, Emission-Computed | 1993 |
FDG accumulation in tumor tissue.
Topics: Cell Division; Deoxyglucose; Flow Cytometry; Fluorodeoxyglucose F18; Humans; Neoplasms; Tomography, Emission-Computed | 1993 |
Detection of malignancies with SPECT versus PET, with 2-[fluorine-18]fluoro-2-deoxy-D-glucose.
Topics: Adult; Aged; Deoxyglucose; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Phantoms, Imaging; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 1996 |
Enhanced FDG-PET tumor imaging with correlation-coefficient filtered influx-constant images.
Topics: Artifacts; Deoxyglucose; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Processing, Computer-Assisted; Male; Neoplasms; Time Factors; Tomography, Emission-Computed | 1996 |
[Use of positron-emission tomography in oncology].
Topics: Deoxyglucose; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Tomography, Emission-Computed | 1996 |
Standardized uptake values of fluorine-18 fluorodeoxyglucose: the value of different normalization procedures.
Topics: Algorithms; Body Constitution; Cohort Studies; Deoxyglucose; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Liver; Lung; Male; Middle Aged; Neoplasms; Prospective Studies; Reference Values; Tissue Distribution; Tomography, Emission-Computed | 1996 |
1996 SNM annual meeting: medical problem solving.
Topics: Artifacts; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Colorectal Neoplasms; Contrast Media; Dementia; Deoxyglucose; Eye Neoplasms; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Genetic Therapy; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Melanoma; Neoplasms; Radioisotopes; Radiotherapy; Rhenium; Societies, Medical; Technetium; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 1996 |
Fluorodeoxyglucose (FDG) and tumour metabolism.
Topics: Deoxyglucose; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Glucose; Humans; Neoplasms; Tomography, Emission-Computed | 1995 |
High-energy (511-keV) imaging with the scintillation camera.
Topics: Brain; Deoxyglucose; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Gamma Cameras; Heart; Humans; Neoplasms; Phantoms, Imaging; Technetium Tc 99m Sestamibi; Technology, Radiologic; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 1996 |
Positron emission tomography in oncology. General acceptance of its role is overdue.
Topics: Deoxyglucose; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Neoplasms; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 1996 |
Evaluation of ion-implanted-silicon detectors for use in intraoperative positron-sensitive probes.
Topics: Beta Particles; Deoxyglucose; Electrons; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Intraoperative Period; Neoplasms; Radiation Dosage; Radiometry; Radionuclide Imaging; Sensitivity and Specificity; Silicon | 1996 |
[Cancer screening with whole-body FDG PET].
Topics: Adult; Aged; Aged, 80 and over; Deoxyglucose; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphoma; Male; Middle Aged; Neoplasms; Prostatic Neoplasms; Tomography, Emission-Computed | 1996 |
Positron emission tomography in oncology: the most sophisticated imaging technology.
Topics: Carbon Radioisotopes; Deoxyglucose; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Methionine; Neoplasms; Tomography, Emission-Computed | 1997 |
Is there a future for PET in oncology?
Topics: Deoxyglucose; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Medical Oncology; Neoplasms; Sensitivity and Specificity; Tomography, Emission-Computed | 1997 |
Development of oncology protocol using fluorine-18-FDG: one center's experience.
Topics: Blood Glucose; Colonic Neoplasms; Deoxyglucose; Esophageal Neoplasms; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Gamma Cameras; Head and Neck Neoplasms; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Lymphoma; Neoplasm Staging; Neoplasms; Patient Education as Topic; Practice Guidelines as Topic; Problem Solving; Quality Control; Quality of Health Care; Radiation Oncology; Radiology Information Systems; Radiopharmaceuticals; Rectal Neoplasms; Stomach Neoplasms; Tomography, Emission-Computed | 1997 |
PET FDG studies in oncology.
Topics: Deoxyglucose; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 1994 |
Molecular nuclear medicine: the best kept secret in medicine.
Topics: Deoxyglucose; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Neoplasms; Nuclear Medicine; Radiopharmaceuticals; Societies, Medical; Tomography, Emission-Computed | 1997 |
Whole-body positron emission tomography in clinical oncology: comparison between attenuation-corrected and uncorrected images.
Topics: Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Neoplasms; Phantoms, Imaging; Radiopharmaceuticals; Tomography, Emission-Computed | 1997 |
Whole-body positron emission tomography: normal variations, pitfalls, and technical considerations.
Topics: Adult; Aged; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Radiopharmaceuticals; Tissue Distribution; Tomography, Emission-Computed | 1997 |
[Positron-emission tomography in oncology].
Topics: Brain Neoplasms; Breast Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 1997 |
Technetium-99m-labeled HL91 to identify tumor hypoxia: correlation with fluorine-18-FDG.
Topics: Aged; Cell Hypoxia; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Male; Neoplasms; Organotechnetium Compounds; Oximes; Pilot Projects; Radiopharmaceuticals; Time Factors; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 1998 |
Hematopoietic cytokine-mediated FDG uptake simulates the appearance of diffuse metastatic disease on whole-body PET imaging.
Topics: Adolescent; Adult; Bone Marrow; Bone Marrow Neoplasms; Female; Fluorodeoxyglucose F18; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasms; Osteosarcoma; Radiopharmaceuticals; Retrospective Studies; Tomography, Emission-Computed | 1998 |
Four cases of Warthin's tumor of the parotid gland detected with FDG PET.
Topics: Adenolymphoma; Aged; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Male; Mass Screening; Middle Aged; Neoplasms; Parotid Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 1998 |
Non-invasive estimation of the net influx constant using the standardized uptake value for quantification of FDG uptake of tumours.
Topics: Carcinoma, Squamous Cell; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 1998 |
[Positron emission tomography using 18F-fluorodeoxyglucose in oncology].
Topics: Female; Fluorodeoxyglucose F18; Humans; Male; Neoplasms; Tomography, Emission-Computed | 1997 |
Procedure guideline for tumor imaging using fluorine-18-FDG. Society of Nuclear Medicine.
Topics: Child; Child, Preschool; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 1998 |
Proposition: positron imaging with SPECT and dual-head scintillation cameras obviates the need for PET in oncologic imaging.
Topics: Fluorodeoxyglucose F18; Gamma Cameras; Humans; Neoplasms; Radiopharmaceuticals; Reproducibility of Results; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 1998 |
FDG PET and dual-head gamma camera positron coincidence detection imaging of suspected malignancies and brain disorders.
Topics: Adult; Aged; Brain; Brain Diseases; Dementia; Female; Fluorodeoxyglucose F18; Gamma Cameras; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Neoplasms; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed | 1999 |
[Positron emission tomography (PET) and (F-18)-fluorodeoxyglucose in (FDG) in cancerology].
Topics: Digestive System Neoplasms; Female; Fluorodeoxyglucose F18; Glucose; Glycolysis; Humans; Lung Neoplasms; Lymphoma; Male; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 1998 |
New equipment in nuclear medicine, part 2: dual-head FDG coincidence detection cameras.
Topics: Fluorodeoxyglucose F18; Gamma Cameras; Humans; Image Processing, Computer-Assisted; Insurance, Health, Reimbursement; Medicare; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; United States | 1999 |
[Onco-PET: lesion detection by monitor versus standardized film documentation].
Topics: Documentation; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lymphoma; Neoplasms; Online Systems; Radiopharmaceuticals; Tomography, Emission-Computed | 1999 |
Increased FDG uptake in the wall of the right atrium in people who participated in a cancer screening program with whole-body PET.
Topics: Adult; Aged; Atrial Fibrillation; Blood Glucose; False Positive Reactions; Fatty Acids, Nonesterified; Female; Fluorodeoxyglucose F18; Heart Atria; Humans; Male; Mass Screening; Middle Aged; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 1999 |
Fluorine-18 fluorodeoxyglucose uptake in the retractile testis.
Topics: False Positive Reactions; Fluorodeoxyglucose F18; Humans; Inguinal Canal; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms; Radiopharmaceuticals; Testis; Tomography, Emission-Computed | 1999 |
[PET in oncology: standardization and specificity].
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, Emission-Computed | 1999 |
Attenuation correction in whole-body FDG oncological studies: the role of statistical reconstruction.
Topics: Adult; Aged; Algorithms; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Neoplasms; Observer Variation; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Time Factors; Tomography, Emission-Computed | 1999 |
F-18-FDG positron imaging in oncological patients: gamma camera coincidence detection versus dedicated PET.
Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Gamma Cameras; Head and Neck Neoplasms; Humans; Lung Neoplasms; Lymphoma; Middle Aged; Neoplasms; Phantoms, Imaging; Radiopharmaceuticals; Recurrence; Sensitivity and Specificity; Tomography, Emission-Computed | 1999 |
Dual-head gamma camera 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography in oncological patients: effects of non-uniform attenuation correction on lesion detection.
Topics: Evaluation Studies as Topic; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Gamma Cameras; Humans; Image Processing, Computer-Assisted; Middle Aged; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 1999 |
[Guidelines for tumor diagnosis with (F-18)-fluorodeoxyglucose (FDG)].
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Practice Guidelines as Topic; Quality Assurance, Health Care; Radiopharmaceuticals; Tomography, Emission-Computed | 1999 |
[Imaging of cancer using positron emission tomography].
Topics: Fluorodeoxyglucose F18; Follow-Up Studies; Half-Life; Humans; Neoplasm Staging; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed; Whole-Body Counting | 1999 |
Pediatric body applications of FDG PET.
Topics: Adolescent; Child; Child, Preschool; Female; Fluorodeoxyglucose F18; Humans; Infant; Male; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 1999 |
To AC or not to AC: that is the question.
Topics: Breast Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 1999 |
[Positron emission tomography ia an effective tool in modern oncology].
Topics: Fluorodeoxyglucose F18; Humans; Methionine; Neoplasm Metastasis; Neoplasms; Tomography, Emission-Computed | 1999 |
[Imaging and oncology: necessarily associated].
Topics: Diagnostic Imaging; Fluorodeoxyglucose F18; Humans; Neoplasms; Radiation Oncology; Radionuclide Imaging; Tomography, Emission-Computed; Tomography, X-Ray Computed | 1999 |
[Visualization of normal organs in whole-body FDG-PET imaging].
Topics: Adult; Age Factors; Fasting; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Smoking; Tomography, Emission-Computed | 1999 |
Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.
Topics: Antineoplastic Agents; Fluorodeoxyglucose F18; Humans; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed; Treatment Outcome | 1999 |
The stage is set for the diffusion of positron emission tomography (PET) in oncology.
Topics: Accreditation; Australia; Cost-Benefit Analysis; Diffusion of Innovation; Fluorodeoxyglucose F18; Humans; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 1999 |
Positron emission tomography (PET): experience with a large-field-of-view three-dimensional PET scanner.
Topics: Cost-Benefit Analysis; Epilepsy; Evaluation Studies as Topic; Fluorodeoxyglucose F18; Humans; Medical Audit; Monitoring, Physiologic; Neoplasm Staging; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed; Victoria | 1999 |
New indications give PET a lift after struggle over regulatory and reimbursement issues.
Topics: Dementia; Fluorodeoxyglucose F18; Health Services Accessibility; Humans; Insurance, Health, Reimbursement; Mobile Health Units; Neoplasms; Nuclear Medicine Department, Hospital; Radiopharmaceuticals; Tomography, Emission-Computed; United States; United States Food and Drug Administration | 2000 |
[Rapid increase of the use of PET in cancer investigation--but Sweden lags behind].
Topics: Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Rectal Neoplasms; Sweden; Tomography, Emission-Computed; United States | 2000 |
Image fusion using an integrated, dual-head coincidence camera with X-ray tube-based attenuation maps.
Topics: Adult; Aged; Brain Neoplasms; Colorectal Neoplasms; Female; Fluorodeoxyglucose F18; Gamma Cameras; Humans; Image Interpretation, Computer-Assisted; Liver Neoplasms; Male; Middle Aged; Neoplasms; Radiopharmaceuticals; Reproducibility of Results; Tomography, Emission-Computed | 2000 |
A combined PET/CT scanner for clinical oncology.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Data Interpretation, Statistical; Duodenal Neoplasms; Equipment Design; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Polyps; Radiopharmaceuticals; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2000 |
Comparing filtered backprojection and ordered-subsets expectation maximization for small-lesion detection and localization in 67Ga SPECT.
Topics: Algorithms; Fluorodeoxyglucose F18; Gallium Radioisotopes; Heart; Humans; Image Processing, Computer-Assisted; Neoplasms; Phantoms, Imaging; Radiopharmaceuticals; Tissue Distribution; Tomography, Emission-Computed, Single-Photon | 2000 |
Fundamental study of hot spot detectability in 3-dimensional positron emission tomography.
Topics: Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Neoplasms; Phantoms, Imaging; Tomography, Emission-Computed | 2000 |
[Added value of positron emission tomography with fluoro-18-deoxyglucose as the tracer (FDG-PET) in clinical problem cases in oncology].
Topics: Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 2000 |
Clinical PET in oncology.
Topics: Artifacts; Blood Glucose; Cooperative Behavior; Cyclotrons; False Positive Reactions; Female; Fluorodeoxyglucose F18; Germany; Humans; Inflammation; Lymphatic Metastasis; Male; Medical Oncology; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms; Nuclear Medicine; Organ Specificity; Practice Guidelines as Topic; Private Practice; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed; Universities | 2000 |
[Positron emission tomography in tumor pathology].
Topics: Europe; Fluorodeoxyglucose F18; Humans; Neoplasms; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed | 2000 |
Image analysis in patients with cancer studied with a combined PET and CT scanner.
Topics: Aged; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2000 |
Anatomy of SUV. Standardized uptake value.
Topics: Biological Transport; Fluorodeoxyglucose F18; Glucose; Humans; Kinetics; Models, Biological; Neoplasms; Radionuclide Imaging; Radiopharmaceuticals | 2000 |
FDG imaging.
Topics: Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 2000 |
Monitoring response to treatment in the development of anticancer drugs using PET.
Topics: Antineoplastic Agents; Carbon Radioisotopes; Drug Monitoring; Fluorodeoxyglucose F18; Humans; Neoplasms; Radiopharmaceuticals; Thymidine; Tomography, Emission-Computed | 2000 |
Application of positron emission tomography imaging to cancer screening.
Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Humans; Male; Mass Screening; Middle Aged; Neoplasms; Reproducibility of Results; Tomography, Emission-Computed | 2000 |
Muscle uptake of 18-fluorine fluorodeoxyglucose.
Topics: Adult; Aged; Aged, 80 and over; Artifacts; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Muscle, Skeletal; Neoplasms; Radiopharmaceuticals; Tissue Distribution; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2000 |
HCFA approves Medicare coverage of PET scans.
Topics: Aged; Centers for Medicare and Medicaid Services, U.S.; Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Medicare; Neoplasm Staging; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed; United States | 2001 |
Positron emission tomography: imaging tumor response.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 2000 |
[Scintigraphy with FDG-PET].
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 2000 |
Combined 18F-FDG-FDOPA tumor imaging for assessing response to therapy.
Topics: Dihydroxyphenylalanine; Fluorodeoxyglucose F18; Humans; Melanoma; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 2001 |
PET scanning in malignancy: infant, adolescent or mature citizen?
Topics: Cost-Benefit Analysis; Decision Trees; Fluorodeoxyglucose F18; Humans; Neoplasm Staging; Neoplasms; Radiopharmaceuticals; Sensitivity and Specificity; Technology Assessment, Biomedical; Tomography, Emission-Computed | 2001 |
An approach to demonstrating cost-effectiveness of diagnostic imaging modalities in Australia illustrated by positron emission tomography.
Topics: Australia; Cardiovascular Diseases; Cost Savings; Cost-Benefit Analysis; Decision Trees; Fluorodeoxyglucose F18; Humans; Neoplasms; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed | 2001 |
Positron-emitting radiopharmaceuticals: how safe are they?
Topics: Electrons; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Gamma Cameras; Humans; Multicenter Studies as Topic; Neoplasms; Occupational Health; Prospective Studies; Radiometry; Radiopharmaceuticals; Safety; Technology, Radiologic; Tomography, Emission-Computed; United States | 2001 |
Tumour detectability in 2-dimensional and 3-dimensional positron emission tomography using the SET-2400W: a phantom study.
Topics: Animals; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Neoplasms; Neoplasms, Muscle Tissue; Phantoms, Imaging; Rabbits; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, Emission-Computed | 2001 |
Impact of fluorine-18 fluorodeoxyglucose positron emission tomography on patient management: first year's experience in a clinical center.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Tomography, Emission-Computed | 2001 |
Increased metabolic activity in the thymus gland studied with 18F-FDG PET: age dependency and frequency after chemotherapy.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents; Child; Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Lymphoma; Middle Aged; Neoplasms; Radiopharmaceuticals; Retrospective Studies; Thymus Gland; Thymus Hyperplasia; Thymus Neoplasms; Tomography, Emission-Computed | 2001 |
[Role of FDG-PET in oncological surgery].
Topics: Blood Glucose; Energy Metabolism; Fluorodeoxyglucose F18; Humans; Neoplasm Recurrence, Local; Neoplasms; Predictive Value of Tests; Reoperation; Tomography, Emission-Computed | 2001 |
Analysis of FDG uptake with hybrid PET using standardised uptake values.
Topics: Calibration; Feasibility Studies; Fluorodeoxyglucose F18; Gamma Cameras; Glucose; Humans; Image Processing, Computer-Assisted; Middle Aged; Neoplasms; Phantoms, Imaging; Radiopharmaceuticals; Reference Standards; Tissue Distribution; Tomography, Emission-Computed | 2001 |
The clinical use of PET--where are we now?
Topics: Cardiomyopathies; Cost-Benefit Analysis; Fluorodeoxyglucose F18; Half-Life; Humans; Neoplasms; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed | 2001 |
[[(18)F]N-(4'-fluorobenzyl)-4-(3-bromophenyl) acetamide for imaging the sigma receptor status of tumors: comparison with [(18)F]FDG, and [(125)I]IUDR.
Topics: Acetamides; Adenocarcinoma; Animals; Female; Fluorodeoxyglucose F18; Idoxuridine; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Neoplasms; Radionuclide Imaging; Radiopharmaceuticals; Receptors, sigma; Tissue Distribution | 2001 |
Usefulness of dual-head coincidence gamma camera with thick NaI crystals for nuclear oncology: comparison with dedicated PET camera and conventional gamma camera with thin NaI crystals.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Female; Fluorodeoxyglucose F18; Gamma Cameras; Humans; Male; Middle Aged; Neoplasms; Radiopharmaceuticals; Sensitivity and Specificity; Sodium Iodide; Technetium Tc 99m Medronate; Tomography, Emission-Computed | 2001 |
Measurement of tumor response using [18F]-2-fluoro-2-deoxy-D-glucose and positron-emission tomography.
Topics: Europe; Fluorodeoxyglucose F18; Humans; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 2001 |
Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes.
Topics: Aged; Animals; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Inflammation; Male; Mice; Middle Aged; Neoplasms; Radiopharmaceuticals; Rats; Rats, Inbred F344; Retrospective Studies; Tomography, Emission-Computed; Tumor Cells, Cultured | 2001 |
Do high glucose levels have differential effect on FDG uptake in inflammatory and malignant disorders?
Topics: Blood Glucose; Fluorodeoxyglucose F18; Humans; Inflammation; Mesothelioma; Monocytes; Neoplasms; Radiopharmaceuticals; Retrospective Studies; Tomography, Emission-Computed; Tumor Cells, Cultured | 2001 |
Coincidence detection FDG PET in the management of oncological patients: attenuation correction versus non-attenuation correction.
Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Gamma Cameras; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Thoracic Neoplasms; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2001 |
[Advances in surgery -- without advance in medical technology?].
Topics: Female; Fluorodeoxyglucose F18; Glucose; Humans; Male; Medical Laboratory Science; Neoplasms; Prognosis; Radiopharmaceuticals; Surgical Procedures, Operative; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2001 |
Coincidence images lag PET in head-to-head comparisons.
Topics: False Negative Reactions; Fluorodeoxyglucose F18; Humans; Neoplasms; Radiopharmaceuticals; Spectrum Analysis; Tomography, Emission-Computed | 1999 |
Feasibility of a short acquisition protocol for whole-body positron emission tomography with fluorine-18 fluorodeoxyglucose.
Topics: Adult; Aged; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Phantoms, Imaging; Prospective Studies; Radiopharmaceuticals; Time Factors; Tomography, Emission-Computed | 2001 |
[The impact of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) on planning of radiotherapy].
Topics: Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Radiopharmaceuticals; Radiotherapy; Retrospective Studies; Tomography, Emission-Computed | 2001 |
Joint accumulations of FDG in whole body PET scans.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biological Transport; Child; Child, Preschool; Female; Fluorodeoxyglucose F18; Humans; Infant; Joints; Knee Joint; Male; Middle Aged; Neoplasm Staging; Neoplasms; Radiopharmaceuticals; Tissue Distribution; Tomography, Emission-Computed | 2001 |
Standardized uptake value in pediatric patients: an investigation to determine the optimum measurement parameter.
Topics: Adolescent; Body Mass Index; Body Surface Area; Body Weight; Child; Child, Preschool; Fluorodeoxyglucose F18; Humans; Liver; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 2002 |
Is quantitation necessary for oncological PET studies? For.
Topics: Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasms; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed | 2002 |
Is quantitation necessary for oncological PET studies? Against.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 2002 |
Guest editorial: the conception of FDG-PET imaging.
Topics: Brain Neoplasms; Fluorodeoxyglucose F18; Glucose; Humans; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed; Whole-Body Counting | 2002 |
FDG-PET as a "metabolic biopsy" tool in non-lung lesions with indeterminate biopsy.
Topics: Adult; Aged; Aged, 80 and over; Biopsy; False Negative Reactions; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Laparoscopy; Male; Middle Aged; Neoplasms; Predictive Value of Tests; Radiopharmaceuticals; Sensitivity and Specificity; Spinal Puncture; Tomography, Emission-Computed | 2002 |
[Impact of [18F]-FDG-PET on medical decision making in oncology: evaluation by the referring physicians during the opening year].
Topics: Colorectal Neoplasms; Decision Making; Fluorodeoxyglucose F18; France; Health Care Surveys; Lung Neoplasms; Lymphoma; Melanoma; Neoplasms; Otorhinolaryngologic Neoplasms; Radionuclide Imaging; Radiopharmaceuticals; Surveys and Questionnaires | 2002 |
Oncological diagnosis using positron coincidence gamma camera with fluorodeoxyglucose in comparison with dedicated PET.
Topics: Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Gamma Cameras; Humans; Male; Middle Aged; Neoplasms; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed | 2002 |
18 F-Fluorodeoxyglucose triple-headed coincidence detection imaging in oncology: preliminary results and comparison with dedicated PET.
Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Tomography, Emission-Computed | 2002 |
Cancer treatment monitoring with fluorine-18 2-fluoro-2-deoxy-D-glucose and positron emission tomography: frustration or future.
Topics: Animals; Combined Modality Therapy; Deoxyglucose; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Neoplasms; Tomography, Emission-Computed; Treatment Outcome | 1992 |
Whole-body positron emission tomography: Part I. Methods and performance characteristics.
Topics: Deoxyglucose; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Neoplasms; Time Factors; Tomography, Emission-Computed | 1992 |
Quantitating tumor glucose metabolism with FDG and PET.
Topics: Deoxyglucose; Fluorodeoxyglucose F18; Glycolysis; Humans; Neoplasms; Tomography, Emission-Computed | 1992 |
PET cancer evaluations with FDG.
Topics: Deoxyglucose; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Glycolysis; Humans; Neoplasms; Tomography, Emission-Computed | 1991 |
Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography.
Topics: Adult; Aged; Carcinoma, Bronchogenic; Combined Modality Therapy; Deoxyglucose; Esophageal Neoplasms; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphoma; Male; Mediastinal Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Rectal Neoplasms; Thyroid Neoplasms; Tomography, Emission-Computed | 1991 |
18F-2-deoxy-2-fluoro-D-glucose uptake into human tumor xenografts. Feasibility studies for cancer imaging with positron-emission tomography.
Topics: Animals; Deoxyglucose; Feasibility Studies; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Tissue Distribution; Tomography, Emission-Computed | 1991 |
New approach to clinical evaluation of cancer chemotherapy using positron emission tomography with 18FDG (2-deoxy-2-[18F]fluoro-D-glucose).
Topics: Adenocarcinoma; Aged; Deoxy Sugars; Deoxyglucose; Female; Fluorine; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasms; Radioisotopes; Stomach Neoplasms; Tomography, Emission-Computed | 1986 |
[Present status and trends in radiopharmacology].
Topics: Antibodies, Monoclonal; Deoxyglucose; Fluorodeoxyglucose F18; Humans; Neoplasms; Radioisotopes; Radionuclide Imaging; Receptors, Dopamine; Technetium | 1987 |
Scintigraphy with [18F]2-fluoro-2-deoxy-D-glucose of cancer patients.
Topics: Adult; Aged; Deoxy Sugars; Deoxyglucose; Female; Fluorine; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Radioisotopes; Radionuclide Imaging | 1986 |